

REFERENCES FOR WEBSITE:

ALL CONDITIONS/DRUGS USED AS OF DECEMBER 2019

1. AA Pharm Inc. (2014). Aventyl (nortriptyline). *CA Product Monograph*,
2. AA Pharma Inc. (2010). Elavil (amitriptyline). *CA Product Monograph*,
3. AA Pharma Inc. (2010). Floctafenine. *CA Product Monograph*,
4. AA Pharma Inc. (2010). ISDN (isosorbide dinitrate). *CA Product Monograph*,
5. AA Pharma Inc. (2010). Sulfinpyrazone. *CA Product Monograph*,
6. AA Pharma Inc. (2010). Tenoxicam. *CA Product Monograph*,
7. AA Pharma Inc. (2011). Ketoprofen. *CA Product Monograph*,
8. AA Pharma Inc. (2012). Desipramine. *CA Product Monograph*,
9. AA Pharma Inc. (2012). Fluphenazine. *CA Product Monograph*,
10. AA Pharma Inc. (2012). Perphenazine. *CA Product Monograph*,
11. AA Pharma Inc. (2013). Lithmax (lithium Carbonate). *CA Product Monograph*,
12. AA Pharma Inc. (2014). Diflunisal. *CA Product Monograph*,
13. AA Pharma Inc. (2014). Trifluoperazine. *CA Product Monograph*,
14. AA Pharma Inc. (2014). Trimethoprim. *CA Product Monograph*,
15. AA Pharma Inc. (2015). Ofloxacin
16. AA Pharma Inc. (2015). ORAP (pimozide). *CA Product Monograph*,
17. AA Pharma Inc. (2016). Nadolol. *CA Product Monograph*,
18. AA Pharma Inc. (2017). Ponstan (mefenamic acid). *CA Product Monograph*,
19. AA Pharma Inc. (2017). Toradol (ketorolac). *CA Product Monograph*,
20. AA Pharma Inc. (2018). Etodolac *CA Product Monograph*,
21. AA Pharma Inc. (2018). Norfloxacin. *CA Product Monograph*,
22. AA Pharma Inc. (2012). Perphenazine. *CA Product Monograph*,
23. Aarnoudse, A. J., Dieleman, J. P., Visser, L. E., Arp, P. P., van der Heiden, I. P., van Schaik, R. H., . . . Stricker, B. H. (2008). Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. *Pharmacogenet Genomics*, 18(4), 299-305.
24. Abbott Laboratories. (2007). Omnicef (cefdinir). *US Product Monograph*,
25. Abbott Laboratories. (2012). Biaxin (clarithromycin). *US Product Monograph*,
26. AbbVie Inc. (2017). Depakene (valproic acid). *US Product Monograph*,
27. AbbVie Inc. (2017). Depakote (divalproex). *US Product Monograph*,
28. AbbVie Inc. (2017). Divalproex sodium. *US Product Monograph*,
29. AbbVie Inc. (2018). Tricor (fenofibrate) *US Product Monograph*,
30. Abdellatif, A. A., & Elkhaili, N. (2014). Management of gouty arthritis in patients with chronic kidney disease. *Am J Ther*, 21(6), 523-534.
31. Abdel-Rahman, S. M., Leeder, J. S., Wilson, J. T., Gaedigk, A., Gotschall, R. R., Medve, R., . . . Kearns, G. L. (2002). Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. *J Clin Pharmacol*, 42(1), 24-29.

32. Abe, M., & Kalantar-Zadeh, K. (2015). Haemodialysis-induced hypoglycaemia and glycaemic disarrays. *Nat Rev Nephrol*, *11*(5), 302-313.
33. About, F., Oudot-Mellakh, T., Niay, J., Rabiega, P., Pedergrana, V., Duffy, D., . . . Abel, L. (2015). Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. *PLoS One*, *10*(12), e0145105.
34. Aboyans, V., Ricco, J. B., Bartelink, M. E. L., Bjorck, M., Brodmann, M., Cohnert, T., . . . Desormais, I. (2018). 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*, *39*(9), 763-816.
35. Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., . . . Tomaselli, G. F. (2010). ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *J Am Coll Cardiol*, *56*(24), 2051-2066.
36. Abramson, M. J., Puy, R. M., & Weiner, J. M. (2010). Injection allergen immunotherapy for asthma. *Cochrane Database Syst Rev*(8), CD001186.
37. Accord Healthcare Inc. (2015). Hydrochlorothiazide. *US Product Monograph*,
38. Achaogen Inc. (2018). Zemdri (plazomicin). *US Product Monograph*,
39. Actavis Kadian LLC. (2014). Kadian (morphine). *US Product Monograph*,
40. Actavis Pharma Company. (2017). Alendronate. *CA Product Monograph*,
41. Actavis Pharma Inc. (2015). Indapamide. *US Product Monograph*,
42. Actavis Pharma Inc. (2015). Nifedipine. *US Product Monograph*,
43. Actavis Pharma Inc. (2015). Trandolapril. *US Product Monograph*,
44. Actavis Pharma Inc. (2016). Propranolol *US Product Monograph*,
45. Actavis Pharma Inc. (2017). Cartia XT (diltiazem). *US Product Monograph*,
46. Actavis Pharma Inc. (2016). Sulindac. *US Product Monograph*,
47. Active Writing Group of the ACTIVE Investigators, Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., . . . Yusuf, S. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet*, *367*(9526), 1903-1912.
48. Adachi, K. (2006). Symptom diversity of patients with reflux esophagitis: Effect of omeprazole treatment. *J Clin Biochem Nutr*, *39*.
49. Adachi, K., Katsube, T., Kawamura, A., Takashima, T., Yuki, M., Amano, K., . . . Kinoshita, Y. (2000). CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. *Aliment Pharmacol Ther*, *14*(10), 1259-1266.

50. Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K. (2014). Chlorpromazine versus placebo for schizophrenia. *Cochrane Database Syst Rev*(1), CD000284.
51. Adams, C. E., Bergman, H., Irving, C. B., & Lawrie, S. (2013). Haloperidol versus placebo for schizophrenia. *Cochrane Database Syst Rev*(11), CD003082.
52. Adelman, J. L., Dale, A. L., Zwier, M. C., Bhatt, D., Chong, L. T., Zuckerman, D. M., & Grabe, M. (2011). Simulations of the alternating access mechanism of the sodium symporter Mhp1. *Biophys J*, *101*(10), 2399-2407.
53. Adelman, J. L., & Grabe, M. (2015). Simulating Current-Voltage Relationships for a Narrow Ion Channel Using the Weighted Ensemble Method. *J Chem Theory Comput*, *11*(4), 1907-1918.
54. Adelman, J. L., Sheng, Y., Choe, S., Abramson, J., Wright, E. M., Rosenberg, J. M., & Grabe, M. (2014). Structural determinants of water permeation through the sodium-galactose transporter vSGLT. *Biophys J*, *106*(6), 1280-1289.
55. Ades, P. A. (2001). Cardiac rehabilitation and secondary prevention of coronary heart disease. *N Engl J Med*, *345*(12), 892-902.
56. Adili, A., & Bhandari, M. (2018). Cochrane in CORR(R): Topical NSAIDs for Chronic Musculoskeletal Pain in Adults. *Clin Orthop Relat Res*, *476*(11), 2128-2134.
57. Adly, C., Straumanis, J., & Chesson, A. (1992). Fluoxetine Prophylaxis of Migraine. *Headache: The Journal of Head and Face Pain*, *32*(2), 101-104.
58. Afilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. *Heart*, *93*(8), 914-921.
59. Afshari, D., Rafizadeh, S., & Rezaei, M. (2012). A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. *Int J Neurosci*, *122*(2), 60-68.
60. Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012). Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, *141*(2 Suppl), e44S-88S.
61. Agrawal, N. M., Van Kerckhove, H. E., Erhardt, L. J., & Geis, G. S. (1995). Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. *Dig Dis Sci*, *40*(5), 1125-1131.
62. Agundez, J. A., Garcia-Martin, E., & Martinez, C. (2009). Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? *Expert Opin Drug Metab Toxicol*, *5*(6), 607-620.
63. Agusti, A., Edwards, L. D., Celli, B., Macnee, W., Calverley, P. M., Mullerova, H., . . . Vestbo, J. (2013). Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. *Eur Respir J*, *42*(3), 636-646.
64. Ahern, M. J., Reid, C., Gordon, T. P., McCredie, M., Brooks, P. M., & Jones, M. (1987). Does colchicine work? The results of the first controlled study in acute gout. *Aust N Z J Med*, *17*(3), 301-304.

65. Ahmed, F., Zafar, H. W., Buture, A., & Khalil, M. (2015). Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. *SpringerPlus*, 4(1), 589.
66. Aithal, G. P., Day, C. P., Leathart, J. B., & Daly, A. K. (2000). Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics*, 10(6), 511-518.
67. Akuta, N., Suzuki, F., Hirakawa, M., Kawamura, Y., Yatsuji, H., Sezaki, H., . . . Kumada, H. (2010). Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. *Hepatology*, 52(2), 421-429.
68. al Deeb, S. M., Biary, N., Bahou, Y., al Jaber, M., & Khoja, W. (1992). Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population). *Headache*, 32(9), 461-462.
69. Alangari, A. A. (2014). Corticosteroids in the treatment of acute asthma. *Ann Thorac Med*, 9(4), 187-192.
70. Albert, N. M., Fonarow, G. C., Yancy, C. W., Curtis, A. B., Stough, W. G., Gheorghide, M., . . . Walsh, M. N. (2010). Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). *Am Heart J*, 159(2), 238-244.
71. Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A., Jr., Criner, G. J., . . . Anthonisen, N. R. (2011). Azithromycin for prevention of exacerbations of COPD. *N Engl J Med*, 365(8), 689-698.
72. Aldekhail, N. M., Logue, J., McLoone, P., & Morrison, D. S. (2015). Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *Obes Rev*, 16(12), 1071-1080.
73. Aldrich, S. L., Poweleit, E. A., Prows, C. A., Martin, L. J., Strawn, J. R., & Ramsey, L. B. (2019). Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. *Front Pharmacol*, 10, 99.
74. Alenius, M., Wadelius, M., Dahl, M. L., Hartvig, P., Lindstrom, L., & Hammarlund-Udenaes, M. (2008). Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. *J Psychiatr Res*, 42(11), 884-893.
75. Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., 3rd, . . . Hawker, G. (2010). 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis*, 69(9), 1580-1588.
76. Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., . . . Wallentin, L. (2011). Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med*, 365(8), 699-708.
77. Alexopoulos, G. S., Murphy, C. F., Gunning-Dixon, F. M., Glatt, C. E., Latoussakis, V., Kelly, R. E., Jr., . . . Hoptman, M. J. (2009). Serotonin transporter polymorphisms,

- microstructural white matter abnormalities and remission of geriatric depression. *J Affect Disord*, 119(1-3), 132-141.
78. Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., & Pirmohamed, M. (2006). HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. *Pharmacogenomics*, 7(6), 813-818.
 79. Alimadadi, M., Seyyedmajidi, M., Amir Khanlou, S., Hafezi, A. A., Homapour, S., Vafaeimanesh, J., & Vakili, M. A. (2015). Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. *Iran J Kidney Dis*, 9(6), 427-432.
 80. Allen, M. H., Debanne, M., Lazignac, C., Adam, E., Dickinson, L. M., & Damsa, C. (2011). Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*, 168(4), 395-399.
 81. Allergan Inc. (2018). Fetzima (levomilnacipran). *CA Product Monograph*,
 82. Allergan Inc. (2019). Viibryd (vilazodone). *CA Product Monograph*,
 83. Allergan Pharma Co. (2017). Actonel/ Actonel DR (risedronate sodium). *CA Product Monograph*,
 84. Allergan Pharma Co. (2017). MacroBID (nitrofurantoin). *CA Product Monograph*,
 85. Allergan USA Inc. (2016). Vraylar (cariprazine) *US Product Monograph*,
 86. Allergan USA Inc. (2017). Saphris (asenapine). *US Product Monograph*,
 87. Allergan USA Inc. (2017). Viibryd (vilazodone). *US Product Monograph*,
 88. Allergan USA Inc. (2018). Actonel (risedronate sodium). *US Product Monograph*,
 89. Allergan USA Inc. (2018). Carafate (sucralfate). *US Product Monograph*,
 90. Allergan USA Inc. (2018). Monurol (fosfomycin). *US Product Monograph*,
 91. Allergan USA Inc. (2018). Vraylar (cariprazine). *US Product Monograph*,
 92. Allergan USA Inc. (2019). Celexa (citalopram). *US Product Monograph*,
 93. Allergan USA Inc. (2019). Ciprexal (escitalopram). *US Product Monograph*,
 94. Allergan USA Inc. (2019). Fetzima (levomilnacipran). *US Product Monograph*,
 95. Allescher, H. D., Bockenhoff, A., Knapp, G., Wienbeck, M., & Hartung, J. (2001). Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. *Scand J Gastroenterol*, 36(9), 934-941.
 96. Allgulander, C., Mangano, R., Zhang, J., Dahl, A. A., Lepola, U., Sjodin, I., & Emilien, G. (2004). Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. *Hum Psychopharmacol*, 19(6), 387-396.
 97. Allgulander, C., Nutt, D., Detke, M., Erickson, J., Spann, M., Walker, D., . . . Russell, J. (2008). A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. *J Psychopharmacol*, 22(4), 417-425.
 98. Allmond, J. M., Stuchbery, A. E., Beene, J. R., Galindo-Uribarri, A., Liang, J. F., Padilla-Rodal, E., . . . Yu, C. H. (2014). Double-magic nature of 132Sn and 208Pb through lifetime and cross-section measurements. *Phys Rev Lett*, 112(17), 172701.
 99. Almatica Pharma Inc. (2017). Naprelan (naproxen sodium). *US Product Monograph*,
 100. Almatica Pharma Inc. (2017). Tenormin (atenolol). *US Product Monograph*,
 101. Almatica Pharma Inc. (2017). Zestril (lisinopril). *US Product Monograph*,

102. Almatica Pharma Inc. (2018). Adalat CC (nifedipine ER). *US Product Monograph*,
103. Almatica Pharma Inc. (2018). Macrobid (nitrofurantoin). *US Product Monograph*,
104. Almatica Pharma Inc. (2018). Macrochantin (nitrofurantoin). *US Product Monograph*,
105. Alstadhaug, K. B., Odeh, F., Salvesen, R., & Bekkelund, S. I. (2010). Prophylaxis of migraine with melatonin: a randomized controlled trial. *Neurology*, 75(17), 1527-1532.
106. Altman, R. D., Honig, S., Levin, J. M., & Lightfoot, R. W. (1988). Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. *J Rheumatol*, 15(9), 1422-1426.
107. Alvarez-Sabin, J., Quintana, M., Hernandez-Presa, M. A., Alvarez, C., Chaves, J., & Ribo, M. (2009). Therapeutic interventions and success in risk factor control for secondary prevention of stroke. *J Stroke Cerebrovasc Dis*, 18(6), 460-465.
108. Amate, J. M., Lopez-Cuadrado, T., Almendro, N., Bouza, C., Saz-Parkinson, Z., Rivas-Ruiz, R., & Gonzalez-Canudas, J. (2015). Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. *Int J Clin Pract*, 69(3), 292-304.
109. Ambrosioni, E., Borghi, C., & Magnani, B. (1995). The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. *N Engl J Med*, 332(2), 80-85.
110. Amedra Pharmaceuticals LLC. (2017). Dexedrine (dextroamphetamine). *US Product Monograph*,
111. American Diabetes, A. (2017). 8. Pharmacologic Approaches to Glycemic Treatment. *Diabetes Care*, 40(Suppl 1), S64-S74.
112. American Diabetes, A. (2017). Erratum. Pharmacologic Approaches to Glycemic Treatment. Sec. 8. In Standards of Medical Care in Diabetes-2017. *Diabetes Care* 2017;40(Suppl. 1);S64-S74. *Diabetes Care*, 40(7), 985.
113. American Diabetes, A. (2019). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. *Diabetes Care*, 42(Suppl 1), S90-S102.
114. American Diabetes, A. (2019). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. *Diabetes Care*, 42(Suppl 1), S103-S123.
115. American Diabetes, A. (2019). 12. Older Adults: Standards of Medical Care in Diabetes-2019. *Diabetes Care*, 42(Suppl 1), S139-S147.
116. American Diabetes, A. (2019). 13. Children and Adolescents: Standards of Medical Care in Diabetes-2019. *Diabetes Care*, 42(Suppl 1), S148-S164.
117. American Diabetes, A. (2019). 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2019. *Diabetes Care*, 42(Suppl 1), S165-S172.
118. American Diabetes Association. (2014). Standards of medical care in diabetes--2014. *Diabetes Care*, 37 Suppl 1, S14-80.
119. American Diabetes Association. (2017). Standards of medical care in diabetes—2017 abridged for primary care providers. *Clinical Diabetes*, 35(1), 5-26.
120. American Geriatrics Society Beers Criteria Update Expert Panel. (2015). American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*, 63(11), 2227-2246.

121. American Psychiatric Association: DSM-5 Task Force. (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. *APA Clinical Guideline*,
122. American Society of Health-System Pharmacists. (2017). Methyldopa. *US Product Monograph*,
123. American Society of Health-Systems Pharmacists. (2018). Probenecid. *US Product Monograph*,
124. Amgen Canada Inc. (2019). Repatha (evolocumab). *CA Product Monograph*,
125. Amgen Inc. (2015). Repatha (evolocumab). *US Product Monograph*,
126. Amgen Inc. (2018). Prolia (denosumab). *US Product Monograph*,
127. Amiel, S. A., Pursey, N., Higgins, B., Dawoud, D., & Guideline Development, G. (2015). Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance. *BMJ*, *351*, h4188.
128. Amiri, S., Farhang, S., Ghoreishizadeh, M. A., Malek, A., & Mohammadzadeh, S. (2012). Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. *Hum Psychopharmacol*, *27*(1), 76-81.
129. Amneal Biosciences LLC. (2018). Methylprednisolone Sodium Succinate. *US Product Monograph*,
130. Amneal Pharmaceuticals. (2013). Esomeprazole Strontium. *US Product Monograph*,
131. Amneal Pharmaceuticals LLC. (2019). Colestipol. *US Product Monograph*,
132. Amneal Pharmaceuticals of New York LLC. (2018). Acebutolol hydrochloride *US Product Monograph*,
133. Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Jr., Ganiats, T. G., Holmes, D. R., Jr., . . . Zieman, S. J. (2014). 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*, *130*(25), 2354-2394.
134. Amsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., Li, S. Q., Mao, J. J., & DeRubeis, R. J. (2015). Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. *J Affect Disord*, *185*, 31-37.
135. Amsterdam, J. D., & Shults, J. (2010). Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. *Am J Psychiatry*, *167*(7), 792-800.
136. Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., . . . Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. *Clin Pharmacol Ther*, *103*(2), 210-216.
137. Amstutz, U., Ross, C. J., Castro-Pastrana, L. I., Rieder, M. J., Shear, N. H., Hayden, M. R., & Carleton, B. C. (2013). HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. *Clin Pharmacol Ther*, *94*(1), 142-149.
138. Amstutz, U., Shear, N. H., Rieder, M. J., Hwang, S., Fung, V., Nakamura, H., . . . Carleton, B. C. (2014). Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to

- reduce the risk of carbamazepine-induced hypersensitivity reactions. *Epilepsia*, 55(4), 496-506.
139. An, D. M., Wu, X. T., Hu, F. Y., Yan, B., Stefan, H., & Zhou, D. (2010). Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. *Epilepsy Res*, 92(2-3), 226-230.
140. Anderson, A., & Singh, J. A. (2010). Pegloticase for chronic gout. *Cochrane Database Syst Rev*(3), CD008335.
141. Anderson, D., Engbers, J. D., Heath, N. C., Bartoletti, T. M., Mehaffey, W. H., Zamponi, G. W., & Turner, R. W. (2013). The Cav3-Kv4 complex acts as a calcium sensor to maintain inhibitory charge transfer during extracellular calcium fluctuations. *J Neurosci*, 33(18), 7811-7824.
142. Anderson, D. E., Kew, K. M., & Boyter, A. C. (2015). Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. *Cochrane Database Syst Rev*(8), CD011397.
143. Anderson, J. L., Horne, B. D., Stevens, S. M., Woller, S. C., Samuelson, K. M., Mansfield, J. W., . . . Carlquist, J. F. (2012). A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). *Circulation*, 125(16), 1997-2005.
144. Anderson, T. J., Boden, W. E., Desvigne-Nickens, P., Fleg, J. L., Kashyap, M. L., McBride, R., . . . Investigators, A.-H. (2014). Safety profile of extended-release niacin in the AIM-HIGH trial. *N Engl J Med*, 371(3), 288-290.
145. Anderson, T. J., Gregoire, J., Hegele, R. A., Couture, P., Mancini, G. B., McPherson, R., . . . Ur, E. (2013). 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol*, 29(2), 151-167.
146. Anderson, T. J., Gregoire, J., Hegele, R. A., Couture, P., Mancini, G. B., McPherson, R., . . . Ur, E. (2014). Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. *Can J Cardiol*, 30(4), 377-380.
147. Anderson, T. J., Gregoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., . . . Ward, R. (2016). 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol*, 32(11), 1263-1282.
148. Anderson, T. J., Mancini, G. B., Genest, J., Jr., Gregoire, J., Lonn, E. M., & Hegele, R. A. (2015). The new dyslipidemia guidelines: what is the debate? *Can J Cardiol*, 31(5), 605-612.
149. Andersson, P. G., Dahl, S., Hansen, J. H., Hansen, P. E., Hedman, C., Kristensen, T. N., & de Fine Olivarius, B. (1983). Prophylactic treatment of classical and non-classical migraine with metoprolol--a comparison with placebo. *Cephalalgia*, 3(4), 207-212.
150. Ando, T., Ishikawa, T., Kokura, S., Naito, Y., Yoshida, N., & Yoshikawa, T. (2008). Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. *Dig Dis Sci*, 53(4), 933-937.

151. Ando, T., Kato, H., Sugimoto, N., Nagao, Y., Seto, N., Hongo, H., . . . Yoshikawa, T. (2005). A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. *Dig Dis Sci*, *50*(9), 1625-1631.
152. Andrade, C. (2018). Relative Efficacy and Acceptability of Antidepressant Drugs in Adults With Major Depressive Disorder: Commentary on a Network Meta-Analysis. *J Clin Psychiatry*, *79*(2).
153. Andrade, J. G., Verma, A., Mitchell, L. B., Parkash, R., Leblanc, K., Atzema, C., . . . Committee, C. C. S. A. F. G. (2018). 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. *Can J Cardiol*, *34*(11), 1371-1392.
154. Andreassen, T. N., Eftedal, I., Klepstad, P., Davies, A., Bjordal, K., Lundstrom, S., . . . Dale, O. (2012). Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. *Eur J Clin Pharmacol*, *68*(1), 55-64.
155. Andres, M., Sivera, F., Falzon, L., Buchbinder, R., & Carmona, L. (2014). Dietary supplements for chronic gout. *Cochrane Database Syst Rev*(10), CD010156.
156. Ang, J. S., Aloise, M. N., Dawes, D., Dempster, M. G., Fraser, R., Paterson, A., . . . Katzov-Eckert, H. (2018). Evaluation of buccal swabs for pharmacogenetics. *BMC Res Notes*, *11*(1), 382.
157. Ang, T. L., Fock, K. M., Teo, E. K., Chan, Y. H., Ng, T. M., Chua, T. S., & Tan, J. Y. (2006). Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. *J Gastroenterol*, *41*(7), 647-653.
158. Angiolillo, D. J., Gibson, C. M., Cheng, S., Ollier, C., Nicolas, O., Bergougnan, L., . . . Dubar, M. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. *Clin Pharmacol Ther*, *89*(1), 65-74.
159. Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., . . . Faxon, D. P. (2016). Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. *Circ Cardiovasc Interv*, *9*(11).
160. Anglicheau, D., Le Corre, D., Lechaton, S., Laurent-Puig, P., Kreis, H., Beaune, P., . . . Thervet, E. (2005). Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. *Am J Transplant*, *5*(3), 595-603.
161. Anglin, R., Yuan, Y., Moayyedi, P., Tse, F., Armstrong, D., & Leontiadis, G. I. (2014). Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. *Am J Gastroenterol*, *109*(6), 811-819.
162. ANI Pharmaceuticals Inc. (2015). Etodolac. *US Product Monograph*,
163. ANI Pharmaceuticals Inc. (2017). Fluvoxamine maleate. *US Product Monograph*,
164. ANI Pharmaceuticals Inc. (2017). Reglan (metoclopramide hydrochloride). *US Product Monograph*,

165. ANI Pharmaceuticals Inc. (2018). Atacand (candesartan). *US Product Monograph*,
166. ANI Pharmaceuticals Inc. (2018). Cholestyramine. *US Product Monograph*,
167. ANI Pharmaceuticals Inc. (2018). Inderal (propranolol hydrochloride). *US Product Monograph*,
168. ANI Pharmaceuticals Inc. (2018). Lithobid (lithium). *US Product Monograph*,
169. ANI Pharmaceuticals Inc. (2018). Terbutaline Sulfate. *US Product Monograph*,
170. Ansari, A., & Osser, D. N. (2010). The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. *Harv Rev Psychiatry*, 18(1), 36-55.
171. Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., . . . Evins, A. E. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet*, 387(10037), 2507-2520.
172. Antithrombotic Trialists, C. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*, 324(7329), 71-86.
173. Anton, R. F., Oroszi, G., O'Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. *Arch Gen Psychiatry*, 65(2), 135-144.
174. Antoniou, G. A., Fisher, R. K., Georgiadis, G. S., Antoniou, S. A., & Torella, F. (2014). Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. *Vascul Pharmacol*, 63(2), 79-87.
175. Antony, J. T., Elias, A., Chacko, F., & Rajan, B. (2008). Is clozapine safe in patients with preexisting epilepsy? A report of 2 cases. *J Clin Psychiatry*, 69(2), 328-329.
176. Aoyama, N., Tanigawara, Y., Kita, T., Sakai, T., Shirakawa, K., Shirasaka, D., . . . Kasuga, M. (1999). Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. *J Gastroenterol*, 34 Suppl 11, 80-83.
177. Aphenia Pharma Solutions. (2017). IBU (ibuprofen). *US Product Monograph*,
178. Aphenia Pharma Solutions. (2018). Toprol XL (metoprolol succinate) *US Product Monograph*,
179. Apotex Inc. (1992). Apo-Theo (theophylline). *CA Product Monograph*,
180. Apotex Inc. (2010). Apo-Piroxicam (piroxicam). *CA Product Monograph*,
181. Apotex Inc. (2010). Apo-Tolbutamide. *CA Product Monograph*,
182. Apotex Inc. (2012). Apo-Methoprazine (methotrimeprazine maleate). *CA Product Monograph*,
183. Apotex Inc. (2013). Apo-Capto (captopril). *CA Product Monograph*,
184. Apotex Inc. (2013). Apo-Lithium Carbonate. *CA Product Monograph*,
185. Apotex Inc. (2013). Apo-Triazide (triamterene / hydrochlorothiazide). *CA Product Monograph*,

186. Apotex Inc. (2014). Apo-Amoxiclav (amoxicillin / clavulanic acid). *CA Product Monograph*,
187. Apotex Inc. (2014). Apo-Carbamazepine. *CA Product Monograph*,
188. Apotex Inc. (2014). Apo-Hydro (hydrochlorothiazide). *CA Product Monograph*,
189. Apotex Inc. (2015). Apo-Clarithromycin. *CA Product Monograph*,
190. Apotex Inc. (2015). Apo-Indapamide. *CA Product Monograph*,
191. Apotex Inc. (2015). Apo-Meloxicam *CA Product Monograph*,
192. Apotex Inc. (2015). Apo-Prednisone. *CA Product Monograph*,
193. Apotex Inc. (2015). Apo-Terazosin. *CA Product Monograph*,
194. Apotex Inc. (2016). Apo-Fosinopril. *CA Product Monograph*,
195. Apotex Inc. (2016). Apo-Pravastatin. *CA Product Monograph*,
196. Apotex Inc. (2016). Apo-Ranitidine. *CA Product Monograph*,
197. Apotex Inc. (2017). Apo-Bisoprolol. *CA Product Monograph*,
198. Apotex Inc. (2017). Apo-Ibuprofen. *CA Product Monograph*,
199. Apotex Inc. (2017). Apo-Sulfatrim (sulfamethoxazole / trimethoprim). *CA Product Monograph*,
200. Apotex Inc. (2018). Apo-Desvenlafaxine. *CA Product Monograph*,
201. Apotex Inc. (2018). Diltiaz (diltiazem hydrochloride) *CA Product Monograph*,
202. Apotex Inc. (2019). Apo-amitriptyline. *CA Product Monograph*,
203. Appco Pharma LLC. (2018). Hydralazine. *US Product Monograph*,
204. Appleton, S., Poole, P., Smith, B., Veale, A., Lasserson, T. J., & Chan, M. M. (2006). Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(3), CD001104.
205. Aprelia Pharmaceuticals LLC. (2018). Spritam (levetiracetam). *US Product Monograph*,
206. Aqua Pharmaceuticals. (2018). Acticlate (doxycycline hyclate). *US Product Monograph*,
207. AR Scientific inc. (2018). Bactrim (sulfamethoxazole / trimethoprim). *US Product Monograph*,
208. Arafa, M. H., & Atteia, H. H. (2018). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity. *Toxicol Appl Pharmacol*, 346, 37-44.
209. Aralez Pharmaceuticals US Inc. (2016). Metoprolol succinate. *US Product Monograph*,
210. Aralez Pharmaceuticals US Inc. (2016). Toprol XL (metoprolol succinate). *US Product Monograph*,
211. Arbor Pharmaceuticals. (2016). Edarbi (azilsartan kamedoxomil). *US Product Monograph*,
212. Arbor Pharmaceuticals. (2018). Ery-tab (erythromycin). *US Product Monograph*,
213. Areberg, J., Petersen, K. B., Chen, G., & Naik, H. (2014). Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. *Basic Clin Pharmacol Toxicol*, 115(6), 552-559.
214. Arfe, A., Scotti, L., Varas-Lorenzo, C., Nicotra, F., Zambon, A., Kollhorst, B., . . . Safety of Non-steroidal Anti-inflammatory Drugs Project, C. (2016). Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. *BMJ*, 354, i4857.

215. Argalacsova, S., Slanar, O., Vitek, P., Tesarova, P., Bakhouche, H., DraZdakova, M., . . . PertuZelka, L. (2015). Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer. *Physiol Res*, *64 Suppl 4*, S539-547.
216. Ariansen, I., Abdelnoor, M., Tveit, A., & Gjesdal, K. (2010). Guidelines' criteria for rate control in atrial fibrillation: are they useful? *Scand Cardiovasc J*, *44*(3), 132-138.
217. Arias, B., Catalan, R., Gasto, C., Gutierrez, B., & Fananas, L. (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. *J Clin Psychopharmacol*, *23*(6), 563-567.
218. Armstrong, C. (2014). JNC8 guidelines for the management of hypertension in adults. *Am Fam Physician*, *90*(7), 503-504.
219. Armstrong, D., & Marchetti, N. (2008). Pharmacist-specific guidelines for the medical management of GERD in adults. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, *141*(1 suppl), S10-S15. e13.
220. Armstrong, D., Marshall, J. K., Chiba, N., Enns, R., Fallone, C. A., Fass, R., . . . Canadian Association of Gastroenterology, G. C. G. (2005). Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. *Can J Gastroenterol*, *19*(1), 15-35.
221. Armstrong, D., & Nakhla, N. (2016). Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist. *Pharm Pract (Granada)*, *14*(4), 868.
222. Armstrong, D., Veldhuyzen van Zanten, S. J., Barkun, A. N., Chiba, N., Thomson, A. B., Smyth, S., . . . White, R. J. (2005). Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study. *Aliment Pharmacol Ther*, *21*(10), 1189-1202.
223. Arnason, T., & Mansell, K. (2017). Diabetes Mellitus. In B. Jovaisas (Ed.), *Therapeutics* (
224. Arnold, S. V., Spertus, J. A., Masoudi, F. A., Daugherty, S. L., Maddox, T. M., Li, Y., . . . Chan, P. S. (2013). Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. *J Am Coll Cardiol*, *62*(19), 1791-1801.
225. Arranz, M. J., Dawson, E., Shaikh, S., Sham, P., Sharma, T., Aitchison, K., . . . Collier, D. A. (1995). Cytochrome P4502D6 genotype does not determine response to clozapine. *Br J Clin Pharmacol*, *39*(4), 417-420.
226. Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(11), CD006633.
227. Ashina, M., Dodick, D., Goadsby, P. J., Reuter, U., Silberstein, S., Zhang, F., . . . Lenz, R. A. (2017). Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. *Neurology*, *89*(12), 1237-1243.
228. Ashtari, F., Shaygannejad, V., & Akbari, M. (2008). A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. *Acta Neurol Scand*, *118*(5), 301-305.

229. Asmal, L., Flegar, S. J., Wang, J., Rummel-Kluge, C., Komossa, K., & Leucht, S. (2013). Quetiapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(11), CD006625.
230. Asnavandi, M., Zargar, M., Vaziri, F., Jamnani, F. R., Gharibzadeh, S., Fateh, A., & Siadat, S. D. (2017). EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. *Genes Immun, 18*(3), 144-151.
231. Association, C. P. (2019). Antacid, Antiflatulent and Antireflux [CPhA monograph]. In *RxTx* (
232. AstraZeneca Canada Inc. (2012). Zomig (zolmitriptan). *CA Product Monograph,*
233. AstraZeneca Canada Inc. (2013). Accolate (zafirlukast). *CA Product Monograph,*
234. AstraZeneca Canada Inc. (2013). Pulmicort Nebuamp (budesonide). *CA Product Monograph,*
235. AstraZeneca Canada Inc. (2014). Merrem (meropenem). *CA Product Monograph,*
236. AstraZeneca Canada Inc. (2015). Plendil (felodipine). *CA Product Monograph,*
237. AstraZeneca Canada Inc. (2015). Seroquel (quetiapine fumarate). *CA Product Monograph,*
238. AstraZeneca Canada Inc. (2015). Seroquel XR (quetiapine fumarate). *CA Product Monograph,*
239. AstraZeneca Canada Inc. (2016). Atacand (candesartan). *CA Product Monograph,*
240. AstraZeneca Canada Inc. (2016). Brilinta (ticagrelor). *CA Product Monograph,*
241. AstraZeneca Canada Inc. (2016). Nexium (esomeprazole). *CA Product Monograph,*
242. AstraZeneca Canada Inc. (2016). Symbicort Turbuhaler (budesonide / formoterol fumarate dihydrate). *CA Product Monograph,*
243. AstraZeneca Canada Inc. (2016). Tenormin (atenolol). *CA Product Monograph,*
244. AstraZeneca Canada Inc. (2017). Alvesco (ciclesonide). *CA Product Monograph,*
245. AstraZeneca Canada Inc. (2017). Bydureon (exenatide). *CA Product Monograph,*
246. AstraZeneca Canada Inc. (2017). Crestor (rosuvastatin). *CA Product Monograph,*
247. Astrazeneca Canada Inc. (2017). Daxas (roflumilast). *CA Product Monograph,*
248. AstraZeneca Canada Inc. (2017). Duaklir Genuair (aclidinium bromide/formoterol fumarate dihydrate). *CA Product Monograph,*
249. AstraZeneca Canada Inc. (2017). Losec (omeprazole). *CA Product Monograph,*
250. AstraZeneca Canada Inc. (2017). Nexium (esomeprazole). *CA Product Monograph,*
251. AstraZeneca Canada Inc. (2017). Pulmicort Turbuhaler (budesonide). *CA Product Monograph,*
252. AstraZeneca Canada Inc. (2017). Tenormin (atenolol). *CA Product Monograph,*
253. AstraZeneca Canada Inc. (2017). Tudorza Genuair (aclidinium bromide). *CA Product Monograph,*
254. Astrazeneca Canada Inc. (2018). Bevespi Aerosphere (glycopyrronium / formoterol fumarate dihydrate). *CA Product Monograph,*
255. AstraZeneca Canada Inc. (2018). Bricanyl Turbuhaler (terbutaline sulfate). *CA Product Monograph,*

256. AstraZeneca Canada Inc. (2018). Oxeze Turbuhaler (formoterol fumarate dihydrate). *CA Product Monograph*,
257. AstraZeneca Canada Inc. (2018). Vimovo (naproxen / esomeprazole). *CA Product Monograph*,
258. AstraZeneca Canada Inc. (2019). Brilinta (ticagrelor). *CA Product Monograph*,
259. AstraZeneca Canada Inc. (2019). Fasenra (benralizumab). *CA Product Monograph*,
260. AstraZeneca Pharmaceuticals LP. (2015). Byetta (exenatide). *US Product Monograph*,
261. AstraZeneca Pharmaceuticals LP. (2016). Pulmicort Flexhaler (budesonide). *US Product Monograph*,
262. AstraZeneca Pharmaceuticals LP. (2017). Bevespi Aerosphere (glycopyrrolate / formoterol fumarate). *US Product Monograph*,
263. AstraZeneca Pharmaceuticals LP. (2017). Crestor (rosuvastatin). *US Product Monograph*,
264. AstraZeneca Pharmaceuticals LP. (2017). Seroquel (quetiapine). *US Product Monograph*,
265. AstraZeneca Pharmaceuticals LP. (2017). Symbicort (budesonide / formoterol fumarate dihydrate). *US Product Monograph*,
266. AstraZeneca Pharmaceuticals LP. (2018). Brilinta (ticagrelor). *US Product Monograph*,
267. AstraZeneca Pharmaceuticals LP. (2018). Bydureon (exenatide extended release). *US Product Monograph*,
268. AstraZeneca Pharmaceuticals LP. (2018). Crestor (rosuvastatin). *US Product Monograph*,
269. AstraZeneca Pharmaceuticals LP. (2018). Daliresp (roflumilast). *US Product Monograph*,
270. AstraZeneca Pharmaceuticals LP. (2018). Farxiga (dapagliflozin). *US Product Monograph*,
271. AstraZeneca Pharmaceuticals LP. (2018). Nexium (esomeprazole). *US Product Monograph*,
272. AstraZeneca Pharmaceuticals LP. (2018). Onglyza (saxagliptin). *US Product Monograph*,
273. AstraZeneca Pharmaceuticals LP. (2018). Pulmicort Flexhaler (budesonide). *US Product Monograph*,
274. AstraZeneca Pharmaceuticals LP. (2018). Pulmicort Respules (budesonide) *US Product Monograph*,
275. AstraZeneca Pharmaceuticals LP. (2018). Seroquel XR (quetiapine fumarate). *US Product Monograph*,
276. AstraZeneca Pharmaceuticals LP. (2018). Tudorza Pressair (aclidinium bromide). *US Product Monograph*,
277. AstraZeneca Pharmaceuticals LP. (2019). Fasenra (benralizumab). *US Product Monograph*,
278. Atasayar, G., Eryilmaz, I. E., Karli, N., Egeli, U., Zarifoglu, M., Cecener, G., . . . Can, F. E. (2016). Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. *J Neurol Sci*, 366, 149-154.
279. Atherton, J. J., Sindone, A., De Pasquale, C. G., Driscoll, A., MacDonald, P. S., Hopper, I., . . . Branagan, M. (2018). National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. *Med J Aust*.
280. Atkinson, J. H., Slater, M. A., Capparelli, E. V., Wallace, M. S., Zisook, S., Abramson, I., . . . Garfin, S. R. (2007). Efficacy of noradrenergic and serotonergic antidepressants in

- chronic back pain: a preliminary concentration-controlled trial. *J Clin Psychopharmacol*, 27(2), 135-142.
281. Atmaca, M., Kuloglu, M., Tezcan, E., & Unal, A. (2002). Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. *Hum Psychopharmacol*, 17(8), 401-405.
282. Aton Pharma Inc. (2012). Edecrin (ethacrynic acid). *US Product Monograph*,
283. Aubier, M. (1988). Pharmacotherapy of respiratory muscles. *Clin Chest Med*, 9(2), 311-324.
284. Aubrun, F., Zahr, N., Langeron, O., Boccheciampe, N., Cozic, N., Belin, L., . . . Riou, B. (2018). Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study. *Eur J Anaesthesiol*, 35(7), 496-504.
285. Augusto, M., Greene, M., Touya, M., Sweeney, S. M., & Waters, H. (2018). Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. *J Comp Eff Res*, 7(7), 627-636.
286. Aung, P. P., Maxwell, H. G., Jepson, R. G., Price, J. F., & Leng, G. C. (2007). Lipid-lowering for peripheral arterial disease of the lower limb. *Cochrane Database Syst Rev*(4), Cd000123.
287. Auro Pharma Inc. (2015). Auro-Cefuroxime. *CA Product Monograph*,
288. Auro Pharma Inc. (2016). Auro-Levofloxacin. *CA Product Monograph*,
289. Auro Pharma Inc. (2018). Ampicillin. *CA Product Monograph*,
290. Auro Pharma Inc. (2018). Auro (ramipril). *CA Product Monograph*,
291. Aurobindo Pharma Limited. (2017). Torsemide. *US Product Monograph*,
292. Aurobindo Pharma Limited. (2018). Cefprozil. *US Product Monograph*,
293. Aurobindo Pharma Limited. (2018). Cefuroxime Axetil. *US Product Monograph*,
294. Aurora, S. K., Dodick, D. W., Diener, H. C., DeGryse, R. E., Turkel, C. C., Lipton, R. B., & Silberstein, S. D. (2014). OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. *Acta Neurol Scand*, 129(1), 61-70.
295. Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., . . . Group, P. C. M. S. (2010). OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia*, 30(7), 793-803.
296. Avula, B., Wang, Y. H., Wang, M., Smillie, T. J., & Khan, I. A. (2012). Simultaneous determination of sesquiterpenes and pyrrolizidine alkaloids from the rhizomes of *Petasites hybridus* (L.) G.M. et Sch. and dietary supplements using UPLC-UV and HPLC-TOF-MS methods. *J Pharm Biomed Anal*, 70, 53-63.
297. Axelsson, I., Naumburg, E., Prietsch, S. O., & Zhang, L. (2019). Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. *Cochrane Database Syst Rev*, 6, CD010126.
298. Ayala, G., Galvan-Portillo, M., Chihu, L., Fierros, G., Sanchez, A., Carrillo, B., . . . Silva-Sanchez, J. (2011). Resistance to antibiotics and characterization of *Helicobacter pylori* strains isolated from antrum and body from adults in Mexico. *Microb Drug Resist*, 17(2), 149-155.

299. Azuma, J., Hasunuma, T., Kubo, M., Miyatake, M., Koue, T., Higashi, K., . . . Hara, S. (2012). The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. *Eur J Clin Pharmacol*, *68*(1), 29-37.
300. Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., . . . Kawase, I. (2013). NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. *Eur J Clin Pharmacol*, *69*(5), 1091-1101.
301. Bader, L. A., & Elewa, H. (2016). The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. *11*(12), e0168732.
302. Bae, J. W., Lee, K. Y., Choi, S. Y., Lee, S. H., Park, H. J., & Kim, U. K. (2008). Molecular analysis of mitochondrial gene mutations in Korean patients with nonsyndromic hearing loss. *Int J Mol Med*, *22*(2), 175-180.
303. Bagger, J. P., Helligsoe, P., Randsbaek, F., Kimose, H. H., & Jensen, B. S. (1997). Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. *Circulation*, *95*(2), 411-414.
304. Baghdady, N. T., Banik, S., Swartz, S. A., & McIntyre, R. S. (2009). Psychotropic drugs and renal failure: translating the evidence for clinical practice. *Adv Ther*, *26*(4), 404-424.
305. Bahr, R., Lopez, A., & Rey, J. A. (2019). Intranasal Esketamine (Spravato(TM)) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant. *P T*, *44*(6), 340-375.
306. Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., . . . Zanchetti, A. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*, *373*(9678), 1849-1860.
307. Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., . . . Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*, *366*(9493), 1267-1278.
308. Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., . . . Collins, R. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*, *377*(9784), 2181-2192.
309. Bailey, K. M., Romaine, S. P., Jackson, B. M., Farrin, A. J., Efthymiou, M., Barth, J. H., . . . Balmforth, A. J. (2010). Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. *Circ Cardiovasc Genet*, *3*(3), 276-285.
310. Bailey, M. A., Grabe, M., & Devor, D. C. (2010). Characterization of the PCMB5-dependent modification of KCa3.1 channel gating. *J Gen Physiol*, *136*(4), 367-387.
311. Bakker, P. R., van Harten, P. N., & van Os, J. (2008). Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. *Mol Psychiatry*, *13*(5), 544-556.

312. Balant-Gorgia, A. E., Schulz, P., Dayer, P., Balant, L., Kubli, A., Gertsch, C., & Garrone, G. (1982). Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. *Arch Psychiatr Nervenkr (1970)*, 232(3), 215-222.
313. Baldwin, D., Zander, J., Munoz, C., Raghu, P., DeLange-Hudec, S., Lee, H., . . . Molitch, M. (2012). A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. *Diabetes Care*, 35(10), 1970-1974.
314. Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., . . . Wittchen, H. U. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. *J Psychopharmacol*, 28(5), 403-439.
315. Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016). The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. *J Psychopharmacol*, 30(3), 242-252.
316. Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007). Discontinuation symptoms in depression and anxiety disorders. *Int J Neuropsychopharmacol*, 10(1), 73-84.
317. Baldwin, D. S., Waldman, S., & Allgulander, C. (2011). Evidence-based pharmacological treatment of generalized anxiety disorder. *Int J Neuropsychopharmacol*, 14(5), 697-710.
318. Baldwin, R. M., Ohlsson, S., Pedersen, R. S., Mwinyi, J., Ingelman-Sundberg, M., Eliasson, E., & Bertilsson, L. (2008). Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. *Br J Clin Pharmacol*, 65(5), 767-774.
319. Bally, M., Dendukuri, N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., & Brophy, J. M. (2017). Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. *BMJ*, 357, j1909.
320. Balyan, R., Mecoli, M., Venkatasubramanian, R., Chidambaran, V., Kamos, N., Clay, S., . . . Sadhasivam, S. (2017). CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. *Pharmacogenomics*, 18(4), 337-348.
321. Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., . . . Taylor, E. (2006). Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. *Eur Child Adolesc Psychiatry*, 15(8), 476-495.
322. Banaschewski, T., Roessner, V., Dittmann, R. W., Santosh, P. J., & Rothenberger, A. (2004). Non-stimulant medications in the treatment of ADHD. *Eur Child Adolesc Psychiatry*, 13 Suppl 1, I102-116.
323. Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. *Int J Neuropsychopharmacol*, 13(3), 305-320.

324. Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. E. (2014). The diagnosis of and treatment recommendations for anxiety disorders. *Dtsch Arztebl Int*, *111*(27-28), 473-480.
325. Bandelow, B., Reitt, M., Rover, C., Michaelis, S., Gorlich, Y., & Wedekind, D. (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. *Int Clin Psychopharmacol*, *30*(4), 183-192.
326. Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Ruther, E. (2007). Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. *World J Biol Psychiatry*, *8*(3), 175-187.
327. Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., . . . Ptsd. (2012). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. *Int J Psychiatry Clin Pract*, *16*(2), 77-84.
328. Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., Zohar, J., . . . Vega, J. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. *World J Biol Psychiatry*, *9*(4), 248-312.
329. Bangalore, S., Fakhri, R., Toklu, B., Ogedegbe, G., Weintraub, H., & Messerli, F. H. (2016). Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. *Mayo Clin Proc*, *91*(1), 51-60.
330. Bangalore, S., Makani, H., Radford, M., Thakur, K., Toklu, B., Katz, S. D., . . . Messerli, F. H. (2014). Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med*, *127*(10), 939-953.
331. Bangalore, S., Steg, G., Deedwania, P., Crowley, K., Eagle, K. A., Goto, S., . . . Bhatt, D. L. (2012). beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. *Jama*, *308*(13), 1340-1349.
332. Banham, L., & Gilbody, S. (2010). Smoking cessation in severe mental illness: what works? *Addiction*, *105*(7), 1176-1189.
333. Bank, J. (1994). A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. *Headache*, *34*(8), 476-478.
334. Bank, P. C. D., Caudle, K. E., Swen, J. J., Gammal, R. S., Whirl-Carrillo, M., Klein, T. E., . . . Guchelaar, H. J. (2018). Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. *Clin Pharmacol Ther*, *103*(4), 599-618.
335. Bannuru, R. R., Schmid, C. H., Kent, D. M., Vaysbrot, E. E., Wong, J. B., & McAlindon, T. E. (2015). Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. *Ann Intern Med*, *162*(1), 46-54.
336. Banzi, R., Cusi, C., Randazzo, C., Sterzi, R., Tedesco, D., & Moja, L. (2015). Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. *Cochrane Database Syst Rev*, *4*, CD002919.

337. Baraf, H. S., Becker, M. A., Gutierrez-Urena, S. R., Treadwell, E. L., Vazquez-Mellado, J., Rehrig, C. D., . . . Yood, R. A. (2013). Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. *Arthritis Res Ther*, *15*(5), R137.
338. Barbui, C., Signoretti, A., Mule, S., Boso, M., & Cipriani, A. (2009). Does the addition of a second antipsychotic drug improve clozapine treatment? *Schizophr Bull*, *35*(2), 458-468.
339. Bardhan, K., Bayerdorffer, E., Veldhuyzen Van Zanten, S. J., Lind, T., Megraud, F., Delchier, J. C., . . . Zeijlon, L. (2000). The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure *Helicobacter pylori* infection. *Helicobacter*, *5*(4), 196-201.
340. Bardin, T., Keenan, R. T., Khanna, P. P., Kopicko, J., Fung, M., Bhakta, N., . . . So, A. (2017). Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). *Ann Rheum Dis*, *76*(5), 811-820.
341. Barkun, A. N., Bardou, M., Kuipers, E. J., Sung, J., Hunt, R. H., Martel, M., & Sinclair, P. (2010). International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med*, *152*(2), 101-113.
342. Barkun, A. N., Crott, R., Fallone, C. A., Kennedy, W. A., Lachaine, J., Levinton, C., . . . Nevin, K. (2010). A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care. *Can J Gastroenterol*, *24*(8), 489-498.
343. Barnes, P. J. (2006). Theophylline for COPD. *Thorax*, *61*(9), 742-744.
344. Barnes, P. J. (2013). New anti-inflammatory targets for chronic obstructive pulmonary disease. *Nat Rev Drug Discov*, *12*(7), 543-559.
345. Barnett, S. D., Kramer, M. L., Casat, C. D., Connor, K. M., & Davidson, J. R. (2002). Efficacy of olanzapine in social anxiety disorder: a pilot study. *J Psychopharmacol*, *16*(4), 365-368.
346. Barr, R. G., Bourbeau, J., Camargo, C. A., & Ram, F. S. (2005). Inhaled tiotropium for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(2), CD002876.
347. Barrickman, L. L., Perry, P. J., Allen, A. J., Kuperman, S., Arndt, S. V., Herrmann, K. J., & Schumacher, E. (1995). Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*, *34*(5), 649-657.
348. Barrie, E. S., Pinsonneault, J. K., Sadee, W., Hollway, J. A., Handen, B. L., Smith, T., . . . Aman, M. G. (2018). Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD. *J Dev Phys Disabil*, *30*(3), 355-371.
349. Bart, G., Lenz, S., Straka, R. J., & Brundage, R. C. (2014). Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. *Drug Alcohol Depend*, *145*, 185-193.
350. Bartoletti, M., Rubin, T., Chalvet, F., Netter, S., Dos Santos, N., Poisot, E., . . . Theodore, L. (2012). Genetic basis for developmental homeostasis of germline stem cell niche number: a network of Tramtrack-Group nuclear BTB factors. *PLoS One*, *7*(11), e49958.

351. Bartoletti, R., Cai, T., Perletti, G., F, M. E. W., & Bjerklund Johansen, T. E. (2015). Finafloxacin for the treatment of urinary tract infections. *Expert Opin Investig Drugs*, 24(7), 957-963.
352. Bartoli, F., Dell'Osso, B., Crocamo, C., Fiorillo, A., Ketter, T. A., Suppes, T., . . . Carra, G. (2017). Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. *J Psychiatr Res*, 88, 38-46.
353. Basu, A., Chadda, R. K., Sood, M., Kaur, H., & Kukreti, R. (2015). Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study. *Indian J Med Res*, 142(1), 40-45.
354. Basu, K., Palmer, C. N., Tavendale, R., Lipworth, B. J., & Mukhopadhyay, S. (2009). Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. *J Allergy Clin Immunol*, 124(6), 1188-1194.e1183.
355. Bateman, E. D., Kornmann, O., Schmidt, P., Pivovarova, A., Engel, M., & Fabbri, L. M. (2011). Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. *J Allergy Clin Immunol*, 128(2), 315-322.
356. Batty, J. A., Hall, A. S., White, H. L., Wikstrand, J., de Boer, R. A., van Veldhuisen, D. J., . . . Balmforth, A. J. (2014). An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. *Clin Pharmacol Ther*, 95(3), 321-330.
357. Baudhuin, L. M., Miller, W. L., Train, L., Bryant, S., Hartman, K. A., Phelps, M., . . . Jaffe, A. S. (2010). Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. *Am J Cardiol*, 106(3), 402-408.
358. Bauer, M., Berman, S., Stamm, T., Plotkin, M., Adli, M., Pilhatsch, M., . . . Schlagenhauf, F. (2016). Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. *Mol Psychiatry*, 21(2), 229-236.
359. Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., . . . Disorders, W. T. F. o. U. D. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. *World J Biol Psychiatry*, 8(2), 67-104.
360. Bauer, M., Dell'osso, L., Kasper, S., Pitchot, W., Dencker Vansvik, E., Kohler, J., . . . Montgomery, S. A. (2013). Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. *J Affect Disord*, 151(1), 209-219.
361. Bauer, M., Hefting, N., Lindsten, A., Josiassen, M. K., & Hobart, M. (2019). A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. *Acta Neuropsychiatr*, 31(1), 27-35.
362. Bauer, M., Thase, M. E., Liu, S., Earley, W., & Eriksson, H. (2015). Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder. *J Psychopharmacol*, 29(5), 565-574.

363. Baumann, P., Jonzier-Perey, M., Koeb, L., Kupfer, A., Tinguely, D., & Schopf, J. (1986). Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. *Int Clin Psychopharmacol*, 1(2), 102-112.
364. Baumann, P., Jonzier-Perey, M., Koeb, L., Le, P. K., Tinguely, D., & Schopf, J. (1986). Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. *Int Clin Psychopharmacol*, 1(2), 89-101.
365. Baumann, P., Meyer, J. W., Amey, M., Baettig, D., Bryois, C., Jonzier-Perey, M., . . . Woggon, B. (1992). Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. *Ther Drug Monit*, 14(1), 1-8.
366. Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., . . . Zamorano, J. L. (2018). 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. *Rev Esp Cardiol (Engl Ed)*, 71(2), 110.
367. Bavishi, C., Khan, A. R., & Ather, S. (2015). Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis. *Int J Cardiol*, 188, 99-101.
368. Bayer HealthCare Pharmaceuticals Inc. (2012). Precose (acarbose). *US Product Monograph*,
369. Bayer HealthCare Pharmaceuticals Inc. (2018). Avelox (moxifloxacin). *US Product Monograph*,
370. Bayer HealthCare Pharmaceuticals Inc. (2018). Cipro (ciprofloxacin). *US Product Monograph*,
371. Bayer Inc. (2010). Glucobay (acarbose). *CA Product Monograph*,
372. Bayer Inc. (2016). Adalat XL (nifedipine). *CA Product Monograph*,
373. Bayer Inc. (2016). Phillips' Milk of Magnesia. In. Whippany, NJ.
374. Bayer Inc. (2017). Aleve (naproxen). *CA Product Monograph*,
375. Bayer Inc. (2017). Cipro (ciprofloxacin). *CA Product Monograph*,
376. Bayer Inc. (2017). Cipro XL (ciprofloxacin). *CA Product Monograph*,
377. Bayer Inc. (2017). Yaz (drospirenone / ethinyl estradiol). *CA Product Monograph*,
378. Bayer Inc. (2018). Xarelto (rivaroxaban). *CA Product Monograph*,
379. Baysal, B., Senturk, H., Masri, O., Tozlu, M., Kayar, Y., Arabaci, E., . . . Ince, A. T. (2015). Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. *Turk J Gastroenterol*, 26(1), 6-14.
380. BC Provincial Academic Detailing Service. (2015). *Proton Pump Inhibitors*. Vancouver
381. BC Renal Agency. (2011). Renal Analgesic Brochure.
382. BC Renal Agency. (2014). Over-the-Counter (non-prescription) medications and your kidneys. In B. R. Agency (Ed.). St. Pauls Hospital: BC Provincial Renal Agency.
383. BC Renal Agency. (2015). Antidepressant use in adults with chronic kidney disease. In. **BC**: BC Renal agency.
384. BC Renal Agency. (2018). Common oral antimicrobial therapy dosage adjustments for renal function. In.
385. Beahm, N. P., Nicolle, L. E., Burse, A., Smyth, D. J., & Tsuyuki, R. T. (2017). The assessment and management of urinary tract infections in adults: Guidelines for pharmacists. *Can Pharm J (Ott)*, 150(5), 298-305.

386. Becker, A. B., & Simons, F. E. (1989). Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. *J Allergy Clin Immunol*, 84(6 Pt 1), 891-895.
387. Becker, M. A., MacDonald, P. A., Hunt, B. J., Lademacher, C., & Joseph-Ridge, N. (2008). Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. *Nucleosides Nucleotides Nucleic Acids*, 27(6), 585-591.
388. Becker, M. A., Schumacher, H. R., Espinoza, L. R., Wells, A. F., MacDonald, P., Lloyd, E., & Lademacher, C. (2010). The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. *Arthritis Res Ther*, 12(2), R63.
389. Becker, M. A., Schumacher, H. R., MacDonald, P. A., Lloyd, E., & Lademacher, C. (2009). Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. *J Rheumatol*, 36(6), 1273-1282.
390. Becker, M. A., Schumacher, H. R., Jr., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., . . . Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med*, 353(23), 2450-2461.
391. Becker, M. L., Visser, L. E., van Schaik, R. H., Hofman, A., Uitterlinden, A. G., & Stricker, B. H. (2009). Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. *Pharmacogenomics*, 10(11), 1743-1751.
392. Becker, M. L., Visser, L. E., van Schaik, R. H., Hofman, A., Uitterlinden, A. G., & Stricker, B. H. (2010). Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. *Pharmacoepidemiol Drug Saf*, 19(1), 75-81.
393. Bedenis, R., Lethaby, A., Maxwell, H., Acosta, S., & Prins, M. H. (2015). Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. *Cochrane Database Syst Rev*(2), Cd000535.
394. Bedenis, R., Stewart, M., Cleanthis, M., Robless, P., Mikhailidis, D. P., & Stansby, G. (2014). Cilostazol for intermittent claudication. *Cochrane Database Syst Rev*(10), Cd003748.
395. Bekhti, A., & Rutgeerts, L. (1979). Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. *Postgrad Med J*, 55, 30-32.
396. Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., . . . Investigators, S. (2014). Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*, 371(13), 1189-1197.
397. Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., . . . MacWalter, R. (2008). The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ*, 337, a1840.
398. Belgamwar, R. B., Ebrahim, F., & Campbell, C. (2010). Lithium in chronic renal failure: a case report. *Gen Hosp Psychiatry*, 32(3), 341 e343-345.
399. Belgamwar, R. B., & El-Sayeh, H. G. (2011). Aripiprazole versus placebo for schizophrenia. *Cochrane Database Syst Rev*(8), CD006622.

400. Bell, A. D., Roussin, A., Cartier, R., Chan, W. S., Douketis, J. D., Gupta, A., . . . Canadian Cardiovascular, S. (2011). The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. *Can J Cardiol, 27 Suppl A*, S1-59.
401. Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R., & Wells, G. (2006). Intraarticular corticosteroid for treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev*(2), CD005328.
402. Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R., & Wells, G. (2006). Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev*(2), CD005321.
403. Bellavance, A. J., & Meloche, J. P. (1990). A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. *Headache, 30*(11), 710-715.
404. Benson, G. D., Koff, R. S., & Tolman, K. G. (2005). The therapeutic use of acetaminophen in patients with liver disease. *Am J Ther, 12*(2), 133-141.
405. Bergen, A. W., Javitz, H. S., Krasnow, R., Nishita, D., Michel, M., Conti, D. V., . . . Swan, G. E. (2013). Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenet Genomics, 23*(2), 94-103.
406. Berger, J. S., Krantz, M. J., Kittelson, J. M., & Hiatt, W. R. (2009). Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. *Jama, 301*(18), 1909-1919.
407. Berger, W. E. (2005). Budesonide inhalation suspension for the treatment of asthma in infants and children. *Drugs, 65*(14), 1973-1989.
408. Bergmann, T. K., Bathum, L., & Brosen, K. (2001). Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. *Eur J Clin Pharmacol, 57*(2), 123-127.
409. Bergmeijer, T. O., Reny, J. L., Pakyz, R. E., Gong, L., Lewis, J. P., Kim, E. Y., . . . Investigators, I. (2018). Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). *Am Heart J, 198*, 152-159.
410. Berigan, T. R. (2002). Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report. *Prim Care Companion J Clin Psychiatry, 4*(2), 78.
411. Berigan, T. R., & Harazin, J. S. (1999). Bupropion-Associated Withdrawal Symptoms: A Case Report. *Prim Care Companion J Clin Psychiatry, 1*(2), 50-51.
412. Berk, M., Ichim, C., & Brook, S. (2001). Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. *Int Clin Psychopharmacol, 16*(2), 87-92.
413. Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., . . . Marcus, R. N. (2009). Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. *CNS Spectr, 14*(4), 197-206.
414. Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in

- major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*, 68(6), 843-853.
415. Bertilsson, L., Åberg-Wistedt, A., Gustafsson, L. L., & Nordin, C. (1985). Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. *Ther Drug Monit*, 7(4), 478-480.
 416. Bertilsson, L., Dahl, M. L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., . . . Ingelman-Sundberg, M. (1993). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. *The Lancet*, 341(8836), 63.
 417. Bertilsson, L., Eichelbaum, M., Mellstrom, B., Sawe, J., Schulz, H. U., & Sjoqvist, F. (1980). Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. *Life Sci*, 27(18), 1673-1677.
 418. Bertilsson, L., Mellstrom, B., Sjoqvist, F., Martenson, B., & Asberg, M. (1981). Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. *Lancet*, 1(8219), 560-561.
 419. Berwaerts, J., Lane, R., Nuamah, I. F., Lim, P., Remmerie, B., & Hough, D. W. (2011). Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. *J Affect Disord*, 129(1-3), 252-260.
 420. Berwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012). A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. *J Affect Disord*, 138(3), 247-258.
 421. Berwaerts, J., Xu, H., Nuamah, I., Lim, P., & Hough, D. (2012). Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. *J Affect Disord*, 136(1-2), e51-60.
 422. Beuten, J., Payne, T. J., Ma, J. Z., & Li, M. D. (2006). Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. *Neuropsychopharmacology*, 31(3), 675-684.
 423. BGP Pharma ULC. (2016). Biaxin (clarithromycin). *CA Product Monograph*,
 424. BGP Pharma ULC. (2016). Depakene (valproic acid). *CA Product Monograph*,
 425. BGP Pharma ULC. (2016). Epival (divalproex). *CA Product Monograph*,
 426. BGP Pharma ULC. (2016). Hp-PAC (lansoprazole / clarithromycin / amoxicillin). *CA Product Monograph*,
 427. BGP Pharma ULC. (2016). Isoptin SR (verapamil hydrochloride). *CA Product Monograph*,
 428. BGP Pharma ULC. (2016). Teveten (eprosartan mesylate). *CA Product Monograph*,
 429. BGP Pharma ULC. (2017). Depakene (valproic acid). *CA Product Monograph*,
 430. BGP Pharma ULC. (2017). Epival (divalproex sodium). *CA Product Monograph*,
 431. BGP Pharma ULC. (2017). Lipidil EZ (fenofibrate). *CA Product Monograph*,
 432. BGP Pharma ULC. (2017). Luvox (fluvoxamine). *CA Product Monograph*,
 433. BGP Pharma ULC. (2017). Prevacid (lansoprazole). *CA Product Monograph*,
 434. BGP Pharma ULC. (2017). Tarka (trandolapril / verapamil hydrochloride). *CA Product Monograph*,

435. Bhalra, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., Baron, J. A., . . . Baigent, C. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*, 382(9894), 769-779.
436. Bhat, V., & Kennedy, S. H. (2017). Recognition and management of antidepressant discontinuation syndrome. *J Psychiatry Neurosci*, 42(4), E7-e8.
437. Bhatnagar, V., O'Connor, D. T., Schork, N. J., Salem, R. M., Nievergelt, C. M., Rana, B. K., . . . Lipkowitz, M. S. (2007). Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. *J Hypertens*, 25(10), 2082-2092.
438. Bhatt, D. K., Mehrotra, A., Gaedigk, A., Chapa, R., Basit, A., Zhang, H., . . . Prasad, B. (2019). Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. *Clin Pharmacol Ther*, 105(1), 131-141.
439. Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanar, A., Schnitzer, T. J., . . . Cannon, C. P. (2010). Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med*, 363(20), 1909-1917.
440. Bhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., . . . Fox, K. A. (2007). Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol*, 49(19), 1982-1988.
441. Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., . . . Topol, E. J. (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*, 354(16), 1706-1717.
442. Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., Furberg, C. D., . . . Wesley, D. J. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*, 52(18), 1502-1517.
443. Bhattacharjee, J., & El-Sayeh, H. G. (2008). Aripiprazole versus typical antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*(3), CD006617.
444. Bianchi Porro, G., Lazzaroni, M., Imbesi, V., Montrone, F., & Santagada, T. (2000). Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. *Dig Liver Dis*, 32(3), 201-208.
445. Bichoupan, K., Tandon, N., Martel-Lafferriere, V., Patel, N. M., Sachs, D., Ng, M., . . . Branch, A. D. (2017). Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. *Liver Int*, 9(11), 551-561.
446. Biederman, J., Baldessarini, R. J., Wright, V., Knee, D., & Harmatz, J. S. (1989). A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. *J Am Acad Child Adolesc Psychiatry*, 28(5), 777-784.
447. Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., & Scherer, N. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended

- release in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics*, 121(1), e73-84.
448. Biederman, J., Spencer, T. J., Wilens, T. E., Weisler, R. H., Read, S. C., Tulloch, S. J., & group, S. L. I. s. (2005). Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. *CNS Spectr*, 10(12 Suppl 20), 16-25.
449. Biederman, J., Swanson, J. M., Wigal, S. B., Kratochvil, C. J., Boellner, S. W., Earl, C. Q., . . . Greenhill, L. (2005). Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. *Pediatrics*, 116(6), e777-784.
450. Bihorac, A., Ozener, C., Akoglu, E., & Kullu, S. (1999). Tetracycline-induced acute interstitial nephritis as a cause of acute renal failure. *Nephron*, 81(1), 72-75.
451. Bijl, M. J., Visser, L. E., Hofman, A., Vulto, A. G., van Gelder, T., Stricker, B. H., & van Schaik, R. H. (2008). Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. *Br J Clin Pharmacol*, 65(4), 558-564.
452. Bijl, M. J., Visser, L. E., van Schaik, R. H., Kors, J. A., Witterman, J. C., Hofman, A., . . . Stricker, B. H. (2009). Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. *Clin Pharmacol Ther*, 85(1), 45-50.
453. Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Putz, B., . . . Muller-Myhsok, B. (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. *Nat Genet*, 36(12), 1319-1325.
454. Bingham, A. L., Brown, R. O., & Dickerson, R. N. (2013). Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. *Nutr Clin Pract*, 28(6), 766-769.
455. Binnington, M. J., Zhu, A. Z., Renner, C. C., Lanier, A. P., Hatsukami, D. K., Benowitz, N. L., & Tyndale, R. F. (2012). CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. *Pharmacogenet Genomics*, 22(6), 429-440.
456. Bird, S., Derry, S., & Moore, R. A. (2014). Zolmitriptan for acute migraine attacks in adults. *Cochrane Database Syst Rev*(5), Cd008616.
457. Birdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadee, W., . . . MacPhee, I. A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. *Clin Pharmacol Ther*, 98(1), 19-24.
458. Birmingham, B. K., Bujac, S. R., Elsby, R., Azumaya, C. T., Wei, C., Chen, Y., . . . Ambrose, H. J. (2015). Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? *Eur J Clin Pharmacol*, 71(3), 341-355.
459. Birmingham, B. K., Bujac, S. R., Elsby, R., Azumaya, C. T., Zalikowski, J., Chen, Y., . . . Ambrose, H. J. (2015). Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. *Eur J Clin Pharmacol*, 71(3), 329-340.

460. Bittl, J. A., Baber, U., Bradley, S. M., & Wijeyesundera, D. N. (2016). Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*, *68*(10), 1116-1139.
461. Bjornsson, E., Lindberg, J., & Olsson, R. (1997). Liver reactions to oral low-dose tetracyclines. *Scand J Gastroenterol*, *32*(4), 390-395.
462. Black, D. (2019). Gentamicin. In *Sanford Guide Web Edition. Sanford Guide Web Edition* (
463. Blake, C. M., Kharasch, E. D., Schwab, M., & Nagele, P. (2013). A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. *Clin Pharmacol Ther*, *94*(3), 394-399.
464. Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013). The evidence-based pharmacotherapy of social anxiety disorder. *Int J Neuropsychopharmacol*, *16*(1), 235-249.
465. Blanco, C., Heimberg, R. G., Schneier, F. R., Fresco, D. M., Chen, H., Turk, C. L., . . . Liebowitz, M. R. (2010). A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. *Arch Gen Psychiatry*, *67*(3), 286-295.
466. Blanco, G., Martinez, C., Ladero, J. M., Garcia-Martin, E., Taxonera, C., Gamito, F. G., . . . Agundez, J. A. (2008). Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. *Pharmacogenet Genomics*, *18*(1), 37-43.
467. Bleecker, E. R., Meyers, D. A., Bailey, W. C., Sims, A. M., Bujac, S. R., Goldman, M., & Martin, U. J. (2012). ADRB2 polymorphisms and budesonide/formoterol responses in COPD. *Chest*, *142*(2), 320-328.
468. Bleecker, E. R., Postma, D. S., Lawrance, R. M., Meyers, D. A., Ambrose, H. J., & Goldman, M. (2007). Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. *Lancet*, *370*(9605), 2118-2125.
469. Bleecker, E. R., Yancey, S. W., Baitinger, L. A., Edwards, L. D., Klotsman, M., Anderson, W. H., & Dorinsky, P. M. (2006). Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. *J Allergy Clin Immunol*, *118*(4), 809-816.
470. Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hebert, C., & Debonnel, G. (2009). Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. *Eur Neuropsychopharmacol*, *19*(7), 457-465.
471. Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hebert, C., & Bergeron, R. (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. *Am J Psychiatry*, *167*(3), 281-288.
472. Bloemenkamp, K. W., Rosendaal, F. R., Buller, H. R., Helmerhorst, F. M., Colly, L. P., & Vandenbroucke, J. P. (1999). Risk of venous thrombosis with use of current low-dose

- oral contraceptives is not explained by diagnostic suspicion and referral bias. *Arch Intern Med*, 159(1), 65-70.
473. Blondal, T., Gudmundsson, L. J., Olafsdottir, I., Gustavsson, G., & Westin, A. (1999). Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. *BMJ*, 318(7179), 285-288.
474. Blondel-Hill, E., & Fryters, S. (2012). *Bugs & Drugs* [2].
475. Blondel-Hill, E., & Fryters, S. (2017). Helicobacter pylori associated duodenal/gastric ulcer. In *Bugs and Drugs*. Alberta: Alberta Health Services.
476. Bloom, A. J., von Weyarn, L. B., Martinez, M., Bierut, L. J., Goate, A., & Murphy, S. E. (2013). The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. *Pharmacogenet Genomics*, 23(12), 706-716.
477. Bluhm, R. E., Wilkinson, G. R., Shelton, R., & Branch, R. A. (1993). Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. *Clin Pharmacol Ther*, 53(1), 89-95.
478. Blum, A. L., Arnold, R., Stolte, M., Fischer, M., & Koelz, H. R. (2000). Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. *Gut*, 47(4), 473-480.
479. Blum, A. L., Bethge, H., Bode, J. C., Domschke, W., Feurle, G., Hackenberg, K., . . . et al. (1990). Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study. *Gut*, 31(7), 825-830.
480. Blum, A. L., Talley, N. J., O'Morain, C., van Zanten, S. V., Labenz, J., Stolte, M., . . . Sundin, M. (1998). Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) study group. *N Engl J Med*, 339.
481. Blumenfeld, A., Silberstein, S. D., Dodick, D. W., Aurora, S. K., Turkel, C. C., & Binder, W. J. (2010). Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. *Headache*, 50.
482. Blumenfeld, A. M., Schim, J. D., & Chippendale, T. J. (2008). Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. *Headache*, 48(2), 210-220.
483. Boardman, C., Chachi, L., Gavrila, A., Keenan, C. R., Perry, M. M., Xia, Y. C., . . . Sharma, P. (2014). Mechanisms of glucocorticoid action and insensitivity in airways disease. *Pulm Pharmacol Ther*, 29(2), 129-143.
484. Bocanegra, T. S., Weaver, A. L., Tindall, E. A., Sikes, D. H., Ball, J. A., Wallemark, C. B., . . . Fort, J. G. (1998). Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. *J Rheumatol*, 25(8), 1602-1611.
485. Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., Desvignes-Nickens, P., Koprowicz, K., . . . Weintraub, W. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*, 365(24), 2255-2267.

486. Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S. S., & Meier, C. R. (2008). Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. *Diabetes Care*, 31(11), 2086-2091.
487. Boehringer Ingelheim (Canada) Inc. (2013). Micardis (telmisartan). *CA Product Monograph*,
488. Boehringer Ingelheim (Canada) Ltd. (2014). Mobicox (meloxicam). *CA Product Monograph*,
489. Boehringer Ingelheim (Canada) Ltd. (2015). Combivent UDV (ipratropium / salbutamol). *CA Product Monograph*,
490. Boehringer Ingelheim (Canada) Ltd. (2016). Atrovent HFA (ipratropium). *CA Product Monograph*,
491. Boehringer Ingelheim (Canada) Ltd. (2016). Combivent Respimat (ipratropium and salbutamol). *CA Product Monograph*,
492. Boehringer Ingelheim (Canada) Ltd. (2016). Spiriva Respimat (tiotropium). *CA Product Monograph*,
493. Boehringer Ingelheim (Canada) Ltd. (2016). Striverdi Respimat (olodaterol). *CA Product Monograph*,
494. Boehringer Ingelheim (Canada) Ltd. (2017). Inspiolto Respimat (tiotropium / olodaterol). *CA Product Monograph*,
495. Boehringer Ingelheim (Canada) Ltd. (2017). Spiriva (tiotropium). *CA Product Monograph*,
496. Boehringer Ingelheim (Canada) Ltd. (2019). Jardiance (empagliflozin). *CA Product Monograph*,
497. Boehringer Ingelheim (Canada) Ltd. (2019). Spiriva Respimat (tiotropium). *CA Product Monograph*,
498. Boehringer Ingelheim Pharmaceuticals Inc. (2012). Atrovent HFA (ipratropium). *US Product Monograph*,
499. Boehringer Ingelheim Pharmaceuticals Inc. (2016). Catapres (clonidine). *US Product Monograph*,
500. Boehringer Ingelheim Pharmaceuticals Inc. (2016). Catapres TTS (clonidine patch). *US Product Monograph*,
501. Boehringer Ingelheim Pharmaceuticals Inc. (2016). Combivent Respimat (ipratropium and albuterol). *US Product Monograph*,
502. Boehringer Ingelheim Pharmaceuticals Inc. (2016). Mobic (meloxicam). *US Product Monograph*,
503. Boehringer Ingelheim Pharmaceuticals Inc. (2017). Tradjenta (linagliptin). *US Product Monograph*,
504. Boehringer Ingelheim Pharmaceuticals Inc. (2018). Jardiance (empagliflozin). *US Product Monograph*,
505. Boehringer Ingelheim Pharmaceuticals Inc. (2018). Micardis (telmisartan). *US Product Monograph*,
506. Boehringer Ingelheim Pharmaceuticals Inc. (2018). Spiriva Handihaler (tiotropium). *US Product Monograph*,

507. Boehringer Ingelheim Pharmaceuticals Inc. (2018). Spiriva Respimat (tiotropium). *US Product Monograph*,
508. Boehringer Ingelheim Pharmaceuticals Inc. (2018). Stiolto Respimat (tiotropium / olodaterol). *US Product Monograph*,
509. Boehringer Ingelheim Pharmaceuticals Inc. (2018). Striverdi Respimat (olodaterol). *US Product Monograph*,
510. Boehringer Ingelheim Pharmaceuticals Inc. (2019). Spiriva Respimat (tiotropium). *US Product Monograph*,
511. Bohadana, A., Nilsson, F., Rasmussen, T., & Martinet, Y. (2000). Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: A randomized, double-blind, placebo-controlled trial. *Arch Intern Med*, *160*(20), 3128-3134.
512. Boissel, J. P., Leizorovicz, A., Picolet, H., & Ducruet, T. (1990). Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators. *Am J Cardiol*, *66*(9), 24C-31C.
513. Bokar, G., Pickard, R., Bartoletti, R., Cai, T., Bruyere, F., Geerlings, S. E., . . . Wagenlehner, F. (2018). EAU Guidelines on Urological Infections.
514. Bolea-Alamanac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., . . . British Association for, P. (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*, *28*(3), 179-203.
515. Bolten, W., Gomes, J. A., Stead, H., & Geis, G. S. (1992). The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. *Br J Rheumatol*, *31*(11), 753-758.
516. Bombardier, C., Hazlewood, G. S., Akhavan, P., Schieir, O., Dooley, A., Haraoui, B., . . . Bykerk, V. (2012). Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. *J Rheumatol*, *39*(8), 1583-1602.
517. Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., . . . Sabatine, M. S. (2015). Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med*, *372*(19), 1791-1800.
518. Bone, H. G., Greenspan, S. L., McKeever, C., Bell, N., Davidson, M., Downs, R. W., . . . Lombardi, A. (2000). Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. *J Clin Endocrinol Metab*, *85*(2), 720-726.
519. Bonini, M., Permaul, P., Kulkarni, T., Kazani, S., Segal, A., Sorkness, C. A., . . . Israel, E. (2013). Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. *Am J Respir Crit Care Med*, *188*(12), 1407-1412.
520. Boone, R. H., Cheung, A. M., Giralan, L. M., & Heathcote, E. J. (2006). Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. *Dig Dis Sci*, *51*(6), 1103-1112.

521. Bork, J. A., Rogers, T., Wedlund, P. J., & de Leon, J. (1999). A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. *J Clin Psychiatry*, *60*(7), 469-476.
522. Borobia, A. M., Novalbos, J., Guerra-Lopez, P., Lopez-Rodriguez, R., Tabares, B., Rodriguez, V., . . . Carcas, A. J. (2009). Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. *Pharmacol Res*, *59*(6), 393-398.
523. Borstad, G. C., Bryant, L. R., Abel, M. P., Scroggie, D. A., Harris, M. D., & Alloway, J. A. (2004). Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. *J Rheumatol*, *31*(12), 2429-2432.
524. Boshuisen, M. L., Slaap, B. R., Vester-Blokland, E. D., & den Boer, J. A. (2001). The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. *Int Clin Psychopharmacol*, *16*(6), 363-368.
525. Bosia, M., Lorenzi, C., Pirovano, A., Guglielmino, C., Cocchi, F., Spangaro, M., . . . Cavallaro, R. (2015). COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. *Pharmacogenomics*, *16*(1), 35-44.
526. Bougea, A., Spantideas, N., Lyras, V., Avramidis, T., & Thomaidis, T. (2016). Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study. *Funct Neurol*, *31*(1), 33-37.
527. Boulet, L. P., Becker, A., Berube, D., Beveridge, R., & Ernst, P. (1999). Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. *CMAJ*, *161*(11 Suppl), S1-61.
528. Bourin, M. S., Severus, E., Schronen, J. P., Gass, P., Szamosi, J., Eriksson, H., & Chandrashekar, H. (2014). Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. *Int J Bipolar Disord*, *2*, 14.
529. Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., . . . Cioppa, G. D. (2005). The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. *Allergy*, *60*(3), 302-308.
530. Bowden, C. L., Brugger, A. M., Swann, A. C., Calabrese, J. R., Janicak, P. G., Petty, F., . . . et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. *Jama*, *271*(12), 918-924.
531. Bowden, C. L., Vieta, E., Ice, K. S., Schwartz, J. H., Wang, P. P., & Versavel, M. (2010). Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. *J Clin Psychiatry*, *71*(2), 130-137.
532. Braak, B., Klooker, T. K., Wouters, M. M., Lei, A., van den Wijngaard, R. M., & Boeckxstaens, G. E. (2011). Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. *Aliment Pharmacol Ther*, *34*(6), 638-648.
533. Bradley, B., Singleton, M., & Lin Wan Po, A. (1989). Bismuth toxicity--a reassessment. *J Clin Pharm Ther*, *14*(6), 423-441.
534. Bradley, P., Shiekh, M., Mehra, V., Vrbicky, K., Layle, S., Olson, M. C., . . . Lukowiak, A. A. (2018). Improved efficacy with targeted pharmacogenetic-guided treatment of patients

- with depression and anxiety: A randomized clinical trial demonstrating clinical utility. *J Psychiatr Res*, 96, 100-107.
535. Bradwejn, J., Ahokas, A., Stein, D. J., Salinas, E., Emilien, G., & Whitaker, T. (2005). Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. *Br J Psychiatry*, 187, 352-359.
536. Brandes, J. L., Poole, A., Kallela, M., Schreiber, C. P., MacGregor, E. A., Silberstein, S. D., . . . Shaw, R. (2009). Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. *Cephalalgia*, 29(11), 1133-1148.
537. Brandes, J. L., Saper, J. R., Diamond, M., Couch, J. R., Lewis, D. W., Schmitt, J., . . . Group, M.-S. (2004). Topiramate for migraine prevention: a randomized controlled trial. *Jama*, 291(8), 965-973.
538. Brandl, E. J., Tiwari, A. K., Zhou, X., Deluce, J., Kennedy, J. L., Muller, D. J., & Richter, M. A. (2014). Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. *Pharmacogenomics J*, 14(2), 176-181.
539. Brass, E. P., & Hiatt, W. R. (2017). Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. *Circulation*, 136(9), 785-786.
540. Brayley, J., & Yellowlees, P. (1987). An interaction between haloperidol and carbamazepine in a patient with cerebral palsy. *Aust N Z J Psychiatry*, 21(4), 605-607.
541. Breitling, L. P., Twardella, D., Hoffmann, M. M., Witt, S. H., Treutlein, J., & Brenner, H. (2010). Prospective association of dopamine-related polymorphisms with smoking cessation in general care. *Pharmacogenomics*, 11(4), 527-536.
542. Breyer-Pfaff, U., Pfandl, B., Nill, K., Nusser, E., Monney, C., Jonzier-Perey, M., . . . Baumann, P. (1992). Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. *Clin Pharmacol Ther*, 52(4), 350-358.
543. Brieger, D., Amerena, J., Attia, J. R., Bajorek, B., Chan, K. H., Connell, C., . . . Zwar, N. A. (2018). National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. *Med J Aust*, 209(8), 356-362.
544. Briggs, G. G., Freeman, R. K., Towers, C. V., & Forinash, A. B. (2017). *Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk* (Eleventh edition. ed.). Philadelphia, PA: Wolters Kluwer.
545. Briggs, R. S., & Millac, P. A. (1979). Timolol in migraine prophylaxis. *Headache*, 19(7), 379-381.
546. Brignole, M., Auricchio, A., Baron-Esquivias, G., Bordachar, P., Boriani, G., Breithardt, O. A., . . . Wilson, C. M. (2013). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J*, 34(29), 2281-2329.
547. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. (2018). Plavix (clopidogrel). *US Product Monograph*,
548. Bristol-Myers Squibb. (2014). Percocet/Percocet-Demi *CA Product Monograph*,
549. Bristol-Myers Squibb. (2016). Pravachol (pravastatin). *US Product Monograph*,

550. Bristol-Myers Squibb. (2018). Glucophage (metformin). *US Product Monograph*,
551. Bristol-Myers Squibb Canada. (2006). Capoten (captopril). *CA Product Monograph*,
552. Bristol-Myers Squibb Canada. (2013). Modecate (fluphenazine decanoate). *CA Product Monograph*,
553. Bristol-Myers Squibb Canada. (2015). Abilify (aripiprazole). *CA Product Monograph*,
554. Bristol-Myers Squibb Canada. (2017). Kenalog-40 (triamcinolone acetonide IA injection). *CA Product Monograph*,
555. Bristol-Myers Squibb Canada. (2017). Pravachol (pravastatin). *CA Product Monograph*,
556. Bristol-Myers Squibb Canada. (2018). Coumadin (warfarin). *CA Product Monograph*,
557. Bristol-Myers Squibb Pharma Company. (2017). Coumadin (warfarin). *US Product Monograph*,
558. British Columbia Guidelines & Protocols Advisory Committee. (2009). Dyspepsia with or without Helicobacter pylori infection - Clinical Approach in Adults. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
559. British Columbia Guidelines & Protocols Advisory Committee. (2009). Gastroesophageal Reflux Disease - Clinical Approach in Adults. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
560. British Columbia Guidelines & Protocols Advisory Committee. (2015). Hypertension-Diagnosis and Management. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
561. British Columbia Guidelines and Protocols Advisory Committee. (2012). Osteoporosis: Diagnosis, Treatment and Fracture Prevention. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
562. British Columbia Guidelines and Protocols Advisory Committee. (2012). Rheumatoid Arthritis: Diagnosis, Management and Monitoring. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
563. British Columbia Guidelines and Protocols Advisory Committee. (2013). Major Depressive Issues in Adults: Appendix D. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
564. British Columbia Guidelines and Protocols Advisory Committee. (2015). Asthma in Adults - Recognition, Diagnosis and Management. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
565. British Columbia Guidelines and Protocols Advisory Committee. (2015). Asthma in children - diagnosis and management.
566. British Columbia Guidelines and Protocols Advisory Committee. (2015). Diabetes Care. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
567. British Columbia Guidelines and Protocols Advisory Committee. (2015). Use of Non-Vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
568. British Columbia Guidelines and Protocols Advisory Committee. (2017). Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and management. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.

569. British Columbia Guidelines and Protocols and Advisory Committee. (2015). Atrial Fibrillation - diagnosis and management. In B. C. M. Association (Ed.). Victoria, BC: Guidelines and Protocols Advisory Committee.
570. British Thoracic, S., & Scottish Intercollegiate Guidelines, N. (2014). British guideline on the management of asthma. *Thorax*, *69 Suppl 1*, 1-192.
571. British Thoracic Society, & Scottish Intercollegiate Guidelines Network. (2016). British Guideline for the management of asthma: SIGN 153.
572. British Thoracic Society, S. I. G. N. (2014). *British guideline for the management of asthma; a national clinical guideline (SIGN 141)*. Retrieved from <https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline>
573. British Thoracic Society, S. I. G. N. (2019). *British guideline for the management of asthma; a national clinical guideline (SIGN 158)*. Retrieved from <https://www.sign.ac.uk/assets/sign158.pdf>
574. Brockmoller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Muller-Oerlinghausen, B., & Roots, I. (2002). The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. *Clin Pharmacol Ther*, *72*(4), 438-452.
575. Brockmoller, J., Meineke, I., & Kirchheiner, J. (2007). Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. *Clin Pharmacol Ther*, *81*(5), 699-707.
576. Brody, I. A. (1959). Shock after administration of prochlorperazine in patient with pheochromocytoma; report of a case with spontaneous tumor destruction. *J Am Med Assoc*, *169*(15), 1749-1752.
577. Brookman, L. J., Rolan, P. E., Benjamin, I. S., Palmer, K. R., Wyld, P. J., Lloyd, P., . . . Mullins, F. (1997). Pharmacokinetics of valsartan in patients with liver disease. *Clin Pharmacol Ther*, *62*(3), 272-278.
578. Brosen, K., & Gram, L. F. (1988). First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. *Clin Pharmacol Ther*, *43*(4), 400-406.
579. Brown, E. B., McElroy, S. L., Keck, P. E., Jr., Deldar, A., Adams, D. H., Tohen, M., & Williamson, D. J. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. *J Clin Psychiatry*, *67*(7), 1025-1033.
580. Brown, G. A. (2013). AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. *J Am Acad Orthop Surg*, *21*(9), 577-579.
581. Brown, J. T., Abdel-Rahman, S. M., van Haandel, L., Gaedigk, A., Lin, Y. S., & Leeder, J. S. (2016). Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. *Clin Pharmacol Ther*, *99*(6), 642-650.
582. Brown, J. T., Bishop, J. R., Sangkuhl, K., Nurmi, E. L., Mueller, D. J., Dinh, J. C., . . . Leeder, J. S. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. *Clin Pharmacol Ther*, *106*(1), 94-102.
583. Brown, R., Taylor, M. J., & Geddes, J. (2013). Aripiprazole alone or in combination for acute mania. *Cochrane Database Syst Rev*(12), CD005000.

584. Bruck, H., Leineweber, K., Buscher, R., Ulrich, A., Radke, J., Insel, P. A., & Brodde, O. E. (2003). The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. *Pharmacogenetics*, *13*(2), 59-66.
585. Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P. J., & Amarenco, P. (2011). Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. *J Cardiovasc Pharmacol*, *57*(2), 267-272.
586. Bruins Slot, K. M., & Berge, E. (2018). Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. *Cochrane Database Syst Rev*, *3*, Cd008980.
587. Brunham, L. R., Lansberg, P. J., Zhang, L., Miao, F., Carter, C., Hovingh, G. K., . . . Hayden, M. R. (2012). Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. *Pharmacogenomics J*, *12*(3), 233-237.
588. Brunton, S. (2014). GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? *Int J Clin Pract*, *68*(5), 557-567.
589. Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., . . . Keller, W. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull*, *36*(1), 71-93.
590. Buettner, C., Nir, R. R., Bertisch, S. M., Bernstein, C., Schain, A., Mittleman, M. A., & Burstein, R. (2015). Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. *Ann Neurol*, *78*(6), 970-981.
591. Bulut, S., Berilgen, M. S., Baran, A., Tekatas, A., Atmaca, M., & Mungen, B. (2004). Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. *Clin Neurol Neurosurg*, *107*(1), 44-48.
592. Burgess, S., Geddes, J., Hawton, K., Townsend, E., Jamison, K., & Goodwin, G. (2001). Lithium for maintenance treatment of mood disorders. *Cochrane Database Syst Rev*(3), CD003013.
593. Burling, T. A., Burling, A. S., & Latini, D. (2001). A controlled smoking cessation trial for substance-dependent inpatients. *J Consult Clin Psychol*, *69*(2), 295-304.
594. Burmester, G., Lanus, A., Biasucci, L., Hermann, M., Lohmander, S., Olivieri, I., . . . Stoevelaar, H. (2011). The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. *Ann Rheum Dis*, *70*(5), 818-822.
595. Burns, J. J., Yu, T. F., Ritterband, A., Perel, J. M., Gutman, A. B., & Brodie, B. B. (1957). A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. *J Pharmacol Exp Ther*, *119*(3), 418-426.
596. Bushu Pharmaceutical Ltd. (2010). Latuda (lurasidone). *US Product Monograph*,
597. Butalia, S., Audibert, F., Cote, A. M., Firoz, T., Logan, A. G., Magee, L. A., . . . Hypertension, C. (2018). Hypertension Canada's 2018 Guidelines for the Management of Hypertension in Pregnancy. *Can J Cardiol*, *34*(5), 526-531.

598. Byeon, J. Y., Kim, Y. H., Na, H. S., Jang, J. H., Kim, S. H., Lee, Y. J., . . . Lee, S. Y. (2015). Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. *Arch Pharm Res*, *38*(11), 2083-2091.
599. Bykerk, V. P., Akhavan, P., Hazlewood, G. S., Schieir, O., Dooley, A., Haraoui, B., . . . Bombardier, C. (2012). Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. *J Rheumatol*, *39*(8), 1559-1582.
600. Bystritsky, A., Kerwin, L., Feusner, J. D., & Vapnik, T. (2008). A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. *Psychopharmacol Bull*, *41*(1), 46-51.
601. Cabaleiro, T., Lopez-Rodriguez, R., Ochoa, D., Roman, M., Novalbos, J., & Abad-Santos, F. (2013). Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. *Hum Psychopharmacol*, *28*(3), 205-214.
602. Cacoub, P. P., Bhatt, D. L., Steg, P. G., Topol, E. J., & Creager, M. A. (2009). Patients with peripheral arterial disease in the CHARISMA trial. *Eur Heart J*, *30*(2), 192-201.
603. Cadila Healthcare Limited. (2017). Diflusalin. *US Product Monograph*,
604. Cady, R. K., Schreiber, C. P., Porter, J. A., Blumenfeld, A. M., & Farmer, K. U. (2011). A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. *Headache*, *51*(1), 21-32.
605. Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016). Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev*(5), CD006103.
606. Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev*(5), CD009329.
607. Cai, T., Mazzoli, S., Lanzafame, P., Caciagli, P., Malossini, G., Nesi, G., . . . Bartoletti, R. (2016). Asymptomatic Bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI. *Pathogens*, *5*(1).
608. Cai, T., Mazzoli, S., Nesi, G., Boddi, V., Mondaini, N., & Bartoletti, R. (2009). 14-day prulifloxacin treatment of acute uncomplicated cystitis in women with recurrent urinary tract infections: a prospective, open-label, pilot trial with 6-month follow-up. *J Chemother*, *21*(5), 535-541.
609. Cai, T., Nesi, G., Mazzoli, S., Meacci, F., Lanzafame, P., Caciagli, P., . . . Bartoletti, R. (2015). Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. *Clin Infect Dis*, *61*(11), 1655-1661.
610. Cairns, J. A., Connolly, S., McMurtry, S., Stephenson, M., & Talajic, M. (2011). Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. *Can J Cardiol*, *27*(1), 74-90.
611. Cajanus, K., Neuvonen, M., Koskela, O., Kaunisto, M. A., Neuvonen, P. J., Niemi, M., & Kalso, E. (2018). Analgesic plasma concentrations of oxycodone after surgery for breast cancer-which factors matter? *Clin Pharmacol Ther*, *103*(4), 653-662.

612. Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., & Rudd, G. D. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. *J Clin Psychiatry, 60*(2), 79-88.
613. Calabrese, J. R., Keck, P. E., Jr., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., . . . Durgam, S. (2015). Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. *J Clin Psychiatry, 76*(3), 284-292.
614. Calabrese, J. R., Pikalov, A., Streicher, C., Cucchiaro, J., Mao, Y., & Loebel, A. (2017). Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. *Eur Neuropsychopharmacol, 27*(9), 865-876.
615. Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., . . . Carson, W. H. (2017). Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. *J Clin Psychiatry, 78*(3), 324-331.
616. Calamita, Z., Saconato, H., Pela, A. B., & Atallah, A. N. (2006). Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. *Allergy, 61*(10), 1162-1172.
617. Calarge, C. A., Ellingrod, V. L., Acion, L., Miller, D. D., Moline, J., Tansey, M. J., & Schlechte, J. A. (2009). Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. *Pharmacogenet Genomics, 19*(5), 373-382.
618. Caldeira, D., David, C., & Sampaio, C. (2012). Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. *Arch Cardiovasc Dis, 105*(4), 226-238.
619. Caldwell, B. O., Adamson, S. J., & Crane, J. (2014). Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation. *Nicotine Tob Res, 16*(10), 1356-1364.
620. Calisti, G., Tavares, A., Macartney, M. J., McCormick, A., Labbett, W., Jacobs, M., . . . Haque, T. (2015). IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders. *SpringerPlus, 4*, 357.
621. Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S. A., . . . Wilber, D. (2012). 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation,

- the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart Rhythm*, 9(4), 632-696 e621.
622. Calver, L., Drinkwater, V., Gupta, R., Page, C. B., & Isbister, G. K. (2015). Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. *Br J Psychiatry*, 206(3), 223-228.
 623. Calverley, P. M., Rabe, K. F., Goehring, U. M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009). Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*, 374(9691), 685-694.
 624. Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., . . . Watts, N. B. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016. *Endocr Pract*, 22(Suppl 4), 1-42.
 625. Camm, A. J., Camm, C. F., & Savelieva, I. (2012). Medical treatment of atrial fibrillation. *J Cardiovasc Med (Hagerstown)*, 13(2), 97-107.
 626. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., . . . Rutten, F. H. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Europace*, 12(10), 1360-1420.
 627. Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., . . . Kirchhof, P. (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J*, 33(21), 2719-2747.
 628. Campa, D., Gioia, A., Tomei, A., Poli, P., & Barale, R. (2008). Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. *Clin Pharmacol Ther*, 83(4), 559-566.
 629. Campbell, N. R., Gibson, P., & Tsuyuki, R. T. (2015). *Hypertension*. In B. Jovaisas (Ed.), *Therapeutics*.
 630. Campbell, R. H., Diduch, M., Gardner, K. N., & Thomas, C. (2017). Review of cariprazine in management of psychiatric illness. *Ment Health Clin*, 7(5), 221-229.
 631. CAN-ADAPTT. (2011). Canadian smoking cessation clinical practice guideline.
 632. Canadian ADHD Resource Alliance (CADDRA). (2018). Canadian ADHD practice guidelines.
 633. Canadian Agency for Drugs and Technologies in Health. (2011). Guidelines and Recommendations for ADHD in Children and Adolescents.
 634. Canadian Agency for Drugs and Technologies in Health. (2012). *Guide to starting and adjusting insulin for Type 2 Diabetes*. Retrieved from Ottawa, Ontario: https://www.cadth.ca/sites/default/files/pdf/InsulinStartTool_e_web.pdf
 635. Canadian Agency for Drugs and Technologies in Health. (2013). Second- and third-line pharmacotherapy for Type 2 Diabetes: Update. (Accession No. 24278998)

636. Canadian Agency for Drugs and Technologies in Health. (2017). New Drugs for Type 2 Diabetes: Second-Line Therapy - Recommendations Report. 4(1c),
637. Canadian Antimicrobial Resistance Alliance. (2014). 2014 National antimicrobial susceptibility testing results: Escherichia coli. Retrieved from <http://www.can-r.com/study.php?study=canw2014&year=2014>
638. Canadian Diabetes Association. (2014). Insulin initiation and titration suggestions for Type 2 Diabetes. In.
639. Canadian Diabetes Association Clinical Practice Guideline Expert Committee. (2016). Appendix 5: Approximate cost reference list for antihyperglycemic agents. *Can J Diabetes*, 40(6).
640. Canadian Diabetes Association Clinical Practice Guidelines Expert, C., Imran, S. A., Rabasa-Lhoret, R., & Ross, S. (2013). Targets for glycemic control. *Can J Diabetes*, 37 Suppl 1, S31-34.
641. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Imran, S. A., Rabasa-Lhoret, R., & Ross, S. (2013). Appendix 3: Examples of insulin initiation and titration regimens in people with Type 2 Diabetes. *Can J Diabetes*, 37 Suppl 1, S200.
642. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Imran, S. A., Rabasa-Lhoret, R., & Ross, S. (2013). Appendix 6: Therapeutic Considerations for Renal Impairment. *Can J Diabetes*, 37 Suppl 1, S207.
643. Canadian Pharmacists Association. (2011). ACE Inhibitors [CPhA monograph]. *RxTx*,
644. Canadian Pharmacists Association. (2011). Calcium Channel Blockers [CPhA monograph]. *RxTx*,
645. Canadian Pharmacists Association. (2011). Moclobemide [CPhA monograph]. *RxTx*,
646. Canadian Pharmacists Association. (2011). Nitrofurantoin [CPhA monograph]. *RxTx*,
647. Canadian Pharmacists Association. (2011). Tobramycin [CPhA monograph]. *RxTx*,
648. Canadian Pharmacists Association. (2012). Bismuth Subsalicylate [CPhA Monograph]. *RxTx*,
649. Canadian Pharmacists Association. (2012). Capsaicin Derivatives [CPhA monograph]. *RxTx*,
650. Canadian Pharmacists Association. (2012). Cyclic Antidepressants [CPhA monograph]. *RxTx*,
651. Canadian Pharmacists Association. (2012). Histamine H2-receptor Antagonists [CPhA monograph]. *RxTx*,
652. Canadian Pharmacists Association. (2012). Misoprostol [CPhA monograph]. *RxTx*,
653. Canadian Pharmacists Association. (2012). Thiazide Diuretics [CPhA monograph]. *RxTx*,
654. Canadian Pharmacists Association. (2013). Histamine H2-receptor Antagonists [CPhA monograph]. *RxTx*,
655. Canadian Pharmacists Association. (2013). Loxapine [CPhA monograph]. *RxTx*,
656. Canadian Pharmacists Association. (2013). Metronidazole [CPhA monograph]. *RxTx*,
657. Canadian Pharmacists Association. (2014). Amiloride [CPhA monograph]. *RxTx*,
658. Canadian Pharmacists Association. (2014). Angiotensin II Receptor Antagonists [CPhA monograph]. *RxTx*,

659. Canadian Pharmacists Association. (2014). Beta-adrenergic Blocking Agents [CPhA monograph]. *RxTx*,
660. Canadian Pharmacists Association. (2014). Bisphosphonates [CPhA monograph]. *RxTx*,
661. Canadian Pharmacists Association. (2014). Calcium Salts (Oral) [CPhA monograph]. *RxTx*,
662. Canadian Pharmacists Association. (2014). Lithium [CPhA monograph]. *RxTx*,
663. Canadian Pharmacists Association. (2014). Methyldopa [CPhA monograph]. *RxTx*,
664. Canadian Pharmacists Association. (2014). Nonsteroidal Anti-inflammatory Drugs [CPhA monograph]. *RxTx*,
665. Canadian Pharmacists Association. (2014). Selective Serotonin Reuptake Inhibitors [CPhA monograph]. *RxTx*,
666. Canadian Pharmacists Association. (2014). Tetracyclines [CPhA monograph]. *RxTx*,
667. Canadian Pharmacists Association. (2015). Alpha1-adrenergic receptor antagonists [CPhA monograph]. *RxTx*,
668. Canadian Pharmacists Association. (2015). Amoxicillin [CPhA monograph]. *RxTx*,
669. Canadian Pharmacists Association. (2015). Cefprozil [CPhA monograph]. *RxTx*,
670. Canadian Pharmacists Association. (2015). Ceftriaxone [CPhA monograph]. *RxTx*,
671. Canadian Pharmacists Association. (2015). Cephalexin [CPhA monograph]. *RxTx*,
672. Canadian Pharmacists Association. (2015). Dihydroergotamine injection [CPhA monograph]. *RxTx*,
673. Canadian Pharmacists Association. (2015). Domperidone [CPhA Monograph]. *RxTx*,
674. Canadian Pharmacists Association. (2015). HMG-CoA Reductase Inhibitors (Statins) [CPhA monograph]. *RxTx*,
675. Canadian Pharmacists Association. (2015). Lamotrigine [CPhA monograph]. *RxTx*,
676. Canadian Pharmacists Association. (2015). Metoclopramide [CPhA Monograph]. *RxTx*,
677. Canadian Pharmacists Association. (2015). Phenothiazines [CPhA monograph]. *RxTx*,
678. Canadian Pharmacists Association. (2015). Sulfonylureas [CPhA monograph]. *RxTx*,
679. Canadian Pharmacists Association. (2016). Acetaminophen [CPhA monograph]. *RxTx*,
680. Canadian Pharmacists Association. (2016). Ceftin [CPhA monograph]. *RxTx*,
681. Canadian Pharmacists Association. (2016). Cefuroxime [CPhA monograph]. *RxTx*,
682. Canadian Pharmacists Association. (2016). Corticosteroids: inhaled [CPhA monograph]. *RxTx*,
683. Canadian Pharmacists Association. (2016). Corticosteroids: systemic [CPhA monograph]. *RxTx*,
684. Canadian Pharmacists Association. (2016). Haloperidol [CPhA monograph]. *RxTx*,
685. Canadian Pharmacists Association. (2016). Tricyclic Antidepressants [CPhA Monograph]. *RxTx*,
686. Canadian Pharmacists Association. (2017). Magnesium Salts [CPhA Monograph]. *TxTx*,
687. Canadian Pharmacists Association. (2017). Nitrates [CPhA monograph]. *RxTx*,
688. Canadian Pharmacists Association. (2017). Vitamin B2 - Riboflavin [CPhA monograph]. *RxTx*,
689. Canadian Pharmacists Association. (2017). Vitamin D [CPhA monograph]. *RxTx*,
690. Canadian Pharmacists Association. (2018). Atorvastatin dosage adjustment in renal impairment. *e-Therapeutics*,

691. Canadian Pharmacists Association. (2018). Erythromycin [CPhA monograph]. *RxTx*,
692. Canadian Pharmacists Association. (2018). Fluoroquinolones [CPhA monograph]. *RxTx*,
693. Canadian Pharmacists Association. (2018). Opioids [CPhA monograph]. *RxTx*,
694. Cange, L., Johnsson, E., Rydholm, H., Lehmann, A., Finizia, C., Lundell, L., & Ruth, M. (2002). Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. *Aliment Pharmacol Ther*, *16*(5), 869-873.
695. Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., . . . Investigators. (2017). Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med*, *377*(16), 1513-1524.
696. Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., . . . Califf, R. M. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, *372*(25), 2387-2397.
697. Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., . . . Skene, A. M. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*, *350*(15), 1495-1504.
698. Cannon, C. P., Cariou, B., Blom, D., McKenney, J. M., Lorenzato, C., Pordy, R., . . . Colhoun, H. M. (2015). Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J*, *36*(19), 1186-1194.
699. Cannon, C. P., Lip, G. Y. H., & Oldgren, J. (2018). Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med*, *378*(5), 485-486.
700. Canuso, C. M., Singh, J. B., Fedgchin, M., Alphas, L., Lane, R., Lim, P., . . . Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*, *175*(7), 620-630.
701. Cao, Y., Wang, J., Bunjhoo, H., Xie, M., Xu, Y., & Fang, H. (2012). Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: a meta-analysis. *Asian Pac J Allergy Immunol*, *30*(2), 130-138.
702. Caprie Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*, *348*(9038), 1329-1339.
703. Caraco, Y., Lagerstrom, P. O., & Wood, A. J. (1996). Ethnic and genetic determinants of omeprazole disposition and effect. *Clin Pharmacol Ther*, *60*(2), 157-167.
704. Caraco, Y., Sheller, J., & Wood, A. J. (1996). Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. *J Pharmacol Exp Ther*, *278*(3), 1165-1174.
705. Cardelli, M., Marchegiani, F., Corsonello, A., Lattanzio, F., & Provinciali, M. (2012). A review of pharmacogenetics of adverse drug reactions in elderly people. *Drug Saf*, *35 Suppl 1*, 3-20.
706. Cardone, D. A., & Tallia, A. F. (2002). Joint and soft tissue injection. *Am Fam Physician*, *66*(2), 283-288.

707. Carette, S., Bell, M. J., Reynolds, W. J., Haraoui, B., McCain, G. A., Bykerk, V. P., . . . et al. (1994). Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. *Arthritis Rheum*, 37(1), 32-40.
708. Cargnin, S., Genazzani, A. A., Canonico, P. L., & Terrazzino, S. (2018). Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. *Pharmacol Res*, 135, 102-111.
709. Cariani, E., Roli, L., Missale, G., Villa, E., Ferrari, C., & Trenti, T. (2016). Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. *Pharmacogenomics J*, 16(1), 18-29.
710. Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004). Atenolol in hypertension: is it a wise choice? *Lancet*, 364(9446), 1684-1689.
711. Carlsbad Technology Inc. (2016). Diclofenac Sodium (Delayed Release). *US Product Monograph*,
712. Carpenter, L. L., Jovic, Z., Hall, J. M., Rasmussen, S. A., & Price, L. H. (1999). Mirtazapine augmentation in the treatment of refractory depression. *J Clin Psychiatry*, 60(1), 45-49.
713. Carpenter, L. L., Yasmin, S., & Price, L. H. (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. *Biol Psychiatry*, 51(2), 183-188.
714. Carrillo, J. A., Dahl, M. L., Svensson, J. O., Alm, C., Rodriguez, I., & Bertilsson, L. (1996). Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. *Clin Pharmacol Ther*, 60(2), 183-190.
715. Carrillo, J. A., Herraiz, A. G., Ramos, S. I., Gervasini, G., Vizcaino, S., & Benitez, J. (2003). Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. *J Clin Psychopharmacol*, 23(2), 119-127.
716. Carroll, J. D., & Maclay, W. P. (1975). Pizotifen (BC 105) in migraine prophylaxis. *Curr Med Res Opin*, 3(2), 68-71.
717. Carter, B. L., Chrischilles, E. A., Rosenthal, G., Gryzlak, B. M., Eisenstein, E. L., & Vander Weg, M. W. (2014). Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial. *J Clin Hypertens (Greenwich)*, 16(2), 115-121.
718. Carvalho, A. T., Esberard, B. C., Froes, R. S., Rapozo, D. C., Grinman, A. B., Simao, T. A., . . . de Souza, H. S. (2014). Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. *World J Gastroenterol*, 20(12), 3327-3334.
719. Casat, C. D., Pleasants, D. Z., & Van Wyck Fleet, J. (1987). A double-blind trial of bupropion in children with attention deficit disorder. *Psychopharmacol Bull*, 23(1), 120-122.
720. Casper Pharma LLC. (2017). Zylprim (allopurinol). *US Product Monograph*,
721. Castelan-Martinez, O. D., Hoyo-Vadillo, C., Bazan-Soto, T. B., Cruz, M., Tesoro-Cruz, E., & Valladares-Salgado, A. (2018). CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. *J Clin Pharm Ther*, 43(6), 768-774.

722. Catalano, M., Born, G., & Peto, R. (2007). Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. *J Intern Med*, *261*(3), 276-284.
723. Catapano, A. L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M. R., Wiklund, O., . . . Wood, D. (2011). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Atherosclerosis*, *217*(1), 3-46.
724. Caudle, K. E., Dunnenberger, H. M., Freimuth, R. R., Peterson, J. F., Burlison, J. D., Whirl-Carrillo, M., . . . Hoffman, J. M. (2017). Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet Med*, *19*(2), 215-223.
725. Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S., Lee, M. T., . . . Clinical Pharmacogenetics Implementation, C. (2014). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. *Clin Pharmacol Ther*, *96*(5), 542-548.
726. Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., LaCroix, A. Z., . . . Women's Health Initiative, I. (2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *Jama*, *290*(13), 1729-1738.
727. Cavallari, L. H., Lee, C. R., Beitelshes, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., . . . Network, I. (2018). Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. *JACC Cardiovasc Interv*, *11*(2), 181-191.
728. Cawston, H., Davie, A., Paget, M. A., Skljarevski, V., & Happich, M. (2013). Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain. *Eur Spine J*, *22*(9), 1996-2009.
729. Cefalu, W. T., Leiter, L. A., Yoon, K. H., Arias, P., Niskanen, L., Xie, J., . . . Meininger, G. (2013). Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. *Lancet*, *382*(9896), 941-950.
730. Cerbo, R., Casacchia, M., Formisano, R., Feliciani, M., Cusimano, G., Buzzi, M. G., & Agnoli, A. (1986). Flunarizine-pizotifen single-dose double-blind cross-over trial in migraine prophylaxis. *Cephalalgia*, *6*(1), 15-18.
731. Cernuda-Morollon, E., Ramon, C., Larrosa, D., Alvarez, R., Riesco, N., & Pascual, J. (2015). Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? *Cephalalgia*, *35*(10), 864-868.
732. Ceron-Litvoc, D., Soares, B. G., Geddes, J., Litvoc, J., & de Lima, M. S. (2009). Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. *Hum Psychopharmacol*, *24*(1), 19-28.
733. Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry*, *158*(4), 518-526.

734. Chakrabarti, A., Bagnall, A., Chue, P., Fenton, M., Palaniswamy, V., Wong, W., & Xia, J. (2007). Loxapine for schizophrenia. *Cochrane Database Syst Rev*(4), CD001943.
735. Chambers, H. F. (2019). Plazomicin. In *Sanford Guide Web Edition. Sanford Guide Web Edition* (
736. Chamnanphon, M., Pechatanan, K., Sirachainan, E., Trachu, N., Chantratita, W., Pasomsub, E., . . . Sukasem, C. (2013). Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. *Pharmgenomics Pers Med*, 6, 37-48.
737. Champion, M. C. (1997). Prokinetic therapy in gastroesophageal reflux disease. *Can J Gastroenterol*, 11 Suppl B, 55b-65b.
738. Chan, F. K., Ching, J. Y., Suen, B. Y., Tse, Y. K., Wu, J. C., & Sung, J. J. (2013). Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. *Gastroenterology*, 144(3), 528-535.
739. Chan, F. K., Wong, V. W., Suen, B. Y., Wu, J. C., Ching, J. Y., Hung, L. C., . . . Sung, J. J. (2007). Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. *Lancet*, 369(9573), 1621-1626.
740. Chan, P., Tomlinson, B., Huang, T. Y., Ko, J. T., Lin, T. S., & Lee, Y. S. (1997). Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. *J Clin Pharmacol*, 37(3), 253-257.
741. Chan, T. K., Todd, D., & Tso, S. C. (1976). Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. *BMJ*, 2(6046), 1227-1229.
742. Chang, A., Krygier, D. S., Chatur, N., & Yoshida, E. M. (2009). Clozapine-induced fatal fulminant hepatic failure: a case report. *Can J Gastroenterol*, 23(5), 376-378.
743. Chang, C. C., Too, C. L., Murad, S., & Hussein, S. H. (2011). Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. *Int J Dermatol*, 50(2), 221-224.
744. Chang, M., Tybring, G., Dahl, M. L., & Lindh, J. D. (2014). Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. *Clin Pharmacokinet*, 53(9), 801-811.
745. Chang, P. H., Chiang, C. H., Ho, W. C., Wu, P. Z., Tsai, J. S., & Guo, F. R. (2015). Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. *BMC Public Health*, 15, 689.
746. Chang, Y., Yang, L. Y., Zhang, M. C., & Liu, S. Y. (2014). Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China. *Eur J Clin Pharmacol*, 70(8), 941-946.
747. Chaparro, L. E., Wiffen, P. J., Moore, R. A., & Gilron, I. (2012). Combination pharmacotherapy for the treatment of neuropathic pain in adults. *Cochrane Database Syst Rev*, 7, CD008943.

748. Charlier, C., Broly, F., Lhermitte, M., Pinto, E., Anseau, M., & Plomteux, G. (2003). Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. *Ther Drug Monit*, 25(6), 738-742.
749. Chasman, D. I., Giulianini, F., MacFadyen, J., Barratt, B. J., Nyberg, F., & Ridker, P. M. (2012). Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. *Circ Cardiovasc Genet*, 5(2), 257-264.
750. Chasman, D. I., Posada, D., Subrahmanyam, L., Cook, N. R., Stanton, V. P., Jr., & Ridker, P. M. (2004). Pharmacogenetic study of statin therapy and cholesterol reduction. *Jama*, 291(23), 2821-2827.
751. Chaudhary, N., Kabra, M., Gulati, S., Gupta, Y. K., Pandey, R. M., & Bhatia, B. D. (2016). Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy. *BMC Pediatr*, 16, 66.
752. Chauhan, B. F., & Ducharme, F. M. (2014). Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. *Cochrane Database Syst Rev*(1), CD003137.
753. Chen, C. B., Hsiao, Y. H., Wu, T., Hsieh, M. S., Tassaneeyakul, W., Jorns, T. P., . . . Chung, W. H. (2017). Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. *Neurology*, 88(1), 78-86.
754. Chen, G., Blevins-Primeau, A. S., Dellinger, R. W., Muscat, J. E., & Lazarus, P. (2007). Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. *Cancer Res*, 67(19), 9024-9029.
755. Chen, G., Dellinger, R. W., Gallagher, C. J., Sun, D., & Lazarus, P. (2008). Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. *Pharmacogenet Genomics*, 18(3), 181-191.
756. Chen, G., He, F., Fu, S., & Dong, J. (2011). GJB2 and mitochondrial DNA 1555A>G mutations in students with hearing loss in the Hubei Province of China. *Int J Pediatr Otorhinolaryngol*, 75(9), 1156-1159.
757. Chen, K., Fields, T., Mancuso, C. A., Bass, A. R., & Vasanth, L. (2010). Anakinra's efficacy is variable in refractory gout: report of ten cases. *Semin Arthritis Rheum*, 40(3), 210-214.
758. Chen, L. S., Bloom, A. J., Baker, T. B., Smith, S. S., Piper, M. E., Martinez, M., . . . Bierut, L. (2014). Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). *Addiction*, 109(1), 128-137.
759. Chen, S., Chou, W. H., Blouin, R. A., Mao, Z., Humphries, L. L., Meek, Q. C., . . . Wedlund, P. J. (1996). The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. *Clin Pharmacol Ther*, 60(5), 522-534.
760. Chen, X., Kang, Y., Wang, L., Lin, L., Zhu, Z., & Chen, R. (2015). Extrafine HFA-beclomethasone dipropionate versus budesonide for asthma: a meta-analysis. *Int J Clin Exp Med*, 8(1), 212-221.
761. Chen, Y., Tudi, M., Sun, J., He, C., Lu, H. L., Shang, Q., . . . Zhang, H. (2011). Genetic mutations in non-syndromic deafness patients of Uyghur and Han Chinese ethnicities in Xinjiang, China: a comparative study. *J Transl Med*, 9, 154.

762. Chen, Z. M., Jiang, L. X., Chen, Y. P., Xie, J. X., Pan, H. C., Peto, R., . . . Liu, L. S. (2005). Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*, *366*(9497), 1607-1621.
763. Chen, Z. M., Pan, H. C., Chen, Y. P., Peto, R., Collins, R., Jiang, L. X., . . . Liu, L. S. (2005). Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*, *366*(9497), 1622-1632.
764. Chen, Z. R., Somogyi, A. A., & Bochner, F. (1988). Polymorphic O-demethylation of codeine. *Lancet*, *2*(8616), 914-915.
765. Chen, Z. R., Somogyi, A. A., Reynolds, G., & Bochner, F. (1991). Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. *Br J Clin Pharmacol*, *31*(4), 381-390.
766. Cheng, J. W. (2006). A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. *Clin Ther*, *28*(5), 666-678.
767. Chenoweth, M. J., O'Loughlin, J., Sylvestre, M. P., & Tyndale, R. F. (2013). CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. *Pharmacogenet Genomics*, *23*(4), 232-235.
768. Chenoweth, M. J., Ware, J. J., Zhu, A. Z. X., Cole, C. B., Cox, L. S., Nollen, N., . . . Cinciripini, P. M. (2017). Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.
769. Cheon, E. J., Lee, K. H., Park, Y. W., Lee, J. H., Koo, B. H., Lee, S. J., & Sung, H. M. (2017). Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. *J Clin Psychopharmacol*, *37*(2), 193-199.
770. Cheung, Y. K., Cheng, S. H., Chan, E. J., Lo, S. V., Ng, M. H., & Kwan, P. (2013). HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. *Epilepsia*, *54*(7), 1307-1314.
771. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol*, *112*(2), 212-239.
772. Chiba, N., De Gara, C. J., Wilkinson, J. M., & Hunt, R. H. (1997). Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. *Gastroenterology*, *112*(6), 1798-1810.
773. Chiba, N., Van Zanten, S. J., Sinclair, P., Ferguson, R. A., Escobedo, S., & Grace, E. (2002). Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. *BMJ*, *324*(7344), 1012-1016.
774. Chiesa, A., Chierzi, F., De Ronchi, D., & Serretti, A. (2012). Quetiapine for bipolar depression: a systematic review and meta-analysis. *Int Clin Psychopharmacol*, *27*(2), 76-90.
775. Chiesi Limited. (2017). Clenil (beclomethasone dipropionate). *UK Product Monograph*,

776. Childress, A. C. (2012). Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. *Adv Ther*, 29(5), 385-400.
777. Cho, H. Y., & Lee, Y. B. (2006). Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. *Arch Pharm Res*, 29(6), 525-533.
778. Choi, H. D., & Shin, W. G. (2015). Association between catechol-O-methyltransferase (COMT) Val/Met genotype and smoking cessation treatment with nicotine: a meta-analysis. *Pharmacogenomics*, 16(16), 1879-1885.
779. Choi, H. D., Suh, J. H., Lee, J. Y., Bae, S. K., Kang, H. E., Lee, M. G., & Shin, W. G. (2013). Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis. *Int J Clin Pharmacol Ther*, 51(9), 718-724.
780. Choi, J. H., Lee, K. W., Oh, H. B., Lee, K. J., Suh, Y. J., Park, C. S., & Park, H. S. (2004). HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. *J Allergy Clin Immunol*, 113(3), 562-564.
781. Choi, J. H., Yee, S. W., Ramirez, A. H., Morrissey, K. M., Jang, G. H., Joski, P. J., . . . Giacomini, K. M. (2011). A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. *Clin Pharmacol Ther*, 90(5), 674-684.
782. Choi, S. W., Lam, D. M. H., Wong, S. S. C., Shiu, H. H. C., Wang, A. X. M., & Cheung, C. W. (2017). Effects of single nucleotide polymorphisms on surgical and postsurgical opioid requirements: a systematic review and meta-analysis. *Clin J Pain*, 33(12), 1117-1130.
783. Chokka, P. R., & Hankey, J. R. (2018). Assessment and management of sexual dysfunction in the context of depression. *Ther Adv Psychopharmacol*, 8(1), 13-23.
784. Chong, J., Haran, C., Chauhan, B. F., & Asher, I. (2015). Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. *Cochrane Database Syst Rev*(7), CD011032.
785. Chong, J., Leung, B., & Poole, P. (2013). Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(11), CD002309.
786. Chong, K. W., Chan, D. W., Cheung, Y. B., Ching, L. K., Hie, S. L., Thomas, T., . . . Tan, E. C. (2014). Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. *Arch Dis Child*, 99(6), 581-584.
787. Choo, E. H., Chang, K., Ahn, Y., Jeon, D. S., Lee, J. M., Kim, D. B., . . . Seung, K. B. (2014). Benefit of beta-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention. *Heart*, 100(6), 492-499.
788. Chou, R., Qaseem, A., Snow, V., Casey, D., Cross, J. T., Jr., Shekelle, P., . . . American Pain Society Low Back Pain Guidelines, P. (2007). Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med*, 147(7), 478-491.
789. Chow, J. C., Huang, C. W., Fang, C. W., Wu, Y. J., & Tsai, J. J. (2013). Lamotrigine-induced hypersensitivity syndrome in a Han Chinese patient with the HLA-B 5801 genotype. *Neurol Sci*, 34(1), 117-119.

790. Chowdhury, N. I., Tiwari, A. K., Souza, R. P., Zai, C. C., Shaikh, S. A., Chen, S., . . . Muller, D. J. (2013). Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. *Pharmacogenomics J*, *13*(3), 272-279.
791. Choy, E. H., Smith, C., Dore, C. J., & Scott, D. L. (2005). A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. *Rheumatology (Oxford)*, *44*(11), 1414-1421.
792. Christensen, M., Tybring, G., Mihara, K., Yasui-Furokori, N., Carrillo, J. A., Ramos, S. I., . . . Bertilsson, L. (2002). Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). *Clin Pharmacol Ther*, *71*(3), 141-152.
793. Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Jung, H. R., Lim, K. S., . . . Shin, S. G. (2005). Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. *Clin Pharmacol Ther*, *77*(6), 486-494.
794. Chung, W. H., Hung, S. I., Hong, H. S., Hsieh, M. S., Yang, L. C., Ho, H. C., . . . Chen, Y. T. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. *Nature*, *428*(6982), 486.
795. Cianci, R., Martina, P., Borghesi, F., di Donato, D., Polidori, L., Lai, S., . . . Barbano, B. (2011). Revascularization versus medical therapy for renal artery stenosis: antihypertensive drugs and renal outcome. *Angiology*, *62*(1), 92-99.
796. Cicoira, M., Rossi, A., Bonapace, S., Zanolla, L., Perrot, A., Francis, D. P., . . . Zardini, P. (2004). Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. *Am J Med*, *116*(10), 657-661.
797. Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., . . . Wetter, D. W. (2013). Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. *JAMA Psychiatry*, *70*(5), 522-533.
798. Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., . . . Geddes, J. R. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *Lancet*, *378*(9799), 1306-1315.
799. Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., . . . Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*, *391*(10128), 1357-1366.
800. Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., . . . Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet*, *373*(9665), 746-758.
801. Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ*, *346*, f3646.

802. Cipriani, A., Reid, K., Young, A. H., Macritchie, K., & Geddes, J. (2013). Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. *Cochrane Database Syst Rev*(10), CD003196.
803. Cipriani, A., Rendell, J. M., & Geddes, J. (2009). Olanzapine in long-term treatment for bipolar disorder. *Cochrane Database Syst Rev*(1), CD004367.
804. Cipriani, A., Rendell, J. M., & Geddes, J. R. (2006). Haloperidol alone or in combination for acute mania. *Cochrane Database Syst Rev*(3), CD004362.
805. Ciszkowski, C., Madadi, P., Phillips, M. S., Lauwers, A. E., & Koren, G. (2009). Codeine, ultrarapid-metabolism genotype, and postoperative death. *N Engl J Med*, *361*(8), 827-828.
806. Citrome, L. (2007). Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. *J Clin Psychiatry*, *68*(12), 1876-1885.
807. Citrome, L. (2010). Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. *Postgrad Med*, *122*(4), 39-48.
808. Citrome, L. (2015). Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract*, *69*(9), 978-997.
809. Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., . . . Louis, B. (2003). Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. *J Consult Clin Psychol*, *71*(6), 1058-1067.
810. Clark, D. W., Morgan, A. K., & Waal-Manning, H. (1984). Adverse effects from metoprolol are not generally associated with oxidation status. *Br J Clin Pharmacol*, *18*(6), 965-967.
811. Clayton, A. H., Baker, R. A., Sheehan, J. J., Cain, Z. J., Forbes, R. A., Marler, S. V., . . . Thase, M. E. (2014). Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. *BMC Res Notes*, *7*, 459.
812. Cleare, A., Pariante, C. M., Young, A. H., Anderson, I. M., Christmas, D., Cowen, P. J., . . . Members of the Consensus Meeting. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. *J Psychopharmacol*, *29*(5), 459-525.
813. Cochran, J. W. (2004). Levetiracetam as migraine prophylaxis. *Clin J Pain*, *20*(3), 198-199.
814. Cockerell, O. C., Johnson, A. L., Sander, J. W., Hart, Y. M., & Shorvon, S. D. (1995). Remission of epilepsy: results from the National General Practice Study of Epilepsy. *Lancet*, *346*(8968), 140-144.
815. Coenen, M. J., de Jong, D. J., van Marrewijk, C. J., Derijks, L. J., Vermeulen, S. H., Wong, D. R., . . . Team, T. R. (2015). Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. *Gastroenterology*, *149*(4), 907-917 e907.

816. Coffman, B. L., King, C. D., Rios, G. R., & Tephly, T. R. (1998). The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). *Drug Metab Dispos*, 26(1), 73-77.
817. Cohen, D., Bogers, J. P., van Dijk, D., Bakker, B., & Schulte, P. F. (2012). Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. *J Clin Psychiatry*, 73(10), 1307-1312.
818. Cohen, M. (2009). Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. *Mayo Clin Proc*, 84(2), 149-160.
819. Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., . . . et al. (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med*, 314(24), 1547-1552.
820. Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., . . . et al. (1991). A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med*, 325(5), 303-310.
821. Cohn, J. N., & Tognoni, G. (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*, 345(23), 1667-1675.
822. Colebatch, A. N., Marks, J. L., & Edwards, C. J. (2011). Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). *Cochrane Database Syst Rev*(11), CD008872.
823. Coleman, T., Chamberlain, C., Davey, M. A., Cooper, S. E., & Leonardi-Bee, J. (2015). Pharmacological interventions for promoting smoking cessation during pregnancy. *Cochrane Database Syst Rev*(12), CD010078.
824. Colgan, R., Johnson, J. R., Kuskowski, M., & Gupta, K. (2008). Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. *Antimicrob Agents Chemother*, 52(3), 846-851.
825. Colgan, R., & Williams, M. (2011). Diagnosis and treatment of acute uncomplicated cystitis. *Am Fam Physician*, 84(7), 771-776.
826. Colgan, R., Williams, M., & Johnson, J. R. (2011). Diagnosis and treatment of acute pyelonephritis in women. *Am Fam Physician*, 84(5), 519-526.
827. Colice, G., Martin, R. J., Israel, E., Roche, N., Barnes, N., Burden, A., . . . Price, D. (2013). Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. *J Allergy Clin Immunol*, 132(1), 45-54.
828. Collier, J. K., Cahill, S., Edmonds, C., Farquharson, A. L., Longo, M., Minniti, R., . . . White, J. M. (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. *Pharmacogenet Genomics*, 21(12), 902-905.
829. Collet, J. P., Hulot, J. S., Cuisset, T., Range, G., Cayla, G., Van Belle, E., . . . Arctic investigators. (2015). Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. *Eur J Clin Pharmacol*, 71(11), 1315-1324.
830. Concordia Pharmaceuticals Inc. (2018). Dyrenium (triamterene). *US Product Monograph*,

831. Concordia Pharmaceuticals Inc. (2018). Kapvay (clonidine ER). *US Product Monograph*,
832. Concordia Pharmaceuticals Inc. (2018). Lanoxin (digoxin). *US Product Monograph*,
833. Concordia Pharmaceuticals Inc. (2018). Parnate (tranylcypromine). *US Product Monograph*,
834. Concordia Pharmaceuticals Inc. (2018). Plaquenil (hydroxychloroquine). *US Product Monograph*,
835. Conners, C. K., Casat, C. D., Gualtieri, C. T., Weller, E., Reader, M., Reiss, A., . . . Ascher, J. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. *J Am Acad Child Adolesc Psychiatry*, 35(10), 1314-1321.
836. Connolly, K. R., & Thase, M. E. (2011). The clinical management of bipolar disorder: a review of evidence-based guidelines. *Prim Care Companion CNS Disord*, 13(4).
837. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., . . . Wallentin, L. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 361(12), 1139-1151.
838. Connor, D. F., Fletcher, K. E., & Swanson, J. M. (1999). A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*, 38(12), 1551-1559.
839. Conti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., . . . Lerman, C. (2008). Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. *Hum Mol Genet*, 17(18), 2834-2848.
840. Cooney, N. L., Cooney, J. L., Perry, B. L., Carbone, M., Cohen, E. H., Steinberg, H. R., . . . Litt, M. D. (2009). Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. *Addiction*, 104(9), 1588-1596.
841. Corazza, G. R., Biagi, F., Albano, O., Bianchi Porro, G., Cheli, R., Mazzacca, G., . . . Gasbarrini, G. (1996). Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. *Ital J Gastroenterol*, 28(6), 317-323.
842. Cording, M., Derry, S., Phillips, T., Moore, R. A., & Wiffen, P. J. (2015). Milnacipran for pain in fibromyalgia in adults. *Cochrane Database Syst Rev*(10), CD008244.
843. Corley, D. A., Kubo, A., Zhao, W., & Quesenberry, C. (2010). Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. *Gastroenterology*, 139(1), 93-101.
844. Correia, C. T., Almeida, J. P., Santos, P. E., Sequeira, A. F., Marques, C. E., Miguel, T. S., . . . Vicente, A. M. (2010). Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. *Pharmacogenomics J*, 10(5), 418-430.
845. Cosio, B. G., Shafiek, H., Iglesias, A., Yanez, A., Cordova, R., Palou, A., . . . Agusti, A. (2016). Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. *Chest*, 150(1), 123-130.
846. Cosio, B. G., Tsaprouni, L., Ito, K., Jazrawi, E., Adcock, I. M., & Barnes, P. J. (2004). Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. *J Exp Med*, 200(5), 689-695.

847. Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., . . . National Osteoporosis, F. (2014). Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int*, 25(10), 2359-2381.
848. Cosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guanabens, N., Kasperk, C., . . . Boonen, S. (2011). Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. *J Bone Miner Res*, 26(3), 503-511.
849. Cossins, L., Okell, R. W., Cameron, H., Simpson, B., Poole, H. M., & Goebel, A. (2013). Treatment of complex regional pain syndrome in adults: a systematic review of randomized controlled trials published from June 2000 to February 2012. *Eur J Pain*, 17(2), 158-173.
850. Couch, J. R. (2011). Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. *Headache*, 51(1), 33-51.
851. Couch, J. R., & Hassanein, R. S. (1979). Amitriptyline in migraine prophylaxis. *Arch Neurol*, 36(11), 695-699.
852. Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii-Saab, T., Al-Rohaimi, A., von Moltke, L. L., & Greenblatt, D. J. (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. *J Pharmacol Exp Ther*, 310(2), 656-665.
853. Coutinho, E., Fenton, M., & Quraishi, S. (2000). Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. *Cochrane Database Syst Rev*(2), CD001164.
854. Covis Pharma. (2018). Alvesco (ciclesonide). *US Product Monograph*,
855. Covis Pharma. (2018). Prilosec (omeprazole). *US Product Monograph*,
856. Cox, C. E. (1993). Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections. *Am J Med*, 94(3a), 118s-125s.
857. Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., . . . Skaar, T. C. (2014). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. *Clin Pharmacol Ther*, 95(4), 376-382.
858. Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., . . . Clinical Pharmacogenetics Implementation, C. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther*, 95(4), 376-382.
859. Crim, C., Dransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., . . . Calverley, P. M. (2015). Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. *Ann Am Thorac Soc*, 12(1), 27-34.
860. Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., . . . Stickland, M. K. (2015). Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest*, 147(4), 894-942.
861. Cristancho, M. A., & Thase, M. E. (2016). Critical appraisal of selegiline transdermal system for major depressive disorder. *Expert Opin Drug Deliv*, 13(5), 659-665.

862. Criswell, L. A., Saag, K. G., Sems, K. M., Welch, V., Shea, B., Wells, G., & Suarez-Almazor, M. E. (2000). Moderate-term, low-dose corticosteroids for rheumatoid arthritis. *Cochrane Database Syst Rev*(2), CD001158.
863. Cross, K. P., Paul, R. I., & Goldman, R. D. (2011). Single-dose dexamethasone for mild-to-moderate asthma exacerbations: effective, easy, and acceptable. *Can Fam Physician*, 57(10), 1134-1136.
864. Crowther, M. A., Ginsberg, J. B., Kearon, C., Harrison, L., Johnson, J., Massicotte, M. P., & Hirsh, J. (1999). A randomized trial comparing 5-mg and 10-mg warfarin loading doses. *Arch Intern Med*, 159(1), 46-48.
865. Cruccu, G., Gronseth, G., Alksne, J., Argoff, C., Brainin, M., Burchiel, K., . . . Zakrzewska, J. M. (2008). AAN-EFNS guidelines on trigeminal neuralgia management. *Eur J Neurol*, 15(10), 1013-1028.
866. Cuadrado-Lavin, A., Salcines-Caviedes, J. R., Carrascosa, M. F., Mellado, P., Monteagudo, I., Llorca, J., . . . Gonzalez-Colominas, E. (2012). Antimicrobial susceptibility of *Helicobacter pylori* to six antibiotics currently used in Spain. *J Antimicrob Chemother*, 67(1), 170-173.
867. Cuchacovich, M., Soto, L., Edwardes, M., Gutierrez, M., Llanos, C., Pacheco, D., . . . Aguillon, J. C. (2006). Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. *Scand J Rheumatol*, 35(6), 435-440.
868. Cui, Y. M., Teng, C. H., Pan, A. X., Yuen, E., Yeo, K. P., Zhou, Y., . . . Wise, S. D. (2007). Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. *Br J Clin Pharmacol*, 64(4), 445-449.
869. Cunill, R., Castells, X., Tobias, A., & Capella, D. (2013). Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. *Pharmacoepidemiol Drug Saf*, 22(9), 961-969.
870. Cupp, M. (2016). Comparison of atypical antipsychotics. *Pharmacist's Letter/Prescriber's Letter*,
871. Curiel, R. V., & Guzman, N. J. (2012). Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. *Semin Arthritis Rheum*, 42(2), 166-178.
872. Curtis, J. R., & Bateman, F. J. (1975). Use of prazosin in management of hypertension in patients with chronic renal failure and in renal transplant recipients. *Br Med J*, 4(5994), 432-434.
873. Cutler, A. J., Datto, C., Nordenhem, A., Minkwitz, M., Acevedo, L., & Darko, D. (2011). Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. *Clin Ther*, 33(11), 1643-1658.
874. Czerwensky, F., Leucht, S., & Steimer, W. (2013). MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? *Int J Neuropsychopharmacol*, 16(9), 2103-2109.
875. da Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Juni, P., & Trelle, S. (2017). Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet*, 390(10090), e21-e33.

876. Daci, A., Beretta, G., Vllasaliu, D., Shala, A., Govori, V., Norata, G. D., & Krasniqi, S. (2015). Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. *PLoS One*, *10*(11), e0142408.
877. Dahl, M. L., Bertilsson, L., & Nordin, C. (1996). Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. *Psychopharmacology (Berl)*, *123*(4), 315-319.
878. Dahl, M. L., Johansson, I., Palmertz, M. P., Ingelman-Sundberg, M., & Sjoqvist, F. (1992). Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. *Clin Pharmacol Ther*, *51*(1), 12-17.
879. Dahl, M. L., Llerena, A., Bondesson, U., Lindstrom, L., & Bertilsson, L. (1994). Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. *Br J Clin Pharmacol*, *37*(1), 71-74.
880. Dahl, R. (2006). Ciclesonide for the treatment of asthma. *Ther Clin Risk Manag*, *2*(1), 25-38.
881. Daien, C. I., Fabre, S., Rittore, C., Soler, S., Daien, V., Tejedor, G., . . . Touitou, I. (2012). TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. *Joint Bone Spine*, *79*(5), 471-475.
882. Daiichi Sankyo Co. (2017). Benicar (olmesartan). *US Product Monograph*,
883. Daiichi Sankyo Co. (2017). Savaysa (edoxaban). *US Product Monograph*,
884. Daiichi Sankyo Inc. (2019). WelChol (colesevelam hydrochloride) *US Product Monograph*,
885. Dalbeth, N., Kumar, S., Stamp, L., & Gow, P. (2006). Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. *J Rheumatol*, *33*(8), 1646-1650.
886. Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2016). Gout. *Lancet*, *388*(10055), 2039-2052.
887. Dalen, P., Dahl, M. L., Bernal Ruiz, M. L., Nordin, J., & Bertilsson, L. (1998). 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. *Clin Pharmacol Ther*, *63*(4), 444-452.
888. Dalen, P., Dahl, M. L., Roh, H. K., Tybring, G., Eichelbaum, M., Wilkinson, G. R., & Bertilsson, L. (2003). Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. *Br J Clin Pharmacol*, *55*(6), 630-634.
889. Dalen, P., Frengell, C., Dahl, M. L., & Sjoqvist, F. (1997). Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. *Ther Drug Monit*, *19*(5), 543-544.
890. Dall, M., Schaffalitzky de Muckadell, O. B., Lassen, A. T., Hansen, J. M., & Hallas, J. (2009). An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. *Clin Gastroenterol Hepatol*, *7*(12), 1314-1321.
891. Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., . . . Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant

- therapy in treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry*, 75(2), 139-148.
892. Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., . . . Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry*.
893. d'Amato, C. C., Pizza, V., Marmolo, T., Giordano, E., Alfano, V., & Nasta, A. (1999). Fluoxetine for migraine prophylaxis: a double-blind trial. *Headache*, 39(10), 716-719.
894. Danchin, N., Cucherat, M., Thuillez, C., Durand, E., Kadri, Z., & Steg, P. G. (2006). Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. *Arch Intern Med*, 166(7), 787-796.
895. Danesch, U., & Rittinghausen, R. (2003). Safety of a patented special butterbur root extract for migraine prevention. *Headache*, 43(1), 76-78.
896. Danielak, D., Karazniewicz-Lada, M., Komosa, A., Burchardt, P., Lesiak, M., Kruszyna, L., . . . Glowka, F. (2017). Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. *Eur J Clin Pharmacol*, 73(12), 1623-1632.
897. Danik, J. S., Chasman, D. I., MacFadyen, J. G., Nyberg, F., Barratt, B. J., & Ridker, P. M. (2013). Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. *Am Heart J*, 165(6), 1008-1014.
898. Dardennes, R., Even, C., Bange, F., & Heim, A. (1995). Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis. *Br J Psychiatry*, 166(3), 378-381.
899. Dargie, H. J. (2001). Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*, 357(9266), 1385-1390.
900. Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K., Cloutier, L., . . . Padwal, R. S. (2015). The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*, 31(5), 549-568.
901. Dason, S., Dason, J. T., & Kapoor, A. (2011). Guidelines for the diagnosis and management of recurrent urinary tract infection in women. *Can Urol Assoc J*, 5(5), 316-322.
902. Datto, C., Pottorf, W. J., Feeley, L., LaPorte, S., & Liss, C. (2016). Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. *Ann Gen Psychiatry*, 15, 9.
903. David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd-Richardson, E. E., Munafo, M. R., . . . Niaura, R. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. *Nicotine Tob Res*, 9(8), 821-833.
904. David, S. P., Strong, D. R., Leventhal, A. M., Lancaster, M. A., McGeary, J. E., Munafo, M. R., . . . Niaura, R. (2013). Influence of a dopamine pathway additive genetic efficacy

- score on smoking cessation: results from two randomized clinical trials of bupropion. *Addiction*, 108(12), 2202-2211.
905. David, S. P., Strong, D. R., Munafo, M. R., Brown, R. A., Lloyd-Richardson, E. E., Wileyto, P. E., . . . Niaura, R. (2007). Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. *Nicotine Tob Res*, 9(12), 1251-1257.
906. Davidson, J., Yaryura-Tobias, J., DuPont, R., Stallings, L., Barbato, L. M., van der Hoop, R. G., & Li, D. (2004). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. *J Clin Psychopharmacol*, 24(2), 118-125.
907. Davidson, J. R., DuPont, R. L., Hedges, D., & Haskins, J. T. (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. *J Clin Psychiatry*, 60(8), 528-535.
908. Davidson, J. R., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., . . . Gadde, K. M. (2004). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. *Arch Gen Psychiatry*, 61(10), 1005-1013.
909. Davis, J. M., & Chen, N. (2001). The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. *J Clin Psychiatry*, 62(10), 757-771.
910. Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry*, 60(6), 553-564.
911. Davis, M. L., Smits, J. A., & Hofmann, S. G. (2014). Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. *Expert Opin Pharmacother*, 15(16), 2281-2291.
912. Dawes, M., Aloise, M. N., Ang, J. S., Cullis, P., Dawes, D., Fraser, R., . . . Katzov-Eckert, H. (2016). Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. *CMAJ Open*, 4(3), E528-E534.
913. Dawson, D. L., Cutler, B. S., Hiatt, W. R., Hobson, R. W., 2nd, Martin, J. D., Bortey, E. B., . . . Strandness, D. E., Jr. (2000). A comparison of cilostazol and pentoxifylline for treating intermittent claudication. *Am J Med*, 109(7), 523-530.
914. de Abajo, F. J., Rodriguez, L. A., & Montero, D. (1999). Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. *BMJ*, 319(7217), 1106-1109.
915. de Blic, J., Ogorodova, L., Klink, R., Sidorenko, I., Valiulis, A., Hofman, J., . . . Poterre, M. (2009). Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. *Pediatr Allergy Immunol*, 20(8), 763-771.
916. De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., . . . Weitz, J. I. (2013). Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. *Thromb Haemost*, 109(5), 769-786.
917. de Denus, S., Dube, M. P., Fouodjio, R., Huynh, T., LeBlanc, M. H., Lepage, S., . . . investigators, C. I. (2018). A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. *Pharmacogenomics*, 19(7), 599-612.

918. de Denus, S., Zakrzewski-Jakubiak, M., Dube, M. P., Belanger, F., Lepage, S., Leblanc, M. H., . . . White, M. (2008). Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. *Ann Pharmacother*, 42(7), 925-932.
919. De Gregori, M., Diatchenko, L., Ingelmo, P. M., Napolioni, V., Klepstad, P., Belfer, I., . . . Allegri, M. (2016). Human genetic variability contributes to postoperative morphine consumption. *J Pain*, 17(5), 628-636.
920. de Keyser, C. E., Eijgelsheim, M., Hofman, A., Sijbrands, E. J., Maitland-van der Zee, A. H., van Duijn, C. M., . . . Ch Stricker, B. H. (2011). Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. *Pharmacogenomics J*, 11(1), 72-80.
921. de Keyser, C. E., Peters, B. J., Becker, M. L., Visser, L. E., Uitterlinden, A. G., Klungel, O. H., . . . Stricker, B. H. (2014). The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. *Pharmacogenet Genomics*, 24(1), 43-51.
922. de la Torre, G. (1987). A comparative, double-blind parallel study with tenoxicam vs placebo in acute gouty arthritis. *Invest Med Int*, 14, 92.
923. de Leon, J., Dinsmore, L., & Wedlund, P. (2003). Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. *J Clin Psychopharmacol*, 23(4), 420-421.
924. de Leon, J., Susce, M. T., Pan, R. M., Fairchild, M., Koch, W. H., & Wedlund, P. J. (2005). The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. *J Clin Psychiatry*, 66(1), 15-27.
925. de Leon, J., Susce, M. T., Pan, R. M., Koch, W. H., & Wedlund, P. J. (2005). Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. *J Clin Psychopharmacol*, 25(5), 448-456.
926. de Leon, J., Susce, M. T., Pan, R. M., Wedlund, P. J., Orrego, M. L., & Diaz, F. J. (2007). A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. *Pharmacopsychiatry*, 40(3), 93-102.
927. de Tommaso, M., Marinazzo, D., Nitti, L., Pellicoro, M., Guido, M., Serpino, C., & Stramaglia, S. (2007). Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. *Clin Neurophysiol*, 118(10), 2297-2304.
928. de Vos, A., van der Weide, J., & Looovers, H. M. (2011). Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. *Pharmacogenomics J*, 11(5), 359-367.
929. de Vries, Y. A., de Jonge, P., van den Heuvel, E., Turner, E. H., & Roest, A. M. (2016). Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. *Br J Psychiatry*, 208(6), 515-521.
930. De Weerd, C. J., Bootsma, H. P., & Hendriks, H. (1996). Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. *Phytomedicine*, 3(3), 225-230.

931. de Wit, M. P., Smolen, J. S., Gossec, L., & van der Heijde, D. M. (2011). Treating rheumatoid arthritis to target: the patient version of the international recommendations. *Ann Rheum Dis*, 70(6), 891-895.
932. DeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Schatzberg, A. F. (2003). A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. *J Clin Psychopharmacol*, 23(1), 27-30.
933. Debette-Gratien, M., Woillard, J. B., Picard, N., Sebah, M., Loustaud-Ratti, V., Sautereau, D., . . . Marquet, P. (2016). Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. *Transplantation*, 100(10), 2129-2137.
934. Decramer, M. L., Chapman, K. R., Dahl, R., Frith, P., Devouassoux, G., Fritscher, C., . . . investigators, I. (2013). Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. *Lancet Respir Med*, 1(7), 524-533.
935. Deedwania, P. C., Giles, T. D., Klibaner, M., Ghali, J. K., Herlitz, J., Hildebrandt, P., . . . Wikstrand, J. (2005). Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. *Am Heart J*, 149(1), 159-167.
936. Deeks, E. D. (2017). Lesinurad: A Review in Hyperuricaemia of Gout. *Drugs Aging*, 34(5), 401-410.
937. DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y. H., Dresser, G. K., Suskin, N., . . . Kim, R. B. (2013). Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. *Circ Cardiovasc Genet*, 6(4), 400-408.
938. Dekker, J. W., Nizankowska, E., Schmitz-Schumann, M., Pile, K., Bochenek, G., Dyczek, A., . . . Szczeklik, A. (1997). Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. *Clin Exp Allergy*, 27(5), 574-577.
939. Delaney, B. C., Qume, M., Moayyedi, P., Logan, R. F., Ford, A. C., Elliott, C., . . . Hobbs, F. D. (2008). Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). *BMJ*, 336(7645), 651-654.
940. Delco, F., Tchambaz, L., Schlienger, R., Drewe, J., & Krahenbuhl, S. (2005). Dose adjustment in patients with liver disease. *Drug Saf*, 28(6), 529-545.
941. Demirbugen Oz, M., Uckun, Z., Yuce-Artun, N., Baskak, B., Ozdemir, H., Kizil Ozel, T., . . . Suzen, H. S. (2018). The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. *Hum Psychopharmacol*, 33(5), e2673.
942. Demolis, J. L., Angebaud, P., Grange, J. D., Coates, P., Funck-Brentano, C., & Jaillon, P. (1996). Influence of liver cirrhosis on sertraline pharmacokinetics. *Br J Clin Pharmacol*, 42(3), 394-397.
943. Deng, Y., Li, S., Zhang, L., Jin, H., & Zou, X. (2018). Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis. *Seizure*, 60, 163-171.

944. Dennis, S. M., Sharp, S. J., Vickers, M. R., Frost, C. D., Crompton, G. K., Barnes, P. J., & Lee, T. H. (2000). Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. *Lancet*, 355(9216), 1675-1679.
945. Depomed Inc. (2011). Glumetza (metformin). *US Product Monograph*,
946. Depomed Inc. (2015). Gralise (gabapentin). *US Product Monograph*,
947. Depping, A. M., Komossa, K., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for anxiety disorders. *Cochrane Database Syst Rev*(12), Cd008120.
948. Derry, C. J., Derry, S., & Moore, R. A. (2014). Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. *Cochrane Database Syst Rev*(5), Cd009108.
949. Derry, S., Conaghan, P., Da Silva, J. A., Wiffen, P. J., & Moore, R. A. (2016). Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*, 4, CD007400.
950. Derry, S., & Moore, R. A. (2012). Topical capsaicin (low concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*, 9, CD010111.
951. Derry, S., & Moore, R. A. (2013). Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*(4), Cd008040.
952. Derry, S., Rabbie, R., & Moore, R. A. (2013). Diclofenac with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*(4), Cd008783.
953. Derry, S., Wiffen, P. J., Moore, R. A., & Quinlan, J. (2014). Topical lidocaine for neuropathic pain in adults. *Cochrane Database Syst Rev*, 7, CD010958.
954. Desai, M., Tanus-Santos, J. E., Li, L., Gorski, J. C., Arefayene, M., Liu, Y., . . . Flockhart, D. A. (2003). Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. *Pharmacogenomics J*, 3(2), 105-113.
955. Deshpande, A., Pant, C., Pasupuleti, V., Rolston, D. D., Jain, A., Deshpande, N., . . . Hernandez, A. V. (2012). Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. *Clin Gastroenterol Hepatol*, 10(3), 225-233.
956. Desmeules, J., Gascon, M. P., Dayer, P., & Magistris, M. (1991). Impact of environmental and genetic factors on codeine analgesia. *Eur J Clin Pharmacol*, 41(1), 23-26.
957. Desta, Z., Kerbusch, T., & Flockhart, D. A. (1999). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). *Clin Pharmacol Ther*, 65(1), 10-20.
958. Dettling, M., Sachse, C., Brockmoller, J., Schley, J., Muller-Oerlinghausen, B., Pickersgill, I., . . . Schmider, J. (2000). Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. *Psychopharmacology (Berl)*, 152(1), 80-86.
959. Dettling, M., Sachse, C., Muller-Oerlinghausen, B., Roots, I., Brockmoller, J., Rofls, A., & Cascorbi, I. (2000). Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. *Pharmacopsychiatry*, 33(6), 218-220.

960. DeVault, K. R., & Castell, D. O. (2005). Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol*, 100.
961. Dewan, B., & Philipose, N. (2011). Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial. *Gastroenterol Res Pract*, 2011, 640685.
962. Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J. P., . . . ten Berg, J. M. (2013). Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet*, 381(9872), 1107-1115.
963. Dezentje, V. O., van Schaik, R. H., Vletter-Bogaartz, J. M., van der Straaten, T., Wessels, J. A., Kranenbarg, E. M., . . . Guchelaar, H. J. (2013). CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. *Breast Cancer Res Treat*, 140(2), 363-373.
964. Dhalla, I. A., Gomes, T., Yao, Z., Nagge, J., Persaud, N., Hellings, C., . . . Juurlink, D. N. (2013). Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. *Ann Intern Med*, 158(6), 447-455.
965. Di Caro, S., Fini, L., Daoud, Y., Grizzi, F., Gasbarrini, A., De Lorenzo, A., . . . Bloom, S. (2012). Levofloxacin/amoxicillin-based schemes vs quadruple therapy for *Helicobacter pylori* eradication in second-line. *World J Gastroenterol*, 18(40), 5669-5678.
966. Di Trapani, G., Mei, D., Marra, C., Mazza, S., & Capuano, A. (2000). Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. *Clin Ter*, 151(3), 145-148.
967. Diabetes Canada Clinical Practice Guidelines Expert Committee, Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., . . . Simpson, S. (2018). Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. *Can J Diabetes*, 42 Suppl 1, S88-S103.
968. Diav-Citrin, O., Arnon, J., Shechtman, S., Schaefer, C., van Tonningen, M. R., Clementi, M., . . . Ornoy, A. (2005). The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. *Aliment Pharmacol Ther*, 21(3), 269-275.
969. Diaz-Villamarin, X., Davila-Fajardo, C. L., Martinez-Gonzalez, L. J., Carmona-Saez, P., Sanchez-Ramos, J., Alvarez Cubero, M. J., . . . Fernandez-Quesada, F. (2016). Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty. *Pharmacogenomics*, 17(12), 1327-1338.
970. Dickerson, J. E., Hingorani, A. D., Ashby, M. J., Palmer, C. R., & Brown, M. J. (1999). Optimisation of antihypertensive treatment by crossover rotation of four major classes. *Lancet*, 353(9169), 2008-2013.
971. Dickstein, K., & Kjeksus, J. (2002). Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. *Lancet*, 360(9335), 752-760.
972. DiDomenico, R. J., Bress, A. P., Na-Thalang, K., Tsao, Y. Y., Groo, V. L., Deyo, K. L., . . . Bauman, J. L. (2014). Use of a simplified nomogram to individualize digoxin dosing

- versus standard dosing practices in patients with heart failure. *Pharmacotherapy*, 34(11), 1121-1131.
973. Diener, H. C., Agosti, R., Allais, G., Bergmans, P., Bussone, G., Davies, B., . . . van Oene, J. (2007). Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*, 6(12), 1054-1062.
974. Diener, H. C., Bussone, G., Van Oene, J. C., Lahaye, M., Schwalen, S., Goadsby, P. J., & Group, T.-M.-S. (2007). Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia*, 27(7), 814-823.
975. Diener, H. C., Dodick, D. W., Aurora, S. K., Turkel, C. C., DeGryse, R. E., Lipton, R. B., . . . Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*, 30.
976. Diener, H. C., Gendolla, A., Feuersenger, A., Evers, S., Straube, A., Schumacher, H., & Davidai, G. (2009). Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. *Cephalalgia*, 29(9), 921-927.
977. Diener, H. C., Pfaffenrath, V., Schnitker, J., Friede, M., & Henneicke-von Zepelin, H. H. (2005). Efficacy and safety of 6.25 mg t.i.d. feverfew CO₂-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. *Cephalalgia*, 25(11), 1031-1041.
978. Diener, H. C., Rahlfs, V. W., & Danesch, U. (2004). The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. *Eur Neurol*, 51(2), 89-97.
979. Diener, H. C., Tfelt-Hansen, P., Dahlof, C., Lainez, M. J., Sandrini, G., Wang, S. J., . . . Group, M.-S. (2004). Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. *J Neurol*, 251(8), 943-950.
980. Dijkstra, A., Koppelman, G. H., Vonk, J. M., Bruinenberg, M., Schouten, J. P., & Postma, D. S. (2008). Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. *J Allergy Clin Immunol*, 121(6), 1510-1513.
981. Dimopoulos, G., Siempos, I. I., Korbila, I. P., Manta, K. G., & Falagas, M. E. (2007). Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. *Chest*, 132(2), 447-455.
982. Dinesh, M., David, A., & Quraishi, S. N. (2004). Depot pipotiazine palmitate and undecylenate for schizophrenia. *Cochrane Database Syst Rev*(4), CD001720.
983. DiNicolantonio, J. J., Bhutani, J., Lavie, C. J., & O'Keefe, J. H. (2015). Evidence-based diuretics: focus on chlorthalidone and indapamide. *Future Cardiol*, 11(2), 203-217.
984. Direct Rx. (2016). Amoxil (amoxicillin). *US Product Monograph*,
985. Dixon, L. B., Lehman, A. F., & Levine, J. (1995). Conventional antipsychotic medications for schizophrenia. *Schizophr Bull*, 21(4), 567-577.
986. Dobrilla, G., Comberlato, M., Steele, A., & Vallaperta, P. (1989). Drug Treatment of Functional Dyspepsia: A Meta-Analysis of Randomized Controlled Clinical Trials. *Journal of Clinical Gastroenterology*, 11(2), 169-177.

987. Doctors of BC. (2015). BC Guidelines Diabetes Care.
988. Dodick, D. W., Freitag, F., Banks, J., Saper, J., Xiang, J., Rupnow, M., . . . Group, C.-I. (2009). Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther*, *31*(3), 542-559.
989. Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., . . . Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*, *50*.
990. Dojo, M., Azuma, T., Saito, T., Ohtani, M., Muramatsu, A., & Kuriyama, M. (2001). Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin and clarithromycin in Japan. *Dig Liver Dis*, *33*(8), 671-675.
991. Dold, M., Samara, M. T., Li, C., Tardy, M., & Leucht, S. (2015). Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. *Cochrane Database Syst Rev*, *1*, CD009831.
992. Domingues, R. B., Silva, A. L., Domingues, S. A., Aquino, C. C., & Kuster, G. W. (2009). A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. *Arq Neuropsiquiatr*, *67*(4), 973-977.
993. Dong, H., Lu, S. J., Zhang, R., Liu, D. D., Zhang, Y. Z., & Song, C. Y. (2015). Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients. *Eur J Clin Pharmacol*, *71*(6), 681-686.
994. Dong, X. W., Zheng, Q., Zhu, M. M., Tong, J. L., & Ran, Z. H. (2010). Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. *World J Gastroenterol*, *16*(25), 3187-3195.
995. Donnelly, L. A., Doney, A. S., Tavendale, R., Lang, C. C., Pearson, E. R., Colhoun, H. M., . . . Palmer, C. N. (2011). Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. *Clin Pharmacol Ther*, *89*(2), 210-216.
996. Donnelly, L. A., van Zuydam, N. R., Zhou, K., Tavendale, R., Carr, F., Maitland-van der Zee, A. H., . . . Palmer, C. N. (2013). Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. *Pharmacogenet Genomics*, *23*(10), 518-525.
997. Donnelly, M., Zemetkin, A. J., Rapoport, J. L., Ismond, D. R., Weingartner, H., Lane, E., . . . Potter, W. Z. (1986). Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. *Clin Pharmacol Ther*, *39*(1), 72-81.
998. Donovan, M. R., Glue, P., Kolluri, S., & Emir, B. (2010). Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. *J Affect Disord*, *123*(1-3), 9-16.

999. Dore, M. P., Leandro, G., Realdi, G., Sepulveda, A. R., & Graham, D. Y. (2000). Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of *Helicobacter pylori* therapy: a meta-analytical approach. *Dig Dis Sci*, *45*(1), 68-76.
1000. Dorsch, M. P., Gillespie, B. W., Erickson, S. R., Bleske, B. E., & Weder, A. B. (2011). Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. *Hypertension*, *57*(4), 689-694.
1001. Dos Santos-Junior, A., Henriques, T. B., de Mello, M. P., Della Torre, O. H., Paes, L. A., Ferreira-Neto, A. P., . . . Dalgalarrodo, P. (2016). Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents. *Int J Endocrinol*, *2016*, 5872423.
1002. Douglas, R. J. (2012). Corticosteroid injection into the osteoarthritic knee: drug selection, dose, and injection frequency. *Int J Clin Pract*, *66*(7), 699-704.
1003. Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., . . . Kunz, R. (2012). Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, *141*(2 Suppl), e326S-350S.
1004. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *Jama*, *315*(15), 1624-1645.
1005. Dowson, A., Ball, K., & Haworth, D. (2000). Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. *Curr Med Res Opin*, *16*(3), 190-197.
1006. Dowswell, T., & Neilson, J. P. (2008). Interventions for heartburn in pregnancy. *Cochrane Database Syst Rev*(4), CD007065.
1007. Dr Reddy's Laboratories Inc. (2016). Augmentin (amoxicillin/clavulanate). *US Product Monograph*,
1008. Du, L. J., Chen, B. R., Kim, J. J., Kim, S., Shen, J. H., & Dai, N. (2016). *Helicobacter pylori* eradication therapy for functional dyspepsia: Systematic review and meta-analysis. *World J Gastroenterol*, *22*(12), 3486-3495.
1009. Duarte, J. D., Turner, S. T., Tran, B., Chapman, A. B., Bailey, K. R., Gong, Y., . . . Johnson, J. A. (2013). Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. *Pharmacogenomics J*, *13*(3), 257-263.
1010. Dubois, R. W., Melmed, G. Y., Henning, J. M., & Laine, L. (2004). Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. *Aliment Pharmacol Ther*, *19*(2), 197-208.
1011. Ducharme, F. M. (2003). Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. *BMJ*, *326*(7390), 621.
1012. Ducharme, F. M., Dell, S. D., Radhakrishnan, D., Grad, R. M., Watson, W. T., Yang, C. L., & Zelman, M. (2015). Diagnosis and management of asthma in preschoolers: A Canadian

- Thoracic Society and Canadian Paediatric Society position paper. *Can Respir J*, 22(3), 135-143.
1013. Ducharme, F. M., Ni Chroinin, M., Greenstone, I., & Lasserson, T. J. (2010). Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. *Cochrane Database Syst Rev*(4), CD005533.
1014. Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005). Olanzapine for schizophrenia. *Cochrane Database Syst Rev*(2), CD001359.
1015. Dujic, T., Zhou, K., Yee, S. W., van Leeuwen, N., de Keyser, C. E., Javorsky, M., . . . Pearson, E. R. (2017). Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. *Clin Pharmacol Ther*, 101(6), 763-772.
1016. Duncan, J. S., Sander, J. W., Sisodiya, S. M., & Walker, M. C. (2006). Adult epilepsy. *Lancet*, 367(9516), 1087-1100.
1017. Dunner, D. L., Laubmeier, K. K., Manos, G., Forbes, R. A., Baker, R. A., & Berman, R. M. (2012). Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials. *Prim Care Companion CNS Disord*, 14(6).
1018. Durgam, S., Earley, W., Lipschitz, A., Guo, H., Laszlovszky, I., Nemeth, G., . . . Yatham, L. N. (2016). An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. *Am J Psychiatry*, 173(3), 271-281.
1019. Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Nemeth, G., & Laszlovszky, I. (2015). The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. *Bipolar Disord*, 17(1), 63-75.
1020. Dutch Pharmacogenetics Working Group (DPWG). (2019). Pharmacogenomics guidelines. Retrieved from <https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>
1021. Dwyer, J. P., Jayasekera, C., & Nicoll, A. (2014). Analgesia for the cirrhotic patient: a literature review and recommendations. *J Gastroenterol Hepatol*, 29(7), 1356-1360.
1022. Eap, C. B., Lessard, E., Baumann, P., Brawand-Amey, M., Yessine, M. A., O'Hara, G., & Turgeon, J. (2003). Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. *Pharmacogenetics*, 13(1), 39-47.
1023. Ebbert, J. O., Croghan, I. T., Sood, A., Schroeder, D. R., Hays, J. T., & Hurt, R. D. (2009). Varenicline and bupropion sustained-release combination therapy for smoking cessation. *Nicotine Tob Res*, 11(3), 234-239.
1024. Ebbert, J. O., Hatsukami, D. K., Croghan, I. T., & et al. (2014). Combination varenicline and bupropion sr for tobacco-dependence treatment in cigarette smokers: A randomized trial. *Jama*, 311(2), 155-163.
1025. Ebell, M. H. (2005). Evidence-based initiation of warfarin (Coumadin). *Am Fam Physician*, 71(4), 763-765.
1026. Ebina, K., Hashimoto, J., Kashii, M., Hirao, M., Kaneshiro, S., Noguchi, T., . . . Yoshikawa, H. (2017). The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. *J Bone Miner Metab*, 35(1), 91-98.

1027. Education Medicaid Integrity Contractor for the CMS Medicaid Integrity Program. (2013). Atypical antipsychotics: US Food and Drug Administration-approved indications and dosages for use in adults. In: Department of Health and Human Services, USA.
1028. Edwards, O. M., Huskisson, E. C., & Taylor, R. T. (1970). Azotaemia aggravated by tetracycline. *Br Med J*, 1(5687), 26-27.
1029. Eichhorn, E. J., Domanski, M. J., Krause-Steinrauf, H., Bristow, M. R., & Lavori, P. W. (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med*, 344(22), 1659-1667.
1030. Einarson, T. R., & Iskedjian, M. (2001). *Novel antipsychotics for patients with attention-deficit hyperactivity disorder: a systematic review* (1894620089). Retrieved from Ottawa:
1031. Eisai Inc. (2018). Aciphex (rabeprazole). *US Product Monograph*,
1032. Eli Lilly and Company. (2016). Forteo (teriparatide). *US Product Monograph*,
1033. Eli Lilly and Company. (2017). Cymbalta (duloxetine). *US Product Monograph*,
1034. Eli Lilly and Company. (2018). Effient (prasugrel). *US Product Monograph*,
1035. Eli Lilly and Company. (2018). Evista (raloxifene). *US Product Monograph*,
1036. Eli Lilly and Company. (2018). Strattera (atomoxetine). *US Product Monograph*,
1037. Eli Lilly and Company. (2018). Trulicity (dulaglutide). *US Product Monograph*,
1038. Eli Lilly and Company. (2018). Zyprexa (olanzapine). *US Product Monograph*,
1039. Eli Lilly Canada Inc. (2008). Evista (raloxifene). *CA Product Monograph*,
1040. Eli Lilly Canada Inc. (2014). Effient (prasugrel). *CA Product Monograph*,
1041. Eli Lilly Canada Inc. (2015). Strattera (atomoxetine). *CA Product Monograph*,
1042. Eli Lilly Canada Inc. (2016). Basaglar (Insulin glargine). *CA Product Monograph*,
1043. Eli Lilly Canada Inc. (2016). Cymbalta (duloxetine). *CA Product Monograph*,
1044. Eli Lilly Canada Inc. (2016). Humalog (Insulin lispro). *CA Product Monograph*,
1045. Eli Lilly Canada Inc. (2016). Humulin N (Insulin NPH). *CA Product Monograph*,
1046. Eli Lilly Canada Inc. (2016). Prozac (fluoxetine). *CA Product Monograph*,
1047. Eli Lilly Canada Inc. (2016). Zyprexa (olanzapine). *CA Product Monograph*,
1048. Eli Lilly Canada Inc. (2017). Trulicity (dulaglutide). *CA Product Monograph*,
1049. Eliopoulos, G. M. (2018). Cefdinir. In *Sanford Guide Web Edition* (
1050. Eliopoulos, G. M. (2018). Cephalexin. In *Sanford Guide Web Edition* (
1051. Eliopoulos, G. M. (2019). Cefepime. In *Sanford Guide Web Edition* (
1052. Eliopoulos, G. M. (2019). Ertapenem. In *Sanford Guide Web Edition* (
1053. Eliopoulos, G. M. (2019). Sulfamethoxazole-trimethoprim. *Sanford Guide Web Edition*,
1054. Ell, C., Schoerner, C., Solbach, W., Stolte, M., Vieth, M., Ridl, W., & Moser, W. (2001). The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxicillin and metronidazole for eradication of *Helicobacter pylori*. *Eur J Gastroenterol Hepatol*, 13(6), 685-691.
1055. Ellingrod, V. L., Miller, D., Schultz, S. K., Wehring, H., & Arndt, S. (2002). CYP2D6 polymorphisms and atypical antipsychotic weight gain. *Psychiatr Genet*, 12(1), 55-58.
1056. Ellingrod, V. L., Perry, P. J., Ringold, J. C., Lund, B. C., Bever-Stille, K., Fleming, F., . . . Miller, D. (2005). Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. *Am J Med Genet B Neuropsychiatr Genet*, 134B(1), 76-78.

1057. El-Mallakh, R. S., Elmaadawi, A. Z., Gao, Y., Lohano, K., & Roberts, R. J. (2011). Current and emerging therapies for the management of bipolar disorders. *J Cent Nerv Syst Dis*, 3, 189-197.
1058. Endo Pharmaceuticals Inc. (2012). Frova (frovatriptan). *US Product Monograph*,
1059. Endo Pharmaceuticals Inc. (2017). Theo 24 (theophylline). *US Product Monograph*,
1060. Endo Pharmaceuticals Inc. (2018). Frova (frovatriptan). *US Product Monograph*,
1061. Endo Pharmaceuticals Inc. (2018). Percocet (oxycodone /acetaminophen). *US Product Monograph*,
1062. Endo Pharmaceuticals Inc. (2018). Voltaren (diclofenac sodium gel). *US Product Monograph*,
1063. Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014). Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. *Lancet*, 384(9961), 2228-2234.
1064. Eng, N. F., Ybazeta, G., Chapman, K., Fraleigh, N. L., Letto, R., Altman, E., & Diaz-Mitoma, F. (2015). Antimicrobial susceptibility of Canadian isolates of *Helicobacter pylori* in Northeastern Ontario. *Can J Infect Dis Med Microbiol*, 26(3), 137-144.
1065. Enggaard, T. P., Poulsen, L., Arendt-Nielsen, L., Brosen, K., Ossig, J., & Sindrup, S. H. (2006). The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. *Anesth Analg*, 102(1), 146-150.
1066. Enthoven, W. T., Roelofs, P. D., Deyo, R. A., van Tulder, M. W., & Koes, B. W. (2016). Non-steroidal anti-inflammatory drugs for chronic low back pain. *Cochrane Database Syst Rev*, 2, CD012087.
1067. Eon Labs Inc. (2016). Bisoprolol. *US Product Monograph*,
1068. Epp, A., Larochelle, A., Lovatsis, D., Walter, J. E., Easton, W., Farrell, S. A., . . . Gynaecologists of, C. (2010). Recurrent urinary tract infection. *J Obstet Gynaecol Can*, 32(11), 1082-1101.
1069. ER Squibb & Sons LLC. (2018). Eliquis (apixaban). *US Product Monograph*,
1070. ERFA Canada 2012 Inc. (2015). Nardil (phenelzine). *CA Product Monograph*,
1071. Eriksson, S., Langstrom, G., Rikner, L., Carlsson, R., & Naesdal, J. (1995). Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. *Eur J Gastroenterol Hepatol*, 7(5), 467-475.
1072. Ermer, J., Corcoran, M., Lassetter, K., Marbury, T., Yan, B., & Martin, P. T. (2016). A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function. *Ther Drug Monit*, 38(4), 546-555.
1073. Eschaliel, R., McMurray, J. J., Swedberg, K., van Veldhuisen, D. J., Krum, H., Pocock, S. J., . . . Pitt, B. (2013). Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). *J Am Coll Cardiol*, 62(17), 1585-1593.
1074. Espadaler, J., Tuson, M., Lopez-Ibor, J. M., Lopez-Ibor, F., & Lopez-Ibor, M. I. (2017). Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. *CNS Spectr*, 22(4), 315-324.

1075. Essa, A. S., Kramer, J. R., Graham, D. Y., & Treiber, G. (2009). Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for *Helicobacter pylori* eradication. *Helicobacter*, *14*(2), 109-118.
1076. Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009). Clozapine versus typical neuroleptic medication for schizophrenia. *Cochrane Database Syst Rev*(1), CD000059.
1077. Ettinger, B., San Martin, J., Crans, G., & Pavo, I. (2004). Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. *J Bone Miner Res*, *19*(5), 745-751.
1078. Evans, D. J., Kew, K. M., Anderson, D. E., & Boyter, A. C. (2015). Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. *Cochrane Database Syst Rev*(7), CD011437.
1079. Evans, K. L., Tuttle, K. R., Folt, D. A., Dawson, T., Haller, S. T., Brewster, P. S., . . . Cooper, C. J. (2014). Use of renin-angiotensin inhibitors in people with renal artery stenosis. *Clin J Am Soc Nephrol*, *9*(7), 1199-1206.
1080. Evans, R. W., Tepper, S. J., Shapiro, R. E., Sun-Edelstein, C., & Tietjen, G. E. (2010). The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. *Headache*, *50*(6), 1089-1099.
1081. Evers, S., Afra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sandor, P. S. (2009). EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. *Eur J Neurol*, *16*(9), 968-981.
1082. Evidence Review Committee, M., Bittl, J. A., Baber, U., Bradley, S. M., & Wijeyesundera, D. N. (2016). Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, *134*(10), e156-178.
1083. Evins, A. E., Cather, C., Culhane, M. A., Birnbaum, A., Horowitz, J., Hsieh, E., . . . Goff, D. C. (2007). A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol*, *27*(4), 380-386.
1084. Evins, A. E., Cather, C., Pratt, S. A., Pachas, G. N., Hoepfner, S. S., Goff, D. C., . . . Schoenfeld, D. A. (2014). Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *Jama*, *311*(2), 145-154.
1085. Ezekowitz, J. A., Becher, H., Belenkie, I., Clark, A. M., Duff, H. J., Friedrich, M. G., . . . Dyck, J. R. (2014). The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. *BMC Cardiovasc Disord*, *14*, 91.
1086. Ezekowitz, J. A., & McAlister, F. A. (2009). Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. *Eur Heart J*, *30*(4), 469-477.

1087. Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., . . . Sussex, B. (2017). 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. *Can J Cardiol*, *33*(11), 1342-1433.
1088. Fabbri, C., Tansey, K. E., Perlis, R. H., Hauser, J., Henigsberg, N., Maier, W., . . . Lewis, C. M. (2018). Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. *Eur Neuropsychopharmacol*, *28*(8), 945-954.
1089. Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009). Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. *Lancet*, *374*(9691), 695-703.
1090. Falk, N. P., Hughes, S. W., & Rodgers, B. C. (2016). Medications for Chronic Asthma. *Am Fam Physician*, *94*(6), 454-462.
1091. Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., & Møller, H. J. (2005). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. *World J Biol Psychiatry*, *6*(3), 132-191.
1092. Fallo, F., Gregianin, M., Bui, F., Macri, C., Folino, P., & Mantero, F. (1991). Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment. *Eur J Clin Pharmacol*, *40*(3), 309-311.
1093. Fallone, C. A., Chiba, N., van Zanten, S. V., Fischbach, L., Gisbert, J. P., Hunt, R. H., . . . Marshall, J. K. (2016). The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. *Gastroenterology*, *151*(1), 51-69.e14.
1094. Fangbin, Z., Xiang, G., Liang, D., Hui, L., Xueding, W., Baili, C., . . . Pinjin, H. (2016). Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease: an observational study. *Medicine (Baltimore)*, *95*(15), e3326.
1095. Faquih, A. E., Memon, R. I., Hafeez, H., Zeshan, M., & Naveed, S. (2019). A Review of Novel Antidepressants: A Guide for Clinicians. *Cureus*, *11*(3), e4185.
1096. Farne, H. A., Wilson, A., Powell, C., Bax, L., & Milan, S. J. (2017). Anti-IL5 therapies for asthma. *Cochrane Database Syst Rev*, *9*, CD010834.
1097. Faruque, L. I., Ehteshami-Afshar, A., Wiebe, N., Tjosvold, L., Homik, J., & Tonelli, M. (2013). A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. *Semin Arthritis Rheum*, *43*(3), 367-375.
1098. Fashner, J., & Gitu, A. C. (2015). Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection. *Am Fam Physician*, *91*(4), 236-242.
1099. Fasipe, O. J. (2019). The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. *IBRO Rep*, *6*, 95-110.
1100. Fava, M. (2006). Prospective studies of adverse events related to antidepressant discontinuation. *J Clin Psychiatry*, *67 Suppl 4*, 14-21.
1101. Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., . . . Ehrlich, E. (2016). Opioid Modulation With Buprenorphine/Samidorphane as Adjunctive

- Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*, appiajp201515070921.
1102. Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., . . . Pollack, M. (2012). A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). *Psychother Psychosom*, *81*(2), 87-97.
 1103. Faxon, D. P., Eikelboom, J. W., Berger, P. B., Holmes, D. R., Jr., Bhatt, D. L., Moliterno, D. J., . . . Angiolillo, D. J. (2011). Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. *Circ Cardiovasc Interv*, *4*(5), 522-534.
 1104. FDA. (2018). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. *FDA Drug Safety Communication*,
 1105. Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., . . . Singh, J. B. (2019). Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). *Int J Neuropsychopharmacol*.
 1106. Fei, X., Shu, Q., Hua, B. Z., Wang, S. Y., Chen, Z. Y., Ge, W. H., & Fang, Y. (2018). NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review. *Medicine (Baltimore)*, *97*(17), e0301.
 1107. Feldman, M., & Belanger, S. (2009). Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder. *Paediatr Child Health*, *14*(9), 593-602.
 1108. Feldman, R. D., Zou, G. Y., Vandervoort, M. K., Wong, C. J., Nelson, S. A., & Feagan, B. G. (2009). A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. *Hypertension*, *53*(4), 646-653.
 1109. Felehgari, V., Rahimi, Z., Mozafari, H., & Vaisi-Raygani, A. (2011). ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. *Mol Cell Biochem*, *346*(1-2), 23-30.
 1110. Felson, D. T. (2006). Clinical practice. Osteoarthritis of the knee. *N Engl J Med*, *354*(8), 841-848.
 1111. Feltner, D. E., Liu-Dumaw, M., Schweizer, E., & Bielski, R. (2011). Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. *Int Clin Psychopharmacol*, *26*(4), 213-220.
 1112. Feng, Q., Wilke, R. A., & Baye, T. M. (2012). Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. *Pharmacogenomics*, *13*(5), 579-594.
 1113. Feng, X., Li, Y., & Gao, W. (2015). Prophylaxis on gout flares after the initiation of urate-lowering therapy: a retrospective research. *Int J Clin Exp Med*, *8*(11), 21460-21465.
 1114. Feng, Y., Pollock, B. G., Ferrell, R. E., Kimak, M. A., Reynolds, C. F., 3rd, & Bies, R. R. (2006). Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. *Br J Clin Pharmacol*, *61*(5), 558-569.
 1115. Fennerty, M. B., Finke, K. B., Kushner, P. R., Peura, D. A., Record, L., Riley, L., . . . Wright, W. L. (2009). Short- and long-term management of heartburn and other acid-related

- disorders: development of an algorithm for primary care providers. *J Fam Pract*, 58(7 Suppl Short), S1-12.
1116. Fernandez-Santander, A., Gaibar, M., Novillo, A., Romero-Lorca, A., Rubio, M., Chicharro, L. M., . . . Bandres, F. (2013). Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. *PLoS One*, 8(7), e70183.
1117. Ferreiros, N., Dresen, S., Hermanns-Clausen, M., Auwaerter, V., Thierauf, A., Muller, C., . . . Weinmann, W. (2009). Fatal and severe codeine intoxication in 3-year-old twins--interpretation of drug and metabolite concentrations. *Int J Legal Med*, 123(5), 387-394.
1118. Fiegenbaum, M., da Silveira, F. R., Van der Sand, C. R., Van der Sand, L. C., Ferreira, M. E., Pires, R. C., & Hutz, M. H. (2005). The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. *Clin Pharmacol Ther*, 78(5), 551-558.
1119. Figueiras, A., Estany-Gestal, A., Aguirre, C., Ruiz, B., Vidal, X., Carvajal, A., . . . group, E. (2016). CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. *Pharmacogenet Genomics*, 26(2), 66-73.
1120. Fijal, B. A., Guo, Y., Li, S. G., Ahl, J., Goto, T., Tanaka, Y., . . . Upadhyaya, H. P. (2015). CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. *J Clin Pharmacol*, 55(10), 1167-1174.
1121. Fijal, B. A., Kinon, B. J., Kapur, S., Stauffer, V. L., Conley, R. R., Jamal, H. H., . . . Houston, J. P. (2009). Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. *Pharmacogenomics J*, 9(5), 311-318.
1122. Filigheddu, F., Argiolas, G., Bulla, E., Troffa, C., Bulla, P., Fadda, S., . . . Glorioso, N. (2008). Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. *Pharmacogenomics*, 9(10), 1419-1427.
1123. Fillion, K. B., Chateau, D., Targownik, L. E., Gershon, A., Durand, M., Tamim, H., . . . Dormuth, C. R. (2014). Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. *Gut*, 63(4), 552-558.
1124. Filipec Kanizaj, T., Katicic, M., Skurla, B., Ticak, M., Plecko, V., & Kalenic, S. (2009). Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. *Helicobacter*, 14(1), 29-35.
1125. Findling, R. L., Greenhill, L. L., McNamara, N. K., Demeter, C. A., Kotler, L. A., O'Riordan, M. A., . . . Reed, M. D. (2007). Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*, 17(4), 433-445.
1126. Findling, R. L., Nucci, G., Piergies, A. A., Gomeni, R., Bartolic, E. I., Fong, R., . . . Danoff, T. M. (2006). Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. *Neuropsychopharmacology*, 31(6), 1274-1285.

1127. Finkelstein, Y., Bournissen, F. G., Hutson, J. R., & Shannon, M. (2009). Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis. *J Asthma*, 46(9), 900-905.
1128. Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., . . . Wallace, M. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*, 14(2), 162-173.
1129. Fischbach, L., & Evans, E. L. (2007). Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for *Helicobacter pylori*. *Aliment Pharmacol Ther*, 26(3), 343-357.
1130. Fischer, A. G., Endrass, T., Goebel, I., Reuter, M., Montag, C., Kubisch, C., & Ullsperger, M. (2015). Interactive effects of citalopram and serotonin transporter genotype on neural correlates of response inhibition and attentional orienting. *Neuroimage*, 116, 59-67.
1131. Fitzcharles, M. A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choiniere, M., . . . Shir, Y. (2013). 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. *Pain Res Manag*, 18(3), 119-126.
1132. Flannery, G., Gehrig-Mills, R., Billah, B., & Krum, H. (2008). Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. *Am J Cardiol*, 101(6), 865-869.
1133. Flather, M. D., Shibata, M. C., Coats, A. J., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., . . . Poole-Wilson, P. A. (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*, 26(3), 215-225.
1134. Flather, M. D., Yusuf, S., Kober, L., Pfeffer, M., Hall, A., Murray, G., . . . Braunwald, E. (2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet*, 355(9215), 1575-1581.
1135. Fleischhacker, W. W., Sanchez, R., Perry, P. P., Jin, N., Peters-Strickland, T., Johnson, B. R., . . . Kane, J. M. (2014). Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. *Br J Psychiatry*, 205(2), 135-144.
1136. Fleischmann, R., Kerr, B., Yeh, L. T., Suster, M., Shen, Z., Polvent, E., . . . Baumgartner, S. (2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. *Rheumatology (Oxford)*, 53(12), 2167-2174.
1137. Florez, J. C., Jablonski, K. A., Taylor, A., Mather, K., Horton, E., White, N. H., . . . Pollin, T. I. (2012). The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. *Diabetes Care*, 35(9), 1864-1867.
1138. Fonarow, G. C., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., . . . Yancy, C. W. (2010). Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). *Circulation*, 122(6), 585-596.

1139. Fonseca, J. E., Carvalho, T., Cruz, M., Nero, P., Sobral, M., Mourao, A. F., . . . Branco, J. C. (2005). Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. *Ann Rheum Dis*, *64*(5), 793-794.
1140. Ford, A. C., Luthra, P., Tack, J., Boeckstaens, G. E., Moayyedi, P., & Talley, N. J. (2017). Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. *Gut*, *66*(3), 411-420.
1141. Ford, A. C., & Moayyedi, P. (2008). Current guidelines for dyspepsia management. *Dig Dis*, *26*(3), 225-230.
1142. Forget, P., le Polain de Waroux, B., Wallemacq, P., & Gala, J. L. (2008). Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. *J Pain Symptom Manage*, *36*(1), 92-96.
1143. Fornaro, M., Martino, M., Mattei, C., Prestia, D., Vinciguerra, V., De Berardis, D., . . . Fornaro, P. (2014). Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. *Eur Neuropsychopharmacol*, *24*(8), 1269-1278.
1144. Forouzanfar, T., Koke, A. J., van Kleef, M., & Weber, W. E. (2002). Treatment of complex regional pain syndrome type I. *Eur J Pain*, *6*(2), 105-122.
1145. Foster, A., Mobley, E., & Wang, Z. (2007). Complicated pain management in a CYP450 2D6 poor metabolizer. *Pain Pract*, *7*(4), 352-356.
1146. Foulds, J. A., Ton, K., Kennedy, M. A., Adamson, S. J., Mulder, R. T., & Sellman, J. D. (2015). OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. *Pharmacogenet Genomics*, *25*(5), 270-273.
1147. Fountoulakis, K. N., & Vieta, E. (2009). Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. *Ann Gen Psychiatry*, *8*, 16.
1148. Fountoulakis, K. N., Vieta, E., & Schmidt, F. (2011). Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. *J Affect Disord*, *133*(3), 361-370.
1149. Fowkes, F. G., Price, J. F., Stewart, M. C., Butcher, I., Leng, G. C., Pell, A. C., . . . Aspirin for Asymptomatic Atherosclerosis, T. (2010). Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. *Jama*, *303*(9), 841-848.
1150. Fox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008). Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. *Lancet*, *372*(9641), 807-816.
1151. Fox, K. M. (2003). Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*, *362*(9386), 782-788.
1152. Francis, R. S., May, J. R., & Spicer, C. C. (1961). Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. A report to the Research Committee of the British Tuberculosis Association by its Bronchitis Subcommittee. *BMJ*, *2*(5258), 979-985.
1153. Frau, F., Zaninello, R., Salvi, E., Ortu, M. F., Braga, D., Velayutham, D., . . . Glorioso, N. (2014). Genome-wide association study identifies CAMKID variants involved in blood

- pressure response to losartan: the SOPHIA study. *Pharmacogenomics*, 15(13), 1643-1652.
1154. Frech, E. J., & Go, M. F. (2009). Treatment and chemoprevention of NSAID-associated gastrointestinal complications. *Ther Clin Risk Manag*, 5, 65-73.
1155. Freedberg, D. E., Kim, L. S., & Yang, Y. X. (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. *Gastroenterology*, 152(4), 706-715.
1156. Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J. (1999). beta Blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*, 318(7200), 1730-1737.
1157. Freitag, F. G., Collins, S. D., Carlson, H. A., Goldstein, J., Saper, J., Silberstein, S., . . . Depakote, E. R. M. S. G. (2002). A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. *Neurology*, 58(11), 1652-1659.
1158. Freitag, F. G., & Diamond, S. (1984). Nadolol and placebo comparison study in the prophylactic treatment of migraine. *J Am Osteopath Assoc*, 84(4), 343-347.
1159. French, J. A., & Pedley, T. A. (2008). Clinical practice. Initial management of epilepsy. *N Engl J Med*, 359(2), 166-176.
1160. Fresenius Kabi Canada Ltd. (2015). Ceftriaxone. *CA Product Monograph*,
1161. Fresenius Kabi Canada Ltd. (2017). Tobramycin. *CA Product Monograph*,
1162. Fricke-Galindo, I., Martinez-Juarez, I. E., Monroy-Jaramillo, N., Jung-Cook, H., Falfan-Valencia, R., Ortega-Vazquez, A., . . . Lopez-Lopez, M. (2014). HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. *Pharmacogenomics*, 15(15), 1881-1891.
1163. Friedman, B. W., Irizarry, E., Solorzano, C., Latev, A., Rosa, K., Zias, E., . . . Gallagher, E. J. (2017). Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. *Neurology*, 89(20), 2075-2082.
1164. Friedrichsdorf, S. J., Nugent, A. P., & Strobl, A. Q. (2013). Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports. *J Opioid Manag*, 9(2), 151-155.
1165. Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T. (2006). Nicotine and non-nicotine smoking cessation pharmacotherapies. *Cardiol Rev*, 14(2), 57-73.
1166. Fu, Q., Li, Y. P., Gao, Y., Yang, S. H., Lu, P. Q., Jia, M., & Zhang, L. R. (2013). Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. *Eur J Clin Pharmacol*, 69(6), 1269-1274.
1167. Fuchs, K. H., Babic, B., Breithaupt, W., Dallemagne, B., Fingerhut, A., Furnee, E., . . . Zaninotto, G. (2014). EAES recommendations for the management of gastroesophageal reflux disease. *Surg Endosc*, 28(6), 1753-1773.
1168. Fukuda, K., Hayashida, M., Ide, S., Saita, N., Kokita, Y., Kasai, S., . . . Ikeda, K. (2009). Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. *Pain*, 147(1-3), 194-201.

1169. Fukuda, T., Nishida, Y., Zhou, Q., Yamamoto, I., Kondo, S., & Azuma, J. (2000). The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. *Eur J Clin Pharmacol*, 56(2), 175-180.
1170. Fukuda, T., Yamamoto, I., Nishida, Y., Zhou, Q., Ohno, M., Takada, K., & Azuma, J. (1999). Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. *Br J Clin Pharmacol*, 47(4), 450-453.
1171. Fumagalli, I., & Hammer, B. (1994). Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. *Scand J Gastroenterol*, 29(1), 33-37.
1172. Furman, K. D., Grimm, D. R., Mueller, T., Holley-Shanks, R. R., Bertz, R. J., Williams, L. A., . . . Katz, D. A. (2004). Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. *Pharmacogenetics*, 14(5), 279-284.
1173. Furmark, T., Appel, L., Michelgard, A., Wahlstedt, K., Ahs, F., Zancan, S., . . . Fredrikson, M. (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. *Biol Psychiatry*, 58(2), 132-142.
1174. Furuta, T., Ohashi, K., Kosuge, K., Zhao, X. J., Takashima, M., Kimura, M., . . . Ishizaki, T. (1999). CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. *Clin Pharmacol Ther*, 65(5), 552-561.
1175. Furuta, T., Sagehashi, Y., Shirai, N., Sugimoto, M., Nakamura, A., Kodaira, M., . . . Hishida, A. (2005). Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. *Clin Gastroenterol Hepatol*, 3(6), 564-573.
1176. Furuta, T., Shirai, N., Kodaira, M., Sugimoto, M., Nogaki, A., Kuriyama, S., . . . Hishida, A. (2007). Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. *Clin Pharmacol Ther*, 81(4), 521-528.
1177. Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Okudaira, K., Kajimura, M., & Hishida, A. (2005). Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. *Aliment Pharmacol Ther*, 22(1), 67-74.
1178. Furuta, T., Shirai, N., Takashima, M., Xiao, F., Hanai, H., Sugimura, H., . . . Kaneko, E. (2001). Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. *Clin Pharmacol Ther*, 69(3), 158-168.
1179. Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., . . . Hanai, H. (2002). Effect of cytochrome P450 C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. *Clin Pharmacol Ther*, 72(4), 453-460.
1180. Furuta, T., Shirai, N., Xiao, F., El-Omar, E. M., Rabkin, C. S., Sugimura, H., . . . Ohashi, K. (2004). Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. *Clin Gastroenterol Hepatol*, 2(1), 22-30.
1181. Furuta, T., Sugimoto, M., Kodaira, C., Nishino, M., Yamade, M., Ikuma, M., . . . Hishida, A. (2009). CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. *Eur J Clin Pharmacol*, 65(7), 693-698.

1182. Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., . . . Yancy, C. W. (2011). 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*, *123*(10), e269-367.
1183. Fux, R., Morike, K., Prohmer, A. M., Delabar, U., Schwab, M., Schaeffeler, E., . . . Kivisto, K. T. (2005). Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. *Clin Pharmacol Ther*, *78*(4), 378-387.
1184. Gaedigk, A., Simon, S. D., Pearce, R. E., Bradford, L. D., Kennedy, M. J., & Leeder, J. S. (2008). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther*, *83*(2), 234-242.
1185. Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., . . . McLeod, H. L. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. *Clin Pharmacol Ther*, *84*(3), 326-331.
1186. Galvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., . . . Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial. *J Psychopharmacol*, *32*(4), 397-407.
1187. Gan, S. H., Ismail, R., Wan Adnan, W. A., & Wan, Z. (2002). Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. *J Pharm Biomed Anal*, *30*(2), 189-195.
1188. Gappa, M., Zachgo, W., von Berg, A., Kamin, W., Stern-Strater, C., & Steinkamp, G. (2009). Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). *Pediatr Pulmonol*, *44*(11), 1132-1142.
1189. Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., . . . Umpierrez, G. E. (2019). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. *Endocr Pract*, *25*(1), 69-100.
1190. Garcia, M., Macias, R. M., Cubero, J. J., Benitez, J., Caravaca, F., & Gervasini, G. (2013). ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. *Eur J Clin Pharmacol*, *69*(3), 385-393.
1191. Garcia-Monco, J. C., Foncea, N., Bilbao, A., Ruiz de Velasco, I., & Gomez-Beldarrain, M. (2007). Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. *Cephalalgia*, *27*(8), 920-928.
1192. Gardner, D. M., Baldessarini, R. J., & Waraich, P. (2005). Modern antipsychotic drugs: a critical overview. *CMAJ*, *172*(13), 1703-1711.
1193. Garg, D. C., Baltodano, N., Jallad, N. S., Perez, G., Oster, J. R., Eshelman, F. N., & Weidler, D. J. (1986). Pharmacokinetics of ranitidine in patients with renal failure. *J Clin Pharmacol*, *26*(4), 286-291.
1194. Garg, R., & Yusuf, S. (1995). Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *Jama*, *273*(18), 1450-1456.

1195. Gargiulo, G., Giugliano, G., Brevetti, L., Sannino, A., Schiattarella, G. G., Serino, F., . . . Esposito, G. (2012). Use of statins in lower extremity artery disease: a review. *BMC Surg, 12 Suppl 1*, S15.
1196. Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., . . . Lohr, K. N. (2011). Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. *Ann Intern Med, 155*(11), 772-785.
1197. Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P., & Desmeules, J. (2004). Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med, 351*(27), 2827-2831.
1198. Gash, A. J., Chhabra, S., & Eccleston, D. (1995). Lithium augmentation in a case of renal impairment: risk vs. benefit. *J Affect Disord, 34*(1), 51-53.
1199. Gasso, P., Rodriguez, N., Mas, S., Pagerols, M., Blazquez, A., Plana, M. T., . . . Lafuente, A. (2014). Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. *Pharmacogenomics J, 14*(5), 457-462.
1200. Gaul, C., Diener, H. C., & Danesch, U. (2015). Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. *J Headache Pain, 16*, 516.
1201. Gauthiez, E., Habfast-Robertson, I., Rueger, S., Kutalik, Z., Aubert, V., Berg, T., . . . Swiss Hepatitis C Cohort Study. (2017). A systematic review and meta-analysis of HCV clearance. *Liver Int, 37*(10), 1431-1445.
1202. Gawronska-Szklarz, B., Adamiak-Giera, U., Wyska, E., Kurzawski, M., Gornik, W., Kaldonska, M., & Drozdziak, M. (2012). CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. *Eur J Clin Pharmacol, 68*(9), 1267-1274.
1203. Gawronska-Szklarz, B., Wrzesniewska, J., Starzynska, T., Pawlik, A., Safranow, K., Ferenc, K., & Drozdziak, M. (2005). Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. *Eur J Clin Pharmacol, 61*(5-6), 375-379.
1204. Gaynes, B. N., Dusetzina, S. B., Ellis, A. R., Hansen, R. A., Farley, J. F., Miller, W. C., & Sturmer, T. (2012). Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. *J Clin Psychopharmacol, 32*(1), 114-119.
1205. Gazouli, M., Pachoula, I., Panayotou, I., Chouliaras, G., Anagnou, N. P., Chrousos, G., & Roma, E. (2012). Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease. *Ann Gastroenterol, 25*(3), 249-253.
1206. GD Searle LLC Division of Pfizer Inc. (2018). Celebrex (celecoxib) *US Product Monograph*,
1207. GD Searle LLC Division of Pfizer Inc. (2018). Cytotec (misoprostol). *US Product Monograph*,
1208. GD Searle LLC Division of Pfizer Inc. (2018). Flagyl (metronidazole). *US Product Monograph*,
1209. GD Searle LLC Division of Pfizer Inc. (2018). Inspra (eplerenone). *US Product Monograph*,

1210. GD Searle LLC Division of Pfizer Inc. (2019). Calan SR (verapamil hydrochloride). *US Product Monograph*,
1211. Gearry, R. B., Barclay, M. L., Roberts, R. L., Harraway, J., Zhang, M., Pike, L. S., . . . Florkowski, C. M. (2005). Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. *Intern Med J*, 35(10), 580-585.
1212. Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. *Br J Psychiatry*, 194(1), 4-9.
1213. Geddes, J. R., Goodwin, G. M., Rendell, J., Azorin, J. M., Cipriani, A., Ostacher, M. J., . . . Juszczak, E. (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. *Lancet*, 375(9712), 385-395.
1214. Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. *Lancet*, 381(9878), 1672-1682.
1215. Gelernter, C. S., Uhde, T. W., Cimbolic, P., Arnkoff, D. B., Vittone, B. J., Tancer, M. E., & Bartko, J. J. (1991). Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. *Arch Gen Psychiatry*, 48(10), 938-945.
1216. Gemini Laboratories LLC. (2019). Prandin (repaglinide). *US Product Monograph*,
1217. Gendep Investigators, Mars Investigators, & Star D Investigators. (2013). Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. *Am J Psychiatry*, 170(2), 207-217.
1218. Genentech Inc. (2010). Naproxen. *US Product Monograph*,
1219. Genentech Inc. (2018). Xolair (omalizumab). *US Product Monograph*,
1220. Genentech Inc. (2019). Xolair (omalizumab). *US Product Monograph*,
1221. Genin, E., Chen, D. P., Hung, S. I., Sekula, P., Schumacher, M., Chang, P. Y., . . . Roujeau, J. C. (2014). HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. *Pharmacogenomics J*, 14(3), 281-288.
1222. Geraud, G., Lanteri-Minet, M., Lucas, C., & Valade, D. (2004). French guidelines for the diagnosis and management of migraine in adults and children. *Clin Ther*, 26(8), 1305-1318.
1223. Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., . . . Walsh, M. E. (2017). 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, 135(12), e726-e779.
1224. Gerson, L. B., McMahon, D., Olkin, I., Stave, C., & Rockson, S. G. (2012). Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. *Dig Dis Sci*, 57(5), 1304-1313.
1225. Gerstenberg, G., Aoshima, T., Fukasawa, T., Yoshida, K., Takahashi, H., Higuchi, H., . . . Otani, K. (2003). Effects of the CYP 2D6 genotype and cigarette smoking on the steady-

- state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. *Ther Drug Monit*, 25(4), 463-468.
1226. Gerstenberg, G., Aoshima, T., Fukasawa, T., Yoshida, K., Takahashi, H., Higuchi, H., . . . Otani, K. (2003). Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. *Psychopharmacology (Berl)*, 167(4), 443-448.
1227. Gex-Fabry, M., Eap, C. B., Oneda, B., Gervasoni, N., Aubry, J. M., Bondolfi, G., & Bertschy, G. (2008). CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. *Ther Drug Monit*, 30(4), 474-482.
1228. Gibbons, R. D., Hur, K., Brown, C. H., & Mann, J. J. (2009). Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. *Arch Gen Psychiatry*, 66(12), 1354-1360.
1229. Gibbons, R. D., & Mann, J. J. (2013). Varenicline, smoking cessation, and neuropsychiatric adverse events. *Am J Psychiatry*, 170(12), 1460-1467.
1230. Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., . . . Fox, K. A. (2016). Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med*, 375(25), 2423-2434.
1231. Gijssman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A., & Goodwin, G. M. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. *Am J Psychiatry*, 161(9), 1537-1547.
1232. Gilbert, D. N. (2019). Ceftazidime/avibactam. In *Sanford Guide Web Edition* (
1233. Gilbert, R. E., Rabi, D., LaRochelle, P., Leiter, L. A., Jones, C., Ogilvie, R., . . . Woo, V. (2013). Treatment of hypertension. *Can J Diabetes*, 37 Suppl 1, S117-118.
1234. Gill, D., Derry, S., Wiffen, P. J., & Moore, R. A. (2011). Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev*(10), CD009183.
1235. Gill, S. K., O'Brien, L., Einarson, T. R., & Koren, G. (2009). The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. *Am J Gastroenterol*, 104(6), 1541-1545; quiz 1540, 1546.
1236. Gillis, A. M., Verma, A., Talajic, M., Nattel, S., & Dorian, P. (2011). Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. *Can J Cardiol*, 27(1), 47-59.
1237. Gillman, P. K. (2010). Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. *Headache*, 50(2), 264-272.
1238. Gilron, I., Jensen, T. S., & Dickenson, A. H. (2013). Combination pharmacotherapy for management of chronic pain: from bench to bedside. *Lancet Neurol*, 12(11), 1084-1095.
1239. Ginsberg, H. N., Elam, M. B., Lovato, L. C., Crouse, J. R., 3rd, Leiter, L. A., Linz, P., . . . Byington, R. P. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*, 362(17), 1563-1574.
1240. Gisbert, J. P., Barrio, J., Modolell, I., Molina-Infante, J., Aisa, A. P., Castro-Fernandez, M., . . . McNicholl, A. G. (2015). Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. *Dig Dis Sci*, 60(2), 458-464.

1241. Gisbert, J. P., & Calvet, X. (2011). Review article: non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther*, *34*(6), 604-617.
1242. Gisbert, J. P., & Calvet, X. (2012). Update on non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. *Clin Exp Gastroenterol*, *5*, 23-34.
1243. Gisbert, J. P., & Calvet, X. (2013). *Helicobacter Pylori* "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. *Clin Transl Gastroenterol*, *4*, e32.
1244. Gisbert, J. P., Romano, M., Gravina, A. G., Solis-Munoz, P., Bermejo, F., Molina-Infante, J., . . . McNicholl, A. G. (2015). *Helicobacter pylori* second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. *Aliment Pharmacol Ther*, *41*(8), 768-775.
1245. Giubergia, V., Gravina, L., Castanos, C., & Chertkoff, L. (2013). Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol. *Ann Allergy Asthma Immunol*, *110*(3), 156-160.
1246. Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., . . . Antman, E. M. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, *369*(22), 2093-2104.
1247. Giusti, A., & Bianchi, G. (2015). Treatment of complex regional pain syndrome type I with bisphosphonates. *RMD Open*, *1*(Suppl 1), e000056.
1248. Glassman, A. H., Stetner, F., Walsh, B. T., Raizman, P. S., Fleiss, J. L., Cooper, T. B., & Covey, L. S. (1988). Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. *Jama*, *259*(19), 2863-2866.
1249. Glauser, T., Ben-Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kalviainen, R., . . . Tomson, T. (2013). Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia*, *54*(3), 551-563.
1250. GlaxoSmithKline. (2019). Breo Ellipta (fluticasone furoate / vilanterol). *US Product Monograph*,
1251. GlaxoSmithKline. (2019). Flovent Diskus (fluticasone propionate). *US Product Monograph*,
1252. GlaxoSmithKline. (2017). Wellbutrin SR (bupropion). *US Product Monograph*,
1253. GlaxoSmithKline Consumer Healthcare Holdings. (2018). Nicoderm CQ (nicotine patch). *US Product Monograph*,
1254. GlaxoSmithKline Consumer Healthcare Holdings. (2018). Nicorette (nicotine polacrilex). *US Product Monograph*,
1255. GlaxoSmithKline Inc. (2014). Imitrex (sumatriptan). *CA Product Monograph*,
1256. GlaxoSmithKline Inc. (2014). Serevent Diskhaler/Diskus (salmeterol). *CA Product Monograph*,
1257. GlaxoSmithKline Inc. (2016). Amerge (naratriptan). *CA Product Monograph*,
1258. GlaxoSmithKline Inc. (2016). Flovent HFA and Diskus (fluticasone propionate). *CA Product Monograph*,
1259. GlaxoSmithKline Inc. (2016). Paxil (paroxetine). *CA Product Monograph*,
1260. GlaxoSmithKline Inc. (2017). Anoro Ellipta (umeclidinium / vilanterol). *CA Product Monograph*,

1261. GlaxoSmithKline Inc. (2017). Arnuity Ellipta (fluticasone furoate DPI). *CA Product Monograph*,
1262. GlaxoSmithKline Inc. (2017). Fortaz (ceftazidime). *CA Product Monograph*,
1263. GlaxoSmithKline Inc. (2017). Incruse Ellipta (umeclidinium). *CA Product Monograph*,
1264. GlaxoSmithKline Inc. (2017). Ventolin Diskus (salbutamol sulfate DPI) *CA Product Monograph*,
1265. GlaxoSmithKline Inc. (2017). Ventolin HFA (salbutamol sulfate). *CA Product Monograph*,
1266. GlaxoSmithKline Inc. (2017). Ventolin Nebules and Respirator (salbutamol sulfate solution). *CA Product Monograph*,
1267. GlaxoSmithKline Inc. (2018). Advair Diskus (fluticasone propionate / salmeterol). *CA Product Monograph*,
1268. GlaxoSmithKline Inc. (2018). Breo Ellipta (fluticasone furoate / vilanterol). *CA Product Monograph*,
1269. GlaxoSmithKline Inc. (2018). Clavulin (amoxicillin / clavulanic acid). *CA Product Monograph*,
1270. GlaxoSmithKline Inc. (2018). Flovent HFA and Diskus (fluticasone propionate). *CA Product Monograph*,
1271. GlaxoSmithKline Inc. (2018). Nucala (mepolizumab). *CA Product Monograph*,
1272. GlaxoSmithKline Inc. (2019). Breo Ellipta (fluticasone furoate / vilanterol). *CA Product Monograph*,
1273. GlaxoSmithKline Inc. (2019). Parnate (tranylcypromine). *CA Product Monograph*,
1274. GlaxoSmithKline Inc. (2019). Tums. *US Product Information*,
1275. GlaxoSmithKline Inc. (2016). Lamictal (lamotrigine). *CA Product Monograph*,
1276. GlaxoSmithKline LLC. (2016). Amerge (naratriptan). *US Product Monograph*,
1277. GlaxoSmithKline LLC. (2016). Serevent Diskus (salmeterol). *US Product Monograph*,
1278. GlaxoSmithKline LLC. (2017). Advair Diskus (fluticasone propionate / salmeterol). *US Product Monograph*,
1279. GlaxoSmithKline LLC. (2017). Anoro Ellipta (umeclidinium bromide / vilanterol trifenantate). *US Product Monograph*,
1280. GlaxoSmithKline LLC. (2017). Breo Ellipta (fluticasone furoate / vilanterol). *US Product Monograph*,
1281. GlaxoSmithKline LLC. (2017). Coreg (carvedilol). *US Product Monograph*,
1282. GlaxoSmithKline LLC. (2017). Dyazide (hydrochlorothiazide / triamterene). *US Product Monograph*,
1283. GlaxoSmithKline LLC. (2017). Imitrex (sumatriptan nasal spray). *US Product Monograph*,
1284. GlaxoSmithKline LLC. (2017). Imitrex (sumatriptan succinate). *US Product Monograph*,
1285. GlaxoSmithKline LLC. (2017). Incruse Ellipta (umeclidinium). *US Product Monograph*,
1286. GlaxoSmithKline LLC. (2017). Lamictal (lamotrigine). *US Product Monograph*,
1287. GlaxoSmithKline LLC. (2017). Paxil (paroxetine). *US Product Monograph*,
1288. GlaxoSmithKline LLC. (2017). Wellbutrin SR (bupropion). *US Product Monograph*,
1289. GlaxoSmithKline LLC. (2017). Zyban (bupropion). *US Product Monograph*,
1290. GlaxoSmithKline LLC. (2018). Arnuity Ellipta (fluticasone furoate). *US Product Monograph*,

1291. GlaxoSmithKline LLC. (2018). Imitrex (sumatriptan succinate injection). *US Product Monograph*,
1292. GlaxoSmithKline LLC. (2018). Ventolin HFA (albuterol sulfate). *US Product Monograph*,
1293. GlaxoSmithKline LLC. (2018). Zantac (ranitidine). *US Product Monograph*,
1294. GlaxoSmithKline LLC. (2019). Advair HFA (fluticasone propionate / salmeterol). *US Product Monograph*,
1295. GlaxoSmithKline LLC. (2019). Avycaz (ceftazidime / avibactam). *US Product Monograph*,
1296. GlaxoSmithKline LLC. (2019). Flovent HFA (fluticasone propionate). *US Product Monograph*,
1297. GlaxoSmithKline LLC. (2019). Nucala (mepolizumab). *US Product Monograph*,
1298. GlaxoSmithKline LLC. (2019). Serevent Diskus (salmeterol). *US Product Monograph*,
1299. Gleason, P. P., Frye, R. F., & O'Toole, T. (1997). Debilitating reaction following the initial dose of tramadol. *Ann Pharmacother*, *31*(10), 1150-1152.
1300. Global Initiative for Asthma. (2017). *Global strategy for asthma management and prevention*. Retrieved from www.ginasthma.org
1301. Global Initiative for Asthma. (2019). *Global strategy for asthma management and prevention*. Retrieved from www.ginasthma.org
1302. Glorioso, N., Filigheddu, F., Cusi, D., Troffa, C., Conti, M., Natalizio, M., . . . Bianchi, G. (2002). alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. *Hypertension*, *39*(2 Pt 2), 357-362.
1303. Glorioso, N., Manunta, P., Filigheddu, F., Troffa, C., Stella, P., Barlassina, C., . . . Bianchi, G. (1999). The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. *Hypertension*, *34*(4 Pt 1), 649-654.
1304. Goadsby, P. J., Reuter, U., Hallstrom, Y., Broessner, G., Bonner, J. H., Zhang, F., . . . Lenz, R. A. (2017). A controlled trial of erenumab for episodic migraine. *N Engl J Med*, *377*(22), 2123-2132.
1305. Goddard, A. W., Brouette, T., Almai, A., Jetty, P., Woods, S. W., & Charney, D. (2001). Early coadministration of clonazepam with sertraline for panic disorder. *Arch Gen Psychiatry*, *58*(7), 681-686.
1306. Godlewska, B. R., Olajosy-Hilkesberger, L., Ciwoniuk, M., Olajosy, M., Marmurowska-Michalowska, H., Limon, J., & Landowski, J. (2009). Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. *Pharmacogenomics J*, *9*(4), 234-241.
1307. Goebel, A., Barker, C. H., & Turner-Stokes, L. (2012). *Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care*.
1308. Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M., Whirl-Carrillo, M., . . . Klein, T. E. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. *Clin Pharmacol Ther*, *103*(5), 770-777.
1310. Goh, K. L., Boonyapisit, S., Lai, K. H., Chang, R., Kang, J. Y., & Lam, S. K. (1995). Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double-blind, placebo-controlled study. *J Gastroenterol Hepatol*, *10*(1), 92-97.

1311. Goikolea, J. M., Colom, F., Capapey, J., Torres, I., Valenti, M., Grande, I., . . . Vieta, E. (2013). Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. *Eur Neuropsychopharmacol*, *23*(4), 305-316.
1312. Goikolea, J. M., Colom, F., Torres, I., Capapey, J., Valenti, M., Undurraga, J., . . . Vieta, E. (2013). Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. *J Affect Disord*, *144*(3), 191-198.
1313. Goktas, M. T., Pepedil, F., Karaca, O., Kalkisim, S., Cevik, L., Gumus, E., . . . Yasar, U. (2016). Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. *Eur Rev Med Pharmacol Sci*, *20*(11), 2460-2467.
1314. Goldberg, M. R., Lowry, R. C., Musson, D. G., Birk, K. L., Fisher, A., De Puy, M. E., & Shadle, C. R. (1999). Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. *J Clin Pharmacol*, *39*(2), 192-199.
1315. Goldberger, J. J., Bonow, R. O., Cuffe, M., Liu, L., Rosenberg, Y., Shah, P. K., . . . Subacius, H. (2015). Effect of beta-Blocker dose on survival after acute myocardial infarction. *J Am Coll Cardiol*, *66*(13), 1431-1441.
1316. Goldenberg, D. L., Burckhardt, C., & Crofford, L. (2004). Management of fibromyalgia syndrome. *Jama*, *292*(19), 2388-2395.
1317. Goldstein, J., Silberstein, S. D., Saper, J. R., Elkind, A. H., Smith, T. R., Gallagher, R. M., . . . Baggish, J. (2005). Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. *Headache*, *45*(8), 973-982.
1318. Goldstein, J., Silberstein, S. D., Saper, J. R., Ryan, R. E., Jr., & Lipton, R. B. (2006). Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. *Headache*, *46*(3), 444-453.
1319. Goldstein, J. L., Larson, L. R., & Yamashita, B. D. (1998). Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol. *Am J Manag Care*, *4*(5), 687-697.
1320. Golomb, B. A., & Evans, M. A. (2008). Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. *Am J Cardiovasc Drugs*, *8*(6), 373-418.
1321. Gomersall, J. D., & Stuart, A. (1973). Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. *J Neurol Neurosurg Psychiatry*, *36*(4), 684-690.
1322. Goncalves, A. L., Martini Ferreira, A., Ribeiro, R. T., Zukerman, E., Cipolla-Neto, J., & Peres, M. F. (2016). Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. *J Neurol Neurosurg Psychiatry*, *87*(10), 1127-1132.
1323. Gong, Y., McDonough, C. W., Beitelshes, A. L., El Rouby, N., Hiltunen, T. P., O'Connell, J. R., . . . Johnson, J. A. (2015). PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. *J Hypertens*, *33*(11), 2278-2285.

1324. Gonvers, J. J., Aenishänslin, W., Backwinkel, K., Bretholz, A., Egger, G., Feyerabend, H., . . . Mattle, W. P. (1987). Gastric ulcer: a double blind comparison of 800 mcg misoprostol versus 300 mg ranitidine. *Hepato-gastroenterology*, 34(5), 233-235.
1325. Good, E. D., & Rogers, F. J. (2012). Patient-centered management of atrial fibrillation: applying evidence-based care to the individual patient. *J Am Osteopath Assoc*, 112(6), 334-342.
1326. Goodman, T., Ferro, A., & Sharma, P. (2008). Pharmacogenetics of aspirin resistance: a comprehensive systematic review. *Br J Clin Pharmacol*, 66(2), 222-232.
1327. Goodwin, F. K., Fireman, B., Simon, G. E., Hunkeler, E. M., Lee, J., & Revicki, D. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. *Jama*, 290(11), 1467-1473.
1328. Goodwin, G. M., Haddad, P. M., Ferrier, I. N., Aronson, J. K., Barnes, T., Cipriani, A., . . . Young, A. H. (2016). Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*, 30(6), 495-553.
1329. Goulding, R., Dawes, D., Price, M., Wilkie, S., & Dawes, M. (2015). Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. *Br J Clin Pharmacol*, 80(4), 868-877.
1330. Gourlay, S. G., Stead, L. F., & Benowitz, N. L. (2004). Clonidine for smoking cessation. *Cochrane Database Syst Rev*(3), CD000058.
1331. Goves, J., Oldring, J. K., Kerr, D., Dallara, R. G., Roffe, E. J., Powell, J. A., & Taylor, M. D. (1998). First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginat liquid: a multicentre study in general practice. *Aliment Pharmacol Ther*, 12(2), 147-157.
1332. Grabe, M. (2011). Antibiotic prophylaxis in urological surgery, a European viewpoint. *Int J Antimicrob Agents*, 38 Suppl, 58-63.
1333. Gradman, A. H., Basile, J. N., Carter, B. L., Bakris, G. L., & American Society of Hypertension Writing, G. (2011). Combination therapy in hypertension. *J Clin Hypertens (Greenwich)*, 13(3), 146-154.
1334. Graham, D. Y., Agrawal, N. M., Campbell, D. R., Haber, M. M., Collis, C., Lukasik, N. L., & Huang, B. (2002). Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. *Arch Intern Med*, 162(2), 169-175.
1335. Graham, D. Y., Lee, Y. C., & Wu, M. S. (2014). Rational *Helicobacter pylori* therapy: evidence-based medicine rather than medicine-based evidence. *Clin Gastroenterol Hepatol*, 12(2), 177-186 e173; Discussion e112-173.
1336. Graham, D. Y., Lew, G. M., Evans, D. G., Evans, D. J., Jr., & Klein, P. D. (1991). Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. *Ann Intern Med*, 115(4), 266-269.
1337. Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., . . . Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 365(11), 981-992.

1338. Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., . . . Swedberg, K. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet*, *362*(9386), 772-776.
1339. Grasmader, K., Verwohlt, P. L., Rietschel, M., Dragicevic, A., Muller, M., Hiemke, C., . . . Rao, M. L. (2004). Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. *Eur J Clin Pharmacol*, *60*(5), 329-336.
1340. Grech-Belanger, O., Gilbert, M., Turgeon, J., & LeBlanc, P. P. (1985). Effect of cigarette smoking on mexiletine kinetics. *Clin Pharmacol Ther*, *37*(6), 638-643.
1341. Greden, J. F., Rosthschild, A. J., Thase, M., Dunlop, B. W., DeBattista, D. C., Conway, C. R., . . . Parikh, S. (2019). 49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial. *CNS Spectr*, *24*(1), 202-203.
1342. Greenhalgh, J., Bagust, A., Boland, A., Martin Saborido, C., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. *Health Technol Assess*, *15*(31), 1-178.
1343. Greenspan, S. L., Resnick, N. M., & Parker, R. A. (2003). Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. *Jama*, *289*(19), 2525-2533.
1344. Grimshaw, G. M., & Stanton, A. (2006). Tobacco cessation interventions for young people. *Cochrane Database Syst Rev*(4), CD003289.
1345. Gronseth, G., Cruccu, G., Alksne, J., Argoff, C., Brainin, M., Burchiel, K., . . . Zakrzewska, J. M. (2008). Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. *Neurology*, *71*(15), 1183-1190.
1346. Grossi, L., Spezzaferro, M., Sacco, L. F., & Marzio, L. (2008). Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. *Neurogastroenterol Motil*, *20*(7), 760-766.
1347. Grossman, E., Verdecchia, P., Shamiss, A., Angeli, F., & Reboldi, G. (2011). Diuretic treatment of hypertension. *Diabetes Care*, *34 Suppl 2*, S313-319.
1348. Grossman, F., Potter, W. Z., Brown, E. A., & Maislin, G. (1999). A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. *J Affect Disord*, *56*(2-3), 237-243.
1349. Groth, H., Vetter, H., Achermann, R., Kuhlmann, U., Siegenthaler, W., & Vetter, W. (1985). [Diuretics and antihypertensive agents in chronic kidney insufficiency: comparison of the effects of metolazone and furosemide]. *Schweiz Med Wochenschr*, *115*(2), 41-45.
1350. Grover, S., Bala, K., Sharma, S., Gourie-Devi, M., Baghel, R., Kaur, H., . . . Kukreti, R. (2010). Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. *Biochimie*, *92*(9), 1207-1212.

1351. Grover, S., & Kukreti, R. (2014). HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. *Pharmacogenet Genomics*, 24(2), 94-112.
1352. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*, 73(24), e285-e350.
1353. Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Moller, H. J., & Kasper, S. (2013). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. *World J Biol Psychiatry*, 14(3), 154-219.
1354. Gschwantler, M., Dragosics, B., Schutze, K., Wurzer, H., Hirschl, A. M., Pasching, E., . . . Weiss, W. (1999). Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of *Helicobacter pylori*--a randomized, controlled trial. *Aliment Pharmacol Ther*, 13(8), 1063-1069.
1355. Guaiana, G., Barbui, C., & Cipriani, A. (2010). Hydroxyzine for generalised anxiety disorder. *Cochrane Database Syst Rev*(12), Cd006815.
1356. Gualtieri, C. T., Keenan, P. A., & Chandler, M. (1991). Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder. *J Clin Psychopharmacol*, 11(3), 155-159.
1357. Guis, S., Balandraud, N., Bouvenot, J., Auger, I., Toussirot, E., Wendling, D., . . . Roudier, C. (2007). Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. *Arthritis Rheum*, 57(8), 1426-1430.
1358. Gulrez, G., Badyal, D. K., Deswal, R. S., & Sharma, A. (2012). Bupropion as an augmenting agent in patients of depression with partial response. *Basic Clin Pharmacol Toxicol*, 110(3), 227-230.
1359. Gumus, E., Karaca, O., Babaoglu, M. O., Baysoy, G., Balamtekin, N., Demir, H., . . . Yasar, U. (2012). Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. *Eur J Clin Pharmacol*, 68(5), 629-636.
1360. Guo, B., Tan, Q., Guo, D., Shi, Z., Zhang, C., & Guo, W. (2014). Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. *J Vasc Surg*, 60(4), 993-1001.
1361. Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., . . . Infectious, D. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*, 52(5), e103-120.

1362. Gupta, K., Hooton, T. M., Roberts, P. L., & Stamm, W. E. (2007). Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. *Arch Intern Med*, 167(20), 2207-2212.
1363. Gupta, P., Singh, S., Goyal, V., Shukla, G., & Behari, M. (2007). Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). *Headache*, 47(3), 402-412.
1364. Gutierrez, C., & Blanchard, D. G. (2011). Atrial fibrillation: diagnosis and treatment. *Am Fam Physician*, 83(1), 61-68.
1365. Guzey, C., Aamo, T., & Spigset, O. (2000). Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. *J Clin Psychiatry*, 61(8), 600-601.
1366. Guzey, C., & Spigset, O. (2006). Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. *J Clin Psychopharmacol*, 26(2), 211-212.
1367. Gwee, K. A., Goh, V., Lima, G., & Setia, S. (2018). Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. *J Pain Res*, 11, 361-374.
1368. Hackam, D. G., Duong-Hua, M. L., Mamdani, M., Li, P., Tobe, S. W., Spence, J. D., & Garg, A. X. (2008). Angiotensin inhibition in renovascular disease: a population-based cohort study. *Am Heart J*, 156(3), 549-555.
1369. Haddad, P. M., & Sharma, S. G. (2007). Adverse effects of atypical antipsychotics : differential risk and clinical implications. *CNS drugs*, 21(11), 911-936.
1370. Haerian, B. S., Baum, L., Kwan, P., Tan, H. J., Raymond, A. A., & Mohamed, Z. (2013). SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. *Pharmacogenomics*, 14(10), 1153-1166.
1371. Hägg, S., Spigset, O., Lakso, H., & Dahlqvist, R. (2001). Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. *Eur J Clin Pharmacol*, 57(6), 493-497.
1372. Hainer, B. L., Matheson, E., & Wilkes, R. T. (2014). Diagnosis, treatment, and prevention of gout. *Am Fam Physician*, 90(12), 831-836.
1373. Hajek, P., Smith, K. M., Dhanji, A. R., & McRobbie, H. (2013). Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. *BMC Med*, 11, 140.
1374. Hall, P., Nakamura, S., Maiello, L., Itoh, A., Blengino, S., Martini, G., . . . Colombo, A. (1996). A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. *Circulation*, 93(2), 215-222.
1375. Hallberg, P., Persson, M., Axelsson, T., Cavalli, M., Norling, P., Johansson, H. E., . . . Wadelius, M. (2017). Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. *Pharmacogenomics*, 18(3), 201-213.
1376. Halling, J., Weihe, P., & Brosen, K. (2008). The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. *Br J Clin Pharmacol*, 65(1), 134-138.
1377. Ham, A. C., Ziere, G., Broer, L., Swart, K. M., Enneman, A. W., van Dijk, S. C., . . . van der Velde, N. (2017). CYP2C9 Genotypes Modify Benzodiazepine-Related Fall Risk: Original

- Results From Three Studies With Meta-Analysis. *J Am Med Dir Assoc*, 18(1), 88 e81-88 e15.
1378. Hamadeh, I. S., Langaee, T. Y., Dwivedi, R., Garcia, S., Burkley, B. M., Skaar, T. C., . . . Johnson, J. A. (2014). Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. *Clin Pharmacol Ther*, 96(2), 175-181.
1379. Hamed, M., Mohammadi, M., Ghaleiha, A., Keshavarzi, Z., Jafarnia, M., Keramatfar, R., . . . Akhondzadeh, S. (2014). Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. *Acta Med Iran*, 52(9), 675-680.
1380. Hande, K. R., Noone, R. M., & Stone, W. J. (1984). Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. *Am J Med*, 76(1), 47-56.
1381. Hanon, O., Assayag, P., Belmin, J., Collet, J. P., Emeriau, J. P., Fauchier, L., . . . Le Heuzey, J. Y. (2013). Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. *Arch Cardiovasc Dis*, 106(5), 303-323.
1382. Hansen, M. L., Sorensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunso, J., Gadsboll, N., . . . Torp-Pedersen, C. (2010). Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med*, 170(16), 1433-1441.
1383. Hanson, K., Allen, S., Jensen, S., & Hatsukami, D. (2003). Treatment of adolescent smokers with the nicotine patch. *Nicotine Tob Res*, 5(4), 515-526.
1384. Harden, R. N., Oaklander, A. L., Burton, A. W., Perez, R. S., Richardson, K., Swan, M., . . . Bruehl, S. (2013). Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. *Pain Med*, 14(2), 180-229.
1385. Harper, C. R., & Jacobson, T. A. (2008). Managing dyslipidemia in chronic kidney disease. *J Am Coll Cardiol*, 51(25), 2375-2384.
1386. Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., . . . Yale, J. F. (2013). Pharmacologic management of type 2 diabetes. *Can J Diabetes*, 37 Suppl 1, S61-68.
1387. Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., . . . Cheng, A. Y. (2015). Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update. *Can J Diabetes*, 39(4), 250-252.
1388. Harrison, L., Johnston, M., Massicotte, M. P., Crowther, M., Moffat, K., & Hirsh, J. (1997). Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. *Ann Intern Med*, 126(2), 133-136.
1389. Hartford, J., Kornstein, S., Liebowitz, M., Pigott, T., Russell, J., Detke, M., . . . Erickson, J. (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. *Int Clin Psychopharmacol*, 22(3), 167-174.
1390. Hartling, L., Abou-Setta, A. M., Dursun, S., Mousavi, S. S., Pasichnyk, D., & Newton, A. S. (2012). Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. *Ann Intern Med*, 157(7), 498-511.

1391. Hartter, S., Grozinger, M., Weigmann, H., Roschke, J., & Hiemke, C. (2000). Increased bioavailability of oral melatonin after fluvoxamine coadministration. *Clin Pharmacol Ther*, 67(1), 1-6.
1392. Hartung, B., Sampson, S., & Leucht, S. (2015). Perphenazine for schizophrenia. *Cochrane Database Syst Rev*(3), CD003443.
1393. Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., . . . Møller, H. J. (2012). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry*, 13(5), 318-378.
1394. Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., . . . Møller, H. J. (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry*, 14(1), 2-44.
1395. Hashash, J. G., Abdul-Baki, H., Azar, C., Elhadj, I. I., El Zahabi, L., Chaar, H. F., & Sharara, A. I. (2008). Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. *Aliment Pharmacol Ther*, 27(11), 1148-1155.
1396. Hashi, S., Yano, I., Shibata, M., Masuda, S., Kinoshita, M., Matsumoto, R., . . . Matsubara, K. (2015). Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. *Eur J Clin Pharmacol*, 71(1), 51-58.
1397. Haslemo, T., Eliasson, E., Jukic, M. M., Ingelman-Sundberg, M., & Molden, E. (2019). Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. *Br J Clin Pharmacol*, 85(1), 194-201.
1398. Hatsukami, D., Mooney, M., Murphy, S., LeSage, M., Babb, D., & Hecht, S. (2007). Effects of high dose transdermal nicotine replacement in cigarette smokers. *Pharmacol Biochem Behav*, 86(1), 132-139.
1399. Hauk, L. (2017). Newly Detected Atrial Fibrillation: AAFP Updates Guideline on Pharmacologic Management. *Am Fam Physician*, 96(5), 332-333.
1400. Hauser, W., Bernardy, K., Uceyler, N., & Sommer, C. (2009). Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. *Jama*, 301(2), 198-209.
1401. Hauser, W., Petzke, F., & Sommer, C. (2010). Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. *J Pain*, 11(6), 505-521.
1402. Hawkey, C. J., Karrasch, J. A., Szczepanski, L., Walker, D. G., Barkun, A., Swannell, A. J., & Yeomans, N. D. (1998). Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. *N Engl J Med*, 338(11), 727-734.
1403. Hayes, J. F., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. (2016). Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for

- bipolar disorder: a population-based UK cohort study using electronic health records. *World Psychiatry*, 15(1), 53-58.
1404. Hayes, J. F., Pitman, A., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. (2016). Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study. *JAMA Psychiatry*, 73(6), 630-637.
1405. He, A., Song, D., Zhang, L., & Li, C. (2017). Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. *J Headache Pain*, 18(1), 26.
1406. He, N., Min, F. L., Shi, Y. W., Guo, J., Liu, X. R., Li, B. M., . . . Liao, W. P. (2012). Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. *Seizure*, 21(8), 614-618.
1407. He, X., Hesse, L. M., Hazarika, S., Masse, G., Harmatz, J. S., Greenblatt, D. J., & Court, M. H. (2009). Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. *Br J Clin Pharmacol*, 68(5), 721-730.
1408. He, X. J., Jian, L. Y., He, X. L., Wu, Y., Xu, Y. Y., Sun, X. J., . . . Zhao, L. M. (2013). Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. *Pharmacol Rep*, 65(5), 1256-1262.
1409. He, Y., Chan, E. W., Man, K. K., Lau, W. C., Leung, W. K., Ho, L. M., & Wong, I. C. (2014). Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study. *Drug Saf*, 37(9), 711-721.
1410. Healey, J. S. (2018). Stroke Prevention in Atrial Fibrillation: What Is Real World, and What Do Real-World Data Reveal? *J Am Coll Cardiol*, 72(2), 154-155.
1411. Health Quality, O. (2017). Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test. *Ont Health Technol Assess Ser*, 17(4), 1-39.
1412. Hedayati, S. S., Yalamanchili, V., & Finkelstein, F. O. (2012). A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. *Kidney Int*, 81(3), 247-255.
1413. Hedman, M., Antikainen, M., Holmberg, C., Neuvonen, M., Eichelbaum, M., Kivisto, K. T., . . . Niemi, M. (2006). Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. *Br J Clin Pharmacol*, 61(6), 706-715.
1414. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H. C., Hacke, W., . . . Kirchhof, P. (2016). Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. *Eur Heart J*.

1415. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., . . . Kirchhof, P. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace*, *15*(5), 625-651.
1416. Held, C., Asenblad, N., Bassand, J. P., Becker, R. C., Cannon, C. P., Claeys, M. J., . . . Wallentin, L. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. *J Am Coll Cardiol*, *57*(6), 672-684.
1417. Hemstreet, B. A. (2001). Use of sucralfate in renal failure. *Ann Pharmacother*, *35*(3), 360-364.
1418. Henderson, J. (2019). Updated guidelines on complex regional pain syndrome in adults. *J Plast Reconstr Aesthet Surg*, *72*(1), 1-3.
1419. Hendset, M., Hermann, M., Lunde, H., Refsum, H., & Molden, E. (2007). Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. *Eur J Clin Pharmacol*, *63*(12), 1147-1151.
1420. Hendset, M., Molden, E., Knape, M., & Hermann, M. (2014). Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. *Ther Drug Monit*, *36*(1), 80-85.
1421. Henske, J. A., Griffith, M. L., & Fowler, M. J. (2009). Initiating and titrating insulin in patients with Type 2 Diabetes. *Clin Diabetes*, *27*(2), 72-76.
1422. Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019). Antidepressant withdrawal and rebound phenomena. *Dtsch Arztebl Int*, *116*(20), 355-361.
1423. Henssler, J., Kurschus, M., Franklin, J., Bschor, T., & Baethge, C. (2018). Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials. *J Clin Psychiatry*, *79*(3).
1424. Herath, S. C., & Poole, P. (2013). Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). *Cochrane Database Syst Rev*(11), CD009764.
1425. Hering, R., & Kuritzky, A. (1992). Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. *Cephalalgia*, *12*(2), 81-84.
1426. Heritage Pharmaceuticals Inc. (2014). Tetracycline. *US Product Monograph*,
1427. Heritage Pharmaceuticals Inc. (2018). Ketoprofen *US Product Monograph*,
1428. Herman, A. I., Jatlow, P. I., Gelernter, J., Listman, J. B., & Sofuoglu, M. (2013). COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers. *Pharmacogenomics J*, *13*(6), 490-497.
1429. Herman, J., & Ben-Meir, S. (1975). Overt hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency: a survey in general practice. *Isr J Med Sci*, *11*(4), 340-346.
1430. Hermann, M., Hendset, M., Fosaas, K., Hjerpset, M., & Refsum, H. (2008). Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. *Eur J Clin Pharmacol*, *64*(5), 483-487.
1431. Hernandez-Avila, C. A., Covault, J., Wand, G., Zhang, H., Gelernter, J., & Kranzler, H. R. (2007). Population-specific effects of the Asn40Asp polymorphism at the mu-opioid

- receptor gene (OPRM1) on HPA-axis activation. *Pharmacogenet Genomics*, 17(12), 1031-1038.
1432. Hernandez-Avila, C. A., Wand, G., Luo, X., Gelernter, J., & Kranzler, H. R. (2003). Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). *Am J Med Genet B Neuropsychiatr Genet*, 118b(1), 60-65.
1433. Herrerias-Gutierrez, J. M., Pardo, L., & Segu, J. L. (1989). Sucralfate versus ranitidine in the treatment of gastric ulcer. Randomized clinical results in short-term and maintenance therapy. *Am J Med*, 86(6A), 94-97.
1434. Hershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E., & Lee, M. T. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. *Clin Pharmacol Ther*, 93(2), 153-158.
1435. Hertz, D. L., Snavely, A. C., McLeod, H. L., Walko, C. M., Ibrahim, J. G., Anderson, S., . . . Irvin, W. J., Jr. (2015). In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. *Br J Clin Pharmacol*, 80(5), 1122-1130.
1436. Hess, C. N., & Hiatt, W. R. (2018). Antithrombotic therapy for peripheral artery disease in 2018. *Jama*, 319(22), 2329-2330.
1437. Hess, P. L., Kim, S., Piccini, J. P., Allen, L. A., Ansell, J. E., Chang, P., . . . Fonarow, G. C. (2013). Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. *Am J Med*, 126(7), 625-632 e621.
1438. Hiatt, W. R., Fowkes, F. G., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., . . . Patel, M. R. (2017). Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. *N Engl J Med*, 376(1), 32-40.
1439. Hicks, J. K., Bishop, J. R., Sangkuhl, K., Muller, D. J., Ji, Y., Leckband, S. G., . . . Clinical Pharmacogenetics Implementation Consortium. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*, 98(2), 127-134.
1440. Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Muller, D. J., Shimoda, K., . . . Stingl, J. C. (2016). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther*.
1441. Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Muller, D. J., Shimoda, K., . . . Stingl, J. C. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther*, 102(1), 37-44.
1442. Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., . . . Zernig, G. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. *Pharmacopsychiatry*, 44(6), 195-235.
1443. Higgs, J. E., Payne, K., Roberts, C., & Newman, W. G. (2010). Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? *Pharmacogenomics*, 11(2), 177-188.
1444. Hikma Americas Inc. (2018). Mitigare (colchicine). *US Product Monograph*,

1445. Hill, E. M., Sky, K., Sit, M., Collamer, A., & Higgs, J. (2015). Does starting allopurinol prolong acute treated gout? A randomized clinical trial. *J Clin Rheumatol*, *21*(3), 120-125.
1446. Hill-McManus, D., Soto, E., Marshall, S., Lane, S., & Hughes, D. (2018). Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. *Br J Clin Pharmacol*, *84*(1), 142-152.
1447. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., . . . Okutani, Y. (2008). Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. *Pharmacogenomics J*, *8*(1), 29-33.
1448. Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L. (2000). Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. *J Clin Psychopharmacol*, *20*(5), 556-559.
1449. Hizawa, N., Makita, H., Nasuhara, Y., Betsuyaku, T., Itoh, Y., Nagai, K., . . . Nishimura, M. (2007). Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. *Chest*, *132*(5), 1485-1492.
1450. Hjalmarson, A., Elmfeldt, D., Herlitz, J., Holmberg, S., Malek, I., Nyberg, G., . . . Wilhelmsson, C. (1981). Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. *Lancet*, *2*(8251), 823-827.
1451. Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjeksus, J., . . . Deedwania, P. (2000). Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *Jama*, *283*(10), 1295-1302.
1452. Hlavaty, T., Batovsky, M., Balakova, D., Pav, I., Celec, P., Gregus, M., . . . Slovak, I. B. D. s. g. (2013). The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases. *Bratisl Lek Listy*, *114*(4), 199-205.
1453. HLS Therapeutics Inc. (2016). Clozaril (clozapine). *CA Product Monograph*,
1454. HLS Therapeutics Inc. (2018). Clozaril (clozapine). *US Product Monograph*,
1455. Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., . . . Kim, R. B. (2007). Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. *Pharmacogenet Genomics*, *17*(8), 647-656.
1456. Hobart, M., Skuban, A., Zhang, P., Augustine, C., Brewer, C., Hefting, N., . . . McQuade, R. D. (2018). A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. *J Clin Psychiatry*, *79*(4).
1457. Hobart, M., Skuban, A., Zhang, P., Josiassen, M. K., Hefting, N., Augustine, C., . . . McQuade, R. D. (2018). Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. *Curr Med Res Opin*, *34*(4), 633-642.
1458. Hobart, M., Zhang, P., Skuban, A., Brewer, C., Hefting, N., Sanchez, R., & McQuade, R. D. (2019). A long-term, open-label study to evaluate the safety and tolerability of

- brexpiprazole as adjunctive therapy in adults with major depressive disorder. *J Clin Psychopharmacol*, 39(3), 203-209.
1459. Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., . . . Tugwell, P. (2012). American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*, 64(4), 465-474.
1460. Hochberg, M. C., Altman, R. D., Brandt, K. D., Clark, B. M., Dieppe, P. A., Griffin, M. R., . . . Schnitzer, T. J. (1995). Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. *Arthritis Rheum*, 38(11), 1541-1546.
1461. Hodgson, K., Tansey, K., Dernovsek, M. Z., Hauser, J., Henigsberg, N., Maier, W., . . . McGuffin, P. (2014). Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. *J Psychopharmacol*, 28(2), 133-141.
1462. Hodgson, K., Tansey, K. E., Uher, R., Dernovsek, M. Z., Mors, O., Hauser, J., . . . McGuffin, P. (2015). Exploring the role of drug-metabolising enzymes in antidepressant side effects. *Psychopharmacology (Berl)*, 232(14), 2609-2617.
1463. Hoepelman, A. I., Kieft, H., Aoun, M., Kosmidis, J., Strand, T., Verhoef, J., . . . Meunier, F. (1993). International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. *J Antimicrob Chemother*, 32 Suppl B, 175-186.
1464. Hoffman, E. J., & Mathew, S. J. (2008). Anxiety disorders: a comprehensive review of pharmacotherapies. *Mt Sinai J Med*, 75(3), 248-262.
1465. Hoffmann-La Roche Limited. (2015). Inhibace (cilazapril). *CA Product Monograph*,
1466. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., John, A., . . . Brinkmann, U. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci U S A*, 97(7), 3473-3478.
1467. Hohnloser, S. H. (2012). Benefit-risk assessment of current antiarrhythmic drug therapy of atrial fibrillation. *Clin Cardiol*, 35 Suppl 1, 28-32.
1468. Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., . . . Guyatt, G. H. (2012). Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, 141(2 Suppl), e152S-184S.
1469. Holgate, S. T., Chuchalin, A. G., Hebert, J., Lotvall, J., Persson, G. B., Chung, K. F., . . . Cioppa, G. D. (2004). Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy*, 34(4), 632-638.
1470. Holman RR, B. M., Mentz RJ, Thompson VP, Likhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*, 377(13), 1228-1239.
1471. Holroyd, K. A., Cottrell, C. K., O'Donnell, F. J., Cordingley, G. E., Drew, J. B., Carlson, B. W., & Himawan, L. (2010). Effect of preventive (beta blocker) treatment, behavioural

- migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. *BMJ*, 341, c4871.
1472. Holstein, A., Hahn, M., Korner, A., Stumvoll, M., & Kovacs, P. (2011). TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. *BMC Med Genet*, 12, 30.
1473. Holtmann, G., Gschossmann, J., Karaus, M., Fischer, T., Becker, B., Mayr, P., & Gerken, G. (1999). Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. *Aliment Pharmacol Ther*, 13(11), 1459-1465.
1474. Holtmann, G., Gschossmann, J., Mayr, P., & Talley, N. J. (2002). A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. *Aliment Pharmacol Ther*, 16(9), 1641-1648.
1475. Honda, M., Ogura, Y., Toyoda, W., Taguchi, M., Nozawa, T., Inoue, H., & Hashimoto, Y. (2006). Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. *Biol Pharm Bull*, 29(4), 772-778.
1476. Hong, J., Shu, X., Liu, D., Zhu, Y., Xie, C., Xie, Y., . . . Lu, N. (2016). Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for *Helicobacter pylori* infection: an open-label, randomized, single-centre clinical trial. *J Antimicrob Chemother*, 71(8), 2280-2285.
1477. Hong, T., Yang, H., Zhang, S. S., Cho, H. C., Kalashnikova, M., Sun, B., . . . Shaw, R. M. (2014). Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia. *Nat Med*, 20(6), 624-632.
1478. Hongo, M., Harasawa, S., Mine, T., Sasaki, I., Matsueda, K., Kusano, M., . . . Shibata, C. (2012). Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). *J Gastroenterol Hepatol*, 27(1), 62-68.
1479. Hoobler, S. W., & Sagastume, E. (1971). Clonidine hydrochloride in the treatment of hypertension. *Am J Cardiol*, 28(1), 67-73.
1480. Hood, S. D. (2015). Latest guidelines for the management of the anxiety disorders - a report from The International Anxiety Disorders Society Conference, Melbourne 2014. *Australas Psychiatry*, 23(4), 388-391.
1481. Hooton, T. M. (2012). Clinical practice. Uncomplicated urinary tract infection. *N Engl J Med*, 366(11), 1028-1037.
1482. Hooton, T. M., Scholes, D., Gupta, K., Stapleton, A. E., Roberts, P. L., & Stamm, W. E. (2005). Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. *Jama*, 293(8), 949-955.
1483. Horai, Y., Kimura, M., Furuie, H., Matsuguma, K., Irie, S., Koga, Y., . . . Ishizaki, T. (2001). Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. *Aliment Pharmacol Ther*, 15(6), 793-803.
1484. Horizon Pharma Inc. (2017). Rayos (prednisone). *US Product Monograph*,
1485. Horizon Pharma USA Inc. (2016). Pennsaid (diclofenac sodium). *US Product Monograph*,
1486. Horizon Pharma USA Inc. (2018). Krystexxa (pegloticase). *US Product Monograph*,
1487. Horizon Pharma USA Inc. (2018). Vimovo (naproxen / esomeprazole magnesium). *US Product Monograph*,

1488. Horstmann, S., Lucae, S., Menke, A., Hennings, J. M., Ising, M., Roeske, D., . . . Binder, E. B. (2010). Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. *Neuropsychopharmacology*, *35*(3), 727-740.
1489. Hospira Inc. (2017). Maxipime (cefepime). *US Product Monograph*,
1490. Hospira Inc. (2018). Gentamicin. *US Product Monograph*,
1491. Hou, X., Shi, J., & Sun, H. (2014). Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. *Eur J Clin Pharmacol*, *70*(9), 1041-1047.
1492. Houston, J. P., Kohler, J., Bishop, J. R., Ellingrod, V. L., Ostbye, K. M., Zhao, F., . . . Fijal, B. A. (2012). Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. *J Clin Psychiatry*, *73*(8), 1077-1086.
1493. Hsiao, Y. H., Hui, R. C., Wu, T., Chang, W. C., Hsieh, M. S., Yang, C. H., . . . Chung, W. H. (2014). Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. *J Dermatol Sci*, *73*(2), 101-109.
1494. Hsu, P. I., Chen, W. C., Tsay, F. W., Shih, C. A., Kao, S. S., Wang, H. M., . . . Taiwan Acid-Related Disease Study, G. (2014). Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for *Helicobacter pylori* infection after failure of sequential therapy. *Helicobacter*, *19*(1), 74-79.
1495. Hu, F. Y., Wu, X. T., An, D. M., Yan, B., Stefan, H., & Zhou, D. (2011). Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. *Seizure*, *20*(2), 160-162.
1496. Hu, M., Lui, S. S., Mak, V. W., Chu, T. T., Lee, V. W., Poon, E. W., . . . Tomlinson, B. (2010). Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. *Pharmacogenet Genomics*, *20*(10), 634-637.
1497. Hu, X. Z., Rush, A. J., Charney, D., Wilson, A. F., Sorant, A. J., Papanicolaou, G. J., . . . Lipsky, R. H. (2007). Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. *Arch Gen Psychiatry*, *64*(7), 783-792.
1498. Hu, Y. M., Mei, Q., Xu, X. H., Hu, X. P., Hu, N. Z., & Xu, J. M. (2006). Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. *World J Gastroenterol*, *12*(29), 4750-4753.
1499. Hua, S., Ma, C., Zhang, J., Li, J., Wu, W., Xu, N., . . . Zhao, J. (2018). Influence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects. *Front Pharmacol*, *9*, 352.
1500. Huang, B., Huang, Y., Li, Y., Yao, H., Jing, X., Huang, H., & Li, J. (2012). Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. *Arch Med Res*, *43*(3), 212-224.

1501. Huang, J., Chuang, S. K., Cheng, C. L., & Lai, M. L. (1999). Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. *Clin Pharmacol Ther*, 65(4), 402-407.
1502. Huang, P., Yao, Y., Yue, M., Tian, T., Chen, H., Chen, M., . . . Yu, R. (2017). Genetic variants in interferon-lambda 4 influences HCV clearance in Chinese Han population. *Sci Rep*, 7, 42408.
1503. Huang, X., Du, H., Gu, J., Zhao, D., Jiang, L., Li, X., . . . Bao, C. (2014). An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. *Int J Rheum Dis*, 17(6), 679-686.
1504. Hubacek, J. A., Adamkova, V., Prusikova, M., Snejdrllova, M., Hirschfeldova, K., Lanska, V., . . . Vrablik, M. (2009). Impact of apolipoprotein A5 variants on statin treatment efficacy. *Pharmacogenomics*, 10(6), 945-950.
1505. Hubacek, J. A., Pankova, A., Stepankova, L., Zvolaska, K., Adamkova, V., Lanska, V., & Kralikova, E. (2017). SNPs within CHRNA5-A3-B4 and CYP2A6/B6 are associated with smoking dependence but not with tobacco dependence treatment outcomes in the Czech population. *Gene*, 606, 35-38.
1506. Huezo-Diaz, P., Uher, R., Smith, R., Rietschel, M., Henigsberg, N., Marusic, A., . . . McGuffin, P. (2009). Moderation of antidepressant response by the serotonin transporter gene. *Br J Psychiatry*, 195(1), 30-38.
1507. Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014). Antidepressants for smoking cessation. *Cochrane Database Syst Rev*(1), CD000031.
1508. Hui, M., Carr, A., Cameron, S., Davenport, G., Doherty, M., Forrester, H., . . . Roddy, E. (2017). The British Society for Rheumatology Guideline for the Management of Gout. *Rheumatology (Oxford)*, 56(7), e1-e20.
1509. Hulot, J. S., Collet, J. P., & Montalescot, G. (2011). Genetic substudy of the PLATO trial. *Lancet*, 377(9766), 637, author reply 637-638.
1510. Humbert, G., Spyker, D. A., Fillastre, J. P., & Leroy, A. (1979). Pharmacokinetics of amoxicillin: Dosage nomogram for patients with impaired renal function. *Antimicrob Agents Chemother*, 15(1), 28-33.
1511. Hunfeld, N. G., Mathot, R. A., Touw, D. J., van Schaik, R. H., Mulder, P. G., Franck, P. F., . . . Geus, W. P. (2008). Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. *Br J Clin Pharmacol*, 65(5), 752-760.
1512. Hunfeld, N. G., Touw, D. J., Mathot, R. A., Mulder, P. G., RH, V. A. N. S., Kuipers, E. J., . . . Geus, W. P. (2010). A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. *Aliment Pharmacol Ther*, 31(1), 150-159.
1513. Hunfeld, N. G., Touw, D. J., Mathot, R. A., van Schaik, R. H., & Kuipers, E. J. (2012). A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. *Aliment Pharmacol Ther*, 35(7), 810-818.
1514. Hung, C. C., Chang, W. L., Ho, J. L., Tai, J. J., Hsieh, T. J., Huang, H. C., . . . Liou, H. H. (2012). Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and

- SCN2A genes with carbamazepine therapy optimization. *Pharmacogenomics*, 13(2), 159-169.
1515. Hung, C. C., Chiou, M. H., Huang, B. H., Hsieh, Y. W., Hsieh, T. J., Huang, C. L., & Lane, H. Y. (2011). Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. *Pharmacogenomics*, 12(11), 1525-1533.
1516. Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., . . . Chen, Y. T. (2006). Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics*, 16(4), 297-306.
1517. Hung, S. I., Chung, W. H., Liu, Z. S., Chen, C. H., Hsieh, M. S., Hui, R. C., . . . Chen, Y. T. (2010). Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. *Pharmacogenomics*, 11(3), 349-356.
1518. Hunt, R., Armstrong, D., Katelaris, P., Afihehene, M., Bane, A., Bhatia, S., . . . LeMair, A. (2017). World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. *J Clin Gastroenterol*, 51(6), 467-478.
1519. Hunter, R. H., Joy, C. B., Kennedy, E., Gilbody, S. M., & Song, F. (2003). Risperidone versus typical antipsychotic medication for schizophrenia. *Cochrane Database Syst Rev*(2), CD000440.
1520. Husain M, B. A., Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*, 381(9), 841-851.
1521. Hwang, S. J., Jeong, Y. H., Kim, I. S., Koh, J. S., Kang, M. K., Park, Y., . . . Hwang, J. Y. (2011). The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. *Thromb Res*, 127(1), 23-28.
1522. Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003). Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med*, 349(11), 1019-1026.
1523. Iakoubova, O. A., Robertson, M., Tong, C. H., Rowland, C. M., Catanese, J. J., Blauw, G. J., . . . Shepherd, J. (2010). KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. *Eur J Cardiovasc Prev Rehabil*, 17(4), 455-461.
1524. Iakoubova, O. A., Tong, C. H., Rowland, C. M., Kirchgessner, T. G., Young, B. A., Arellano, A. R., . . . Sacks, F. M. (2008). Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. *J Am Coll Cardiol*, 51(4), 435-443.
1525. Iannaccone, C. K., Lee, Y. C., Cui, J., Frits, M. L., Glass, R. J., Plenge, R. M., . . . Shadick, N. A. (2011). Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. *Rheumatology (Oxford)*, 50(1), 40-46.

1526. Ide, T., Sasaki, T., Maeda, K., Higuchi, S., Sugiyama, Y., & Ieiri, I. (2009). Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCG2 polymorphisms. *J Clin Pharmacol*, 49(11), 1309-1317.
1527. Igel, M., Arnold, K. A., Niemi, M., Hofmann, U., Schwab, M., Lutjohann, D., . . . Kivisto, K. T. (2006). Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. *Clin Pharmacol Ther*, 79(5), 419-426.
1528. Ihtisham, K., Ramanujam, B., Srivastava, S., Mehra, N. K., Kaur, G., Khanna, N., . . . Tripathi, M. (2019). Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. *Seizure*, 66, 99-103.
1529. Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kitajima, T., Yoshimura, R., Hashimoto, S., . . . Iwata, N. (2008). Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. *Pharmacogenomics*, 9(10), 1437-1443.
1530. Illi, A., Poutanen, O., Setala-Soikkeli, E., Kampman, O., Viikki, M., Huhtala, H., . . . Lehtimäki, T. (2011). Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? *Eur Arch Psychiatry Clin Neurosci*, 261(2), 95-102.
1531. Illi, A., Setala-Soikkeli, E., Viikki, M., Poutanen, O., Huhtala, H., Mononen, N., . . . Kampman, O. (2009). 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. *NeuroReport*, 20(12), 1125-1128.
1532. Impax Generics. (2017). Levalbuterol. *US Product Monograph*,
1533. Impax Specialty Pharma. (2018). Zomig (zolmitriptan). *US Product Monograph*,
1534. Impax Specialty Pharma. (2018). Zomig nasal spray (zolmitriptan). *US Product Monograph*,
1535. Inaba, T., Mizuno, M., Kawai, K., Yokota, K., Oguma, K., Miyoshi, M., . . . Tsuji, T. (2002). Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. *J Gastroenterol Hepatol*, 17(7), 748-753.
1536. Inada, T., Senoo, H., Iijima, Y., Yamauchi, T., & Yagi, G. (2003). Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. *Psychiatr Genet*, 13(3), 163-168.
1537. Inadomi, J. M., Jamal, R., Murata, G. H., Hoffman, R. M., Lavezo, L. A., Vigil, J. M., . . . Sonnenberg, A. (2001). Step-down management of gastroesophageal reflux disease. *Gastroenterology*, 121(5), 1095-1100.
1538. Infirst Healthcare Inc. (2019). Mylanta. *US Product Information*,
1539. Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J*, 5(1), 6-13.
1540. Inomata, S., Nagashima, A., Itagaki, F., Homma, M., Nishimura, M., Osaka, Y., . . . Toyooka, H. (2005). CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. *Clin Pharmacol Ther*, 78(6), 647-655.

1541. Inoue, K., Yamamoto, Y., Suzuki, E., Takahashi, T., Umemura, A., Takahashi, Y., . . . Itoh, K. (2016). Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. *Eur J Clin Pharmacol*, 72(5), 555-562.
1542. Inwood Laboratories Inc. (2006). Theophylline. *US Product Monograph*,
1543. Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014). Metformin in patients with type 2 diabetes and kidney disease: a systematic review. *Jama*, 312(24), 2668-2675.
1544. Ip, C. K., Jin, D. M., Gao, J. J., Meng, Z., Meng, J., Tan, Z., . . . Geng, D. F. (2015). Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. *Int J Cardiol*, 191, 138-148.
1545. Iroko Pharmaceuticals LLC. (2016). Tivorbex (indomethacin). *US Product Monograph*,
1546. Iroko Pharmaceuticals LLC. (2018). Indocin (indomethacin). *US Product Monograph*,
1547. Irvin, M. R., Lynch, A. I., Kabagambe, E. K., Tiwari, H. K., Barzilay, J. I., Eckfeldt, J. H., . . . Arnett, D. K. (2010). Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. *J Hypertens*, 28(10), 2076-2083.
1548. Ishida, Y., & Kawai, S. (2004). Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. *Am J Med*, 117(8), 549-555.
1549. Ishiguro, S., Watanabe, T., Ueda, M., Saeki, Y., Hayashi, Y., Akiyama, K., . . . Shimoda, K. (2011). Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. *Eur J Clin Pharmacol*, 67(12), 1213-1221.
1550. Isomoto, H., Inoue, K., Furusu, H., Nishiyama, H., Shikuwa, S., Omagari, K., . . . Kohno, S. (2003). Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of *Helicobacter pylori*. *Helicobacter*, 8(2), 111-119.
1551. Israel, E., Chinchilli, V. M., Ford, J. G., Boushey, H. A., Cherniack, R., Craig, T. J., . . . Drazen, J. M. (2004). Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. *Lancet*, 364(9444), 1505-1512.
1552. Ito, A., Shimada, H., Ishikawa, K., Takeo, N., Hatano, Y., Katagiri, K., . . . Fujiwara, S. (2015). Association between HLA-DRB1*0405, -DQB1*0401 and -DQA1*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan. *J Affect Disord*, 179, 47-50.
1553. Iwakiri, K., Kinoshita, Y., Habu, Y., Oshima, T., Manabe, N., Fujiwara, Y., . . . Shimosegawa, T. (2016). Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. *J Gastroenterol*, 51(8), 751-767.
1554. Iwakiri, R., Higuchi, K., Kato, M., Fujishiro, M., Kinoshita, Y., Watanabe, T., . . . Fujimoto, K. (2014). Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. *Aliment Pharmacol Ther*, 40(7), 780-795.

1555. Jaanson, P., Marandi, T., Kiivet, R. A., Vasar, V., Vaan, S., Svensson, J. O., & Dahl, M. L. (2002). Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. *Psychopharmacology (Berl)*, *162*(1), 67-73.
1556. Jackson, D. J., Bacharier, L. B., Mauger, D. T., Boehmer, S., Beigelman, A., Chmiel, J. F., . . . Blood Institute, A. (2018). Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. *N Engl J Med*, *378*(10), 891-901.
1557. Jackson, J. L., Cogbill, E., Santana-Davila, R., Eldredge, C., Collier, W., Gradall, A., . . . Kuester, J. (2015). A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. *PLoS One*, *10*(7), e0130733.
1558. Jackson, J. L., Shimeall, W., Sessums, L., Dezee, K. J., Becher, D., Diemer, M., . . . O'Malley, P. G. (2010). Tricyclic antidepressants and headaches: systematic review and meta-analysis. *BMJ*, *341*, c5222.
1559. Jacob, S., Bharadwaj, A. S., Panaich, S. S., Mathew, A., & Afonso, L. (2010). Cardiac resynchronization therapy: current trends and future directions. *Minerva Cardioangiol*, *58*(6), 717-729.
1560. Jacobsen, P., Rossing, K., Rossing, P., Tarnow, L., Mallet, C., Poirier, O., . . . Parving, H. H. (1998). Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. *Kidney Int*, *53*(4), 1002-1006.
1561. Jafarinia, M., Mohammadi, M. R., Modabbernia, A., Ashrafi, M., Khajavi, D., Tabrizi, M., . . . Akhondzadeh, S. (2012). Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. *Hum Psychopharmacol*, *27*(4), 411-418.
1562. Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011). Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*, *50*(2), 171-179.
1563. Jamerson, K., Weber, M. A., Bakris, G. L., Dahlof, B., Pitt, B., Shi, V., . . . Velazquez, E. J. (2008). Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, *359*(23), 2417-2428.
1564. James, D. R., & Lyttle, M. D. (2016). British guideline on the management of asthma: SIGN Clinical Guideline 141, 2014. *Arch Dis Child Educ Pract Ed*, *101*(6), 319-322.
1565. James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., . . . Ortiz, E. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *Jama*, *311*(5), 507-520.
1566. James, S. K., Roe, M. T., Cannon, C. P., Cornel, J. H., Horrow, J., Husted, S., . . . Harrington, R. A. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. *BMJ*, *342*, d3527.
1567. Jamnani, F. R., Gharibzadeh, S., Fateh, A., Siadat, S. D., Sakhaee, F., Ghazanfari, M., . . . Siadat, S. D. (2017). The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. *Genes Immun*, *54*, 330-337.

1568. Janarthanan, S., Ditah, I., Adler, D. G., & Ehrinpreis, M. N. (2012). Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. *Am J Gastroenterol*, 107(7), 1001-1010.
1569. Janosi, A., Ghali, J. K., Herlitz, J., Czuriga, I., Klibaner, M., Wikstrand, J., & Hjalmarson, A. (2003). Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. *Am Heart J*, 146(4), 721-728.
1570. Janssen Inc. (2014). Risperdal (risperidone oral). *CA Product Monograph*,
1571. Janssen Inc. (2015). Invega Sustenna (paliperidone palmitate injectable). *CA Product Monograph*,
1572. Janssen Inc. (2015). Risperdal Consta (risperidone IM injection). *CA Product Monograph*,
1573. Janssen Inc. (2016). Invega (paliperidone extended release). *CA Product Monograph*,
1574. Janssen Inc. (2016). Topamax (topiramate). *CA Product Monograph*,
1575. Janssen Inc. (2017). Evra (norelgestromin / ethinyl estradiol). *CA Product Monograph*,
1576. Janssen Inc. (2017). Invokana (canagliflozin). *CA Product Monograph*,
1577. Janssen Inc. (2018). Pariet (rabeprazole). *CA Product Monograph*,
1578. Janssen Inc. (2018). Tramacet (tramadol hydrochloride / acetaminophen). *CA Product Monograph*,
1579. Janssen Inc. (2018). Ultram (tramadol hydrochloride). *CA Product Monograph*,
1580. Janssen Inc. (2019). Invokana (canagliflozin). *CA Product Monograph*,
1581. Janssen, J., Kinkade, A., & Man, D. (2015). CARBapenem utilization evaluation in a large community hospital (CARBON): A Quality Improvement Study. *Can J Hosp Pharm*, 68(4), 327-331.
1582. Janssen Pharmaceuticals Inc. (2017). Axert (almotriptan). *US Product Monograph*,
1583. Janssen Pharmaceuticals Inc. (2017). Haldol Deconoate (haloperidol). *US Product Monograph*,
1584. Janssen Pharmaceuticals Inc. (2017). Ultracet (tramadol hydrochloride / acetaminophen) *US Product Monograph*,
1585. Janssen Pharmaceuticals Inc. (2018). Invega (paliperidone extended release). *US Product Monograph*,
1586. Janssen Pharmaceuticals Inc. (2018). Invokana (canagliflozin). *US Product Monograph*,
1587. Janssen Pharmaceuticals Inc. (2018). Risperdal (risperidone oral). *US Product Monograph*,
1588. Janssen Pharmaceuticals Inc. (2018). Risperdal Consta (risperidone IM injection). *US Product Monograph*,
1589. Janssen Pharmaceuticals Inc. (2018). Topamax (topiramate). *US Product Monograph*,
1590. Janssen Pharmaceuticals Inc. (2018). Tylenol with Codeine (acetaminophen / codeine phosphate). *US Product Monograph*,
1591. Janssen Pharmaceuticals Inc. (2018). Ultram (tramadol). *US Product Monograph*,
1592. Janssen Pharmaceuticals Inc. (2018). Xarelto (rivaroxaban). *US Product Monograph*,
1593. Janssen Pharmaceuticals Inc. (2019). Invega Trinza (paliperidone injectable). *US Product Monograph*,
1594. Janssen Pharmaceuticals Inc. (2019). Invokana (canagliflozin) *US Product Monograph*,
1595. Janssen_Pharmaceuticals_Inc_CA. (2019). Canagliflozin. *Health Canada Monograph*,

1596. Janssen_Pharmaceuticals_Inc_US. (2019). Canagliflozin. *FDA Monograph*,
1597. Janssens, H. J., Janssen, M., van de Lisdonk, E. H., van Riel, P. L., & van Weel, C. (2008). Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. *Lancet*, *371*(9627), 1854-1860.
1598. Janssens, H. J., Lucassen, P. L., Van de Laar, F. A., Janssen, M., & Van de Lisdonk, E. H. (2008). Systemic corticosteroids for acute gout. *Cochrane Database Syst Rev*(2), CD005521.
1599. January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Jr., . . . Yancy, C. W. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*, *64*(21), e1-76.
1600. January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Jr., . . . Yancy, C. W. (2019). 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*, *16*(8), e66-e93.
1601. Jaquenoud Sirot, E., Harenberg, S., Vandael, P., Lima, C. A., Perrenoud, P., Kemmerling, K., . . . Baumann, P. (2012). Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. *J Clin Psychopharmacol*, *32*(5), 622-629.
1602. Jaquenoud Sirot, E., Knezevic, B., Morena, G. P., Harenberg, S., Oneda, B., Crettol, S., . . . Eap, C. B. (2009). ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. *J Clin Psychopharmacol*, *29*(4), 319-326.
1603. Jarupongprapa, S., Ussavasodhi, P., & Katchamart, W. (2013). Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. *J Gastroenterol*, *48*(7), 830-838.
1604. Jasmine, F., Ahsan, H., Andrulis, I. L., John, E. M., Chang-Claude, J., & Kibriya, M. G. (2008). Whole-genome amplification enables accurate genotyping for microarray-based high-density single nucleotide polymorphism array. *Cancer Epidemiol Biomarkers Prev*, *17*(12), 3499-3508.
1605. Javorsky, M., Babjakova, E., Klimcakova, L., Schroner, Z., Zidzik, J., Stolfova, M., . . . Tkac, I. (2013). Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. *Int J Endocrinol*, *2013*, 374858.
1606. Javorsky, M., Klimcakova, L., Schroner, Z., Zidzik, J., Babjakova, E., Fabianova, M., . . . Tkac, I. (2012). KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. *Eur J Intern Med*, *23*(3), 245-249.
1607. Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., . . . Davidson, M. (2017). American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*, *23*(Suppl 2), 1-87.

1608. Jensen, B., & Regier, L. (2019). Antidepressants: Comparison Chart. In. RxFiles.ca: RxFiles Academic Detailing.
1609. Jensen, R., Brinck, T., & Olesen, J. (1994). Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. *Neurology*, 44(4), 647-651.
1610. Jerling, M., Dahl, M. L., Aberg-Wistedt, A., Liljenberg, B., Landell, N. E., Bertilsson, L., & Sjoqvist, F. (1996). The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. *Clin Pharmacol Ther*, 59(4), 423-428.
1611. Jerling, M., Merle, Y., Mentre, F., & Mallet, A. (1994). Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. *Br J Clin Pharmacol*, 38(5), 453-462.
1612. Jevsevar, D. S., Shores, P. B., Mullen, K., Schulte, D. M., Brown, G. A., & Cummins, D. S. (2018). Mixed treatment comparisons for nonsurgical treatment of knee osteoarthritis: A network meta-analysis. *J Am Acad Orthop Surg*, 26(9), 325-336.
1613. Jheng, G. H., Wu, I. C., Shih, H. Y., Wu, M. C., Kuo, F. C., Hu, H. M., . . . Hsu, P. I. (2015). Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. *Biomed Res Int*, 2015, 163960.
1614. Ji, S., Kim, H. S., Kim, J. W., Jee, M. K., Park, K. W., Uh, Y., . . . Kwon, S. O. (2006). Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. *J Gastroenterol Hepatol*, 21(9), 1381-1387.
1615. Jiang, Z. P., Shu, Y., Chen, X. P., Huang, S. L., Zhu, R. H., Wang, W., . . . Zhou, H. H. (2002). The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. *Eur J Clin Pharmacol*, 58(2), 109-113.
1616. Jin, S. K., Chung, H. J., Chung, M. W., Kim, J. I., Kang, J. H., Woo, S. W., . . . Roh, J. (2008). Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. *J Clin Pharm Ther*, 33(5), 567-573.
1617. Jing, W., Zongjie, H., Denggang, F., Na, H., Bin, Z., Aifen, Z., . . . Ring, B. Z. (2015). Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis. *J Med Genet*, 52(2), 95-103.
1618. Johansson, H., Gandini, S., Serrano, D., Gjerde, J., Lattanzi, M., Macis, D., . . . Bonanni, B. (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. *Breast Cancer Res Treat*, 159(1), 97-108.
1619. Johnson & Johnson Consumer Inc. (2018). Tylenol 8hr Arthritis (acetaminophen ER). *US Product Monograph*,
1620. Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., . . . Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. *Clin Pharmacol Ther*, 102(3), 397-404.
1621. Johnson, R. F., Cohen, A. P., Guo, Y., Schibler, K., & Greinwald, J. H. (2010). Genetic mutations and aminoglycoside-induced ototoxicity in neonates. *Otolaryngol Head Neck Surg*, 142(5), 704-707.

1622. Johnston, R. N., McNeill, R. S., Smith, D. H., Dempster, M. B., Nairn, J. R., Purvis, M. S., . . . Ward, F. G. (1969). Five-year winter chemoprophylaxis for chronic bronchitis. *BMJ*, 4(5678), 265-269.
1623. Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F., Walton, R. T., & Munafo, M. R. (2007). Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. *Cancer Epidemiol Biomarkers Prev*, 16(6), 1065-1069.
1624. Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., . . . Lewis, S. W. (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry*, 63(10), 1079-1087.
1625. Jones, R., & Crouch, S. L. (1999). Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. *Aliment Pharmacol Ther*, 13(3), 413-419.
1626. Jones, R. H., & Baxter, G. (1997). Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. *Aliment Pharmacol Ther*, 11(3), 541-546.
1627. Jongkhajornpong, P., Lekhanont, K., Pisuchpen, P., Chantaren, P., Puangsrucharern, V., Prabhasawat, P., . . . Ueta, M. (2018). Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. *Br J Ophthalmol*, 102(9), 1303-1307.
1628. Joos, S., Miksch, A., Szecsenyi, J., Wieseler, B., Grouven, U., Kaiser, T., & Schneider, A. (2008). Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. *Thorax*, 63(5), 453-462.
1629. Jordan, K. M., Cameron, J. S., Snaith, M., Zhang, W., Doherty, M., Seckl, J., . . . Nuki, G. (2007). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. *Rheumatology (Oxford)*, 46(8), 1372-1374.
1630. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., . . . Baker, T. B. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med*, 340(9), 685-691.
1631. Jorns, T. P., & Zakrzewska, J. M. (2007). Evidence-based approach to the medical management of trigeminal neuralgia. *Br J Neurosurg*, 21(3), 253-261.
1632. Jose, M., Mathaiyan, J., Kattimani, S., Adithan, S., & Chandrasekaran, A. (2016). Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population. *Eur J Clin Pharmacol*, 72(7), 807-812.
1633. Joseph, A., Ayyagari, R., Xie, M., Cai, S., Xie, J., Huss, M., & Sikirica, V. (2017). Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. *Eur Child Adolesc Psychiatry*, 26(8), 875-897.
1634. Joseph, A. M., Willenbring, M. L., Nugent, S. M., & Nelson, D. B. (2004). A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. *J Stud Alcohol*, 65(6), 681-691.

1635. Jubilant Cadista Pharmaceuticals Inc. (2018). Levofloxacin. *US Product Monograph*,
1636. Jukic, M. M., Haslemo, T., Molden, E., & Ingelman-Sundberg, M. (2018). Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. *Am J Psychiatry*, *175*(5), 463-470.
1637. Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., . . . Perkovic, V. (2010). Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet*, *375*(9729), 1875-1884.
1638. Jung, J. A., & Lim, H. S. (2014). Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. *Pharmacogenomics*, *15*(1), 49-60.
1639. Jungers, P., Ganeval, D., Pertuiset, N., & Chauveau, P. (1986). Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. *Am J Med*, *80*(5b), 94-99.
1640. Juraschek, S. P., Miller, E. R., 3rd, & Gelber, A. C. (2011). Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken)*, *63*(9), 1295-1306.
1641. Jusko, W. J., Szeffler, S. J., & Goldfarb, A. L. (1974). Pharmacokinetic design of digoxin dosage regimens in relation to renal function. *J Clin Pharmacol*, *14*(10), 525-535.
1642. Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., . . . Grobbee, D. E. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet*, *371*(9618), 1085-1097.
1643. Kakihara, S., Yoshimura, R., Shinkai, K., Matsumoto, C., Goto, M., Kaji, K., . . . Nakamura, J. (2005). Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. *Int Clin Psychopharmacol*, *20*(2), 71-78.
1644. Kakuta, Y., Kawai, Y., Okamoto, D., Takagawa, T., Ikeya, K., Sakuraba, H., . . . group, M. s. (2018). NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. *J Gastroenterol*, *53*(9), 1065-1078.
1645. Kalita, J., Bhoi, S. K., & Misra, U. K. (2013). Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. *Acta Neurol Scand*, *128*(1), 65-72.
1646. Kalman, L. V., Agundez, J., Appell, M. L., Black, J. L., Bell, G. C., Boukouvala, S., . . . Zanger, U. M. (2016). Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. *Clin Pharmacol Ther*, *99*(2), 172-185.
1647. Kamijima, K., Higuchi, T., Ishigooka, J., Ohmori, T., Ozaki, N., Kanba, S., . . . Koyama, T. (2013). Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). *J Affect Disord*, *151*(3), 899-905.
1648. Kamijima, K., Yasuda, M., Yamamura, K., & Fukuta, Y. (2018). Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. *Curr Med Res Opin*, *34*(12), 2105-2112.

1649. Kanazawa, H., Hirata, K., & Yoshikawa, J. (2003). Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. *Thorax*, *58*(7), 629-631.
1650. Kanba, S., Kawasaki, H., Ishigooka, J., Sakamoto, K., Kinoshita, T., & Kuroki, T. (2014). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). *World J Biol Psychiatry*, *15*(2), 113-121.
1651. Kane, J. M., Leucht, S., Carpenter, D., & Docherty, J. P. (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. *J Clin Psychiatry*, *64 Suppl 12*, 5-19.
1652. Kane, J. M., Mackle, M., Snow-Adami, L., Zhao, J., Szegedi, A., & Panagides, J. (2011). A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. *J Clin Psychiatry*, *72*(3), 349-355.
1653. Kang, J. M., Kim, N., Lee, D. H., Park, Y. S., Kim, J. S., Chang, I. J., . . . Jung, H. C. (2008). Effect of the CYP2C19 polymorphism on the eradication rate of *Helicobacter pylori* infection by 7-day triple therapy with regular proton pump inhibitor dosage. *J Gastroenterol Hepatol*, *23*(8 Pt 1), 1287-1291.
1654. Kangasniemi, P., Andersen, A. R., Andersson, P. G., Gilhus, N. E., Hedman, C., Hultgren, M., . . . Olesen, J. (1987). Classic migraine: effective prophylaxis with metoprolol. *Cephalalgia*, *7*(4), 231-238.
1655. Kaniecki, R. G. (1997). A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. *Arch Neurol*, *54*(9), 1141-1145.
1656. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., . . . Hasegawa, R. (2010). HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. *Epilepsia*, *51*(12), 2461-2465.
1657. Kannabiran, C., Ueta, M., Sangwan, V., Rathi, V., Basu, S., Tokunaga, K., & Kinoshita, S. (2017). Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. *Sci Rep*, *7*(1), 15960.
1658. Kapczynski, F., Lima, M. S., Souza, J. S., & Schmitt, R. (2003). Antidepressants for generalized anxiety disorder. *Cochrane Database Syst Rev*(2), Cd003592.
1659. Karner, C., & Cates, C. J. (2012). Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(4), CD008989.
1660. Kashiwara, Y., Ieiri, I., Yoshikado, T., Maeda, K., Fukae, M., Kimura, M., . . . Sugiyama, Y. (2017). Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. *J Pharm Sci*, *106*(9), 2688-2694.
1661. Kashiwagi, M., Aihara, M., Takahashi, Y., Yamazaki, E., Yamane, Y., Song, Y., . . . Ikezawa, Z. (2008). Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. *J Dermatol*, *35*(10), 683-685.

1662. Kasper, S., Gastpar, M., Muller, W. E., Volz, H. P., Moller, H. J., Schlafke, S., & Dienel, A. (2014). Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. *Int J Neuropsychopharmacol*, *17*(6), 859-869.
1663. Kasper, S., Herman, B., Nivoli, G., Van Ameringen, M., Petralia, A., Mandel, F. S., . . . Bandelow, B. (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. *Int Clin Psychopharmacol*, *24*(2), 87-96.
1664. Kasper, S., & Pail, G. (2010). Milnacipran: a unique antidepressant? *Neuropsychiatr Dis Treat*, *6*, 23-31.
1665. Kasper, S., Sacher, J., Klein, N., Mossaheb, N., Attarbaschi-Steiner, T., Lanzenberger, R., . . . Dudczak, R. (2009). Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. *Int Clin Psychopharmacol*, *24*(3), 119-125.
1666. Katchamart, W., Trudeau, J., Phumethum, V., & Bombardier, C. (2010). Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. *Cochrane Database Syst Rev*(4), CD008495.
1667. Kato, D., Kawanishi, C., Kishida, I., Furuno, T., Matsumura, T., Hasegawa, H., & Hirayasu, Y. (2005). Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype. *Psychosomatics*, *46*(4), 374-375.
1668. Kato, M., & Serretti, A. (2010). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. *Mol Psychiatry*, *15*(5), 473-500.
1669. Katoh, Y., Uchida, S., Kawai, M., Takei, N., Mori, N., Kawakami, J., . . . Hashimoto, H. (2010). Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. *Biol Pharm Bull*, *33*(2), 285-288.
1670. Katz, P. O., Gerson, L. B., & Vela, M. F. (2013). Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol*, *108*(3), 308-328; quiz 329.
1671. Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., . . . Walker, J. R. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. *BMC Psychiatry*, *14 Suppl 1*, S1.
1672. Kaufmann, A., Hitsman, B., Goelz, P. M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., . . . Schnoll, R. A. (2015). Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. *Addict Behav*, *51*, 93-99.
1673. Kaur, G., Phillips, C. L., Wong, K., McLachlan, A. J., & Saini, B. (2016). Timing of administration: For commonly-prescribed medicines in Australia. *Pharmaceutics*, *8*(2).
1674. Kaur-Knudsen, D., Bojesen, S. E., & Nordestgaard, B. G. (2014). CHRNA3 and CYP3A5*3 genotype, lung function and chronic obstructive pulmonary disease in the general population. *Pharmacogenet Genomics*, *24*(4), 220-229.

1675. Kawaguchi, D. M., & Glatt, S. J. (2014). GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. *Pharmacogenomics*, *15*(11), 1451-1459.
1676. Kawalec, P., Cierniak, A., Pilc, A., & Nowak, G. (2015). Pregabalin for the treatment of social anxiety disorder. *Expert Opin Investig Drugs*, *24*(4), 585-594.
1677. Kawamura, M., Ohara, S., Koike, T., Iijima, K., Suzuki, H., Kayaba, S., . . . Shimosegawa, T. (2007). Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. *J Gastroenterol Hepatol*, *22*(2), 222-226.
1678. Kawamura, M., Ohara, S., Koike, T., Iijima, K., Suzuki, J., Kayaba, S., . . . Shimosegawa, T. (2003). The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. *Aliment Pharmacol Ther*, *17*(7), 965-973.
1679. Kawanishi, C., Lundgren, S., Agren, H., & Bertilsson, L. (2004). Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. *Eur J Clin Pharmacol*, *59*(11), 803-807.
1680. Kazeem, G. R., Cox, C., Aponte, J., Messenheimer, J., Brazell, C., Nelsen, A. C., . . . Foot, E. (2009). High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. *Pharmacogenet Genomics*, *19*(9), 661-665.
1681. Kean, W. F., Kean, C. A., & Hogan, M. G. (2015). Osteoarthritis. In B. Jovaisas (Ed.), *Therapeutics* (
1682. Keane, S., Lane, A., Larkin, T., & Clarke, M. (2009). Management of clozapine-related hepatotoxicity. *J Clin Psychopharmacol*, *29*(6), 606-607.
1683. Keating, G. M., & Siddiqui, M. A. (2006). Varenicline: a review of its use as an aid to smoking cessation therapy. *CNS drugs*, *20*(11), 945-960.
1684. Keck, P. E., Jr., Calabrese, J. R., McQuade, R. D., Carson, W. H., Carlson, B. X., Rollin, L. M., . . . Sanchez, R. (2006). A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. *J Clin Psychiatry*, *67*(4), 626-637.
1685. Keck, P. E., Jr., Versiani, M., Potkin, S., West, S. A., Giller, E., & Ice, K. (2003). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. *Am J Psychiatry*, *160*(4), 741-748.
1686. Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., Taskinen, M. R., . . . Laakso, M. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*, *366*(9500), 1849-1861.
1687. Keel, C., Kraenzlin, M. E., Kraenzlin, C. A., Muller, B., & Meier, C. (2010). Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. *J Bone Miner Metab*, *28*(1), 68-76.
1688. Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014). Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. *BMJ*, *349*, g4379.

1689. Keers, R., Uher, R., Huezo-Diaz, P., Smith, R., Jaffee, S., Rietschel, M., . . . Aitchison, K. J. (2011). Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. *Pharmacogenomics J*, *11*(2), 138-145.
1690. Keks, N., Hope, J., & Keogh, S. (2016). Switching and stopping antidepressants. *Aust Prescr*, *39*(3), 76-83.
1691. Kemp, D. E., Johnson, E., Wang, W. V., Tohen, M., & Calabrese, J. R. (2011). Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. *J Clin Psychiatry*, *72*(9), 1236-1241.
1692. Kennard, L., & O'Shaughnessy, K. M. (2016). Treating hypertension in patients with medical comorbidities. *BMJ*, *352*, i101.
1693. Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., . . . Uher, R. (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. *Can J Psychiatry*, *61*(9), 540-560.
1694. Kennedy, S. H., Parikh, S., & Grigoriadis, S. (2016). Depression. In B. Jovaisas (Ed.), *Therapeutics [Internet]* (
1695. Keskinbora, K., & Aydinli, I. (2008). A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. *Clin Neurol Neurosurg*, *110*(10), 979-984.
1696. Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. *Clin Pharmacol Ther*, *86*(2), 197-203.
1697. Kessler, D., Burns, A., Tallon, D., Lewis, G., MacNeill, S., Round, J., . . . Wiles, N. (2018). Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. *Health Technol Assess*, *22*(63), 1-136.
1698. Ketter, T. A., Sarma, K., Silva, R., Kroger, H., Cucchiaro, J., & Loebel, A. (2016). Lurasidone in the Long-Term Treatment of Patients with Bipolar Disorder: A 24-Week Open-Label Extension Study. *Depress Anxiety*, *33*(5), 424-434.
1699. Kew, K. M., & Dahri, K. (2016). Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. *Cochrane Database Syst Rev*(1), CD011721.
1700. Kew, K. M., Evans, D. J., Allison, D. E., & Boyter, A. C. (2015). Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. *Cochrane Database Syst Rev*(6), CD011438.
1701. Keyvan, G., & Abolfazl, M. B. (2009). Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine. *Pak J Biol Sci*, *12*(15), 1098-1101.
1702. Khan, A., Fortier, M., Menopause, & Osteoporosis Working Group. (2014). Osteoporosis in menopause. *J Obstet Gynaecol Can*, *36*(9), 839-840.
1703. Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., & Eriksson, H. (2011). A randomized, double-blind study of once-daily extended release quetiapine fumarate

- (quetiapine XR) monotherapy in patients with generalized anxiety disorder. *J Clin Psychopharmacol*, 31(4), 418-428.
1704. Khan, N., & McAlister, F. A. (2006). Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. *CMAJ*, 174(12), 1737-1742.
1705. Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., . . . Terkeltaub, R. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)*, 64(10), 1431-1446.
1706. Khanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., . . . Terkeltaub, R. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res (Hoboken)*, 64(10), 1447-1461.
1707. Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., . . . Xia, J. (2014). Aripiprazole versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(1), CD006569.
1708. Kheiri, B., Osman, M., Abdalla, A., Haykal, T., Pandrangi, P. V., Chahine, A., . . . Bhatt, D. L. (2019). CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. *Catheter Cardiovasc Interv*, 93(7), 1246-1252.
1709. Khor, A. H., Lim, K. S., Tan, C. T., Wong, S. M., & Ng, C. C. (2014). HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. *Epilepsia*, 55(11), e120-124.
1710. Kidd, S., Chopra, P., Stone, J., Jackson, T., Gwee, K., Maynard, S., . . . Judd, F. (2013). Monitoring of long-term cardiac complications in patients receiving clozapine. *Australas Psychiatry*, 21(1), 77-78.
1711. Kidney Disease Outcomes Quality, I. (2004). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*, 43(5 Suppl 1), S1-290.
1712. Killen, J. D., Robinson, T. N., Ammerman, S., Hayward, C., Rogers, J., Stone, C., . . . Schatzberg, A. F. (2004). Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. *J Consult Clin Psychol*, 72(4), 729-735.
1713. Kim, B. K., Jung, J. W., Kim, T. B., Chang, Y. S., Park, H. S., Moon, J., . . . Park, H. W. (2017). HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population. *Ann Allergy Asthma Immunol*, 118(5), 629-630.
1714. Kim, D. H., Jung, H. D., Kim, J. G., Lee, J. J., Yang, D. H., Park, Y. H., . . . Sohn, S. K. (2006). FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. *Blood*, 108(8), 2720-2725.
1715. Kim, E., Yu, K. S., Cho, J. Y., Shin, Y. W., Yoo, S. Y., Kim, Y. Y., . . . Kwon, J. S. (2006). Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. *Hum Psychopharmacol*, 21(8), 519-528.

1716. Kim, H. S., Cheon, J. H., Jung, E. S., Park, J., Aum, S., Park, S. J., . . . Lee, M. G. (2017). A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. *Gut*, *66*(11), 1926-1935.
1717. Kim, K. M., Murray, M. D., Tu, W., Robarge, J., Ding, Y., Brater, D. C., & Flockhart, D. A. (2012). Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. *Eur J Clin Pharmacol*, *68*(11), 1483-1491.
1718. Kim, S. G., Kim, C. M., Choi, S. W., Jae, Y. M., Lee, H. G., Son, B. K., . . . Oslin, D. W. (2009). A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. *Psychopharmacology (Berl)*, *201*(4), 611-618.
1719. Kim, S. H., Kim, D. H., Byeon, J. Y., Kim, Y. H., Kim, D. H., Lim, H. J., . . . Lee, S. Y. (2017). Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. *Arch Pharm Res*, *40*(3), 382-390.
1720. Kim, S. H., Lee, K. W., Song, W. J., Kim, S. H., Jee, Y. K., Lee, S. M., . . . Chang, Y. S. (2011). Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. *Epilepsy Res*, *97*(1-2), 190-197.
1721. Kim, S. H., Ye, Y. M., Hur, G. Y., Lee, H. Y., Jee, Y. K., Lee, S. H., . . . Park, H. S. (2009). Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment. *Yonsei Med J*, *50*(2), 182-188.
1722. Kim, W. J., Oh, Y. M., Sung, J., Kim, T. H., Huh, J. W., Jung, H., . . . Lee, S. D. (2008). Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. *Lung*, *186*(6), 381-386.
1723. Kim, W. J., Sheen, S. S., Kim, T. H., Huh, J. W., Lee, J. H., Kim, E. K., . . . Lee, S. D. (2009). Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. *Respirology*, *14*(2), 260-263.
1724. Kimmel, S. E., French, B., Kasner, S. E., Johnson, J. A., Anderson, J. L., Gage, B. F., . . . Ellenberg, J. H. (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med*, *369*(24), 2283-2293.
1725. King, D. P., Paciga, S., Pickering, E., Benowitz, N. L., Bierut, L. J., Conti, D. V., . . . Park, P. W. (2012). Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. *Neuropsychopharmacology*, *37*(3), 641-650.
1726. Kinze, S., Clauss, M., Reuter, U., Wolf, T., Dreier, J. P., Einhaupl, K. M., & Arnold, G. (2001). Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. *Headache*, *41*(8), 774-778.
1727. Kips, J. C., & Pauwels, R. A. (2001). Long-acting inhaled beta(2)-agonist therapy in asthma. *Am J Respir Crit Care Med*, *164*(6), 923-932.
1728. Kirch, W., Kohler, H., & Braun, W. (1980). Elimination of guanfacine in patients with normal and impaired renal function. *Br J Clin Pharmacol*, *10 Suppl 1*, 33s-35s.
1729. Kirch, W., Rose, I., Demers, H. G., Leopold, G., Pabst, J., & Ohnhaus, E. E. (1987). Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. *Clin Pharmacokinet*, *13*(2), 110-117.

1730. Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., . . . Brockmøller, J. (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. *Acta Psychiatr Scand*, 104(3), 173-192.
1731. Kirchheiner, J., Heesch, C., Bauer, S., Meisel, C., Seringer, A., Goldammer, M., . . . Brockmoller, J. (2004). Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. *Clin Pharmacol Ther*, 76(4), 302-312.
1732. Kirchheiner, J., Henckel, H. B., Franke, L., Meineke, I., Tzvetkov, M., Uebelhack, R., . . . Brockmoller, J. (2005). Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. *Pharmacogenet Genomics*, 15(8), 579-587.
1733. Kirchheiner, J., Henckel, H. B., Meineke, I., Roots, I., & Brockmoller, J. (2004). Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. *J Clin Psychopharmacol*, 24(6), 647-652.
1734. Kirchheiner, J., Meineke, I., Muller, G., Roots, I., & Brockmoller, J. (2002). Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. *Pharmacogenetics*, 12(7), 571-580.
1735. Kirchheiner, J., Meineke, I., Steinbach, N., Meisel, C., Roots, I., & Brockmoller, J. (2003). Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. *Br J Clin Pharmacol*, 55(1), 51-61.
1736. Kirchheiner, J., Schmidt, H., Tzvetkov, M., Keulen, J. T., Lotsch, J., Roots, I., & Brockmoller, J. (2007). Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. *Pharmacogenomics J*, 7(4), 257-265.
1737. Kirchheiner, J., Stormer, E., Meisel, C., Steinbach, N., Roots, I., & Brockmoller, J. (2003). Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. *Pharmacogenetics*, 13(8), 473-480.
1738. Kirchheiner, J., Thomas, S., Bauer, S., Tomalik-Scharte, D., Hering, U., Doroshenko, O., . . . Fuhr, U. (2006). Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. *Clin Pharmacol Ther*, 80(6), 657-667.
1739. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., . . . Vardas, P. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*, 37(38), 2893-2962.
1740. Kirthi, V., Derry, S., & Moore, R. A. (2013). Aspirin with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*(4), Cd008041.
1741. Kishi, T., & Iwata, N. (2015). Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci*, 265(3), 259-268.
1742. Kishi, T., Yoshimura, R., Kitajima, T., Okochi, T., Okumura, T., Tsunoka, T., . . . Iwata, N. (2010). HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. *Neuromolecular Med*, 12(3), 237-242.

1743. Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2013). Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry*, *18*(1), 53-66.
1744. Klapper, J. (1997). Divalproex sodium in migraine prophylaxis: a dose-controlled study. *Cephalalgia*, *17*(2), 103-108.
1745. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., . . . Johnson, J. A. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med*, *360*(8), 753-764.
1746. Kleinbloesem, C. H., van Harten, J., Wilson, J. P., Danhof, M., van Brummelen, P., & Breimer, D. D. (1986). Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. *Clin Pharmacol Ther*, *40*(1), 21-28.
1747. Kloppenburg, M., Kroon, F. P., Blanco, F. J., Doherty, M., Dziedzic, K. S., Greibrokk, E., . . . Carmona, L. (2019). 2018 update of the EULAR recommendations for the management of hand osteoarthritis. *Ann Rheum Dis*, *78*(1), 16-24.
1748. Knauf, H., Mohrke, W., & Mutschler, E. (1983). Delayed elimination of triamterene and its active metabolite in chronic renal failure. *Eur J Clin Pharmacol*, *24*(4), 453-456.
1749. Kobak, K. A., Greist, J. H., Jefferson, J. W., & Katzelnick, D. J. (2002). Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. *J Clin Psychopharmacol*, *22*(3), 257-262.
1750. Kobayashi, K., Oguchi, T., Asamura, K., Miyagawa, M., Horai, S., Abe, S., & Usami, S. (2005). Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation. *Auris Nasus Larynx*, *32*(2), 119-124.
1751. Kober, L., Torp-Pedersen, C., Carlsen, J. E., Bagger, H., Eliassen, P., Lyngborg, K., . . . Pauly, N. C. (1995). A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med*, *333*(25), 1670-1676.
1752. Koch, K., Mansi, K., Haynes, E., Adams, C. E., Sampson, S., & Furtado, V. A. (2014). Trifluoperazine versus placebo for schizophrenia. *Cochrane Database Syst Rev*(1), CD010226.
1753. Koegelenberg, C. F., Noor, F., Bateman, E. D., van Zyl-Smit, R. N., Bruning, A., O'Brien, J. A., . . . Iruken, E. M. (2014). Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *Jama*, *312*(2), 155-161.
1754. Koek, G. H., Sifrim, D., Lerut, T., Janssens, J., & Tack, J. (2003). Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. *Gut*, *52*(10), 1397-1402.
1755. Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017). Vortioxetine for depression in adults. *Cochrane Database Syst Rev*, *7*, Cd011520.

1756. Kohli, P., Whelton, S. P., Hsu, S., Yancy, C. W., Stone, N. J., Chrispin, J., . . . Blumenthal, R. S. (2014). Clinician's guide to the updated ABCs of cardiovascular disease prevention. *J Am Heart Assoc*, 3(5), e001098.
1757. Kohnke, M. D., Griese, E. U., Stosser, D., Gaertner, I., & Barth, G. (2002). Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. *Pharmacopsychiatry*, 35(3), 116-118.
1758. Komajda, M., Bohm, M., Borer, J., Ford, I., Krum, H., Tase, A., . . . Swedberg, K. (2013). Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. *Eur J Heart Fail*, 15(1), 79-84.
1759. Komajda, M., Follath, F., Swedberg, K., Cleland, J., Aguilar, J. C., Cohen-Solal, A., . . . Mason, J. (2003). The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. *Eur Heart J*, 24(5), 464-474.
1760. Komajda, M., Hanon, O., Hochadel, M., Lopez-Sendon, J. L., Follath, F., Ponikowski, P., . . . Nieminen, M. (2009). Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. *Eur Heart J*, 30(4), 478-486.
1761. Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for major depressive disorder and dysthymia. *Cochrane Database Syst Rev*(12), Cd008121.
1762. Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., . . . Leucht, S. (2010). Olanzapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(3), CD006654.
1763. Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009). Ziprasidone versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(4), CD006627.
1764. Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Schmidt, F., Lewis, R., . . . Leucht, S. (2009). Sertindole versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(2), CD006752.
1765. Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., El-Sayeh, H. G., . . . Leucht, S. (2009). Aripiprazole versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(4), CD006569.
1766. Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., . . . Leucht, S. (2010). Quetiapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(1), CD006625.
1767. Komossa, K., Rummel-Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., & Leucht, S. (2011). Risperidone versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*(1), CD006626.
1768. Konstam, M. A., Neaton, J. D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F. A., . . . Poole-Wilson, P. A. (2009). Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet*, 374(9704), 1840-1848.
1769. Koomdee, N., Pratoomwun, J., Jantararoungtong, T., Theeramoke, V., Tassaneeyakul, W., Klaewsongkram, J., . . . Sukasem, C. (2017). Association of HLA-A and HLA-B alleles

- with lamotrigine-induced cutaneous adverse drug reactions in the Thai population. *Front Pharmacol*, 8, 879.
1770. Koponen, H., Allgulander, C., Erickson, J., Dunayevich, E., Pritchett, Y., Detke, M. J., . . . Russell, J. M. (2007). Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. *Prim Care Companion J Clin Psychiatry*, 9(2), 100-107.
1771. Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., & Leeder, S. J. (2006). Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet*, 368(9536), 704.
1772. Kornitzer, M., Boutsen, M., Dramaix, M., Thijs, J., & Gustavsson, G. (1995). Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med*, 24(1), 41-47.
1773. Kosaki, K., Tamura, K., Sato, R., Samejima, H., Tanigawara, Y., & Takahashi, T. (2004). A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethyloclobazam. *Brain Dev*, 26(8), 530-534.
1774. Koski, A., Ojanpera, I., Sistonen, J., Vuori, E., & Sajantila, A. (2007). A fatal doxepin poisoning associated with a defective CYP2D6 genotype. *Am J Forensic Med Pathol*, 28(3), 259-261.
1775. Koski, A., Sistonen, J., Ojanpera, I., Gergov, M., Vuori, E., & Sajantila, A. (2006). CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. *Forensic Sci Int*, 158(2-3), 177-183.
1776. Kostis, J. B., Packer, M., Black, H. R., Schmieder, R., Henry, D., & Levy, E. (2004). Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. *Am J Hypertens*, 17(2), 103-111.
1777. Kotecha, D., Holmes, J., Krum, H., Altman, D. G., Manzano, L., Cleland, J. G., . . . Flather, M. D. (2014). Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet*, 384(9961), 2235-2243.
1778. Kotz, D., Viechtbauer, W., Simpson, C., van Schayck, O. C., West, R., & Sheikh, A. (2015). Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. *Lancet Respir Med*, 3(10), 761-768.
1779. Koup, J. R., Jusko, W. J., Elwood, C. M., & Kohli, R. K. (1975). Digoxin pharmacokinetics: role of renal failure in dosage regimen design. *Clin Pharmacol Ther*, 18(1), 9-21.
1780. Kovacs, M. J., Rodger, M., Anderson, D. R., Morrow, B., Kells, G., Kovacs, J., . . . Wells, P. S. (2003). Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. *Ann Intern Med*, 138(9), 714-719.
1781. Kowa Pharmaceuticals America Inc. (2009). Cambia (diclofenac potassium). *US Product Monograph*,
1782. Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S., Totsuka, S., & Ishizaki, T. (1996). Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. *J Clin Psychopharmacol*, 16(4), 286-293.

1783. Koytchev, R., Alken, R. G., Vlahov, V., Kirkov, V., Kaneva, R., Thyroff-Friesinger, U., & Rehak, E. (1998). Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. *Eur J Clin Pharmacol*, *54*(6), 469-474.
1784. Krauss, R. M., Mangravite, L. M., Smith, J. D., Medina, M. W., Wang, D., Guo, X., . . . Rotter, J. I. (2008). Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. *Circulation*, *117*(12), 1537-1544.
1785. Kroon, F. P. B., Carmona, L., Schoones, J. W., & Kloppenburg, M. (2018). Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. *RMD Open*, *4*(2), e000734.
1786. Krymchantowski, A. V., & Jevoux, C. C. (2011). Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. *Headache*, *51*(4), 554-558.
1787. Krymchantowski, A. V., Silva, M. T., Barbosa, J. S., & Alves, L. A. (2002). Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. *Headache*, *42*(6), 510-514.
1788. Kubo, M., Koue, T., Inaba, A., Takeda, H., Maune, H., Fukuda, T., & Azuma, J. (2005). Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. *Drug Metab Pharmacokinet*, *20*(1), 55-64.
1789. Kubo, M., Koue, T., Maune, H., Fukuda, T., & Azuma, J. (2007). Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. *Drug Metab Pharmacokinet*, *22*(5), 358-366.
1790. Kuhn, U. D., Kirsch, M., Merkel, U., Eberhardt, A. M., Wenda, B., Maurer, I., . . . Balogh, A. (2007). Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans. *Int J Clin Pharmacol Ther*, *45*(1), 36-46.
1791. Kuijpers, T., van Middelkoop, M., Rubinstein, S. M., Ostelo, R., Verhagen, A., Koes, B. W., & van Tulder, M. W. (2011). A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. *Eur Spine J*, *20*(1), 40-50.
1792. Kulkantrakorn, K., Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Prabmechai, N., Vannaprasaht, S., . . . Sritipsukho, P. (2012). HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. *Pain Pract*, *12*(3), 202-208.
1793. Kumar, A., & Strech, D. (2005). Zuclopenthixol dihydrochloride for schizophrenia. *Cochrane Database Syst Rev*(4), CD005474.
1794. Kumar, Y., Kung, S., & Shinozaki, G. (2014). CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. *J Psychopharmacol*, *28*(12), 1143-1148.

1795. Kumari, R., Lakhan, R., Garg, R. K., Kalita, J., Misra, U. K., & Mittal, B. (2011). Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. *Indian J Hum Genet, 17 Suppl 1*, S32-40.
1796. Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Jr., Goto, S., . . . Bhatt, D. L. (2014). Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. *Eur Heart J, 35*(41), 2864-2872.
1797. Kundu, A. K. (2000). Ciprofloxacin-induced severe cutaneous reaction and haemolysis in a young adult. *J Assoc Physicians India, 48*(6), 649-650.
1798. Kuo, C. H., Wang, S. S., Hsu, W. H., Kuo, F. C., Weng, B. C., Li, C. J., . . . Wu, D. C. (2010). Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. *Helicobacter, 15*(4), 265-272.
1799. Kuperman, S., Perry, P. J., Gaffney, G. R., Lund, B. C., Bever-Stille, K. A., Arndt, S., . . . Paulsen, J. S. (2001). Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. *Ann Clin Psychiatry, 13*(3), 129-134.
1800. Kupstyte, N., Zaliunas, R., Tatarunas, V., Skipskis, V., Zaliaduonyte-Peksiene, D., Grabauskyste, I., . . . Lesauskaite, V. (2015). Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis. *Pharmacogenomics, 16*(3), 181-189.
1801. Kurata, Y., Ieiri, I., Kimura, M., Morita, T., Irie, S., Urae, A., . . . Otsubo, K. (2002). Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. *Clin Pharmacol Ther, 72*(2), 209-219.
1802. Kurzawski, M., Gawronska-Szklarz, B., Wrzesniewska, J., Siuda, A., Starzynska, T., & Drozdziak, M. (2006). Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. *Eur J Clin Pharmacol, 62*(10), 877-880.
1803. Kusunoki, H., Kusaka, M., Kido, S., Yamauchi, R., Fujimura, Y., Watanabe, Y., . . . Kin, Y. (2009). Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. *J Gastroenterol, 44*.
1804. Kvist, E. E., Al-Shurbaji, A., Dahl, M. L., Nordin, C., Alvan, G., & Stahle, L. (2001). Quantitative pharmacogenetics of nortriptyline: a novel approach. *Clin Pharmacokinet, 40*(11), 869-877.
1805. Kwok, C. S., Arthur, A. K., Anibueze, C. I., Singh, S., Cavallazzi, R., & Loke, Y. K. (2012). Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol, 107*(7), 1011-1019.
1806. Kwok, C. S., Nijjar, R. S., & Loke, Y. K. (2011). Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. *Drug Saf, 34*(1), 47-57.
1807. Kydd, A. S., Seth, R., Buchbinder, R., Edwards, C. J., & Bombardier, C. (2014). Uricosuric medications for chronic gout. *Cochrane Database Syst Rev*(11), CD010457.
1808. Labenz, J., & Malfertheiner, P. (2005). Treatment of uncomplicated reflux disease. *World J Gastroenterol, 11*(28), 4291-4299.
1809. Laboratoire Riva Inc. (2018). Codeine. *CA Product Monograph*,

1810. Lacruz-Guzman, D., Torres-Moreno, D., Pedrero, F., Romero-Cara, P., Garcia-Tercero, I., Trujillo-Santos, J., & Conesa-Zamora, P. (2013). Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. *Eur J Clin Pharmacol*, *69*(3), 431-438.
1811. Lacy, B. E., Talley, N. J., Locke, G. R., 3rd, Bouras, E. P., DiBaise, J. K., El-Serag, H. B., . . . Prather, C. (2012). Review article: current treatment options and management of functional dyspepsia. *Aliment Pharmacol Ther*, *36*(1), 3-15.
1812. Lader, M., & Scotto, J. C. (1998). A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. *Psychopharmacology (Berl)*, *139*(4), 402-406.
1813. Lage, M., & Hwang, P. (2004). Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. *J Child Adolesc Psychopharmacol*, *14*(4), 575-581.
1814. Lahaie, R. G., & Gaudreau, C. (2000). Helicobacter pylori antibiotic resistance: trends over time. *Can J Gastroenterol*, *14*(10), 895-899.
1815. Lai, K. C., Lam, S. K., Chu, K. M., Wong, B. C., Hui, W. M., Hu, W. H., . . . Wong, J. (2002). Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. *N Engl J Med*, *346*(26), 2033-2038.
1816. Lai, K. L., Niddam, D. M., Fuh, J. L., Chen, S. P., Wang, Y. F., Chen, W. T., . . . Wang, S. J. (2017). Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. *Acta Neurol Scand*, *135*(4), 476-483.
1817. Laika, B., Leucht, S., Heres, S., Schneider, H., & Steimer, W. (2010). Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. *Pharmacogenomics J*, *10*(1), 20-29.
1818. Laine, L., Schoenfeld, P., & Fennerty, M. B. (2001). Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. *Ann Intern Med*, *134*(5), 361-369.
1819. Lakhan, R., Misra, U. K., Kalita, J., Pradhan, S., Gogtay, N. J., Singh, M. K., & Mittal, B. (2009). No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. *Epilepsy Behav*, *14*(1), 78-82.
1820. LaLonde, C. D., & Van Lieshout, R. J. (2011). Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. *J Clin Psychopharmacol*, *31*(3), 326-333.
1821. Lam, J., Kelly, L., Matok, I., Ross, C. J., Carleton, B. C., Hayden, M. R., . . . Koren, G. (2013). Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. *Ther Drug Monit*, *35*(4), 466-472.
1822. Lam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004). Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. *J Clin Psychiatry*, *65*(3), 337-340.
1823. Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., . . . Anxiety, T. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *J Affect Disord*, *117* Suppl 1, S26-43.

1824. Lam, Y. W., Gaedigk, A., Ereshefsky, L., Alfaro, C. L., & Simpson, J. (2002). CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. *Pharmacotherapy*, 22(8), 1001-1006.
1825. Lamb, S. A., Al Hamarneh, Y. N., Houle, S. K. D., Leung, A. A., & Tsuyuki, R. T. (2018). Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults for pharmacists: An update. *Can Pharm J (Ott)*, 151(1), 33-42.
1826. Lambrakis, P., Rushworth, G. F., Adamson, J., & Leslie, S. J. (2011). Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients. *Ther Adv Drug Saf*, 2(6), 263-270.
1827. Lamsudin, R., & Sadjimin, T. (1993). Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. *Headache*, 33(6), 335-338.
1828. Lanas, A., & Chan, F. K. (2017). Peptic ulcer disease. *Lancet*.
1829. Lanas, A., Garcia-Rodriguez, L. A., Arroyo, M. T., Bujanda, L., Gomollon, F., Forne, M., . . . Arenas, J. (2007). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. *Am J Gastroenterol*, 102(3), 507-515.
1830. Landau, R., Kern, C., Columb, M. O., Smiley, R. M., & Blouin, J. L. (2008). Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. *Pain*, 139(1), 5-14.
1831. Landray, M. J., Haynes, R., Hopewell, J. C., Parish, S., Aung, T., Tomson, J., . . . Armitage, J. (2014). Effects of extended-release niacin with laropirant in high-risk patients. *N Engl J Med*, 371(3), 203-212.
1832. Landy, S., McGinnis, J., Curlin, D., & Laizure, S. C. (1999). Selective serotonin reuptake inhibitors for migraine prophylaxis. *Headache*, 39(1), 28-32.
1833. Lane, H. Y., Liu, Y. C., Huang, C. L., Chang, Y. C., Wu, P. L., Lu, C. T., & Chang, W. H. (2006). Risperidone-related weight gain: genetic and nongenetic predictors. *J Clin Psychopharmacol*, 26(2), 128-134.
1834. Lang, G. R., Westenfelder, C., Nascimento, L., Dhupelia, V. B., Arruda, J. A., & Kane, R. E. (1977). Metolazone and spironolactone in cirrhosis and the nephrotic syndrome. *Clin Pharmacol Ther*, 21(2), 234-243.
1835. Langohr, H. D., Gerber, W. D., Koletzki, E., Mayer, K., & Schroth, G. (1985). Clomipramine and metoprolol in migraine prophylaxis--a double-blind crossover study. *Headache*, 25(2), 107-113.
1836. Langosch, J. M., & Trimble, M. R. (2002). Epilepsy, psychosis and clozapine. *Hum Psychopharmacol*, 17(2), 115-119.
1837. Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009). Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. *J Allergy Clin Immunol*, 124(6), 1210-1216.
1838. Lannett Company Inc. (2018). Metolazone. *US Product Monograph*,

1839. Lanza, F., Goff, J., Silvers, D., Winters, J., Jhala, N., Jennings, D., & Greski-Rose, P. (1997). Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. *Dig Dis Sci*, 42(12), 2529-2536.
1840. Lanza, F. L., Chan, F. K., & Quigley, E. M. (2009). Guidelines for prevention of NSAID-related ulcer complications. *Am J Gastroenterol*, 104(3), 728-738.
1841. Laurent-Kenesi, M. A., Funck-Brentano, C., Poirier, J. M., Decolin, D., & Jaillon, P. (1993). Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. *Br J Clin Pharmacol*, 36(6), 531-538.
1842. Lavelle, K. J., Atkinson, K. F., & Kleit, S. A. (1976). Hyperlactatemia and hemolysis in G6PD deficiency after nitrofurantoin ingestion. *Am J Med Sci*, 272(2), 201-204.
1843. Law, M. R., Morris, J. K., & Wald, N. J. (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*, 338, b1665.
1844. Law, S., Derry, S., & Moore, R. A. (2013). Naproxen with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*(10), Cd009455.
1845. Law, S., Derry, S., & Moore, R. A. (2016). Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. *Cochrane Database Syst Rev*, 4, Cd008541.
1846. Lawrence, E. R., Hossain, M., & Littlestone, W. (1977). Sanomigran for migraine prophylaxis, controlled multicenter trial in general practice. *Headache*, 17(3), 109-112.
1847. Lazzaroni, M., Bargiggia, S., & Bianchi Porro, G. (1997). Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. *Am J Gastroenterol*, 92(4), 649-652.
1848. Le Meur, Y., Djebli, N., Szelag, J. C., Hoizey, G., Toupance, O., Rerolle, J. P., & Marquet, P. (2006). CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. *Clin Pharmacol Ther*, 80(1), 51-60.
1849. Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Jr., Tran, E., Berger, R., . . . Clinical Pharmacogenetics Implementation, C. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. *Clin Pharmacol Ther*, 94(3), 324-328.
1850. Leder, B. Z., Tsai, J. N., Jiang, L. A., & Lee, H. (2017). Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). *Bone*, 98, 54-58.
1851. Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett-Bowie, S. A. (2015). Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. *Lancet*, 386(9999), 1147-1155.
1852. Lee, A. M., Jepson, C., Hoffmann, E., Epstein, L., Hawk, L. W., Lerman, C., & Tyndale, R. F. (2007). CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. *Biol Psychiatry*, 62(6), 635-641.
1853. Lee, E. J., Oh, M. S., Kim, J. S., Chang, D. I., Park, J. H., Cha, J. K., . . . investigators, E. (2018). Serotonin transporter gene polymorphisms may be associated with poststroke

- neurological recovery after escitalopram use. *J Neurol Neurosurg Psychiatry*, 89(3), 271-276.
1854. Lee, H. K., Hu, M., Lui, S., Ho, C. S., Wong, C. K., & Tomlinson, B. (2013). Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. *Pharmacogenomics*, 14(11), 1283-1294.
1855. Lee, H. Y., Chung, W. J., Jeon, H. K., Seo, H. S., Choi, D. J., Jeon, E. S., . . . Baek, S. H. (2016). Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study. *Korean J Intern Med*, 31(2), 277-287.
1856. Lee, H. Y., Lee, J. W., Lee, K. W., Park, M. H., & Park, H. S. (2009). The HLA allele marker for differentiating ASA hypersensitivity phenotypes. *Allergy*, 64(9), 1385-1387.
1857. Lee, J. H., Jung, H. Y., Choi, K. D., Song, H. J., Lee, G. H., & Kim, J. H. (2010). The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. *Gut Liver*, 4(2), 201-206.
1858. Lee, J. H., Kim, T. J., Kim, E. R., Hong, S. N., Chang, D. K., Choi, L. H., . . . Kim, Y. H. (2017). Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease. *PLoS One*, 12(12), e0188925.
1859. Lee, M., Jensen, B., & Regier, L. (2016). Antidepressants comparison chart. In *RxFiles*. Saskatoon, SK: Saskatoon Health Region.
1860. Lee, M., Jensen, B., & Regier, L. (2016). Antipsychotics comparison chart. In *RxFiles*. Saskatoon, SK: Saskatoon Health Region.
1861. Lee, M., Jensen, B., & Regier, L. (2016). Bipolar Disorder treatment chart. In *RxFiles*. Saskatoon, SK: Saskatoon Health Region.
1862. Lee, M., Jensen, B., & Regier, L. (2017). NSAIDs & coxib analgesics comparison chart. In *RxFiles*. Saskatoon, SK: Saskatoon Health Region.
1863. Lee, M., Jensen, B., & Regier, L. (2018). ADHD treatment chart. In *RxFiles*. Saskatoon, SK: Saskatoon Health Region.
1864. Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011). Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. *Atherosclerosis*, 217(2), 492-498.
1865. Lee, S. K., Lee, S. W., Park, J. Y., Kwon, B. S., Kim, S. Y., Hyun, J. J., . . . Choi, J. H. (2011). Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. *Helicobacter*, 16(5), 410-414.
1866. Lee, S. Y., Ki, C. S., Hong, K. S., & Kim, J. W. (2004). A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. *J Korean Med Sci*, 19(5), 750-752.
1867. Lee, S. Y., Sohn, K. M., Ryu, J. Y., Yoon, Y. R., Shin, J. G., & Kim, J. W. (2006). Sequence-based CYP2D6 genotyping in the Korean population. *Ther Drug Monit*, 28(3), 382-387.

1868. Lee, V. C., Rhew, D. C., Dylan, M., Badamgarav, E., Braunstein, G. D., & Weingarten, S. R. (2004). Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med*, 141(9), 693-704.
1869. Lee, W. M. (2003). Drug-induced hepatotoxicity. *N Engl J Med*, 349(5), 474-485.
1870. Lee, Y. C., Cui, J., Costenbader, K. H., Shadick, N. A., Weinblatt, M. E., & Karlson, E. W. (2009). Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. *Rheumatology (Oxford)*, 48(6), 613-617.
1871. Lee, Y. J., Lee, M. G., Lim, L. A., Jang, S. B., & Chung, J. Y. (2010). Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. *Int J Clin Pharmacol Ther*, 48(1), 36-45.
1872. Lee, Y. S., Kim, H., Wu, T. X., Wang, X. M., & Dionne, R. A. (2006). Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. *Clin Pharmacol Ther*, 79(5), 407-418.
1873. Lefebvre, Y., & Hesseltine, H. (1965). The peripheral white blood cells and metronidazole. *Jama*, 194(1), 15-18.
1874. Legnani, C., Palareti, G., Guazzaloca, G., Cosmi, B., Lunghi, B., Bernardi, F., & Coccheri, S. (2002). Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. *Eur Heart J*, 23(12), 984-990.
1875. Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O., & Kreyenbuhl, J. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*, 161(2 Suppl), 1-56.
1876. Leiman, D. A., Riff, B. P., Morgan, S., Metz, D. C., Falk, G. W., French, B., . . . Lewis, J. D. (2017). Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. *Dis Esophagus*, 30(5), 1-9.
1877. Lekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J., . . . Paddock, S. (2008). The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. *Biol Psychiatry*, 63(12), 1103-1110.
1878. Lemanske, R. F., Jr., Mauger, D. T., Sorkness, C. A., Jackson, D. J., Boehmer, S. J., Martinez, F. D., . . . Blood Institute. (2010). Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *N Engl J Med*, 362(11), 975-985.
1879. Lems, W. F., Dreinhöfer, K. E., Bischoff-Ferrari, H., Blauth, M., Czerwinski, E., da Silva, J., . . . Geusens, P. (2017). EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. *Ann Rheum Dis*, 76(5), 802-810.
1880. Lencz, T., Robinson, D. G., Xu, K., Ekholm, J., Sevy, S., Gunduz-Bruce, H., . . . Malhotra, A. K. (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. *Am J Psychiatry*, 163(3), 529-531.
1881. Lenze, E. J., Mulsant, B. H., Shear, M. K., Dew, M. A., Miller, M. D., Pollock, B. G., . . . Reynolds, C. F., 3rd. (2005). Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. *Am J Psychiatry*, 162(1), 146-150.

1882. Leo Pharma Inc. (2018). Burinex (bumetanide). *CA Product Monograph*,
1883. Leon, J., Susce, M. T., Pan, R. M., Wedlund, P. J., Orrego, M. L., & Diaz, F. J. (2007). A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. *Pharmacopsych*, *40*(3), 93-102.
1884. Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K., . . . Kuntz, R. E. (1998). A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med*, *339*(23), 1665-1671.
1885. Lepantalo, A., Mikkelsen, J., Resendiz, J. C., Viiri, L., Backman, J. T., Kankuri, E., . . . Lassila, R. (2006). Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. *Thromb Haemost*, *95*(2), 253-259.
1886. Lerman, C., Jepson, C., Wileyto, E. P., Patterson, F., Schnoll, R., Mroziewicz, M., . . . Tyndale, R. F. (2010). Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. *Clin Pharmacol Ther*, *87*(5), 553-557.
1887. Lerman, C., Schnoll, R. A., Hawk, L. W., Jr., Cinciripini, P., George, T. P., Wileyto, E. P., . . . Tyndale, R. F. (2015). Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med*, *3*(2), 131-138.
1888. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Hawk, L. H., Jr., Pinto, A., . . . Epstein, L. H. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. *Health Psychol*, *22*(5), 541-548.
1889. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., . . . Epstein, L. (2002). Pharmacogenetic investigation of smoking cessation treatment. *Pharmacogenetics*, *12*(8), 627-634.
1890. Lessard, E., Yessine, M. A., Hamelin, B. A., O'Hara, G., LeBlanc, J., & Turgeon, J. (1999). Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. *Pharmacogenetics*, *9*(4), 435-443.
1891. Leucht, C., Kitzmantel, M., Chua, L., Kane, J., & Leucht, S. (2008). Haloperidol versus chlorpromazine for schizophrenia. *Cochrane Database Syst Rev*(1), CD004278.
1892. Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet*, *373*(9657), 31-41.
1893. Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., . . . Davis, J. M. (2009). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry*, *166*(2), 152-163.
1894. Leuchter, A. F., Lesser, I. M., Trivedi, M. H., Rush, A. J., Morris, D. W., Warden, D., . . . Stewart, J. W. (2008). An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. *J Psychiatr Pract*, *14*(5), 271-280.
1895. Leung, A. A., Daskalopoulou, S. S., Dasgupta, K., McBrien, K., Butalia, S., Zarnke, K. B., . . . Hypertension, C. (2017). Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. *Can J Cardiol*, *33*(5), 557-576.

1896. Leung, W. K., Wu, J. C., Chan, F. K., Fung, S. S., Wong, V. W., Hui, A. J., . . . Sung, J. J. (2007). Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. *Am J Gastroenterol*, *102*(7), 1483-1488.
1897. Leuppi, J. D., Schuetz, P., Bingisser, R., Bodmer, M., Briel, M., Drescher, T., . . . Rutishauser, J. (2013). Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. *Jama*, *309*(21), 2223-2231.
1898. Leusink, M., Maitland-van der Zee, A. H., Ding, B., Drenos, F., van Iperen, E. P., Warren, H. R., . . . Onland-Moret, N. C. (2016). A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. *Pharmacogenomics*, *17*(6), 583-591.
1899. Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., . . . Smith, S. C., Jr. (2016). 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation*, *134*(10), e123-155.
1900. Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., . . . Wijeyesundera, D. N. (2016). 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Thorac Cardiovasc Surg*, *152*(5), 1243-1275.
1901. Levison, M. E., & Kaye, D. (2013). Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. *Curr Infect Dis Rep*, *15*(2), 109-115.
1902. Levran, O., Peles, E., Hamon, S., Randesi, M., Adelson, M., & Kreek, M. J. (2013). CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. *Addict Biol*, *18*(4), 709-716.
1903. Lewin van den Broek, N. T., Numans, M. E., Buskens, E., Verheij, T. J., de Wit, N. J., & Smout, A. J. (2001). A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. *Br J Gen Pract*, *51*(469), 619-624.
1904. Lewis, J. H., & Stine, J. G. (2013). Review article: prescribing medications in patients with cirrhosis - a practical guide. *Aliment Pharmacol Ther*, *37*(12), 1132-1156.
1905. Lewis, J. P., Horenstein, R. B., Ryan, K., O'Connell, J. R., Gibson, Q., Mitchell, B. D., . . . Shuldiner, A. R. (2013). The functional G143E variant of carboxylesterase 1 is associated

- with increased clopidogrel active metabolite levels and greater clopidogrel response. *Pharmacogenet Genomics*, 23(1), 1-8.
1906. Lewis, R. V., Ramsay, L. E., Jackson, P. R., Yeo, W. W., Lennard, M. S., & Tucker, G. T. (1991). Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. *Br J Clin Pharmacol*, 31(4), 391-398.
1907. Lexicomp. (2017). Ubiquinone. *Natural Products Database*,
1908. Lexicomp. (2018). Aspirin (acetylsalicylic acid) *Lexi-Drugs*,
1909. Lexicomp. (2018). Chlorthalidone. *Lexi-Drugs*,
1910. Lexicomp. (2018). Cytochrome P450. *Lexi-Drugs*,
1911. Lexicomp. (2018). Dextroamphetamine and amphetamine. *LexiDrugs*,
1912. Lexicomp. (2018). Diclofenac (Systemic). *Lexi-Drugs*,
1913. Lexicomp. (2018). Dihydroergotamine. *Lexi-Drugs*,
1914. Lexicomp. (2018). Domperidone. *Lexi-Drugs*,
1915. Lexicomp. (2018). Eletriptan. *Lexi-Drugs*,
1916. Lexicomp. (2018). Ethacrynic Acid. *Lexi-Drugs*,
1917. Lexicomp. (2018). Guanfacine. *Lexi-Drugs*,
1918. Lexicomp. (2018). Hydrochlorothiazide. *Lexi-Drugs*,
1919. Lexicomp. (2018). Ibuprofen. *Lexi-Drugs*,
1920. Lexicomp. (2018). Metoclopramide. *Lexi-Drugs*,
1921. Lexicomp. (2018). Naproxen. *Lexi-Drugs*,
1922. Lexicomp. (2018). Raloxifene. *Lexi-Drugs*,
1923. Lexicomp. (2017). Butterbur. *Natural Products Database*,
1924. Li, C. I., Malone, K. E., Porter, P. L., Weiss, N. S., Tang, M. T., Cushing-Haugen, K. L., & Daling, J. R. (2003). Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. *Jama*, 289(24), 3254-3263.
1925. Li, G. F., Wang, K., Chen, R., Zhao, H. R., Yang, J., & Zheng, Q. S. (2012). Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. *Acta Pharmacol Sin*, 33(11), 1359-1371.
1926. Li, H., Wang, X., Zhou, Y., Ni, G., Su, Q., Chen, Z., . . . Huang, M. (2015). Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid. *Int J Neuropsychopharmacol*, 18(7), pyv021.
1927. Li, L. J., Hu, F. Y., Wu, X. T., An, D. M., Yan, B., & Zhou, D. (2013). Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. *Epilepsy Res*, 106(1-2), 296-300.
1928. Li, S., Lin, H., Sun, W., Wang, Y., Ding, Y., Zhao, H., & Liu, S. (2017). A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol. *Int J Clin Pharmacol Ther*, 55(6), 483-492.
1929. Li, S., Shi, S., Chen, F., & Lin, J. (2014). The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. *Gastroenterol Res Pract*, 2014, 307805.

1930. Li, T., Chen, S. L., Dai, Q., Han, X. H., Li, Z. G., Wu, D. H., . . . Bao, C. D. (2013). Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial. *Chin Med J (Engl)*, *126*(10), 1867-1871.
1931. Li, X., Zhang, L., Chen, X., Qu, F., Li, J., Ma, C., . . . Yin, T. (2013). PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. *Thromb Res*, *132*(4), 444-449.
1932. Li, X. B., Tang, Y. L., Wang, C. Y., & de Leon, J. (2015). Clozapine for treatment-resistant bipolar disorder: a systematic review. *Bipolar Disord*, *17*(3), 235-247.
1933. Li, Y., Sabatine, M. S., Tong, C. H., Ford, I., Kirchgessner, T. G., Packard, C. J., . . . Iakoubova, O. A. (2011). Genetic variants in the KIF6 region and coronary event reduction from statin therapy. *Hum Genet*, *129*(1), 17-23.
1934. Li, Y., Yan, L., Shi, Y., Bai, Y., Tang, J., & Wang, L. (2015). CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. *SpringerPlus*, *4*, 637.
1935. Li, Z., Li, R., Chen, J., Liao, Z., Zhu, Y., Qian, Y., . . . Guan, M. X. (2005). Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. *Hum Genet*, *117*(1), 9-15.
1936. Liang, R., Wang, C., Zhao, H., Huang, J., Hu, D., & Sun, Y. (2012). Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. *Thromb Res*, *130*(1), 38-44.
1937. Liao, J., Zheng, Q., Liang, X., Zhang, W., Sun, Q., Liu, W., . . . Lu, H. (2013). Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. *Helicobacter*, *18*(5), 373-377.
1938. Liao, Z., Feng, S., Ling, P., & Zhang, G. (2015). Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. *J Thromb Thrombolysis*, *39*(2), 228-234.
1939. Lieberman, J. A. (2007). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. *J Clin Psychiatry*, *68*(2), e04.
1940. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., . . . Clinical Antipsychotic Trials of Intervention Effectiveness, I. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*, *353*(12), 1209-1223.
1941. Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. (2005). Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. *Arch Gen Psychiatry*, *62*(2), 190-198.
1942. Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., . . . et al. (1992). Phenzelzine vs atenolol in social phobia. A placebo-controlled comparison. *Arch Gen Psychiatry*, *49*(4), 290-300.
1943. LifeLabs Medical Laboratory Services. (2015). 2015 Antibiograms Lower Mainland. In. Burnaby BC: LifeLabs Medical Laboratory Services.
1944. LifeLabs Medical Laboratory Services. (2015). 2015 Antibiograms Vancouver Island. In. Victoria BC: LifeLabs Medical Laboratory Services.

1945. LifeLabs Medical Laboratory Services. (2017). 2017 Lower Mainland Outpatient/Community Antibigram. In. Burnaby, BC: LifeLabs Medical Laboratory Services.
1946. LifeLabs Medical Laboratory Services. (2017). 2017 Mississauga Outpatient antibiogram. In. Mississauga, ON: LifeLabs Medical Laboratory Services.
1947. LifeLabs Medical Laboratory Services. (2017). 2017 Toronto Central Outpatient Antibigram. In. Toronto, ON: LifeLabs Medical Laboratory Services.
1948. LifeLabs Medical Laboratory Services. (2017). 2017 Vancouver Island Outpatient/Community Antibigram. In. BC: LifeLabs Medical Laboratory Services.
1949. Lilly USA LLC. (2017). Prozac (fluoxetine). *US Product Monograph*,
1950. Lilly USA LLC. (2017). Strattera (atomoxetine). *US Product Monograph*,
1951. Lilly USA LLC. (2018). Humulin N (human insulin). *US Product Monograph*,
1952. Lim, S. H., Calkins, H., & Sinha, S. K. (2011). Update on the management of atrial fibrillation: anticoagulation and medical therapy. *Curr Cardiol Rep*, 13(5), 387-393.
1953. Lima, J. J., Lang, J. E., Mougey, E. B., Blake, K. B., Gong, Y., Holbrook, J. T., . . . Teague, W. G. (2013). Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. *J Pediatr*, 163(3), 686-691.
1954. Limdi, N. A., Brown, T. M., Yan, Q., Thigpen, J. L., Shendre, A., Liu, N., . . . Beasley, T. M. (2015). Race influences warfarin dose changes associated with genetic factors. *Blood*, 126(4), 539-545.
1955. Limsrivilai, J., Charatcharoenwitthaya, P., Pausawasdi, N., & Leelakusolvong, S. (2016). Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial. *Am J Gastroenterol*, 111(2), 217-224.
1956. Lin, C. H., Lin, S. H., & Jang, F. L. (2011). Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. *J Clin Psychopharmacol*, 31(5), 563-568.
1957. Lin, V., Holman, J. R., & Jamieson, B. (2010). Clinical Inquiries: Which drugs should post-MI patients routinely receive? *J Fam Pract*, 59(9), 527-529.
1958. Lin, X. Q., Wang, P., Cai, W. K., Xu, G. L., Yang, M., Zhou, M. D., . . . He, G. H. (2019). The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. *Pharmacopsychiatry*, 52(5), 222-231.
1959. Lin, Y. C., Ellingrod, V. L., Bishop, J. R., & Miller, D. D. (2006). The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. *Ther Drug Monit*, 28(5), 668-672.
1960. Lin, Z., Zhang, J., Ma, X., Yang, S., Tian, N., Lin, X., . . . Gao, Y. (2016). The role of Interferon Lambda 3 genetic polymorphisms in response to interferon therapy in chronic hepatitis B patients: an updated meta-analysis. *Hepat Mon*, 16(7), e37534.
1961. Lind, A. B., Reis, M., Bengtsson, F., Jonzier-Perey, M., Powell Golay, K., Ahlner, J., . . . Dahl, M. L. (2009). Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. *Clin Pharmacokinet*, 48(1), 63-70.

1962. Lind, T., Havelund, T., Lundell, L., Glise, H., Lauritsen, K., Pedersen, S. A., . . . Junghard, O. (1999). On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. *Aliment Pharmacol Ther*, 13(7), 907-914.
1963. Linde, K., Kriston, L., Rucker, G., Jamil, S., Schumann, I., Meissner, K., . . . Schneider, A. (2015). Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. *Ann Fam Med*, 13(1), 69-79.
1964. Linde, K., & Rossnagel, K. (2004). Propranolol for migraine prophylaxis. *Cochrane Database Syst Rev*(2), CD003225.
1965. Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013). Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*(6), Cd010608.
1966. Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013). Topiramate for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*(6), Cd010610.
1967. Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013). Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*(6), Cd010611.
1968. Lindson, N., Chepkin, S. C., Ye, W., Fanshawe, T. R., Bullen, C., & Hartmann-Boyce, J. (2019). Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*, 4, CD013308.
1969. Linnet, K., & Wiborg, O. (1996). Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. *Ther Drug Monit*, 18(6), 629-634.
1970. Liou, J. M., Lin, J. T., Chang, C. Y., Chen, M. J., Cheng, T. Y., Lee, Y. C., . . . Wu, M. S. (2010). Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for *Helicobacter pylori* infection: a randomised comparative trial with crossover design. *Gut*, 59(5), 572-578.
1971. Lip, G. Y. (2011). The role of aspirin for stroke prevention in atrial fibrillation. *Nat Rev Cardiol*, 8(10), 602-606.
1972. Lip, G. Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, K. J., Cuisset, T., . . . Marin, F. (2010). Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. *Thromb Haemost*, 103(1), 13-28.
1973. Lip, G. Y., & Ramsay, S. G. (2012). Insights from the RCPE UK Consensus Conference on approaching the comprehensive management of atrial fibrillation. *Expert Rev Cardiovasc Ther*, 10(6), 697-700.
1974. Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., . . . Simpson, S. (2018). Pharmacologic glycemic management of Type 2 diabetes in adults. *Can J Diabetes*, 42 Suppl 1, S88-S103.
1975. Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011). Use of metformin in the setting of mild-to-moderate renal insufficiency. *Diabetes Care*, 34(6), 1431-1437.

1976. Lipton, R. B., Gobel, H., Einhaupl, K. M., Wilks, K., & Mauskop, A. (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. *Neurology*, 63(12), 2240-2244.
1977. Lipton, R. B., Silberstein, S., Dodick, D., Cady, R., Freitag, F., Mathew, N., . . . Hulihan, J. (2011). Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. *Cephalalgia*, 31(1), 18-30.
1978. Lipton, R. B., & Silberstein, S. D. (2015). Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. *Headache*, 55 Suppl 2, 103-122; quiz 123-106.
1979. Lipworth, B. J., Basu, K., Donald, H. P., Tavendale, R., Macgregor, D. F., Ogston, S. A., . . . Mukhopadhyay, S. (2013). Tailored second-line therapy in asthmatic children with the Arg(16) genotype. *Clin Sci (Lond)*, 124(8), 521-528.
1980. Lisbeth, P., Vincent, H., Kristof, M., Bernard, S., Manuel, M., & Hugo, N. (2016). Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. *Eur J Clin Pharmacol*, 72(2), 175-184.
1981. Liu, J. E., Liu, X. Y., Chen, S., Zhang, Y., Cai, L. Y., Yang, M., . . . Zhong, S. L. (2017). SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. *Eur J Clin Pharmacol*, 73(11), 1409-1416.
1982. Liu, R., Gong, C., Tao, L., Yang, W., Zheng, X., Ma, P., & Ding, L. (2015). Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects. *Eur J Pharm Sci*, 79, 13-19.
1983. Liu, S. C., Tu, Y. K., Chien, M. N., & Chien, K. L. (2012). Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. *Diabetes Obes Metab*, 14(9), 810-820.
1984. Liu, Y. C., & Wang, W. S. (2012). Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. *Cancer*, 118(6), 1718-1725.
1985. Llerena, A., Alm, C., Dahl, M. L., Ekqvist, B., & Bertilsson, L. (1992). Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. *Ther Drug Monit*, 14(2), 92-97.
1986. Llerena, A., Berecz, R., Dorado, P., & de la Rubia, A. (2004). QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. *J Psychopharmacol*, 18(2), 189-193.
1987. Llerena, A., Dahl, M. L., Ekqvist, B., & Bertilsson, L. (1992). Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. *Ther Drug Monit*, 14(3), 261-264.
1988. Llerena, A., de la Rubia, A., Berecz, R., & Dorado, P. (2004). Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. *Pharmacopsychiatry*, 37(2), 69-73.

1989. Llorca, P. M., Spadone, C., Sol, O., Danniau, A., Bougerol, T., Corruble, E., . . . Servant, D. (2002). Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. *J Clin Psychiatry, 63*(11), 1020-1027.
1990. Lloyd-Jones, D. M., Goff, D., & Stone, N. J. (2014). Statins, risk assessment, and the new American prevention guidelines. *Lancet, 383*(9917), 600-602.
1991. Lloyd-Jones, D. M., Goff, D. C., Jr., & Stone, N. J. (2014). Guidelines for cardiovascular risk assessment and cholesterol treatment. *Jama, 311*(21), 2235.
1992. Lobello, K. W., Preskorn, S. H., Guico-Pabia, C. J., Jiang, Q., Paul, J., Nichols, A. I., . . . Ninan, P. T. (2010). Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. *J Clin Psychiatry, 71*(11), 1482-1487.
1993. Lochareernkul, C., Loplumert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., . . . Shotelersuk, V. (2008). Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. *Epilepsia, 49*(12), 2087-2091.
1994. Loder, E., Burch, R., & Rizzoli, P. (2012). The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. *Headache, 52*(6), 930-945.
1995. Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014). Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry, 171*(2), 160-168.
1996. Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014). Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry, 171*(2), 169-177.
1997. Loghin, C., Haber, H., Beasley, C. M., Jr., Kothare, P. A., Kauffman, L., April, J., . . . Mitchell, M. I. (2013). Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. *Br J Clin Pharmacol, 75*(2), 538-549.
1998. Loke, Y. K., Trivedi, A. N., & Singh, S. (2008). Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. *Aliment Pharmacol Ther, 27*(1), 31-40.
1999. Lomen, P. L., Turner, L. F., Lamborn, K. R., Winblad, M. A., Sack, R. L., & Brinn, E. L. (1986). Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. *Am J Med, 80*(3A), 134-139.
2000. Lonn, E. M., Bosch, J., Lopez-Jaramillo, P., Zhu, J., Liu, L., Pais, P., . . . Yusuf, S. (2016). Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med, 374*(21), 2009-2020.
2001. Lopez-Rodriguez, R., Cabaleiro, T., Ochoa, D., Roman, M., Borobia, A. M., Carcas, A. J., . . . Abad-Santos, F. (2013). Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. *Pharmacogenomics, 14*(10), 1203-1214.
2002. Lorenz, R. A., Jackson, C. W., & Saitz, M. (2010). Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. *Pharmacotherapy, 30*(9), 942-951.

2003. Losito, A., Errico, R., Santirosi, P., Lupattelli, T., Scalera, G. B., & Lupattelli, L. (2005). Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. *Nephrol Dial Transplant*, 20(8), 1604-1609.
2004. Lotsch, J., Rohrbacher, M., Schmidt, H., Doehring, A., Brockmoller, J., & Geisslinger, G. (2009). Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? *Pain*, 144(1-2), 119-124.
2005. Lotsch, J., Skarke, C., Schmidt, H., Rohrbacher, M., Hofmann, U., Schwab, M., & Geisslinger, G. (2006). Evidence for morphine-independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites. *Clin Pharmacol Ther*, 79(1), 35-48.
2006. Lotsch, J., von Hentig, N., Freynhagen, R., Griessinger, N., Zimmermann, M., Doehring, A., . . . Geisslinger, G. (2009). Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. *Pharmacogenet Genomics*, 19(6), 429-436.
2007. Lotufo-Neto, F., Trivedi, M., & Thase, M. E. (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. *Neuropsychopharmacology*, 20(3), 226-247.
2008. Lou, H. Y., Chang, C. C., Sheu, M. T., Chen, Y. C., & Ho, H. O. (2009). Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. *Eur J Clin Pharmacol*, 65(1), 55-64.
2009. Loughheed, M. D., Lemiere, C., Dell, S. D., Ducharme, F. M., Fitzgerald, J. M., Leigh, R., . . . Canadian Thoracic Society Asthma, C. (2010). Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults. *Can Respir J*, 17(1), 15-24.
2010. Loughheed, M. D., Lemiere, C., Ducharme, F. M., Liciskai, C., Dell, S. D., Rowe, B. H., . . . Boulet, L. P. (2012). Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. *Can Respir J*, 19(2), 127-164.
2011. Louis, E. K. (2010). The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life. *Pharmaceuticals (Basel)*, 3(9), 2956-2969.
2012. Louis, P., & Spierings, E. L. (1982). Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. *Cephalalgia*, 2(4), 197-203.
2013. Love, R. R., Desta, Z., Flockhart, D., Skaar, T., Ogburn, E. T., Ramamoorthy, A., . . . Jarjoura, D. (2013). CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. *SpringerPlus*, 2(1), 52.
2014. Lowenthal, D. T., & Dickerman, D. (1983). The use of diuretics in varying degrees of renal impairment: an overview. *Clin Exp Hypertens A*, 5(2), 297-307.
2015. Lowenthal, D. T., Pitone, J. M., Affrime, M. B., Shirk, J., Busby, P., Kim, K. E., . . . Onesti, G. (1978). Timolol kinetics in chronic renal insufficiency. *Clin Pharmacol Ther*, 23(5), 606-615.

2016. Lu, J., Li, Z., Zhu, Y., Yang, A., Li, R., Zheng, J., . . . Guan, M. X. (2010). Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. *Mitochondrion*, *10*(4), 380-390.
2017. Lu, W. R., Defilippi, J., & Braun, A. (2013). Unleash metformin: reconsideration of the contraindication in patients with renal impairment. *Ann Pharmacother*, *47*(11), 1488-1497.
2018. Lu, Y., Chen, M., Huang, Z., & Tang, C. (2016). Antidepressants in the treatment of functional dyspepsia: A systematic review and meta-analysis. *PLoS One*, *11*(6).
2019. Lu, Y., Dai, D., Chen, Z., Cao, X., Bu, X., Wei, Q., & Xing, G. (2011). Molecular screening of patients with nonsyndromic hearing loss from Nanjing city of China. *J Biomed Res*, *25*(5), 309-318.
2020. Luan, S., Wan, H., Zhang, L., & Zhao, H. (2018). Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. *Neuropsychiatr Dis Treat*, *14*, 467-477.
2021. Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., . . . Daly, A. K. (2011). Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*, *141*(1), 338-347.
2022. Lundbeck Canada Inc. (2014). Clopixol (zuclopenthixol). *CA Product Monograph*,
2023. Lundbeck Canada Inc. (2016). Celexa (citalopram). *CA Product Monograph*,
2024. Lundbeck Canada Inc. (2016). Ciprallex (escitalopram). *CA Product Monograph*,
2025. Lundbeck Canada Inc. (2016). Fluvoxol (flupentixol). *CA Product Monograph*,
2026. Lundbeck Canada Inc. (2019). Trintellix (vortioxetine). *CA Product Monograph*,
2027. Lunde, I., Bremer, S., Midtvedt, K., Mohebi, B., Dahl, M., Bergan, S., . . . Christensen, H. (2014). The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. *Eur J Clin Pharmacol*, *70*(6), 685-693.
2028. Lund-Johansen, P. (1962). Shock after administration of phenothiazines in patients with pheochromocytoma. *Acta Med Scand*, *172*, 525-529.
2029. Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014). Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database Syst Rev*, *1*, CD007115.
2030. Luo, J. C., Huang, K. W., Leu, H. B., Chen, L. C., Hou, M. C., Li, C. P., . . . Lee, S. D. (2011). Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. *Aliment Pharmacol Ther*, *34*(5), 519-525.
2031. Luo, N., Di, W., Zhang, A., Wang, Y., Ding, M., Qi, W., . . . Fang, Y. (2012). A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. *Pain Med*, *13*(1), 80-86.
2032. Luo, Y., Jin, C., Ling, Z., Mou, X., Zhang, Q., & Xiang, C. (2013). Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. *Gene*, *513*(2), 292-296.
2033. Lupin Pharmaceuticals Inc. (2017). Trimethoprim. *US Product Monograph*,

2034. Lupin Pharmaceuticals Inc. (2018). Suprax (cefixime). *US Product Monograph*,
2035. Luqmani, R., Hennell, S., Estrach, C., Basher, D., Birrell, F., Bosworth, A., . . . Wilkinson, M. (2009). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). *Rheumatology (Oxford)*, 48(4), 436-439.
2036. Luqmani, R., Hennell, S., Estrach, C., Birrell, F., Bosworth, A., Davenport, G., . . . Webb, F. (2006). British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). *Rheumatology (Oxford)*, 45(9), 1167-1169.
2037. Luscher, T. F., & Waeber, B. (1993). Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. *J Cardiovasc Pharmacol*, 21(2), 305-309.
2038. Luther, J., Higgins, P. D., Schoenfeld, P. S., Moayyedi, P., Vakil, N., & Chey, W. D. (2010). Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol*, 105(1), 65-73.
2039. Luzum, J. A., Sweet, K. M., Binkley, P. F., Schmidlen, T. J., Jarvis, J. P., Christman, M. F., . . . Kitzmiller, J. P. (2017). CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. *Pharm Res*, 34(8), 1615-1625.
2040. Luzum, J. A., Theusch, E., Taylor, K. D., Wang, A., Sadee, W., Binkley, P. F., . . . Kitzmiller, J. P. (2015). Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. *J Cardiovasc Pharmacol*, 66(1), 80-85.
2041. Lv, Y. D., Min, F. L., Liao, W. P., He, N., Zeng, T., Ma, D. H., & Shi, Y. W. (2013). The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population. *BMC Neurol*, 13, 75.
2042. Ma, C. L., Jiao, Z., Wu, X. Y., Hong, Z., Wu, Z. Y., & Zhong, M. K. (2015). Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. *Pharmacogenomics*, 16(13), 1499-1512.
2043. Ma, C. L., Wu, X. Y., Zheng, J., Wu, Z. Y., Hong, Z., & Zhong, M. K. (2014). Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. *Pharmacogenomics*, 15(10), 1323-1336.
2044. Ma, X., Maimaitirexiati, T., Zhang, R., Gui, X., Zhang, W., Xu, G., & Hu, G. (2014). HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. *Int J Psychiatry Clin Pract*, 18(4), 229-242.
2045. Maayan, N., Quraishi, S. N., David, A., Jayaswal, A., Eisenbruch, M., Rathbone, J., . . . Adams, C. E. (2015). Fluphenazine decanoate (depot) and enanthate for schizophrenia. *Cochrane Database Syst Rev*(2), CD000307.
2046. Maccagno, A., Di Giorgio, E., & Romanowicz, A. (1991). Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. *Curr Med Res Opin*, 12(7), 423-429.

2047. Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Hauser, W., Fluss, E., . . . Jones, G. T. (2016). EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis*.
2048. MacGregor, E. A., Wilkinson, M., & Bancroft, K. (1993). Domperidone plus paracetamol in the treatment of migraine. *Cephalalgia*, *13*(2), 124-127.
2049. Machado, G. C., Maher, C. G., Ferreira, P. H., Pinheiro, M. B., Lin, C. W., Day, R. O., . . . Ferreira, M. L. (2015). Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. *BMJ*, *350*, h1225.
2050. Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., . . . Committee, C. C. S. A. F. G. (2016). 2016 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Can J Cardiol*, *32*(10), 1170-1185.
2051. MacLean, S., Mulla, S., Akl, E. A., Jankowski, M., Vandvik, P. O., Ebrahim, S., . . . Guyatt, G. H. (2012). Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, *141*(2 Suppl), e1S-23S.
2052. Macritchie, K., Geddes, J. R., Scott, J., Haslam, D., de Lima, M., & Goodwin, G. (2003). Valproate for acute mood episodes in bipolar disorder. *Cochrane Database Syst Rev*(1), CD004052.
2053. Madadi, P., Amstutz, U., Rieder, M., Ito, S., Fung, V., Hwang, S., . . . Carleton, B. C. (2013). Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. *J Popul Ther Clin Pharmacol*, *20*(3), e369-396.
2054. Madadi, P., Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., Leeder, J. S., . . . Aleksa, K. (2007). Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. *Can Fam Physician*, *53*(1), 33-35.
2055. Madadi, P., Ross, C. J., Hayden, M. R., Carleton, B. C., Gaedigk, A., Leeder, J. S., & Koren, G. (2009). Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. *Clin Pharmacol Ther*, *85*(1), 31-35.
2056. Maddocks, I., Somogyi, A., Abbott, F., Hayball, P., & Parker, D. (1996). Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. *J Pain Symptom Manage*, *12*(3), 182-189.
2057. Magalhaes, E., Menezes, C., Cardeal, M., & Melo, A. (2010). Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. *Clin Neurol Neurosurg*, *112*(6), 463-466.
2058. Magee, L. A., Schick, B., Donnenfeld, A. E., Sage, S. R., Conover, B., Cook, L., . . . Koren, G. (1996). The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol*, *174*(3), 823-828.
2059. Magnussen, H., Disse, B., Rodriguez-Roisin, R., Kirsten, A., Watz, H., Tetzlaff, K., . . . Calverley, P. M. (2014). Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med*, *371*(14), 1285-1294.

2060. Mahapatra, J., Quraishi, S. N., David, A., Sampson, S., & Adams, C. E. (2014). Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. *Cochrane Database Syst Rev*(6), CD001470.
2061. Mahmoudpour, S. H., Leusink, M., van der Putten, L., Terreehorst, I., Asselbergs, F. W., de Boer, A., & Maitland-van der Zee, A. H. (2013). Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. *Pharmacogenomics*, *14*(3), 249-260.
2062. Maity, S., Choudhury, S., Hazra, A., & Das, A. K. (2014). Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia. *Indian J Pharmacol*, *46*(5), 498-502.
2063. Maizels, M., Blumenfeld, A., & Burchette, R. (2004). A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache*, *44*(9), 885-890.
2064. Makhija, Z., Allen, M. S., Wigle, D. A., Shen, K. R., Cassivi, S. D., Nichols, F. C., 3rd, & Deschamps, C. (2011). Routine anticoagulation is not indicated for postoperative general thoracic surgical patients with new-onset atrial fibrillation. *Ann Thorac Surg*, *92*(2), 421-426; discussion 426-427.
2065. Makmor-Bakry, M., Sills, G. J., Hitiris, N., Butler, E., Wilson, E. A., & Brodie, M. J. (2009). Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. *Clin Neuropharmacol*, *32*(4), 205-212.
2066. Malaiyandi, V., Lerman, C., Benowitz, N. L., Jepson, C., Patterson, F., & Tyndale, R. F. (2006). Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Mol Psychiatry*, *11*(4), 400-409.
2067. Malfertheiner, P., Megraud, F., O'morain, C., Gisbert, J., Kuipers, E., Axon, A., . . . Graham, D. Y. (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. *Gut*, *66*(1), 6-30.
2068. Malhi, G. S. (2013). Have the CANMAT bipolar guidelines transmogrified from do matter to can matter? *Bipolar Disord*, *15*(1), 54-57.
2069. Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., . . . Singh, A. B. (2015). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry*, *49*(12), 1087-1206.
2070. Malhotra, A. K., Correll, C. U., Chowdhury, N. I., Muller, D. J., Gregersen, P. K., Lee, A. T., . . . Kennedy, J. L. (2012). Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. *Arch Gen Psychiatry*, *69*(9), 904-912.
2071. Malik, A. H., Yandrapalli, S., Aronow, W. S., Panza, J. A., & Cooper, H. A. (2019). Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age. *Am J Cardiol*, *123*(12), 2051-2057.
2072. Malik, S. G., Pieter, N., Sudoyo, H., Kadir, A., & Marzuki, S. (2003). Prevalence of the mitochondrial DNA A1555G mutation in sensorineural deafness patients in island Southeast Asia. *J Hum Genet*, *48*(9), 480-483.
2073. Mallin, R. (2002). Smoking cessation: integration of behavioral and drug therapies. *Am Fam Physician*, *65*(6), 1107-1114.

2074. Mallinckrodt Brand Pharmaceuticals Inc. (2013). Exalgo (hydromorphone ER). *US Product Monograph*,
2075. Man, C. Y., Cheung, I. T., Cameron, P. A., & Rainer, T. H. (2007). Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. *Ann Emerg Med*, 49(5), 670-677.
2076. Manara, M., Bortoluzzi, A., Favero, M., Prevete, I., Scire, C. A., Bagnato, G., . . . Minisola, G. (2013). Italian Society for Rheumatology recommendations for the management of hand osteoarthritis. *Reumatismo*, 65(4), 167-185.
2077. Manchikanti, L., Boswell, M. V., & Singh, V. (2004). Monitoring of patients receiving long-term opioid therapy. *Anesth Analg*, 99(1), 304; author reply 304-305.
2078. Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M., . . . Wood, D. A. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*, 34(28), 2159-2219.
2079. Mancini, G. B., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., . . . Tashakkor, A. Y. (2016). Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). *Can J Cardiol*, 32(7 Suppl), S35-65.
2080. Mancini, G. B., Gosselin, G., Chow, B., Kostuk, W., Stone, J., Yvorchuk, K. J., . . . Canadian Cardiovascular, S. (2014). Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. *Can J Cardiol*, 30(8), 837-849.
2081. Mangione, A., Imhoff, T. E., Lee, R. V., Shum, L. Y., & Jusko, W. J. (1978). Pharmacokinetics of theophylline in hepatic disease. *Chest*, 73(5), 616-622.
2082. Mangravite, L. M., Engelhardt, B. E., Medina, M. W., Smith, J. D., Brown, C. D., Chasman, D. I., . . . Krauss, R. M. (2013). A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. *Nature*, 502(7471), 377-380.
2083. Manicourt, D. H., Brasseur, J. P., Boutsen, Y., Depreseux, G., & Devogelaer, J. P. (2004). Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. *Arthritis Rheum*, 50(11), 3690-3697.
2084. Maniglia, L. P., Moreira, B. C., Silva, M. A., Piatto, V. B., & Maniglia, J. V. (2008). Screening of the mitochondrial A1555G mutation in patients with sensorineural hearing loss. *Braz J Otorhinolaryngol*, 74(5), 731-736.
2085. Manley, H. J., & Stack, N. M. (2008). Smoking cessation therapy considerations for patients with chronic kidney disease. *Nephrol Nurs J*, 35(4), 357-363, 394; quiz 364.
2086. Manlucu, J., Tonelli, M., Ray, J. G., Papaioannou, A., Youssef, G., Thiessen-Philbrook, H. R., . . . Garg, A. X. (2005). Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. *Nephrol Dial Transplant*, 20(11), 2376-2384.
2087. Manna, I., Gambardella, A., Bianchi, A., Striano, P., Tozzi, R., Aguglia, U., . . . Perucca, E. (2011). A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. *Epilepsia*, 52(5), e40-44.

2088. Manning, P., Gibson, P. G., & Lasserson, T. J. (2008). Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. *Cochrane Database Syst Rev*(2), CD007031.
2089. Manunta, P., Lavery, G., Lanzani, C., Braund, P. S., Simonini, M., Bodycote, C., . . . Samani, N. J. (2008). Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. *Hypertension*, *52*(2), 366-372.
2090. Mao, L., Jian, C., Changzhi, L., Dan, H., Suihua, H., Wenyi, T., & Wei, W. (2013). Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. *Arch Cardiovasc Dis*, *106*(10), 517-527.
2091. Marciante, K. D., Durda, J. P., Heckbert, S. R., Lumley, T., Rice, K., McKnight, B., . . . Psaty, B. M. (2011). Cerivastatin, genetic variants, and the risk of rhabdomyolysis. *Pharmacogenet Genomics*, *21*(5), 280-288.
2092. Marcucci, R., Giusti, B., Panicia, R., Gori, A. M., Saracini, C., Valente, S., . . . Abbate, R. (2012). High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. *Platelets*, *23*(8), 586-593.
2093. Marcus, R., Khan, A., Rollin, L., Morris, B., Timko, K., Carson, W., & Sanchez, R. (2011). Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. *Bipolar Disord*, *13*(2), 133-144.
2094. Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., . . . Berman, R. M. (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*, *28*(2), 156-165.
2095. Marcus, S. C., Wan, G. J., Kemner, J. E., & Olfson, M. (2005). Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. *Arch Pediatr Adolesc Med*, *159*(6), 572-578.
2096. Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., . . . Schooler, N. R. (2002). The Mount Sinai conference on the pharmacotherapy of schizophrenia. *Schizophr Bull*, *28*(1), 5-16.
2097. Marelli, S., & Pace, F. (2012). Rabeprazole for the treatment of acid-related disorders. *Expert Rev Gastroenterol Hepatol*, *6*(4), 423-435.
2098. Marin, A. C., McNicholl, A. G., & Gisbert, J. P. (2013). A review of rescue regimens after clarithromycin-containing triple therapy failure (for *Helicobacter pylori* eradication). *Expert Opin Pharmacother*, *14*(7), 843-861.
2099. Marin, A. C., Nyssen, O. P., McNicholl, A. G., & Gisbert, J. P. (2017). Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for *Helicobacter pylori* eradication: Systematic review and meta-analysis. *Drugs*, *77*(7), 765-776.
2100. Marini, F., Falchetti, A., Silvestri, S., Bagger, Y., Luzi, E., Tanini, A., . . . Brandi, M. L. (2008). Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480

- polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. *Curr Med Res Opin*, 24(9), 2609-2615.
2101. Marini, F., Tonelli, P., Cavalli, L., Cavalli, T., Masi, L., Falchetti, A., & Brandi, M. L. (2011). Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. *Front Biosci (Elite Ed)*, 3, 364-370.
2102. Marino, M. R., Langenbacher, K. M., Raymond, R. H., Ford, N. F., & Lasseter, K. C. (1998). Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. *J Clin Pharmacol*, 38(4), 347-356.
2103. Marino, M. R., & Vachharajani, N. N. (2002). Pharmacokinetics of irbesartan are not altered in special populations. *J Cardiovasc Pharmacol*, 40(1), 112-122.
2104. Marinsek, M., & Sinkovic, A. (2016). Ramipril and Losartan exert a similar long-term effect upon markers of heart failure, endogenous fibrinolysis, and platelet aggregation in survivors of ST-elevation myocardial infarction: A single centre randomized trial. *Biomed Res Int*, 2016, 9040457.
2105. Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2012). Long term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev*(7), Cd004143.
2106. Markkula, A., Hjertberg, M., Rose, C., Ingvar, C., & Jernstrom, H. (2014). No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients. *Acta Oncol*, 53(2), 195-200.
2107. Markley, H. G., Cheronis, J. C., & Piepho, R. W. (1984). Verapamil in prophylactic therapy of migraine. *Neurology*, 34(7), 973-976.
2108. Markowitz, N., & Saravolatz, L. D. (1987). Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. *Rev Infect Dis*, 9 Suppl 2, S218-229.
2109. Marmura, M. J., Silberstein, S. D., & Schwedt, T. J. (2015). The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. *Headache*, 55(1), 3-20.
2110. Maron, E., Tammiste, A., Kallassalu, K., Eller, T., Vasar, V., Nutt, D. J., & Metspalu, A. (2009). Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. *Eur Neuropsychopharmacol*, 19(6), 451-456.
2111. Marotte, H., Arnaud, B., Diasparra, J., Zrioual, S., & Miossec, P. (2008). Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. *Arthritis Rheum*, 58(5), 1258-1263.
2112. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jodar, E., Leiter, L. A., . . . Investigators, S.-. (2016). Semaglutide and cardiovascular outcomes in patients with Type 2 Diabetes. *N Engl J Med*, 375(19), 1834-1844.
2113. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., . . . Investigators, L. T. (2016). Liraglutide and cardiovascular outcomes in Type 2 Diabetes. *N Engl J Med*, 375(4), 311-322.

2114. Marso, S. P., Holst, A. G., & Vilsboll, T. (2017). Semaglutide and cardiovascular outcomes in patients with Type 2 Diabetes. *N Engl J Med*, 376(9), 891-892.
2115. Marso SP, B. S., Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*, 375(19), 1834-1844.
2116. Martin, J., Williams, A. K., Klein, M. D., Sriramoju, V. B., Madan, S., Rossi, J. S., . . . Lee, C. R. (2019). Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. *Genet Med*.
2117. Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R., & Barclay, M. L. (2001). Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? *Br J Clin Pharmacol*, 51(6), 627-630.
2118. Martin, N. G., Li, K. W., Murray, H., Putt, W., Packard, C. J., & Humphries, S. E. (2012). The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. *Br J Clin Pharmacol*, 73(2), 303-306.
2119. Martinez, C., Blanco, G., Ladero, J. M., Garcia-Martin, E., Taxonera, C., Gamito, F. G., . . . Agundez, J. A. (2004). Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. *Br J Pharmacol*, 141(2), 205-208.
2120. Martinez de Duenas, E., Ochoa Aranda, E., Blancas Lopez-Barajas, I., Ferrer Magdalena, T., Bandres Moya, F., Chicharro Garcia, L. M., . . . Olmos Anton, S. (2014). Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. *Breast*, 23(4), 400-406.
2121. Martinez, F. J., Calverley, P. M., Goehring, U. M., Brose, M., Fabbri, L. M., & Rabe, K. F. (2015). Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *Lancet*, 385(9971), 857-866.
2122. Martinez, F. J., Rabe, K. F., Sethi, S., Pizzichini, E., Mclvor, A., Anzueto, A., . . . Rennard, S. I. (2016). Effect of roflumilast and inhaled corticosteroid/long-acting beta2-Agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. *Am J Respir Crit Care Med*, 194(5), 559-567.
2123. Masclee, G. M., Valkhoff, V. E., van Soest, E. M., Schade, R., Mazzaglia, G., Molokhia, M., . . . Sturkenboom, M. C. (2013). Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? *Aliment Pharmacol Ther*, 38(2), 178-189.
2124. Mason, I., Millar, L. J., Sheikh, R. R., Evans, W. M., Todd, P. L., Turbitt, M. L., & Taylor, M. D. (1998). The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. *Aliment Pharmacol Ther*, 12(3), 263-271.
2125. Masso Gonzalez, E. L., Patrignani, P., Tacconelli, S., & Garcia Rodriguez, L. A. (2010). Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. *Arthritis Rheum*, 62(6), 1592-1601.

2126. Mastalerz, L., Setkowicz, M., Sanak, M., Rybarczyk, H., & Szczeklik, A. (2006). Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. *Br J Dermatol*, *154*(2), 256-260.
2127. Mastalerz, L., Setkowicz, M., Sanak, M., & Szczeklik, A. (2004). Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. *J Allergy Clin Immunol*, *113*(4), 771-775.
2128. Mastrosimone, F., Iaccarino, C., & de Caterina, G. (1992). Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. *J Med*, *23*(1), 1-16.
2129. Matar, H. E., Almerie, M. Q., & Sampson, S. (2013). Fluphenazine (oral) versus placebo for schizophrenia. *Cochrane Database Syst Rev*(7), CD006352.
2130. Mathew, N. T., & Jaffri, S. F. (2009). A double-blind comparison of onabotulinumtoxin A (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. *Headache*, *49*(10), 1466-1478.
2131. Mathew, N. T., Rapoport, A., Saper, J., Magnus, L., Klapper, J., Ramadan, N., . . . Tepper, S. (2001). Efficacy of gabapentin in migraine prophylaxis. *Headache*, *41*(2), 119-128.
2132. Mathew, N. T., Saper, J. R., Silberstein, S. D., Rankin, L., Markley, H. G., Solomon, S., . . . Deaton, R. L. (1995). Migraine prophylaxis with divalproex. *Arch Neurol*, *52*(3), 281-286.
2133. Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015). Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. *Int Clin Psychopharmacol*, *30*(2), 67-74.
2134. Matic, M., Jongen, J. L., Elens, L., de Wildt, S. N., Tibboel, D., Sillevius Smitt, P. A., & van Schaik, R. H. (2017). Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. *Pharmacogenomics*, *18*(12), 1133-1142.
2135. Matsubara, Y., Murata, M., Watanabe, G., & Ikeda, Y. (2008). Enhancing effect of the (145)Met-allele of GPIIb/alpha on platelet sensitivity to aspirin under high-shear conditions. *Thromb Res*, *123*(2), 331-335.
2136. Matsui, A., Azuma, J., Witcher, J. W., Long, A. J., Sauer, J. M., Smith, B. P., . . . Nakano, M. (2012). Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. *J Clin Pharmacol*, *52*(3), 388-403.
2137. Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., . . . Massaro, J. M. (2014). Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*, *371*(23), 2155-2166.
2138. Maxwell, J. R., Potter, C., Hyrich, K. L., Barton, A., Worthington, J., Isaacs, J. D., . . . Wilson, A. G. (2008). Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet*, *17*(22), 3532-3538.
2139. Mazza, M., Mazza, O., Pazzaglia, C., Padua, L., & Mazza, S. (2010). Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. *Expert Opin Pharmacother*, *11*(7), 1049-1052.
2140. McAlindon, T. E., Bannuru, R. R., Sullivan, M. C., Arden, N. K., Berenbaum, F., Bierma-Zeinstra, S. M., . . . Underwood, M. (2014). OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage*, *22*(3), 363-388.

2141. McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W. (2009). Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. *Ann Intern Med*, *150*(11), 784-794.
2142. McAlpine, D. E., O'Kane, D. J., Black, J. L., & Mrazek, D. A. (2007). Cytochrome P450 2D6 genotype variation and venlafaxine dosage. *Mayo Clin Proc*, *82*(9), 1065-1068.
2143. McBride, P., Stone, N. J., & Blum, C. B. (2014). Should family physicians follow the new ACC/AHA cholesterol treatment guideline? Yes: implementing the new ACC/AHA cholesterol guideline will improve cardiovascular outcomes. *Am Fam Physician*, *90*(4), 212-216.
2144. McCormack, J., Carleton, B., & Calissi, P. (2015). *Dosage Adjustment in Renal Impairment Therapeutics*.
2145. McCormack J, C. B., Calissi P. (2018). *Dosage Adjustment in Renal Impairment Therapeutics*.
2146. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperaviciute, D., Carrington, M., . . . Pirmohamed, M. (2011). HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *N Engl J Med*, *364*(12), 1134-1143.
2147. McCormack, M., Gui, H., Ingason, A., Speed, D., Wright, G. E. B., Zhang, E. J., . . . Cavalleri, G. L. (2018). Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. *Neurology*, *90*(4), e332-e341.
2148. McDermott, M. M., Guralnik, J. M., Greenland, P., Pearce, W. H., Criqui, M. H., Liu, K., . . . Quann, M. (2003). Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. *Circulation*, *107*(5), 757-761.
2149. McDonough, C. W., Burbage, S. E., Duarte, J. D., Gong, Y., Langae, T. Y., Turner, S. T., . . . Johnson, J. A. (2013). Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens*, *31*(4), 698-704.
2150. McDonough, C. W., McClure, L. A., Mitchell, B. D., Gong, Y., Horenstein, R. B., Lewis, J. P., . . . Shuldiner, A. R. (2015). CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. *J Am Heart Assoc*, *4*(6), e001652.
2151. McElroy, S. L., Martens, B. E., Creech, R. S., Welge, J. A., Jefferson, L., Guerdjikova, A. I., & Keck, P. E., Jr. (2010). Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. *J Clin Psychiatry*, *71*(5), 557-565.
2152. McElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., . . . Young, A. H. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). *J Clin Psychiatry*, *71*(2), 163-174.
2153. McEvoy, J. P., Byerly, M., Hamer, R. M., Dominik, R., Swartz, M. S., Rosenheck, R. A., . . . Stroup, T. S. (2014). Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. *Jama*, *311*(19), 1978-1987.

2154. McFarlane, P., Gilbert, R. E., MacCallum, L., & Senior, P. (2013). Chronic kidney disease in diabetes. *Can J Diabetes*, *37 Suppl 1*, S129-136.
2155. McGeachie, M. J., Wu, A. C., Chang, H. H., Lima, J. J., Peters, S. P., & Tantisira, K. G. (2013). Predicting inhaled corticosteroid response in asthma with two associated SNPs. *Pharmacogenomics J*, *13*(4), 306-311.
2156. McGettigan, P., & Henry, D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. *PLoS Med*, *8*(9), e1001098.
2157. McGirr, A., Vohringer, P. A., Ghaemi, S. N., Lam, R. W., & Yatham, L. N. (2016). Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. *Lancet Psychiatry*, *3*(12), 1138-1146.
2158. McGourty, J. C., Silas, J. H., Lennard, M. S., Tucker, G. T., & Woods, H. F. (1985). Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. *Br J Clin Pharmacol*, *20*(6), 555-566.
2159. McIntosh, D., & Procyshyn, R. (2019). SwitchRx. Retrieved from <https://www.switchrx.com/antidepressants.php/switch>
2160. McIntyre, R. S. (2017). The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. *Neuropsychiatr Dis Treat*, *13*, 2913-2919.
2161. McIntyre, R. S., Cohen, M., Zhao, J., Alphas, L., Macek, T. A., & Panagides, J. (2009). A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disord*, *11*(7), 673-686.
2162. McIntyre, R. S., Cohen, M., Zhao, J., Alphas, L., Macek, T. A., & Panagides, J. (2009). Asenapine versus olanzapine in acute mania: a double-blind extension study. *Bipolar Disord*, *11*(8), 815-826.
2163. McIntyre, R. S., Cohen, M., Zhao, J., Alphas, L., Macek, T. A., & Panagides, J. (2010). Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. *J Affect Disord*, *126*(3), 358-365.
2164. McIntyre, R. S., Cohen, M., Zhao, J., Alphas, L., Macek, T. A., & Panagides, J. (2010). Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *J Affect Disord*, *122*(1-2), 27-38.
2165. McIntyre, R. S., Gommoll, C., Chen, C., & Ruth, A. (2016). The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. *CNS Spectr*, *21*(5), 385-392.
2166. McIvor, R. A. (2017). Chronic Obstructive Pulmonary Disease. In J. Gray (Ed.), *Therapeutics* (
2167. McKay, S. E., Howie, C. A., Thomson, A. H., Whiting, B., & Addis, G. J. (1993). Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. *Thorax*, *48*(3), 227-232.
2168. McKelvie, R. S., Moe, G. W., Ezekowitz, J. A., Heckman, G. A., Costigan, J., Ducharme, A., . . . Sussex, B. (2013). The 2012 Canadian Cardiovascular Society heart failure

- management guidelines update: focus on acute and chronic heart failure. *Can J Cardiol*, 29(2), 168-181.
2169. McKendrick, M. W., & Geddes, A. M. (1979). Neutropenia associated with metronidazole. *Br Med J*, 2(6193), 795.
2170. McKenna, F. (1995). Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis. *Br J Rheumatol*, 34 Suppl 1, 11-18.
2171. McKevitt, F. M., Randall, M. S., Cleveland, T. J., Gaines, P. A., Tan, K. T., & Venables, G. S. (2005). The benefits of combined anti-platelet treatment in carotid artery stenting. *Eur J Vasc Endovasc Surg*, 29(5), 522-527.
2172. McLeod, D. R., Hoehn-Saric, R., Porges, S. W., & Zimmerli, W. D. (1992). Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder. *Psychopharmacology (Berl)*, 107(4), 535-540.
2173. McMahan, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., . . . Manji, H. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. *Am J Hum Genet*, 78(5), 804-814.
2174. McMurray, J. J., Ostergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., . . . Pfeffer, M. A. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*, 362(9386), 767-771.
2175. McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., . . . Committees. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 371(11), 993-1004.
2176. McNamara, D. M., Taylor, A. L., Tam, S. W., Worcel, M., Yancy, C. W., Hanley-Yanez, K., . . . Feldman, A. M. (2014). G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. *JACC Heart Fail*, 2(6), 551-557.
2177. McNeil Consumer Healthcare. (2016). Axert (almotriptan malate). *CA Product Monograph*,
2178. McNeil Consumer Healthcare. (2016). Nicoderm. *CA Product Monograph*,
2179. McNeil Consumer Healthcare. (2016). Nicorette Gum. *CA Product Monograph*,
2180. McNeil Consumer Healthcare. (2016). Nicorette Inhaler. *CA Product Monograph*,
2181. McNeil Consumer Healthcare. (2016). Nicorette Mini Lozenge. *CA Product Monograph*,
2182. McNeil Consumer Healthcare. (2016). Nicorette QuickMist. *CA Product Monograph*,
2183. Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002). Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. *BMJ*, 325(7373), 1139.
2184. Medscape LLC. (2019). Aluminum hydroxide/magnesium hydroxide/simethicone (OTC). *US Product Information*,
2185. Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J. P., Bhatt, D. L., Bode, C., . . . Gibson, C. M. (2012). Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med*, 366(1), 9-19.

2186. Mega, J. L., Morrow, D. A., Brown, A., Cannon, C. P., & Sabatine, M. S. (2009). Identification of genetic variants associated with response to statin therapy. *Arterioscler Thromb Vasc Biol*, 29(9), 1310-1315.
2187. Megraud, F., Coenen, S., Versporten, A., Kist, M., Lopez-Brea, M., Hirschl, A. M., . . . Glupczynski, Y. (2013). Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut*, 62(1), 34-42.
2188. Mehta, R. H., & Eagle, K. A. (1998). Secondary prevention in acute myocardial infarction. *BMJ*, 316(7134), 838-842.
2189. Mehta, S. R., Bassand, J. P., Chrolavicius, S., Diaz, R., Eikelboom, J. W., Fox, K. A., . . . Yusuf, S. (2010). Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med*, 363(10), 930-942.
2190. Mehta, S. R., Tanguay, J. F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., . . . Yusuf, S. (2010). Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet*, 376(9748), 1233-1243.
2191. Mehta, T. Y., Prajapati, L. M., Mittal, B., Joshi, C. G., Sheth, J. J., Patel, D. B., . . . Goyal, R. K. (2009). Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. *Indian J Dermatol Venereol Leprol*, 75(6), 579-582.
2192. Mei, D., Capuano, A., Vollono, C., Evangelista, M., Ferraro, D., Tonali, P., & Di Trapani, G. (2004). Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. *Neurol Sci*, 25(5), 245-250.
2193. Mei, D., Ferraro, D., Zelano, G., Capuano, A., Vollono, C., Gabriele, C., & Di Trapani, G. (2006). Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. *Clin Neuropharmacol*, 29(5), 269-275.
2194. Meineche-Schmidt, V. (2004). Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption. *Am J Gastroenterol*, 99(6), 1050-1058.
2195. Meineche-Schmidt, V., Talley, N., Pap, A., Kordecki, H., Schmid, V., Ohlsson, L., . . . Bolling-Sternevald, E. (1999). Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment: a multicentre 3-month follow-up study. *Scandinavian journal of gastroenterology*, 34(6), 566-574.
2196. Mellstrom, B., Bertilsson, L., Lou, Y. C., Sawe, J., & Sjoqvist, F. (1983). Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. *Clin Pharmacol Ther*, 34(4), 516-520.
2197. Mellstrom, B., Sawe, J., Bertilsson, L., & Sjoqvist, F. (1986). Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. *Clin Pharmacol Ther*, 39(4), 369-371.
2198. Melo Gomes, J. A., Roth, S. H., Zeeh, J., Bruyn, G. A., Woods, E. M., & Geis, G. S. (1993). Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. *Ann Rheum Dis*, 52(12), 881-885.

2199. Meltzer, H. Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu, J., . . . Loebel, A. (2011). Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. *Am J Psychiatry, 168*(9), 957-967.
2200. Mendell, J., Johnson, L., & Chen, S. (2015). An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. *J Clin Pharmacol, 55*(12), 1395-1405.
2201. Mendenopoulos, G., Manafi, T., Logothetis, I., & Bostantjopoulou, S. (1985). Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. *Cephalalgia, 5*(1), 31-37.
2202. Mentz, R. J., Thompson, V. P., Aguilar, D., Choi, J., Gustavson, S. M., Iqbal, N., . . . Hernandez, A. F. (2018). Effects of once-weekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease. *Circulation, 138*(22), 2576-2578.
2203. Merck Canada Inc. (2014). Invanz (ertapenem).
2204. Merck Canada Inc. (2014). Zenhale (mometasone furoate / formoterol fumarate dihydrate). *CA Product Monograph,*
2205. Merck Canada Inc. (2015). Maxalt (rizatriptan). *CA Product Monograph,*
2206. Merck Canada Inc. (2015). Primaxin (imipenem / cilastatin sodium).
2207. Merck Canada Inc. (2016). Olmetec (olmesartan medoxomil). *CA Product Monograph,*
2208. Merck Canada Inc. (2016). Singulair (montelukast). *CA Product Monograph,*
2209. Merck Canada Inc. (2017). Celestone Soluspan (betamethasone sodium phosphate / betamethasone acetate). *CA Product Monograph,*
2210. Merck Canada Inc. (2017). Prinivil (lisinopril). *CA Product Monograph,*
2211. Merck Canada Inc. (2017). Remeron (mirtazapine). *CA Product Monograph,*
2212. Merck Canada Inc. (2017). Vasotec (enalapril). *CA Product Monograph,*
2213. Merck Canada Inc. (2018). Asmanex Twisthaler (mometasone furoate DPI). *CA Product Monograph,*
2214. Merck Canada Inc. (2018). Cozaar (losartan potassium). *CA Product Monograph,*
2215. Merck Canada Inc. (2018). Vasotec (enalapril). *CA Product Monograph,*
2216. Merck Canada Inc. (2018). Zenhale (mometasone furoate / formoterol fumarate dihydrate). *CA Product Monograph,*
2217. Merck Canada Inc. (2018). Zocor (pravastatin). *CA Product Monograph,*
2218. Merck Canada Inc. (2018). Zocor (simvastatin). *CA Product Monograph,*
2219. Merck Canada Inc. (2019). Remeron (mirtazapine). *CA Product Monograph,*
2220. Merck Canada Inc. (2019). Singulair (montelukast) *CA Product Monograph,*
2221. Merck Canada Inc. (2016). Saphris (asenapine). *CA Product Monograph,*
2222. Merck Sharp & Dohme Corp. (2015). Fosamax (alendronate). *US Product Monograph,*
2223. Merck Sharp & Dohme Corp. (2015). Rizatriptan. *US Product Monograph,*
2224. Merck Sharp & Dohme Corp. (2016). Fosamax Plus D (alendronate sodium / cholecalciferol). *US Product Monograph,*
2225. Merck Sharp & Dohme Corp. (2016). Remeron (mirtazapine). *US Product Monograph,*
2226. Merck Sharp & Dohme Corp. (2018). Asmanex HFA (mometasone furoate). *US Product Monograph,*

2227. Merck Sharp & Dohme Corp. (2018). Celestone Soluspan (betamethasone sodium phosphate / betamethasone acetate). *US Product Monograph*,
2228. Merck Sharp & Dohme Corp. (2018). Cozaar (losartan). *US Product Monograph*,
2229. Merck Sharp & Dohme Corp. (2018). Dulera (mometasone furoate / formoterol fumarate dihydrate). *US Product Monograph*,
2230. Merck Sharp & Dohme Corp. (2018). Invanz (ertapenem). *US Product Monograph*,
2231. Merck Sharp & Dohme Corp. (2018). Januvia (sitagliptin). *US Product Monograph*,
2232. Merck Sharp & Dohme Corp. (2018). Singulair (montelukast). *US Product Monograph*,
2233. Merck Sharp & Dohme Corp. (2018). Zocor (simvastatin). *US Product Monograph*,
2234. Merck Sharp & Dohme Corp. (2019). Dulera (mometasone furoate / formoterol fumarate dihydrate). *US Product Monograph*,
2235. Merck Sharp & Dohme Corp. (2019). Singulair (montelukast) *US Product Monograph*,
2236. Merideth, C., Cutler, A. J., She, F., & Eriksson, H. (2012). Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. *Int Clin Psychopharmacol*, 27(1), 40-54.
2237. Merrill, D. B., Dec, G. W., & Goff, D. C. (2005). Adverse cardiac effects associated with clozapine. *J Clin Psychopharmacol*, 25(1), 32-41.
2238. Mertz, H., Fass, R., Kodner, A., Yan-Go, F., Fullerton, S., & Mayer, E. A. (1998). Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. *Am J Gastroenterol*, 93(2), 160-165.
2239. Methapharm Inc. (2015). Anaprox (naproxen). *CA Product Monograph*,
2240. Metz, D. C., Inadomi, J. M., Howden, C. W., van Zanten, S. J., & Bytzer, P. (2007). On-demand therapy for gastroesophageal reflux disease. *Am J Gastroenterol*, 102(3), 642-653.
2241. Meuldijk, D., Carlier, I. V., van Vliet, I. M., van Veen, T., Wolterbeek, R., van Hemert, A. M., & Zitman, F. G. (2016). The clinical effectiveness of concise cognitive behavioral therapy with or without pharmacotherapy for depressive and anxiety disorders; a pragmatic randomized controlled equivalence trial in clinical practice. *Contemp Clin Trials*, 47, 131-138.
2242. Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., . . . Schellens, J. H. (2015). Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. *Lancet Oncol*, 16(16), 1639-1650.
2243. Mezhebovsky, I., Magi, K., She, F., Datto, C., & Eriksson, H. (2013). Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. *Int J Geriatr Psychiatry*, 28(6), 615-625.
2244. Miao, L. Y., Huang, C. R., Hou, J. Q., & Qian, M. Y. (2008). Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. *Biopharm Drug Dispos*, 29(1), 1-5.

2245. Miceli-Richard, C., Comets, E., Verstuyft, C., Tamouza, R., Loiseau, P., Ravaud, P., . . . Mariette, X. (2008). A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. *Ann Rheum Dis*, 67(4), 478-484.
2246. Michelson, D., Read, H. A., Ruff, D. D., Witcher, J., Zhang, S., & McCracken, J. (2007). CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. *J Am Acad Child Adolesc Psychiatry*, 46(2), 242-251.
2247. Mihara, K., Kondo, T., Yasui-Furukori, N., Suzuki, A., Ishida, M., Ono, S., . . . Kaneko, S. (2003). Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. *Ther Drug Monit*, 25(3), 287-293.
2248. Mihara, K., Suzuki, A., Kondo, T., Yasui, N., Furukori, H., Nagashima, U., . . . Inoue, Y. (1999). Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. *Clin Pharmacol Ther*, 65(3), 291-294.
2249. Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E. H., . . . Baigent, C. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*, 380(9841), 581-590.
2250. Miki, I., Aoyama, N., Sakai, T., Shirasaka, D., Wambura, C. M., Maekawa, S., . . . Kasuga, M. (2003). Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. *Eur J Gastroenterol Hepatol*, 15(1), 27-33.
2251. Mikus, G., Trausch, B., Rodewald, C., Hofmann, U., Richter, K., Gramatte, T., & Eichelbaum, M. (1997). Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. *Clin Pharmacol Ther*, 61(4), 459-466.
2252. Miller, P. D., Jamal, S. A., Evenepoel, P., Eastell, R., & Boonen, S. (2013). Renal safety in patients treated with bisphosphonates for osteoporosis: a review. *J Bone Miner Res*, 28(10), 2049-2059.
2253. Mills, E. J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2014). Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. *Circulation*, 129(1), 28-41.
2254. Min, W., Li, T., Ma, X., Li, Z., Yu, T., Gao, D., . . . Sun, X. (2009). Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. *Psychopharmacology (Berl)*, 205(3), 409-417.
2255. Minne, H., Audran, M., Simoes, M. E., Obermayer-Pietsch, B., Sigurethsson, G., Marin, F., . . . Nickelsen, T. (2008). Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORs study. *Curr Med Res Opin*, 24(11), 3117-3128.
2256. Mint Pharmaceuticals Inc. (2014). Mint-Hydrochlorothiazide. *CA Product Monograph*,
2257. Mint Pharmaceuticals Inc. (2017). Mint-Clonidine (clonidine hydrochloride). *CA Product Monograph*,
2258. Mint Pharmaceuticals Inc. (2017). Mint-Hydralazine (hydralazine hydrochloride). *CA Product Monograph*,

2259. Miravittles, M., & Anzueto, A. (2015). Antibiotic prophylaxis in COPD: Why, when, and for whom? *Pulm Pharmacol Ther*, *32*, 119-123.
2260. Miravittles, M., Soler-Cataluna, J. J., Calle, M., Molina, J., Almagro, P., Quintano, J. A., . . . Ancochea, J. (2017). Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. *Arch Bronconeumol*, *53*(6), 324-335.
2261. Mischoulon, D., Witte, J., Levy, M., Papakostas, G. I., Pet, L. R., Hsieh, W. H., . . . Fava, M. (2012). Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. *J Clin Psychiatry*, *73*(3), 353-357.
2262. Mission Pharmacal Company. (2016). Binosto (alendronate sodium). *US Product Monograph*,
2263. Mist Pharmaceuticals LLC. (2016). Nitromist (nitroglycerin). *US Product Monograph*,
2264. Mitha, E., Schumacher, H. R., Fouche, L., Luo, S. F., Weinstein, S. P., Yancopoulos, G. D., . . . Evans, R. R. (2013). Riloncept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. *Rheumatology (Oxford)*, *52*(7), 1285-1292.
2265. Mitsikostas, D. D., & Polychronidis, I. (1997). Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial. *Funct Neurol*, *12*(5), 267-276.
2266. Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005). A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. *J Clin Psychopharmacol*, *25*(2), 141-150.
2267. Miura, T., Noma, H., Furukawa, T. A., Mitsuyasu, H., Tanaka, S., Stockton, S., . . . Kanba, S. (2014). Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. *Lancet Psychiatry*, *1*(5), 351-359.
2268. Miwa, H., Kusano, M., Arisawa, T., Oshima, T., Kato, M., Joh, T., . . . Japanese Society of, G. (2015). Evidence-based clinical practice guidelines for functional dyspepsia. *J Gastroenterol*, *50*(2), 125-139.
2269. Miwa, H., Misawa, H., Yamada, T., Nagahara, A., Ohtaka, K., & Sato, N. (2001). Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of *H. pylori* infection: a multiple logistic regression analysis. *Dig Dis Sci*, *46*(11), 2445-2450.
2270. Miyoshi, M., Mizuno, M., Ishiki, K., Nagahara, Y., Maga, T., Torigoe, T., . . . Tsuji, T. (2001). A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for *Helicobacter pylori* infection in relation to CYP2C19 genetic polymorphism. *J Gastroenterol Hepatol*, *16*(7), 723-728.
2271. Mizuiri, S., Hemmi, H., Inoue, A., Takano, M., Kadomatsu, S., Tanimoto, H., . . . Hasegawa, A. (1997). Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. *Nephron*, *75*(3), 310-314.

2272. Moayyedi, P., Delaney, B. C., Vakil, N., Forman, D., & Talley, N. J. (2004). The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. *Gastroenterology*, *127*(5), 1329-1337.
2273. Moayyedi, P., Lacy, B. E., Andrews, C. N., Enns, R. A., Howden, C. W., & Vakil, N. (2017). ACG and CAG Clinical Guideline: Management of Dyspepsia. *Am J Gastroenterol*, *112*(7), 988-1013.
2274. Moayyedi, P., Shelly, S., Deeks, J. J., Delaney, B., Innes, M., & Forman, D. (2011). Pharmacological interventions for non-ulcer dyspepsia. *Cochrane Database Syst Rev*(2), Cd001960.
2275. Moayyedi, P., Soo, S., Deeks, J., Delaney, B., Harris, A., Innes, M., . . . Forman, D. (2006). Eradication of *Helicobacter pylori* for non-ulcer dyspepsia. *Cochrane Database Syst Rev*(2), Cd002096.
2276. Moayyedi, P., Soo, S., Deeks, J., Delaney, B., Innes, M., & Forman, D. (2006). Pharmacological interventions for non-ulcer dyspepsia. *Cochrane Database Syst Rev*(4), Cd001960.
2277. Moayyedi, P., Soo, S., Deeks, J. J., Delaney, B., Harris, A., Innes, M., . . . Forman, D. (2011). Eradication of *Helicobacter pylori* for non-ulcer dyspepsia. *Cochrane Database Syst Rev*(2), Cd002096.
2278. Mochcovitch, M. D., & Nardi, A. E. (2010). Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. *Expert Rev Neurother*, *10*(8), 1285-1293.
2279. Modlin, I. M., Hunt, R. H., Malfertheiner, P., Moayyedi, P., Quigley, E. M., Tytgat, G. N., . . . Moss, S. F. (2009). Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. *Digestion*, *80*(2), 74-88.
2280. Moes, D. J., Swen, J. J., den Hartigh, J., van der Straaten, T., van der Heide, J. J., Sanders, J. S., . . . Guchelaar, H. J. (2014). Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. *CPT Pharmacometrics Syst Pharmacol*, *3*, e100.
2281. Mohamed, S., Johnson, G. R., Chen, P., Hicks, P. B., Davis, L. L., Yoon, J., . . . Little, J. T. (2017). Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: The VAST-D randomized clinical trial. *Jama*, *318*(2), 132-145.
2282. Mohammad, O., & Osser, D. N. (2014). The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for acute mania. *Harv Rev Psychiatry*, *22*(5), 274-294.
2283. Mohammadi, M. R., Kazemi, M. R., Zia, E., Rezazadeh, S. A., Tabrizi, M., & Akhondzadeh, S. (2010). Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. *Hum Psychopharmacol*, *25*(7-8), 560-565.
2284. Mohler, E. R., 3rd, Hiatt, W. R., & Creager, M. A. (2003). Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation*, *108*(12), 1481-1486.

2285. Mokhber, N., Azarpazhooh, M. R., Khajehdaluae, M., Velayati, A., & Hopwood, M. (2010). Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. *Psychiatry Clin Neurosci*, *64*(2), 128-133.
2286. Molanaei, H., Carrero, J. J., Heimbürger, O., Nordfors, L., Lindholm, B., Stenvinkel, P., . . . Bertilsson, L. (2010). Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *Eur J Clin Pharmacol*, *66*(3), 269-273.
2287. Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sanchez, E., Gutierrez-Rojas, L., & Meana, J. J. (2018). Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. *CNS drugs*, *32*(5), 411-420.
2288. Molina-Infante, J., Romano, M., Fernandez-Bermejo, M., Federico, A., Gravina, A. G., Pozzati, L., . . . Gisbert, J. P. (2013). Optimized nonbismuth quadruple therapies cure most patients with *Helicobacter pylori* infection in populations with high rates of antibiotic resistance. *Gastroenterology*, *145*(1), 121-128.e121.
2289. Momsen, A. H., Jensen, M. B., Norager, C. B., Madsen, M. R., Vestersgaard-Andersen, T., & Lindholt, J. S. (2009). Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. *Eur J Vasc Endovasc Surg*, *38*(4), 463-474.
2290. Montalescot, G., Wiviott, S. D., Braunwald, E., Murphy, S. A., Gibson, C. M., McCabe, C. H., . . . investigators, T.-T. (2009). Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet*, *373*(9665), 723-731.
2291. Moolchan, E. T., Robinson, M. L., Ernst, M., Cadet, J. L., Pickworth, W. B., Heishman, S. J., & Schroeder, J. R. (2005). Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. *Pediatrics*, *115*(4), e407-414.
2292. Moon, J., Kim, T. J., Lim, J. A., Sunwoo, J. S., Byun, J. I., Lee, S. T., . . . Lee, S. K. (2016). HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. *Epilepsia*, *57*(11), 1879-1886.
2293. Moon, J., Park, H. K., Chu, K., Sunwoo, J. S., Byun, J. I., Lim, J. A., . . . Lee, S. K. (2015). The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. *Epilepsia*, *56*(10), e161-167.
2294. Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2015). Amitriptyline for neuropathic pain in adults. *Cochrane Database Syst Rev*(7), CD008242.
2295. Moore, R. A., Wiffen, P. J., Derry, S., Toelle, T., & Rice, A. S. (2014). Gabapentin for chronic neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev*, *4*, CD007938.
2296. Mora, J. C., Przkora, R., & Cruz-Almeida, Y. (2018). Knee osteoarthritis: pathophysiology and current treatment modalities. *J Pain Res*, *11*, 2189-2196.
2297. Morgan, D. (1999). Arthrotec: the evidence speaks for itself. *Scand J Rheumatol Suppl*, *109*, 13-18.

2298. Morgan, M. H., & Read, A. E. (1972). Antidepressants and liver disease. *Gut*, 13(9), 697-701.
2299. Morice, A. H., Peterson, S., Beckman, O., & Kukova, Z. (2008). Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. *Pulm Pharmacol Ther*, 21(1), 152-159.
2300. Morita, S., Shimoda, K., Someya, T., Yoshimura, Y., Kamijima, K., & Kato, N. (2000). Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. *J Clin Psychopharmacol*, 20(2), 141-149.
2301. Mortimer, O., Persson, K., Ladona, M. G., Spalding, D., Zanger, U. M., Meyer, U. A., & Rane, A. (1990). Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. *Clin Pharmacol Ther*, 47(1), 27-35.
2302. Mosbech, H., Deckelmann, R., de Blay, F., Pastorello, E. A., Trebas-Pietras, E., Andres, L. P., . . . Canonica, G. W. (2014). Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*, 134(3), 568-575 e567.
2303. Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., . . . Wenger, N. K. (2011). Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol*, 57(12), 1404-1423.
2304. Mosley, J. D., Shaffer, C. M., Van Driest, S. L., Weeke, P. E., Wells, Q. S., Karnes, J. H., . . . Roden, D. M. (2015). A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. *Pharmacogenomics J*.
2305. Mosley, J. D., Shaffer, C. M., Van Driest, S. L., Weeke, P. E., Wells, Q. S., Karnes, J. H., . . . Roden, D. M. (2016). A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. *Pharmacogenomics J*, 16(3), 231-237.
2306. Mothi, M., & Sampson, S. (2013). Pimozide for schizophrenia or related psychoses. *Cochrane Database Syst Rev*(11), CD001949.
2307. Mougey, E. B., Chen, C., Tantisira, K. G., Blake, K. V., Peters, S. P., Wise, R. A., . . . Lima, J. J. (2013). Pharmacogenetics of asthma controller treatment. *Pharmacogenomics J*, 13(3), 242-250.
2308. Moulin, D., Boulanger, A., Clark, A. J., Clarke, H., Dao, T., Finley, G. A., . . . Canadian Pain, S. (2014). Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. *Pain Res Manag*, 19(6), 328-335.
2309. Mouly, S., Bloch, V., Peoc'h, K., Houze, P., Labat, L., Ksouda, K., . . . Vorspan, F. (2015). Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. *Br J Clin Pharmacol*, 79(6), 967-977.
2310. Moyer, V. A. (2013). Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*, 158(1), 47-54.

2311. Mrazek, D. A., Biernacka, J. M., O'Kane, D. J., Black, J. L., Cunningham, J. M., Drews, M. S., . . . Weinshilboum, R. M. (2011). CYP2C19 variation and citalopram response. *Pharmacogenet Genomics*, *21*(1), 1-9.
2312. Mrazek, D. A., Rush, A. J., Biernacka, J. M., O'Kane, D. J., Cunningham, J. M., Wieben, E. D., . . . Weinshilboum, R. M. (2009). SLC6A4 variation and citalopram response. *Am J Med Genet B Neuropsychiatr Genet*, *150B*(3), 341-351.
2313. Muchao, F. P., Souza, J. M., Torres, H. C., De Lalibera, I. B., de Souza, A. V., Rodrigues, J. C., . . . da Silva Filho, L. V. (2016). Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe. *Pediatr Pulmonol*, *51*(11), 1122-1130.
2314. Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. *Am Fam Physician*, *81*(5), 617-622.
2315. Mugnier, B., Balandraud, N., Darque, A., Roudier, C., Roudier, J., & Reviron, D. (2003). Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. *Arthritis Rheum*, *48*(7), 1849-1852.
2316. Muir, A. J., Gong, L., Johnson, S. G., Lee, M. T., Williams, M. S., Klein, T. E., . . . Clinical Pharmacogenetics Implementation, C. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. *Clin Pharmacol Ther*, *95*(2), 141-146.
2317. Mukaddes, N. M., & Abali, O. (2004). Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. *Psychiatry Clin Neurosci*, *58*(1), 92-95.
2318. Mulder, H., Cohen, D., Scheffer, H., Gispen-de Wied, C., Arends, J., Wilmink, F. W., . . . Egberts, A. C. (2009). HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. *J Clin Psychopharmacol*, *29*(1), 16-20.
2319. Mulder, H., Franke, B., van der-Beek van der, A. A., Arends, J., Wilmink, F. W., Scheffer, H., & Egberts, A. C. (2007). The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. *J Clin Psychopharmacol*, *27*(4), 338-343.
2320. Mulleners, W. M., McCrory, D. C., & Linde, M. (2015). Antiepileptics in migraine prophylaxis: an updated Cochrane review. *Cephalalgia*, *35*(1), 51-62.
2321. Muller, D. J., Brandl, E. J., Hwang, R., Tiwari, A. K., Sturgess, J. E., Zai, C. C., . . . Richter, M. A. (2012). The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. *Genet Test Mol Biomarkers*, *16*(8), 897-903.
2322. Muller, D. J., Zai, C. C., Sicard, M., Remington, E., Souza, R. P., Tiwari, A. K., . . . Kennedy, J. L. (2012). Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. *Pharmacogenomics J*, *12*(2), 156-164.
2323. Muller, P., Hotz, J., Franz, E., & Simon, B. (1994). Ranitidine in the treatment of non-ulcer dyspepsia. A placebo-controlled study in the Federal Republic of Germany. *Arzneimittelforschung*, *44*(10), 1130-1132.
2324. Mullish, B. H., Kabir, M. S., Thursz, M. R., & Dhar, A. (2014). Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. *Aliment Pharmacol Ther*, *40*(8), 880-892.

2325. Mullish, B. H., Kabir, M. S., Thursz, M. R., & Dhar, A. (2014). Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. *Aliment Pharmacol Ther*, *40*(8), 880-892.
2326. Munafo, M. R., Johnstone, E. C., Guo, B., Murphy, M. F., & Aveyard, P. (2008). Association of COMT Val108/158Met genotype with smoking cessation. *Pharmacogenet Genomics*, *18*(2), 121-128.
2327. Munar, M. Y., & Singh, H. (2007). Drug dosing adjustments in patients with chronic kidney disease. *Am Fam Physician*, *75*(10), 1487-1496.
2328. Muramoto, M. L., Leischow, S. J., Sherrill, D., Matthews, E., & Strayer, L. J. (2007). Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. *Arch Pediatr Adolesc Med*, *161*(11), 1068-1074.
2329. Murphy, E. J. (2005). Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. *Anaesth Intensive Care*, *33*(3), 311-322.
2330. Murphy, G. M., Jr., Kremer, C., Rodrigues, H. E., & Schatzberg, A. F. (2003). Pharmacogenetics of antidepressant medication intolerance. *Am J Psychiatry*, *160*(10), 1830-1835.
2331. Murphy, G. M., Jr., Pollock, B. G., Kirshner, M. A., Pascoe, N., Cheuk, W., Mulsant, B. H., & Reynolds, C. F., 3rd. (2001). CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. *Neuropsychopharmacology*, *25*(5), 737-743.
2332. Murphy, J. J., Heptinstall, S., & Mitchell, J. R. (1988). Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. *Lancet*, *2*(8604), 189-192.
2333. Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., . . . Braunwald, E. (2016). Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. *J Am Coll Cardiol*, *67*(4), 353-361.
2334. Murto, K., Lamontagne, C., McFaul, C., MacCormick, J., Ramakko, K. A., Aglipay, M., . . . Vaillancourt, R. (2015). Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study. *Can J Anaesth*, *62*(7), 785-797.
2335. Musey, V. C., Preedy, J. R., Musey, P. I., Blank, M. S., Brogan, D. R., Bain, R. P., & Collins, D. C. (1986). Prolactin and blood pressure responses to perphenazine in human subjects: comparison of the oral and intramuscular routes. *Am J Med Sci*, *291*(6), 380-385.
2336. Mushiroda, T., Takahashi, Y., Onuma, T., Yamamoto, Y., Kamei, T., Hoshida, T., . . . Gencat Study Group. (2018). Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. *JAMA Neurol*, *75*(7), 842-849.
2337. Musini, V. M., Nazer, M., Bassett, K., & Wright, J. M. (2014). Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. *Cochrane Database Syst Rev*(5), CD003824.
2338. Muskiet, M. H., van Raalte, D. H., van Bommel, E., Smits, M. M., & Tonneijck, L. (2015). Understanding EMPA-REG OUTCOME. *Lancet Diabetes Endocrinol*, *3*(12), 928-929.

2339. Mutai, H., Kouike, H., Teruya, E., Takahashi-Kodomari, I., Kakishima, H., Taiji, H., . . . Matsunaga, T. (2011). Systematic analysis of mitochondrial genes associated with hearing loss in the Japanese population: dHPLC reveals a new candidate mutation. *BMC Med Genet*, *12*, 135.
2340. Muzina, D. J., Chambers, J. S., Camacho, T. A., Eudicone, J. M., Forbes, R. A., Berman, R. M., & Baker, R. A. (2011). Adjunctive aripiprazole for depression: predictive value of early assessment. *Am J Manag Care*, *17*(12), 793-801.
2341. Muzina, D. J., Gao, K., Kemp, D. E., Khalife, S., Ganocy, S. J., Chan, P. K., . . . Calabrese, J. R. (2011). Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. *J Clin Psychiatry*, *72*(6), 813-819.
2342. Mwenifumbo, J. C., Al Koudsi, N., Ho, M. K., Zhou, Q., Hoffmann, E. B., Sellers, E. M., & Tyndale, R. F. (2008). Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. *Hum Mutat*, *29*(5), 679-688.
2343. Mwinyi, J., John, A., Bauer, S., Roots, I., & Gerloff, T. (2004). Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. *Clin Pharmacol Ther*, *75*(5), 415-421.
2344. Mwinyi, J., Vokinger, K., Jetter, A., Breitenstein, U., Hiller, C., Kullak-Ublick, G. A., & Trojan, A. (2014). Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. *Cancer Chemother Pharmacol*, *73*(6), 1181-1188.
2345. Mylan Pharmaceuticals Inc. (2006). Chlorothiazide. *US Product Monograph*,
2346. Mylan Pharmaceuticals Inc. (2006). Probenecid. *US Product Monograph*,
2347. Mylan Pharmaceuticals Inc. (2006). Timolol. *US Product Monograph*,
2348. Mylan Pharmaceuticals Inc. (2012). Acebutolol. *US Product Monograph*,
2349. Mylan Pharmaceuticals Inc. (2013). Felodipine. *US Product Monograph*,
2350. Mylan Pharmaceuticals Inc. (2014). Eprosartan. *US Product Monograph*,
2351. Mylan Pharmaceuticals Inc. (2015). Ketorolac. *US Product Monograph*,
2352. Mylan Pharmaceuticals Inc. (2015). Trifluoperazine. *US Product Monograph*,
2353. Mylan Pharmaceuticals Inc. (2016). Amitriptyline. *US Product Monograph*,
2354. Mylan Pharmaceuticals Inc. (2016). Fluphenazine. *US Product Monograph*,
2355. Mylan Pharmaceuticals Inc. (2016). Flurbiprofen *US Product Monograph*,
2356. Mylan Pharmaceuticals Inc. (2016). Nizatidine *US Product Monograph*,
2357. Mylan Pharmaceuticals Inc. (2016). Pindolol. *US Product Monograph*,
2358. Mylan Pharmaceuticals Inc. (2017). Captopril. *US Product Monograph*,
2359. Mylan Pharmaceuticals Inc. (2017). Chlorthalidone. *US Product Monograph*,
2360. Mylan Pharmaceuticals Inc. (2017). Diclofenac Potassium *US Product Monograph*,
2361. Mylan Pharmaceuticals Inc. (2017). Loxapine. *US Product Monograph*,
2362. Mylan Pharmaceuticals Inc. (2018). Ipratropium bromide / Albuterol sulfate. *US Product Monograph*,
2363. Mylan Pharmaceuticals Inc. (2018). Maxzide (triamterene/hydrochlorothiazide). *US Product Monograph*,
2364. Mylan Pharmaceuticals Inc. (2018). Methotrexate. *US Product Monograph*,

2365. Mylan Pharmaceuticals Inc. (2018). Perphenazine. *US Product Monograph*,
2366. Mylan Pharmaceuticals Inc. (2018). Spironolactone. *US Product Monograph*,
2367. Mylan Pharmaceuticals Inc. (2019). Fenofibrate. *US Product Monograph*,
2368. Mylan Pharmaceuticals ULC. (2009). Verapamil. *CA Drug Monograph*,
2369. Mylan Pharmaceuticals ULC. (2014). Piperacillin / tazobactam. *CA Product Monograph*,
2370. Mylan Pharmaceuticals ULC. (2014). Tobramycin. *CA Product Monograph*,
2371. Mylan Pharmaceuticals ULC. (2017). Mylan-carvedilol. *CA Product Monograph*,
2372. Mylan Pharmaceuticals ULC. (2017). Verapamil hydrochloride sustained-release. *CA Product Monograph*,
2373. Nagata, N., Niikura, R., Aoki, T., Shimbo, T., Kishida, Y., Sekine, K., . . . Uemura, N. (2014). Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. *Gastrointest Endosc*, *80*(6), 1124-1131.
2374. Nagler, E. V., Webster, A. C., Vanholder, R., & Zoccali, C. (2012). Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). *Nephrol Dial Transplant*, *27*(10), 3736-3745.
2375. Nahili, H., Charif, M., Boulouiz, R., Bounaceur, S., Benrahma, H., Abidi, O., . . . Barakat, A. (2010). Prevalence of the mitochondrial A 1555G mutation in Moroccan patients with non-syndromic hearing loss. *Int J Pediatr Otorhinolaryngol*, *74*(9), 1071-1074.
2376. Nakagawa, A., Watanabe, N., Omori, I. M., Barbui, C., Cipriani, A., McGuire, H., . . . Furukawa, T. A. (2009). Milnacipran versus other antidepressive agents for depression. *Cochrane Database Syst Rev*(3), CD006529.
2377. Nakajima, S. (2009). Stepwise diagnosis and treatment from uninvestigated dyspepsia to functional dyspepsia in clinical practice in Japan: proposal of a 4-step algorithm. *Digestion*, *79*.
2378. Nasr, S., Wendt, B., Popli, A., & Crayton, J. (2014). Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. *J Affect Disord*, *162*, 50-54.
2379. Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., . . . European Association for Study of, D. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, *32*(1), 193-203.
2380. National Asthma Council Australia. (2016). Acute asthma. In *Australian Asthma Handbook* (Vol. 1.2,
2381. National Clinical Guideline Centre. (2012). National Institute for Health and Clinical Excellence: Guidance. In *The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care: Pharmacological Update of Clinical Guideline 20*. London: Royal College of Physicians (UK), National Clinical Guideline Centre.
2382. National Clinical Guideline Centre. (2012). National Institute for Health and Clinical Excellence: Guidance. In *Headaches: Diagnosis and Management of Headaches in Young People and Adults*. London: Royal College of Physicians (UK), National Clinical Guideline Centre.

2383. National Clinical Guideline Centre. (2014). National Institute for Health and Clinical Excellence: Guidance. In *Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease*. London: National Institute for Health and Care Excellence (UK).
2384. National Clinical Guideline Centre (UK). (2014). Osteoarthritis: Care and Management in Adults.
2385. National Collaborating Centre for Chronic Conditions. (2008). National Institute for Health and Clinical Excellence: Guidance. In *Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)*. London: Royal College of Physicians (UK), Royal College of Physicians of London.
2386. National Collaborating Centre for Chronic Conditions. (2009). National Institute for Health and Clinical Excellence: Guidance. In *Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults*. London: Royal College of Physicians (UK), Royal College of Physicians of London.
2387. National Collaborating Centre for Mental Health. (2009). National Institute for Health and Clinical Excellence: Guidance. In *Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update)*. Leicester (UK): British Psychological Society, National Collaborating Centre for Mental Health.
2388. National Collaborating Centre for Mental Health (Great Britain), National Institute for Health and Clinical Excellence (Great Britain), British Psychological Society., Royal College of Psychiatrists., & National Library of Medicine. (2011). Generalised anxiety disorder in adults management in primary, secondary and community care [Clinical guideline 113].
2389. National Collaborating Centre for Mental Health (Great Britain), & National Library of Medicine. (2013). Social anxiety disorder recognition, assessment and treatment [Clinical guideline 159].
2390. National Institute for Health and Care Evidence. (2002). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. [NICE Guideline TAG43].
2391. National Institute for Health and Care Evidence. (2007). Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management. [NICE Guideline 53].
2392. National Institute for Health and Care Evidence. (2008). Attention deficit hyperactivity disorder: diagnosis and management [NICE Guideline CG72].
2393. National Institute for Health and Care Evidence. (2008). Stop smoking services [NICE Guideline PH10].
2394. National Institute for Health and Care Evidence. (2009). Low back pain in adults: early management. [NICE Guideline 88].
2395. National Institute for Health and Care Evidence. (2011). Update: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. [NICE technology appraisal 160].

2396. National Institute for Health and Care Evidence. (2013). Hypertension: Evidence Update March 2013 [NICE Guideline CG127 update].
2397. National Institute for Health and Care Evidence. (2014). Canagliflozin in combination therapy for treating type 2 diabetes [NICE Guideline TA315].
2398. National Institute for Health and Care Evidence. (2014). Chronic kidney disease in adults: assessment and management. [NICE Guideline CG182].
2399. National Institute for Health and Care Evidence. (2014). Migraine Prophylaxis: Flunarizine. [NICE guideline esuom33].
2400. National Institute for Health and Care Evidence. (2014). The pharmacological management of neuropathic pain in adults in non-specialist settings. [NICE Guideline CG173].
2401. National Institute for health and Care Evidence. (2015). Empagliflozin in combination therapy for treating type 2 diabetes. [NICE Guideline TA336].
2402. National Institute for Health and Care Evidence. (2015). Type 2 diabetes in adults: management. [NICE Guideline 28].
2403. National Institute for Health and Care Excellence. (2012). Depression Evidence Update: A summary of selected new evidence relevant to NICE clinical guideline 90 'The treatment and management of depression in adults'.
2404. National Institute for Health and Care Excellence. (2013). Dapagliflozin in combination therapy for treating type 2 diabetes. [NICE Guideline TA288].
2405. National Institute for Health and Care Excellence. (2013). Generalized anxiety disorder: queitapine. [NICE evidence summary ESUOM12].
2406. National Institute for Health and Care Excellence. (2013). Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease. [NICE Guideline CG172].
2407. National Institute for Health and Care Excellence. (2013). Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist [NICE guideline CG173]. (Accession No. 25577930)
2408. National Institute for Health and Care Excellence. (2013). Smoking: acute, maternity and mental health services. [NICE Guideline PH48].
2409. National Institute for Health and Care Excellence. (2014). Bipolar disorder: assessment and management. [NICE Guideline CG185]. (Accession No. 31556980)
2410. National Institute for Health and Care Excellence. (2014). Cardiovascular disease: risk assessment and reduction, including lipid modification [NICE Guideline CG181].
2411. National Institute for Health and Care Excellence. (2014). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management [NICE Guideline CG184].
2412. National Institute for Health and Care Excellence. (2014). The management of type 2 diabetes. [NICE Guideline CG87].
2413. National Institute for Health and Care Excellence. (2015). Dyspepsia and gastro-oesophageal reflux disease in adults [NICE Guideline QS96].
2414. National Institute for Health and Care Excellence. (2015). Non-steroidal anti-inflammatory drugs [NICE Guideline KTT13].
2415. National Institute for Health and Care Excellence. (2017). Asthma: diagnosis, monitoring and chronic asthma management [NICE Guideline NG80].

2416. National Institute for Health and Care Excellence. (2017). Chronic asthma: management [NICE Guideline NG80].
2417. National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: diagnosis and management. [NICE Guideline NG87].
2418. National Institute for Health and Care Excellence. (2018). Chronic Heart Failure in Adults: Diagnosis and Management. [NICE Guideline NG106].
2419. National Institute for Health and Care Excellence. (2018). Pyelonephritis (acute): antimicrobial prescribing [NICE Guideline NG111]. *Addiction*,
2420. National Institute for Health and Care Excellence. (2019). Hypertension in adults: diagnosis and management. [NICE Guideline NG136].
2421. National Institute for Health and Care Excellence (UK). (2015). Type 2 Diabetes in Adults: Management.
2422. National Institute for Health and Clinical Excellence. (2010). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. [NICE Guideline CG12].
2423. National Institute for Health and Clinical Excellence. (2012). Lower Limb Peripheral Arterial Disease: Diagnosis and Management [NICE Guideline CG147].
2424. National Institute for Health and Clinical Excellence. (2014). Atrial Fibrillation: management [NICE guideline CG180].
2425. National Institute for Health and Clinical Excellence. (2014). Psychosis and schizophrenia in adults: prevention and management [NICE Guideline CG178]. *Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014*,
2426. National Kidney Foundation. (2012). KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis*, 60(5), 850-886.
2427. National Toxicology Program. (2009). Chemical Information Review Document for Butterbur.
2428. Natural Medicines. (2017). Butterbur. *CA Product Monograph*,
2429. Natural Medicines. (2017). Coenzyme Q10. *CA Product Monograph*,
2430. Natural Medicines. (2017). Riboflavin. *CA Product Monograph*,
2431. Naumann, M., So, Y., Argoff, C. E., Childers, M. K., Dykstra, D. D., Gronseth, G. S., . . . Simpson, D. M. (2008). Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*, 70(19), 1707-1714.
2432. Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erond, N., . . . Group, C. P. C. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*, 377(7), 644-657.
2433. Negro, A., & Martelletti, P. (2011). Chronic migraine plus medication overuse headache: two entities or not? *J Headache Pain*, 12.
2434. Nelson, A. E., Allen, K. D., Golightly, Y. M., Goode, A. P., & Jordan, J. M. (2014). A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. *Semin Arthritis Rheum*, 43(6), 701-712.

2435. Nelson, J. C., Rahman, Z., Laubmeier, K. K., Eudicone, J. M., McQuade, R. D., Berman, R. M., . . . Sheehan, J. J. (2014). Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. *CNS Spectr*, *19*(6), 528-534.
2436. Nelson, J. C., Thase, M. E., Bellocchio, E. E., Rollin, L. M., Eudicone, J. M., McQuade, R. D., . . . Baker, R. A. (2012). Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. *Int Clin Psychopharmacol*, *27*(3), 125-133.
2437. Nelson, J. C., Thase, M. E., Trivedi, M. H., Fava, M., Han, J., Van Tran, Q., . . . Berman, R. M. (2009). Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). *Prim Care Companion J Clin Psychiatry*, *11*(6), 344-352.
2438. Nerenberg, K. A., Zarnke, K. B., Leung, A. A., Dasgupta, K., Butalia, S., McBrien, K., . . . Daskalopoulou, S. S. (2018). Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. *Can J Cardiol*, *34*(5), 506-525.
2439. Netz, U., Carter, J. V., Eichenberger, M. R., Dryden, G. W., Pan, J., Rai, S. N., & Galandiuk, S. (2017). Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. *World J Gastroenterol*, *23*(27), 4958-4967.
2440. New Haven Pharmaceuticals Inc. (2015). Durlaza (ASA). *US Product Monograph*.
2441. Newcorn, J. H., Stein, M. A., Childress, A. C., Youcha, S., White, C., Enright, G., & Rubin, J. (2013). Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. *J Am Acad Child Adolesc Psychiatry*, *52*(9), 921-930.
2442. Newman, L., Mannix, L. K., Landy, S., Silberstein, S., Lipton, R. B., Putnam, D. G., . . . O'Quinn, S. (2001). Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. *Headache*, *41*(3), 248-256.
2443. Ng, C., Sarris, J., Singh, A., Bousman, C., Byron, K., Peh, L. H., . . . Schweitzer, I. (2013). Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. *Hum Psychopharmacol*, *28*(5), 516-522.
2444. Ng, C. Y., Yeh, Y. T., Wang, C. W., Hung, S. I., Yang, C. H., Chang, Y. C., . . . Chung, W. H. (2016). Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. *J Invest Dermatol*, *136*(7), 1373-1381.
2445. Ng, F. H., Wong, S. Y., Lam, K. F., Chu, W. M., Chan, P., Ling, Y. H., . . . Wong, B. C. (2010). Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. *Gastroenterology*, *138*(1), 82-88.
2446. Nguyen, D. V., Chu, H. C., Nguyen, D. V., Phan, M. H., Craig, T., Baumgart, K., & van Nunen, S. (2015). HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. *Asia Pac Allergy*, *5*(2), 68-77.
2447. Ni Chroinin, M., Lasserson, T. J., Greenstone, I., & Ducharme, F. M. (2009). Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. *Cochrane Database Syst Rev*(3), CD007949.

2448. Ni, W., Shao, X., Cai, X., Wei, C., Cui, J., Wang, R., & Liu, Y. (2015). Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. *PLoS One*, *10*(3), e0121257.
2449. Nicolle, L. (2017). Urinary Tract Infection. In *RxTx* (
2450. Nicolle, L. E. (2005). Catheter-related urinary tract infection. *Drugs Aging*, *22*(8), 627-639.
2451. Nicolle, L. E. (2005). Managing recurrent urinary tract infections in women. *Womens Health (Lond Engl)*, *1*(1), 39-50.
2452. Nicolle, L. E. (2005). Urinary tract infection in diabetes. *Curr Opin Infect Dis*, *18*(1), 49-53.
2453. Nicolle, L. E., Bradley, S., Colgan, R., Rice, J. C., Schaeffer, A., Hooton, T. M., . . . American Geriatric, S. (2005). Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*, *40*(5), 643-654.
2454. Nicolle, L. E., & Committee*, A. C. G. (2005). Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol*, *16*(6), 349-360.
2455. Nicolle, L. E., Zhanel, G. G., & Harding, G. K. (2006). Microbiological outcomes in women with diabetes and untreated asymptomatic bacteriuria. *World J Urol*, *24*(1), 61-65.
2456. Niederhofer, H., & Huber, M. (2004). Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results. *Pharmacotherapy*, *24*(11), 1524-1528.
2457. Nielsen, J., Kane, J. M., & Correll, C. U. (2012). Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. *Bipolar Disord*, *14*(8), 863-869.
2458. Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M., Lutjohann, D., . . . Kivisto, K. T. (2005). Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. *Pharmacogenet Genomics*, *15*(5), 303-309.
2459. Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., . . . Kivisto, K. T. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). *Pharmacogenetics*, *14*(7), 429-440.
2460. Nierenberg, A. A., Farabaugh, A. H., Alpert, J. E., Gordon, J., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (2000). Timing of onset of antidepressant response with fluoxetine treatment. *Am J Psychiatry*, *157*(9), 1423-1428.
2461. Nierenberg, A. A., Friedman, E. S., Bowden, C. L., Sylvia, L. G., Thase, M. E., Ketter, T., . . . Calabrese, J. R. (2013). Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. *Am J Psychiatry*, *170*(1), 102-110.
2462. Nierenberg, A. A., McElroy, S. L., Friedman, E. S., Ketter, T. A., Shelton, R. C., Deckersbach, T., . . . Thase, M. E. (2016). Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. *J Clin Psychiatry*, *77*(1), 90-99.

2463. Nierenberg, A. A., McLean, N. E., Alpert, J. E., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1995). Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. *Am J Psychiatry*, *152*(10), 1500-1503.
2464. Nieto, A., Mazon, A., Pamies, R., Bruno, L., Navarro, M., & Montanes, A. (2009). Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. *J Allergy Clin Immunol*, *124*(1), 157-161 e151-132.
2465. Niihara, H., Kakamu, T., Fujita, Y., Kaneko, S., & Morita, E. (2012). HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. *J Dermatol*, *39*(7), 594-601.
2466. Niitsu, T., Fabbri, C., Bentini, F., & Serretti, A. (2013). Pharmacogenetics in major depression: a comprehensive meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*, *45*, 183-194.
2467. Nikfar, S., Abdollahi, M., Moretti, M. E., Magee, L. A., & Koren, G. (2002). Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. *Dig Dis Sci*, *47*(7), 1526-1529.
2468. Nikolaidou, T., & Channer, K. S. (2009). Chronic atrial fibrillation: a systematic review of medical heart rate control management. *Postgrad Med J*, *85*(1004), 303-312.
2469. Nishimura, M., Ueda, M., Saruwatari, J., Nakashima, H., Ogusu, N., Aoki, A., . . . Yasui-Furukori, N. (2016). Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis. *Pharmacogenet Genomics*, *26*(9), 403-413.
2470. Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., 3rd, Fleisher, L. A., . . . Thompson, A. (2017). 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*, *70*(2), 252-289.
2471. Nishio, M., Endo, T., Fujimoto, K., Yamamoto, S., Obara, M., Yamaguchi, K., . . . Koike, T. (2009). FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. *Eur J Haematol*, *82*(2), 143-147.
2472. Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., . . . Sugiyama, Y. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. *Clin Pharmacol Ther*, *73*(6), 554-565.
2473. Nishizawa, D., Fukuda, K., Kasai, S., Hasegawa, J., Aoki, Y., Nishi, A., . . . Ikeda, K. (2014). Genome-wide association study identifies a potent locus associated with human opioid sensitivity. *Mol Psychiatry*, *19*(1), 55-62.
2474. Nivoli, A. M., Colom, F., Murru, A., Pacchiarotti, I., Castro-Loli, P., Gonzalez-Pinto, A., . . . Vieta, E. (2011). New treatment guidelines for acute bipolar depression: a systematic review. *J Affect Disord*, *129*(1-3), 14-26.
2475. Noai, M., Soraoka, H., Kajiwara, A., Tanamachi, Y., Oniki, K., Nakagawa, K., . . . Saruwatari, J. (2016). Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. *Acta Neurol Scand*, *133*(3), 216-223.

2476. Nolen, W. A., & Weisler, R. H. (2013). The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). *Bipolar Disord*, 15(1), 100-109.
2477. Nordahl, H. M., Vogel, P. A., Morken, G., Stiles, T. C., Sandvik, P., & Wells, A. (2016). Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial. *Psychother Psychosom*, 85(6), 346-356.
2478. Nordin, C., Siwers, B., Benitez, J., & Bertilsson, L. (1985). Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. *Br J Clin Pharmacol*, 19(6), 832-835.
2479. Norman, G., Faria, R., Paton, F., Llewellyn, A., Fox, D., Palmer, S., . . . McKenna, C. (2013). Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. *Health Technol Assess*, 17(52), 1-342.
2480. Normansell, R., Kew, K. M., & Mansour, G. (2016). Different oral corticosteroid regimens for acute asthma. *Cochrane Database Syst Rev*(5), CD011801.
2481. Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014). Omalizumab for asthma in adults and children. *Cochrane Database Syst Rev*(1), CD003559.
2482. Noro, M., Antonijevic, I., Forray, C., Kasper, S., Kocabas, N. A., Lecrubier, Y., . . . Massat, I. (2010). 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. *Int Clin Psychopharmacol*, 25(4), 228-231.
2483. North American Menopause Society. (2012). The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause*, 19(3), 257-271.
2484. Norton, P. J., & Price, E. C. (2007). A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. *J Nerv Ment Dis*, 195(6), 521-531.
2485. Noruzzadeh, R., Modabbernia, A., Aghamollai, V., Ghaffarpour, M., Harirchian, M. H., Salahi, S., . . . Tafakhori, A. (2016). Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. *Headache*, 56(1), 95-103.
2486. Norwegian Multicenter Study Group. (1981). Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. *N Engl J Med*, 304(14), 801-807.
2487. Norwich Pharmaceuticals Inc. (2015). Atelvia (risedronate). *US Product Monograph*,
2488. Novack, L., Kogan, S., Gimpelevich, L., Howell, M., Borer, A., Kelly, C. P., . . . Novack, V. (2014). Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. *PLoS One*, 9(10), e110790.
2489. Novartis Pharmaceuticals Canada Inc. (2013). Foradil (formoterol). *CA Product Monograph*,
2490. Novartis Pharmaceuticals Canada Inc. (2014). Aclasta (zoledronic acid injection). *CA Product Monograph*,
2491. Novartis Pharmaceuticals Canada Inc. (2014). Tegretol (carbamazepine). *CA Product Monograph*,

2492. Novartis Pharmaceuticals Canada Inc. (2014). Voltaren (diclofenac). *CA Product Monograph*,
2493. Novartis Pharmaceuticals Canada Inc. (2015). Diovan (valsartan). *CA Product Monograph*,
2494. Novartis Pharmaceuticals Canada Inc. (2015). Onbrez Breezhaler (indacaterol maleate). *CA Product Monograph*,
2495. Novartis Pharmaceuticals Canada Inc. (2016). Lopresor (metoprolol). *CA Product Monograph*,
2496. Novartis Pharmaceuticals Canada Inc. (2016). Lotensin (benazepril). *CA Product Monograph*,
2497. Novartis Pharmaceuticals Canada Inc. (2016). Seebri Breezhaler (glycopyrronium). *CA Product Monograph*,
2498. Novartis Pharmaceuticals Canada Inc. (2016). Voltaren Rapide (diclofenac potassium). *CA Product Monograph*,
2499. Novartis Pharmaceuticals Canada Inc. (2017). Entresto (sacubitril / valsartan). *CA Product Monograph*,
2500. Novartis Pharmaceuticals Canada Inc. (2017). Revolade (eltrombopag). *CA Product Monograph*,
2501. Novartis Pharmaceuticals Canada Inc. (2017). Ritalin (methylphenidate hydrochloride). *CA Product Monograph*,
2502. Novartis Pharmaceuticals Canada Inc. (2017). Xolair (omalizumab). *CA Product Monograph*,
2503. Novartis Pharmaceuticals Canada Inc. (2018). Ultibro Breezhaler (indacaterol /glycopyrronium). *CA Product Monograph*,
2504. Novartis Pharmaceuticals Canada Inc. (2018). Voltaren (diclofenac). *CA Product Monograph*,
2505. Novartis Pharmaceuticals Corporation. (2015). Tegretol (carbamazepine). *US Product Monograph*,
2506. Novartis Pharmaceuticals Corporation. (2017). Diovan (valsartan). *US Product Monograph*,
2507. Novartis Pharmaceuticals Corporation. (2018). Reclast (zoledronic acid). *US Product Monograph*,
2508. Novartis Pharmaceuticals Corporation. (2018). Seebri Neohaler (glycopyrrolate). *US Product Monograph*,
2509. Novartis Pharmaceuticals Corporation. (2018). Utibron Neohaler (indacaterol / glycopyrrolate). *US Product Monograph*,
2510. Novartis Pharmaceuticals Corporation. (2019). Ritalin (methylphenidate hydrochloride) *US Product Monograph*,
2511. Novartis Pharmaceuticals Corporation. (2019). Trileptal (oxcarbazepine). *US Product Monograph*,
2512. Novo Nordisk Canada Inc. (2015). GlucoNorm (repaglinide). *CA Product Monograph*,
2513. Novo Nordisk Canada Inc. (2017). Levemir (insulin detemir). *CA Product Monograph*,
2514. Novo Nordisk Canada Inc. (2018). NovoRapid (insulin aspart). *CA Product Monograph*,

2515. Novo Nordisk Canada Inc. (2018). Ozempic (semaglutide). *CA Product Monograph*,
2516. Novo Nordisk Inc. (2017). Ozempic (semaglutide). *US Product Monograph*,
2517. Novo Nordisk Inc. (2018). Victoza (liraglutide). *US Product Monograph*,
2518. Novo Nordisk Inc. (2019). Levemir (insulin detemir). *US Product Monograph*,
2519. Noyes, R., Jr., Moroz, G., Davidson, J. R., Liebowitz, M. R., Davidson, A., Siegel, J., . . . Uhlenhuth, E. H. (1997). Moclobemide in social phobia: a controlled dose-response trial. *J Clin Psychopharmacol*, 17(4), 247-254.
2520. Nozawa, M., Ohnuma, T., Matsubara, Y., Sakai, Y., Hatano, T., Hanzawa, R., . . . Arai, H. (2008). The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). *Ther Drug Monit*, 30(1), 35-40.
2521. Nozawa, T., Taguchi, M., Tahara, K., Hashimoto, Y., Igarashi, N., Nonomura, M., . . . Inoue, H. (2005). Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. *J Cardiovasc Pharmacol*, 46(5), 713-720.
2522. Nurmi, E., Spilman, S., Whelan, F., Scahill, L., Aman, M., McDougale, C., . . . Sukhodolsky, D. (2013). Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. *Translational psychiatry*, 3(6), e274.
2523. Nurmi, E. L., Spilman, S. L., Whelan, F., Scahill, L. L., Aman, M. G., McDougale, C. J., . . . McCracken, J. T. (2013). Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. *Transl Psychiatry*, 3, e274.
2524. Nussbaum, A., & Stroup, T. S. (2008). Paliperidone for schizophrenia. *Cochrane Database Syst Rev*(2), CD006369.
2525. Nussbaum, A. M., & Stroup, T. S. (2012). Paliperidone palmitate for schizophrenia. *Cochrane Database Syst Rev*(6), CD008296.
2526. Nyssen, O. P., McNicholl, A. G., Megraud, F., Savarino, V., Oderda, G., Fallone, C. A., . . . Gisbert, J. P. (2016). Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. *Cochrane Database Syst Rev*(6), Cd009034.
2527. O'Byrne, P. M., Barnes, P. J., Rodriguez-Roisin, R., Runnerstrom, E., Sandstrom, T., Svensson, K., & Tattersfield, A. (2001). Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. *Am J Respir Crit Care Med*, 164(8 Pt 1), 1392-1397.
2528. O'Connell, N. E., Wand, B. M., McAuley, J., Marston, L., & Moseley, G. L. (2013). Interventions for treating pain and disability in adults with complex regional pain syndrome. *Cochrane Database Syst Rev*, 4, CD009416.
2529. Odahara, S., Uchiyama, K., Kubota, T., Ito, Z., Takami, S., Kobayashi, H., . . . Ohkusa, T. (2015). A prospective study evaluating metabolic capacity of thiopurine and associated adverse reactions in Japanese patients with inflammatory bowel disease (IBD). *PLoS One*, 10(9), e0137798.
2530. Odan Laboratories Ltd. (2016). Cholestyramine. *CA Product Monograph*,
2531. Odan Laboratories Ltd. (2016). Colchicine. *CA Product Monograph*,

2532. Odan Laboratories Ltd. (2018). Suprax (cefixime). *CA Product Monograph*,
2533. O'Dell, J. R., Leff, R., Paulsen, G., Haire, C., Mallek, J., Eckhoff, P. J., . . . Moore, G. (2002). Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, *46*(5), 1164-1170.
2534. O'Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., . . . Voduc, N. (2007). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. *Can Respir J*, *14 Suppl B*, 5b-32b.
2535. O'Donnell, D. E., Hernandez, P., Kaplan, A., Aaron, S., Bourbeau, J., Marciniuk, D., . . . Voduc, N. (2008). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. *Can Respir J*, *15 Suppl A*, 1A-8A.
2536. O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Jr., Chung, M. K., de Lemos, J. A., . . . Yancy, C. W. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*, *61*(4), e78-140.
2537. Ogusu, N., Saruwatari, J., Nakashima, H., Noai, M., Nishimura, M., Deguchi, M., . . . Nakagaswa, K. (2014). Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of gamma-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. *PLoS One*, *9*(11), e111066.
2538. Oguzhanoglu, A., Sahiner, T., Kurt, T., & Akalin, O. (1999). Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. *Cephalalgia*, *19*(5), 531-532.
2539. Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L., & Hegele, R. A. (2007). Genetic determinants of statin intolerance. *Lipids Health Dis*, *6*, 7.
2540. Oh, J. H., Choi, M. G., Dong, M. S., Park, J. M., Paik, C. N., Cho, Y. K., . . . Chung, I. S. (2007). Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. *J Gastroenterol Hepatol*, *22*(9), 1429-1434.
2541. Ohara, K., Nagai, M., Tani, K., Nakamura, Y., Ino, A., & Ohara, K. (1998). Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. *Psychiatry Res*, *81*(2), 117-123.
2542. Ohara, K., Nagai, M., Tani, K., Nakamura, Y., Ino, A., & Ohara, K. (1998). Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. *Psychiatry Research*, *81*(2), 117-123.
2543. Ohara, K., Tanabu, S., Ishibashi, K., Ikemoto, K., Yoshida, K., & Shibuya, H. (2003). CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. *Eur J Clin Pharmacol*, *58*(10), 659-661.
2544. Ohara, K., Tanabu, S., Yoshida, K., Ishibashi, K., Ikemoto, K., & Shibuya, H. (2003). Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. *Prog Neuropsychopharmacol Biol Psychiatry*, *27*(6), 945-949.

2545. Ohkusa, T., Maekawa, T., Arakawa, T., Nakajima, M., Fujimoto, K., Hoshino, E., . . . Sato, N. (2005). Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. *Aliment Pharmacol Ther*, *21*(11), 1331-1339.
2546. Ohnuma, T., Shibata, N., Matsubara, Y., & Arai, H. (2003). Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. *Br J Clin Pharmacol*, *56*(3), 315-320.
2547. Oishi, M. L., & Xing, S. (2013). Atrial fibrillation: management strategies in the emergency department. *Emerg Med Pract*, *15*(2), 1-26; quiz 27.
2548. Oka, Y., Okamoto, K., Kawashita, N., Shirakuni, Y., & Takagi, T. (2014). Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. *Biol Pharm Bull*, *37*(6), 947-953.
2549. Okudaira, K., Furuta, T., Shirai, N., Sugimoto, M., & Miura, S. (2005). Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. *Aliment Pharmacol Ther*, *21*(4), 491-497.
2550. Olde Engberink, R. H., Frenkel, W. J., van den Bogaard, B., Brewster, L. M., Vogt, L., & van den Born, B. J. (2015). Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. *Hypertension*, *65*(5), 1033-1040.
2551. Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., . . . Wallentin, L. (2011). Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J*, *32*(22), 2781-2789.
2552. Oledzki, S., Kornacewicz-Jach, Z., Safranow, K., Kiedrowicz, R., Gawronska-Szklarz, B., Jastrzebska, M., & Goracy, J. (2017). Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. *Eur J Clin Pharmacol*.
2553. Olerud, B., Gustavsson, C. L., & Furberg, B. (1986). Nadolol and propranolol in migraine management. *Headache*, *26*(10), 490-493.
2554. Olesen, J., Bousser, M. G., Diener, H. C., Dodick, D., First, M., Goadsby, P. J., . . . Steiner, T. J. (2006). New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia*, *26*.
2555. Olfson, M., Marcus, S. C., Zhang, H. F., & Wan, G. J. (2007). Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. *J Manag Care Pharm*, *13*(7), 570-577.
2556. Olmos, J. M., Zarrabeitia, M. T., Hernandez, J. L., Sanudo, C., Gonzalez-Macias, J., & Riancho, J. A. (2012). Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates. *Pharmacogenomics J*, *12*(3), 227-232.
2557. Olmos, M. (1997). Lansoprazole vs. omeprazole in speed of duo-denal ulcer healing. *Gut*, *41*(Suppl. 3):, A97.

2558. Omori, I. M., & Wang, J. (2009). Sulpiride versus placebo for schizophrenia. *Cochrane Database Syst Rev*(2), CD007811.
2559. Oncken, C., Dornelas, E., Greene, J., Sankey, H., Glasmann, A., Feinn, R., & Kranzler, H. R. (2008). Nicotine gum for pregnant smokers: a randomized controlled trial. *Obstet Gynecol*, *112*(4), 859-867.
2560. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C. B., . . . Reeves, K. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med*, *166*(15), 1571-1577.
2561. Oosterhuis, M., Van De Kraats, G., & Tenback, D. (2007). Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient. *Am J Psychiatry*, *164*(1), 175.
2562. Oparil, S., Cushman, W. C., & Lederle, F. A. (2014). Chlorthalidone versus hydrochlorothiazide in hypertension treatment: do we have the evidence to decide? *Am J Kidney Dis*, *63*(3), 387-389.
2563. Orr, W. C., Goodrich, S., Wright, S., Shepherd, K., & Mellow, M. (2012). The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. *Neurogastroenterol Motil*, *24*(6), 553-559, e253.
2564. Ortega-Vazquez, A., Dorado, P., Fricke-Galindo, I., Jung-Cook, H., Monroy-Jaramillo, N., Martinez-Juarez, I. E., . . . Lopez-Lopez, M. (2016). CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. *Pharmacogenomics J*, *16*(3), 286-292.
2565. Osadchy, A., Kazmin, A., & Koren, G. (2009). Nicotine replacement therapy during pregnancy: recommended or not recommended? *J Obstet Gynaecol Can*, *31*(8), 744-747.
2566. Oshima, T., Kudo, T., & Ikeda, K. (2001). Point mutation of the mitochondrial genome in Japanese deaf-mutism. *ORL J Otorhinolaryngol Relat Spec*, *63*(6), 329-332.
2567. Oslin, D. W., Leong, S. H., Lynch, K. G., Berrettini, W., O'Brien, C. P., Gordon, A. J., & Rukstalis, M. (2015). Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. *JAMA Psychiatry*, *72*(5), 430-437.
2568. Ostacher, M. J., Suppes, T., Swann, A. C., Eudicone, J. M., Landsberg, W., Baker, R. A., & Carlson, B. X. (2015). Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. *Int J Bipolar Disord*, *3*, 11.
2569. O'Toole, L., Stewart, M., Padfield, P., & Channer, K. (1998). Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. *J Cardiovasc Pharmacol*, *32*(6), 988-994.
2570. Otsuka America Pharmaceutical Inc. (2013). Abilify Maintena (aripiprazole depot). *US Product Monograph*,
2571. Otsuka America Pharmaceutical Inc. (2015). Pletal (cilostazol) *US Product Monograph*,
2572. Otsuka America Pharmaceutical Inc. (2017). Abilify (aripiprazole). *US Product Monograph*,
2573. Otsuka Canada Pharmaceutical Inc. (2016). Abilify Maintena (aripiprazole depot). *CA Product Monograph*,

2574. Ottaviani, S., Molto, A., Ea, H. K., Neveu, S., Gill, G., Brunier, L., . . . Dieude, P. (2013). Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. *Arthritis Res Ther*, *15*(5), R123.
2575. Outhred, T., Das, P., Dobson-Stone, C., Felmingham, K. L., Bryant, R. A., Nathan, P. J., . . . Kemp, A. H. (2016). Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study. *J Affect Disord*, *196*, 11-19.
2576. Ouyang, A. J., Lv, Y. N., Zhong, H. L., Wen, J. H., Wei, X. H., Peng, H. W., . . . Liu, L. L. (2015). Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. *Am J Cardiol*, *115*(7), 901-906.
2577. Ozaki, N., Otsubo, T., Kato, M., Higuchi, T., Ono, H., & Kamijima, K. (2015). Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. *Psychiatry Clin Neurosci*, *69*(1), 34-42.
2578. Ozdemir, V., Tyndale, R. F., Reed, K., Herrmann, N., Sellers, E. M., Kalow, W., & Naranjo, C. A. (1999). Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. *J Clin Psychopharmacol*, *19*(5), 472-475.
2579. Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., . . . Nakamura, Y. (2011). Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet*, *20*(5), 1034-1041.
2580. Ozyalcin, S. N., Talu, G. K., Kiziltan, E., Yucel, B., Ertas, M., & Disci, R. (2005). The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache*, *45*(2), 144-152.
2581. Paar, W. D., Poche, S., Gerloff, J., & Dengler, H. J. (1997). Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. *Eur J Clin Pharmacol*, *53*(3-4), 235-239.
2582. Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., . . . Vieta, E. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. *Am J Psychiatry*, *170*(11), 1249-1262.
2583. Pace, F., Tonini, M., Pallotta, S., Molteni, P., & Porro, G. B. (2007). Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. *Aliment Pharmacol Ther*, *26*(2), 195-204.
2584. Pachas, G. N., Cather, C., Pratt, S. A., Hoepfner, B., Nino, J., Carlini, S. V., . . . Evins, A. E. (2012). Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. *J Dual Diagn*, *8*(2), 117-125.
2585. Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med*, *334*(21), 1349-1355.
2586. Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., . . . DeMets, D. L. (2001). Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*, *344*(22), 1651-1658.

2587. Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J., Katus, H. A., Krum, H., . . . DeMets, D. L. (2002). Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation, 106*(17), 2194-2199.
2588. Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G., Horowitz, J. D., Massie, B. M., . . . Uretsky, B. F. (1999). Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation, 100*(23), 2312-2318.
2589. Paddock Laboratories LLC. (2018). Amiloride. *US Product Monograph*,
2590. Paddock, S., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J., . . . McMahon, F. J. (2007). Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. *Am J Psychiatry, 164*(8), 1181-1188.
2591. Padol, S., Yuan, Y., Thabane, M., Padol, I. T., & Hunt, R. H. (2006). The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. *Am J Gastroenterol, 101*(7), 1467-1475.
2592. Padwal, R., Gibson, P., & Tsuyuki, R. T. (2017). Hypertension. *Compendium of Therapeutic Choices*,
2593. Padyukov, L., Lampa, J., Heimbürger, M., Ernestam, S., Cederholm, T., Lundkvist, I., . . . Bratt, J. (2003). Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. *Ann Rheum Dis, 62*(6), 526-529.
2594. Pae, C. U., Seo, H. J., Lee, B. C., Seok, J. H., Jeon, H. J., Paik, J. W., . . . Lee, S. J. (2014). A meta-analysis comparing open-label versus placebo-controlled clinical trials for aripiprazole augmentation in the treatment of major depressive disorder: lessons and promises. *Psychiatry Investig, 11*(4), 371-379.
2595. Page, N. A., & Schroeder, W. S. (2007). Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. *Ann Pharmacother, 41*(1), 61-67.
2596. Paladin Labs Inc. (2016). Dexedrine (dextroamphetamine). *CA Product Monograph*,
2597. Paladin Labs Inc. (2016). Trandate (labetalol). *CA Product Monograph*,
2598. Paladin Labs Inc. (2017). Monurol (fosfomycin). *CA Product Monograph*,
2599. Palmer, C. N., Lipworth, B. J., Lee, S., Ismail, T., Macgregor, D. F., & Mukhopadhyay, S. (2006). Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. *Thorax, 61*(11), 940-944.
2600. Palmer, G. (2015). Complex regional pain syndrome. *Aust Prescr, 38*(3), 82-86.
2601. Palmer, R. H., Frank, W. O., & Karlstadt, R. (1990). Maintenance therapy of duodenal ulcer with H2-receptor antagonists--a meta-analysis. *Aliment Pharmacol Ther, 4*(3), 283-294.
2602. Palumbo, D. R., Sallee, F. R., Pelham, W. E., Jr., Bukstein, O. G., Daviss, W. B., & McDermott, M. P. (2008). Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. *J Am Acad Child Adolesc Psychiatry, 47*(2), 180-188.
2603. Pan, L., & Belpaire, F. M. (1999). In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. *Eur J Clin Pharmacol, 55*(8), 599-604.

2604. Pan, L., Vander Stichele, R., Rosseel, M. T., Berlo, J. A., De Schepper, N., & Belpaire, F. M. (1999). Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. *Ther Drug Monit*, 21(5), 489-497.
2605. Pan, X., Li, Y., Qiu, Y., Tang, Q., Qian, B., Yao, L., . . . Zhang, G. (2010). Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of *Helicobacter pylori* infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. *Clin Ther*, 32(12), 2003-2011.
2606. Pan, Y., Chen, W., Xu, Y., Yi, X., Han, Y., Yang, Q., . . . Wang, Y. (2017). Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. *Circulation*, 135(1), 21-33.
2607. Panagiotidis, G., Arthur, H. W., Lindh, J. D., Dahl, M. L., & Sjoqvist, F. (2007). Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. *Ther Drug Monit*, 29(4), 417-422.
2608. Panagiotou, O. A., Schuit, E., Munafo, M. R., Bennett, D. A., Bergen, A. W., & David, S. P. (2019). Smoking cessation pharmacotherapy based on genetically-informed biomarkers: what is the evidence? *Nicotine Tob Res*.
2609. Pande, A. C., Davidson, J. R., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., . . . Sutherland, S. M. (1999). Treatment of social phobia with gabapentin: a placebo-controlled study. *J Clin Psychopharmacol*, 19(4), 341-348.
2610. Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R., Pollack, M., Stein, M. B., . . . Werth, J. L. (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. *J Clin Psychopharmacol*, 24(2), 141-149.
2611. Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017). Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. *Curr Med Res Opin*, 33(4), 701-711.
2612. Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., . . . Scientific Advisory Council of Osteoporosis, C. (2010). 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ*, 182(17), 1864-1873.
2613. Papakostas, G. I., & Fava, M. (2006). A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. *Can J Psychiatry*, 51(12), 783-790.
2614. Papakostas, G. I., & Fava, M. (2007). A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. *Eur Neuropsychopharmacol*, 17(1), 32-36.
2615. Papakostas, G. I., Worthington, J. J., 3rd, Iosifescu, D. V., Kinrys, G., Burns, A. M., Fisher, L. B., . . . Fava, M. (2006). The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. *Depress Anxiety*, 23(3), 178-181.

2616. Par Pharmaceutical Inc. (2015). Accolate (zafirlukast). *US Product Monograph*,
2617. Pareek, A. K., Messerli, F. H., Chandurkar, N. B., Dharmadhikari, S. K., Godbole, A. V., Kshirsagar, P. P., . . . Kumbha, M. M. (2016). Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. *J Am Coll Cardiol*, 67(4), 379-389.
2618. Parikh, S. V. (2016). Bipolar Disorder. In B. Jovaisas (Ed.), *RxTx* (
2619. Parikh, S. V. (2018). Bipolar Disorder. In *RxTx* (
2620. Park, B. L., Kim, T. H., Kim, J. H., Bae, J. S., Pasaje, C. F., Cheong, H. S., . . . Park, C. S. (2013). Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. *Hum Genet*, 132(3), 313-321.
2621. Park, H. J., Kim, Y. J., Kim, D. H., Kim, J., Park, K. H., Park, J. W., & Lee, J. H. (2016). HLA allele frequencies in 5802 Koreans: Varied allele types associated with SJS/TEN according to culprit drugs. *Yonsei Med J*, 57(1), 118-126.
2622. Park, H. S., Kim, S. H., Sampson, A. P., Lee, K. W., & Park, C. S. (2004). The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma. *J Allergy Clin Immunol*, 114(3), 688-689.
2623. Park, J. Y., Shon, J. H., Kim, K. A., Jung, H. J., Shim, J. C., Yoon, Y. R., . . . Shin, J. G. (2006). Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. *J Clin Psychopharmacol*, 26(2), 135-142.
2624. Park, J.-Y., Shon, J.-H., Kim, K.-A., Jung, H.-J., Shim, J.-C., Yoon, Y.-R., . . . Shin, J.-G. (2006). Combined effects of itraconazole and CYP2D6* 10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. *Journal of clinical psychopharmacology*, 26(2), 135-142.
2625. Park, S. M., Kim, J. S., Kim, B. W., Ji, J. S., & Choi, H. (2017). Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. *J Gastroenterol Hepatol*, 32(3), 589-594.
2626. Parke-Davis Div of Pfizer Inc. (2007). Nardil (phenelzine). *US Product Monograph*,
2627. Parke-Davis Div of Pfizer Inc. (2017). Gemfibrozil. *FDA Product Monograph*,
2628. Parke-Davis Div of Pfizer Inc. (2017). Neurontin (gabapentin). *US Product Monograph*,
2629. Parke-Davis Div of Pfizer Inc. (2018). Accupril (quinapril). *US Product Monograph*,
2630. Parke-Davis Div of Pfizer Inc. (2018). Lipitor (atorvastatin). *US Product Monograph*,
2631. Parke-Davis Div of Pfizer Inc. (2018). Lyrica (pregabalin). *US Product Monograph*,
2632. Parke-Davis Div of Pfizer Inc. (2018). Zaronin (ethosuximide). *US Product Monograph*,
2633. Parving, H. H., Jacobsen, P., Tarnow, L., Rossing, P., Lecerf, L., Poirier, O., & Cambien, F. (1996). Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. *BMJ*, 313(7057), 591-594.
2634. Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. *Clin Pharmacol Ther*, 82(6), 726-733.

2635. Pasanen, M. K., Miettinen, T. A., Gylling, H., Neuvonen, P. J., & Niemi, M. (2008). Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. *Pharmacogenet Genomics*, *18*(10), 921-926.
2636. Pascual, J., Rivas, M. T., & Leira, R. (2007). Testing the combination beta-blocker plus topiramate in refractory migraine. *Acta Neurol Scand*, *115*(2), 81-83.
2637. Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. *Ther Adv Psychopharmacol*, *6*(2), 99-144.
2638. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., . . . Califf, R. M. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*, *365*(10), 883-891.
2639. Paterson, R., Douglas, C., Hallmayer, J., Hagan, M., & Krupenia, Z. (1999). A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. *Aust N Z J Psychiatry*, *33*(4), 494-502.
2640. Patheon Inc. (2019). WelChol (colesevelam hydrochloride) *CA Product Monograph*.
2641. Patino-Garcia, A., Zalacain, M., Marrodan, L., San-Julian, M., & Sierrasesumaga, L. (2009). Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. *J Pediatr*, *154*(5), 688-693.
2642. Patkar, A. A., Pae, C. U., Vohringer, P. A., Mauer, S., Narasimhan, M., Dalley, S., . . . Ghaemi, S. N. (2015). A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. *J Clin Psychopharmacol*, *35*(3), 319-323.
2643. Patnode, C. D., Henderson, J. T., Thompson, J. H., Senger, C. A., Fortmann, S. P., & Whitlock, E. P. (2015). In *Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force*. Rockville (MD).
2644. Patnode, C. D., O'Connor, E., Whitlock, E. P., Perdue, L. A., Soh, C., & Hollis, J. (2013). Primary care-relevant interventions for tobacco use prevention and cessation in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med*, *158*(4), 253-260.
2645. Paulus, H. E., Schlosstein, L. H., Godfrey, R. G., Klinenberg, J. R., & Bluestone, R. (1974). Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. *Arthritis Rheum*, *17*(5), 609-614.
2646. Pauwels, R. A., Pedersen, S., Busse, W. W., Tan, W. C., Chen, Y. Z., Ohlsson, S. V., . . . O'Byrne, P. M. (2003). Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. *Lancet*, *361*(9363), 1071-1076.
2647. Payakachat, N., Summers, K. H., & Barbuto, J. P. (2006). A comparison of clinical practice guidelines in the initial pharmacological management of new-onset epilepsy in adults. *J Manag Care Pharm*, *12*(1), 55-60.
2648. Payton, C. D., Fox, J. G., Pauleau, N. F., Boulton-Jones, J. M., Ioannides, C., Johnston, A., & Thomas, P. (1987). The single dose pharmacokinetics of bisoprolol (10 mg) in renal

- insufficiency: the clinical significance of balanced clearance. *Eur Heart J*, 8 Suppl M, 15-22.
2649. Pearlman, D., Qaqundah, P., Matz, J., Yancey, S. W., Stempel, D. A., & Ortega, H. G. (2009). Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. *Pediatr Pulmonol*, 44(5), 429-435.
2650. Pearson, E. R., Donnelly, L. A., Kimber, C., Whitley, A., Doney, A. S., McCarthy, M. I., . . . Palmer, C. N. (2007). Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. *Diabetes*, 56(8), 2178-2182.
2651. Pedersen, A. J. T., Stage, T. B., Glintborg, D., Andersen, M., & Christensen, M. M. H. (2018). The pharmacogenetics of metformin in women with polycystic ovary syndrome: a randomized trial. *Basic Clin Pharmacol Toxicol*, 122(2), 239-244.
2652. Pedersen, T. R. (1983). The Norwegian Multicenter Study of Timolol after Myocardial Infarction. *Circulation*, 67(6 Pt 2), 149-53.
2653. Peikert, A., Wilimzig, C., & Kohne-Volland, R. (1996). Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. *Cephalalgia*, 16(4), 257-263.
2654. Pekarek, B., Osher, L., Buck, S., & Bowen, M. (2011). Intra-articular corticosteroid injections: a critical literature review with up-to-date findings. *Foot (Edinb)*, 21(2), 66-70.
2655. Pelletier, J. P., Martel-Pelletier, J., Rannou, F., & Cooper, C. (2016). Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. *Semin Arthritis Rheum*, 45(4 Suppl), S22-27.
2656. Pendopharm Division of Pharmascience Inc. (2012). Xylac (loxapine). *CA Product Monograph*,
2657. Pendopharm Division of Pharmascience Inc. (2014). Axid (nizatidine). *CA Product Monograph*,
2658. Pendopharm Division of Pharmascience Inc. (2014). Metonia (metoclopramide). *CA Product Monograph*,
2659. Pendopharm Division of Pharmascience Inc. (2016). Toloxin (digoxin). *CA Product Monograph*,
2660. Penenberg, D., Chung, M., Walmsley, P., & Vashi, V. (2000). The effects of hepatic impairment on the pharmacokinetics of doxazosin. *J Clin Pharmacol*, 40(1), 67-73.
2661. Pengo, V., Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., . . . Manotti, C. (2011). Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). *Thromb Haemost*, 106(5), 868-876.
2662. Penn Medicine. (2018). Antimicrobial Dosing in Renal Impairment. In *University of Pennsylvania Health System*. Philadelphia, PA: The Trustees of the University of Pennsylvania
2663. Perahia, D. G., Pritchett, Y. L., Kajdasz, D. K., Bauer, M., Jain, R., Russell, J. M., . . . Thase, M. E. (2008). A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. *J Psychiatr Res*, 42(1), 22-34.

2664. Perahia, D. G., Quail, D., Desai, D., Corruble, E., & Fava, M. (2008). Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. *J Clin Psychiatry, 69*(1), 95-105.
2665. Perez, M. I., Musini, V. M., & Wright, J. M. (2009). Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. *Cochrane Database Syst Rev*(4), CD006743.
2666. Perez, R. S., Zollinger, P. E., Dijkstra, P. U., Thomassen-Hilgersom, I. L., Zuurmond, W. W., Rosenbrand, K. C., & Geertzen, J. H. (2010). Evidence based guidelines for complex regional pain syndrome type 1. *BMC Neurol, 10*, 20.
2667. Perez, R. S., Zuurmond, W. W., Bezemer, P. D., Kuik, D. J., van Loenen, A. C., de Lange, J. J., & Zuidhof, A. J. (2003). The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study. *Pain, 102*(3), 297-307.
2668. Perez, V., Salavert, A., Espadaler, J., Tuson, M., Saiz-Ruiz, J., Saez-Navarro, C., . . . Menchon, J. M. (2017). Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. *BMC Psychiatry, 17*(1), 250.
2669. Perez-Ruiz, F., Calabozo, M., Fernandez-Lopez, M. J., Herrero-Beites, A., Ruiz-Lucea, E., Garcia-Erauskin, G., . . . Alonso-Ruiz, A. (1999). Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. *J Clin Rheumatol, 5*(2), 49-55.
2670. Perez-Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero-Beites, A. M., & Ruibal, A. (2002). Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. *Arthritis Rheum, 47*(4), 356-360.
2671. Perez-Ruiz, F., Sundry, J. S., Miner, J. N., Cravets, M., & Storgard, C. (2016). Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. *Ann Rheum Dis, 75*(6), 1074-1080.
2672. Perkins, K. A., Lerman, C., Mercincavage, M., Fonte, C. A., & Briski, J. L. (2009). Nicotinic acetylcholine receptor beta2 subunit (CHRN2) gene and short-term ability to quit smoking in response to nicotine patch. *Cancer Epidemiol Biomarkers Prev, 18*(10), 2608-2612.
2673. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., . . . Investigators, C. T. (2019). Canagliflozin and renal outcomes in Type 2 Diabetes and nephropathy. *N Engl J Med, 380*(24), 2295-2306.
2674. Perroud, N., Bondolfi, G., Uher, R., Gex-Fabry, M., Aubry, J. M., Bertschy, G., . . . Kosel, M. (2011). Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. *Pharmacogenomics, 12*(3), 365-377.
2675. Persson, K., Sjostrom, S., Sigurdardottir, I., Molnar, V., Hammarlund-Udenaes, M., & Rane, A. (1995). Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. *Br J Clin Pharmacol, 39*(2), 182-186.

2676. Peters, E. J., Slager, S. L., Jenkins, G. D., Reinalda, M. S., Garriock, H. A., Shyn, S. I., . . . Hamilton, S. P. (2009). Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. *Pharmacogenet Genomics, 19*(1), 1-10.
2677. Peters, R. J., Mehta, S. R., Fox, K. A., Zhao, F., Lewis, B. S., Kopecky, S. L., . . . Yusuf, S. (2003). Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. *Circulation, 108*(14), 1682-1687.
2678. Peura, D. A., Kovacs, T. O., Metz, D. C., Siepman, N., Pilmer, B. L., & Talley, N. J. (2004). Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. *Am J Med, 116*(11), 740-748.
2679. Pfaffenrath, V., Diener, H. C., Fischer, M., Friede, M., & Henneicke-von Zepelin, H. H. (2002). The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. *Cephalalgia, 22*(7), 523-532.
2680. Pfaffenrath, V., Wessely, P., Meyer, C., Isler, H. R., Evers, S., Grotemeyer, K. H., . . . Fischer, M. (1996). Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. *Cephalalgia, 16*(6), 436-440.
2681. Pfeffer, M. A., Braunwald, E., Moye, L. A., Basta, L., Brown, E. J., Jr., Cuddy, T. E., . . . et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med, 327*(10), 669-677.
2682. Pfeffer, M. A., McMurray, J. J., Velazquez, E. J., Rouleau, J. L., Kober, L., Maggioni, A. P., . . . Califf, R. M. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med, 349*(20), 1893-1906.
2683. Pfizer Canada Inc. (2012). Inderal-LA (propranolol). *CA Product Monograph,*
2684. Pfizer Canada Inc. (2013). Colestid (colestipol). *CA Product Monograph,*
2685. Pfizer Canada Inc. (2013). Relpax (eletriptan hydrobromide). *CA Product Monograph,*
2686. Pfizer Canada Inc. (2013). Salazpyrin (sulfasalazine). *CA Product Monograph,*
2687. Pfizer Canada Inc. (2015). Aldactone (spironolactone). *CA Product Monograph,*
2688. Pfizer Canada Inc. (2015). Depo-Medrol (methylprednisolone). *CA Product Monograph,*
2689. Pfizer Canada Inc. (2015). Solu-Medrol (methylprednisolone). *CA Product Monograph,*
2690. Pfizer Canada Inc. (2016). Inderal-LA (propranolol). *CA Product Monograph,*
2691. Pfizer Canada Inc. (2016). Inspra (eplerenone). *CA Product Monograph,*
2692. Pfizer Canada Inc. (2016). Lipitor (atorvastatin). *CA Product Monograph,*
2693. Pfizer Canada Inc. (2016). Propranolol. *CA Product Monograph,*
2694. Pfizer Canada Inc. (2016). Zeldox (ziprasidone). *CA Product Monograph,*
2695. Pfizer Canada Inc. (2017). Arthrotec (diclofenac / misoprostol). *CA Product Monograph,*
2696. Pfizer Canada Inc. (2017). Cardura (doxazosin mesylate). *CA Product Monograph,*
2697. Pfizer Canada Inc. (2017). Celebrex (celecoxib). *CA Product Monograph,*
2698. Pfizer Canada Inc. (2017). Celecoxib. *CA Product Monograph,*
2699. Pfizer Canada Inc. (2017). Champix (varenicline). *CA Product Monograph,*
2700. Pfizer Canada Inc. (2017). Eryc (erythromycin delayed release). *CA Product Monograph,*
2701. Pfizer Canada Inc. (2017). Lipitor (atorvastatin). *CA Product Monograph,*

2702. Pfizer Canada Inc. (2017). Methotrexate. *CA Product Monograph*,
2703. Pfizer Canada Inc. (2017). Norvasc (amlodipine besylate). *CA Product Monograph*,
2704. Pfizer Canada Inc. (2017). Zithromax (azithromycin). *CA Product Monograph*,
2705. Pfizer Canada Inc. (2018). Depo-Medrol (methylprednisolone). *CA Product Monograph*,
2706. Pfizer Canada Inc. (2018). Effexor XR (venlafaxine). *CA Product Monograph*,
2707. Pfizer Canada Inc. (2018). Eliquis (apixaban). *CA Product Monograph*,
2708. Pfizer Canada Inc. (2018). Mycobutin (rifabutin). *CA Product Monograph*,
2709. Pfizer Canada Inc. (2018). Neurontin (gabapentin). *CA Product Monograph*,
2710. Pfizer Canada Inc. (2018). Zoloft (sertraline). *CA Product Monograph*,
2711. Pfizer Canada ULC. (2011). Eliquis (apixaban). *CA Product Monograph*,
2712. Pfizer Canada ULC. (2019). Celebrex (celecoxib). *CA Product Monograph*,
2713. Pfizer Canada ULC. (2019). Lyrica (pregabalin). *CA Product Monograph*,
2714. Pfizer Consumer Healthcare. (2017). Advil (ibuprofen). *CA Product Monograph*,
2715. Pfizer Inc. (2016). Ansaid (flurbiprofen) *US Product Monograph*,
2716. Pfizer Inc. (2016). Feldene (piroxicam). *US Product Monograph*,
2717. Pfizer Inc. (2018). Flector (diclofenac epolamine). *US Product Monograph*,
2718. Pfizer Inc. (2019). AXID AR (nizatidine). *US Product Monograph*,
2719. Pfizer Laboratories Div Pfizer Inc. (2013). Corgard (nadolol). *US Product Monograph*,
2720. Pfizer Laboratories Div Pfizer Inc. (2017). Feldene (piroxicam). *US Product Monograph*,
2721. Pfizer Laboratories Div Pfizer Inc. (2018). Altace (ramipril). *US Product Monograph*,
2722. Pfizer Laboratories Div Pfizer Inc. (2018). Chantix (varenicline). *US Product Monograph*,
2723. Pfizer Laboratories Div Pfizer Inc. (2018). Norvasc (amlodipine besylate). *US Product Monograph*,
2724. Pfizer Laboratories Div Pfizer Inc. (2018). Zithromax (azithromycin). *US Product Monograph*,
2725. Pflieger, M., Winslow, B. T., Mills, K., & Dauber, I. M. (2011). Medical management of stable coronary artery disease. *Am Fam Physician*, 83(7), 819-826.
2726. Phani, N. M., Vohra, M., Adhikari, P., Nagri, S. K., Shashikiran, U., D'Souza, S. C., . . . Rai, P. S. (2017). Genetic variants identified from GWAS for predisposition to Type 2 Diabetes predict sulfonylurea drug response. *Curr Mol Med*, 17(8), 580-586.
2727. Pharmacia and Upjohn Company LLC. (2018). Azulfidine EN-tabs (sulfasalazine). *US Product Monograph*,
2728. Pharmacia and Upjohn Company LLC. (2018). Depo-Medrol (methylprednisolone). *US Product Monograph*,
2729. Pharmacia and Upjohn Company LLC. (2018). Glynase (glyburide). *US Product Monograph*,
2730. Pharmacia and Upjohn Company LLC. (2018). Mycobutin (rifabutin). *US Product Monograph*,
2731. Pharmacia and Upjohn Company LLC. (2018). Nicotrol inhaler (nicotine). *US Product Monograph*,
2732. Pharmascience Inc. (2016). pms-Lovastatin. *CA Product Monograph*,
2733. Pharmascience Inc. (2017). Olestyr (cholestyramine). *CA Product Monograph*,

2734. Pharmascience Inc. (2017). pms-Quinapril (quinapril hydrochloride). *CA Product Monograph*,
2735. Pharmascience Inc. (2018). pms-Trandolapril. *CA Product Monograph*,
2736. PharmGKB. (2016). Nitrofurantoin. Retrieved from <https://www.pharmgkb.org>
2737. PharmGKB. (2016). Norfloxacin. Retrieved from <https://www.pharmgkb.org>
2738. PharmGKB. (2016). Simvastatin. Retrieved from <https://www.pharmgkb.org>
2739. PharmGKB. (2016). Trimethoprim. Retrieved from <https://www.pharmgkb.org>
2740. PharmGKB. (2017). Clinical Annotation for rs2231142 (ABCG2), rosuvastatin, Hypercholesterolemia and Myocardial Infarction (level 2B Efficacy). Retrieved from <https://www.pharmgkb.org>
2741. PharmGKB. (2017). Omalizumab. Retrieved from <https://www.pharmgkb.org>
2742. PharmGKB. (2017). Theophylline. Retrieved from <https://www.pharmgkb.org>
2743. PharmGKB. (2017). Tiotropium. Retrieved from <https://www.pharmgkb.org>
2744. Pheasant, H., Bursk, A., Goldfarb, J., Azen, S. P., Weiss, J. N., & Borelli, L. (1983). Amitriptyline and chronic low-back pain. A randomized double-blind crossover study. *Spine (Phila Pa 1976)*, 8(5), 552-557.
2745. Phillips, E. J., Sukasem, C., Whirl-Carrillo, M., Muller, D. J., Dunnenberger, H. M., Chantratita, W., . . . Pirmohamed, M. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. *Clin Pharmacol Ther*, 103(4), 574-581.
2746. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. *Jama*, 286(18), 2270-2279.
2747. Phillips, M. E., Eastwood, J. B., Curtis, J. R., Gower, P. C., & De Wardener, H. E. (1974). Tetracycline poisoning in renal failure. *Br Med J*, 2(5911), 149-151.
2748. Phung, O. J., Scholle, J. M., Talwar, M., & Coleman, C. I. (2010). Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. *Jama*, 303(14), 1410-1418.
2749. Phupong, V., & Hanprasertpong, T. (2015). Interventions for heartburn in pregnancy. *Cochrane Database Syst Rev*(9), Cd011379.
2750. Physicians Total Care Inc. (2012). Foradil (formoterol fumarate). *US Product Monograph*,
2751. Pidlich, J., Cichini, G. M., Reinisch, W., Peck-Radosavljevic, M., & Renner, F. (1997). Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. *Acta Med Austriaca*, 24(1), 15-18.
2752. Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., . . . Zamorano, J. L. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Eur J Prev Cardiol*, 23(11), NP1-NP96.
2753. Pilotto, A., Seripa, D., Franceschi, M., Scarcelli, C., Colaizzo, D., Grandone, E., . . . Dallapiccola, B. (2007). Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. *Gastroenterology*, 133(2), 465-471.

2754. Pintarelli, G., Galvan, A., Pozzi, P., Noci, S., Pasetti, G., Sala, F., . . . Colombo, F. (2017). Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies. *Sci Rep*, 7(1), 16730.
2755. Pinto-Sanchez, M. I., Yuan, Y., Bercik, P., & Moayyedi, P. (2017). Proton pump inhibitors for functional dyspepsia. *Cochrane Database Syst Rev*, 3, Cd011194.
2756. Piper, M. E., Smith, S. S., Schlam, T. R., Fiore, M. C., Jorenby, D. E., Fraser, D., & Baker, T. B. (2009). A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry*, 66(11), 1253-1262.
2757. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., . . . Gatlin, M. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*, 348(14), 1309-1321.
2758. Pitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M., . . . Vincent, J. (2005). Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. *J Am Coll Cardiol*, 46(3), 425-431.
2759. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., . . . Wittes, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*, 341(10), 709-717.
2760. Piuizzi, N. S., Manner, P., & Levine, B. (2018). American academy of orthopaedic surgeons appropriate use criteria: Management of osteoarthritis of the hip. *J Am Acad Orthop Surg*, 26(20), e437-e441.
2761. Pliszka, S. R., Crismon, M. L., Hughes, C. W., Corners, C. K., Emslie, G. J., Jensen, P. S., . . . Lopez, M. (2006). The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*, 45(6), 642-657.
2762. Poiley, J., Steinberg, A. S., Choi, Y. J., Davis, C. S., Martin, R. L., McWherter, C. A., & Boudes, P. F. (2016). A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout. *Arthritis Rheumatol*, 68(8), 2027-2034.
2763. Pokorney, S. D., Gersh, B. J., Ahmad, A., Al-Khatib, S. M., Blank, M., Coylewright, M., . . . Granger, C. B. (2019). Stroke prevention in atrial fibrillation: Closing the gap. *Am Heart J*, 210, 29-38.
2764. Pol, S., Aerssens, J., Zeuzem, S., Andreone, P., Lawitz, E. J., Roberts, S., . . . Picchio, G. (2013). Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. *J Hepatol*, 58(5), 883-889.
2765. Poland, R. E., Lesser, I. M., Wan, Y. J., Gertsik, L., Yao, J., Raffel, L. J., . . . Myers, H. F. (2013). Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. *Life Sci*, 92(20-21), 967-970.
2766. Polisecki, E., Muallem, H., Maeda, N., Peter, I., Robertson, M., McMahan, A. D., . . . Prospective Study of Pravastatin in the Elderly at Risk, I. (2008). Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. *Atherosclerosis*, 200(1), 109-114.

2767. Pollack, M., Mangano, R., Entsuah, R., Tzanis, E., Simon, N. M., & Zhang, Y. (2007). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. *Psychopharmacology (Berl)*, *194*(2), 233-242.
2768. Pollack, M. H., Lepola, U., Koponen, H., Simon, N. M., Worthington, J. J., Emilien, G., . . . Gao, B. (2007). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. *Depress Anxiety*, *24*(1), 1-14.
2769. Pollack, M. H., Simon, N. M., Worthington, J. J., Doyle, A. L., Peters, P., Toshkov, F., & Otto, M. W. (2003). Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. *J Psychopharmacol*, *17*(3), 276-282.
2770. Pollak, K. I., Oncken, C. A., Lipkus, I. M., Lyna, P., Swamy, G. K., Pletsch, P. K., . . . Myers, E. R. (2007). Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. *Am J Prev Med*, *33*(4), 297-305.
2771. Pomares, X., Monton, C., Espasa, M., Casabon, J., Monso, E., & Gallego, M. (2011). Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. *Int J Chron Obstruct Pulmon Dis*, *6*, 449-456.
2772. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., . . . Document, R. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur J Heart Fail*, *18*(8), 891-975.
2773. Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di Lenarda, A., Hanrath, P., Komajda, M., . . . Skene, A. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*, *362*(9377), 7-13.
2774. Poolsup, N., Li Wan Po, A., & de Oliveira, I. R. (2000). Systematic overview of lithium treatment in acute mania. *J Clin Pharm Ther*, *25*(2), 139-156.
2775. Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., . . . Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. *Am J Psychiatry*, *176*(6), 428-438.
2776. Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., . . . Singh, J. B. (2019). Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression. *European Neuropsychopharmacology*, *29*, S35-S36.
2777. Porcelli, S., Fabbri, C., & Serretti, A. (2012). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. *Eur Neuropsychopharmacol*, *22*(4), 239-258.
2778. Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., . . . Mintz, J. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. *Br J Psychiatry*, *189*, 124-131.
2779. Postal, M., Palodeto, B., Sartorato, E. L., & Oliveira, C. A. (2009). C1494T mitochondrial DNA mutation, hearing loss, and aminoglycosides antibiotics. *Braz J Otorhinolaryngol*, *75*(6), 884-887.

2780. Postmus, I., Trompet, S., Deshmukh, H. A., Barnes, M. R., Li, X., Warren, H. R., . . . Caulfield, M. J. (2014). Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nat Commun*, *5*, 5068.
2781. Potkin, S. G., Cohen, M., & Panagides, J. (2007). Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. *J Clin Psychiatry*, *68*(10), 1492-1500.
2782. Poulsen, L., Arendt-Nielsen, L., Broesen, K., & Sindrup, S. H. (1996). The hypoalgesic effect of tramadol in relation to CYP2D6. *Clin Pharmacol Ther*, *60*(6), 636-644.
2783. Poulsen, L., Broesen, K., Arendt-Nielsen, L., Gram, L. F., Elbaek, K., & Sindrup, S. H. (1996). Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. *Eur J Clin Pharmacol*, *51*(3-4), 289-295.
2784. Poulsen, L., Riishede, L., Broesen, K., Clemensen, S., & Sindrup, S. H. (1998). Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. *Eur J Clin Pharmacol*, *54*(6), 451-454.
2785. Poulussen, F. C. P., Peters, B. J., Hua, K. H., Houthuizen, P., Grouls, R. J., & Deenen, M. J. (2019). The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population. *Pharmacogenet Genomics*, *29*(7), 179-182.
2786. Poweleit, E. A., Aldrich, S. L., Martin, L. J., Hahn, D., Strawn, J. R., & Ramsey, L. B. (2019). Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders. *J Child Adolesc Psychopharmacol*, *29*(5), 348-361.
2787. Powell, C., Milan, S. J., Dwan, K., Bax, L., & Walters, N. (2015). Mepolizumab versus placebo for asthma. *Cochrane Database Syst Rev*(7), CD010834.
2788. Pradalier, A., Serratrice, G., Collard, M., Hirsch, E., Feve, J., Masson, M., . . . et al. (1989). Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. *Cephalalgia*, *9*(4), 247-253.
2789. Prado, Y., Saavedra, N., Zambrano, T., Lagos, J., Rosales, A., & Salazar, L. A. (2015). SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. *Int J Mol Sci*, *16*(9), 20609-20619.
2790. Pragma Pharmaceuticals LLC. (2018). Desyrel (trazodone). *US Product Monograph*,
2791. Pragma Pharmaceuticals LLC. (2018). Keflex (cephalexin). *US Product Monograph*,
2792. Prasun, M. A. (2012). Providing best practice in the management of atrial fibrillation in the United States. *J Cardiovasc Nurs*, *27*(5), 445-456.
2793. Preskorn, S., Patroneva, A., Silman, H., Jiang, Q., Isler, J. A., Burczynski, M. E., . . . Nichols, A. I. (2009). Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. *J Clin Psychopharmacol*, *29*(1), 39-43.
2794. Preskorn, S. H. (2012). Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 3. Effects of renal and hepatic impairment. *J Psychiatr Pract*, *18*(6), 430-437.
2795. Prevention, E. N. f. S. a. T. (2012). European Smoking Cessation Guidelines.

2796. Price, A. L., & Marzani-Nissen, G. R. (2012). Bipolar disorders: a review. *Am Fam Physician, 85*(5), 483-493.
2797. Price, M. J., Berger, P. B., Teirstein, P. S., Tanguay, J. F., Angiolillo, D. J., Spriggs, D., . . . Topol, E. J. (2011). Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *Jama, 305*(11), 1097-1105.
2798. Prieto-Perez, R., Ochoa, D., Cabaleiro, T., Roman, M., Sanchez-Rojas, S. D., Talegon, M., & Abad-Santos, F. (2013). Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. *J Clin Pharmacol, 53*(12), 1261-1267.
2799. Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polisner, D. A., & Bostic, J. Q. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. *J Child Adolesc Psychopharmacol, 10*(3), 193-204.
2800. Prince, R., Sipos, A., Hossain, A., Syversen, U., Ish-Shalom, S., Marcinowska, E., . . . Mitrak, B. H. (2005). Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. *J Bone Miner Res, 20*(9), 1507-1513.
2801. Pringsheim, T., Davenport, W., Mackie, G., Worthington, I., Aube, M., Christie, S. N., . . . Becker, W. J. (2012). Canadian Headache Society guideline for migraine prophylaxis. *Can J Neurol Sci, 39*(2 Suppl 2), S1-59.
2802. Prochaska, J. J., Delucchi, K., & Hall, S. M. (2004). A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. *J Consult Clin Psychol, 72*(6), 1144-1156.
2803. Prochaska, J. J., & Hilton, J. F. (2012). Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. *BMJ, 344*, e2856.
2804. Procter & Gamble Manufacturing Company. (2018). PeptoBismol (bismuth subsalicylate). *US Product Monograph*,
2805. Prometheus Laboratories Inc. (2009). Trandate (labetalol hydrochloride). *US Product Monograph*,
2806. Province, M. A., Goetz, M. P., Brauch, H., Flockhart, D. A., Hebert, J. M., Whaley, R., . . . Klein, T. E. (2014). CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. *Clin Pharmacol Ther, 95*(2), 216-227.
2807. Pruteanu, A. I., Chauhan, B. F., Zhang, L., Prietsch, S. O., & Ducharme, F. M. (2014). Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. *Cochrane Database Syst Rev*(7), CD009878.
2808. Prystowsky, E. N., Camm, J., Lip, G. Y., Allessie, M., Bergmann, J. F., Breithardt, G., . . . Tamargo, J. (2010). The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. *J Cardiovasc Electrophysiol, 21*(8), 946-958.
2809. Prystowsky, E. N., & Padanilam, B. J. (2010). All's well that ends well, or is it? *J Am Coll Cardiol, 55*(21), 2317-2318.
2810. Pu, M., Zhang, Z., Xu, Z., Shi, Y., Geng, L., Yuan, Y., . . . Reynolds, G. P. (2013). Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their

- interactions with environmental stressors on antidepressant response. *Pharmacogenomics*, 14(3), 277-288.
2811. Puccetti, L., Ciani, F., & Auteri, A. (2010). Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. *Atherosclerosis*, 211(1), 28-29.
2812. Pulley, J. M., Denny, J. C., Peterson, J. F., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., . . . Roden, D. M. (2012). Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. *Clin Pharmacol Ther*, 92(1), 87-95.
2813. Puranik, Y. G., Birnbaum, A. K., Marino, S. E., Ahmed, G., Cloyd, J. C., Rempel, R. P., . . . Lamba, J. K. (2013). Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. *Pharmacogenomics*, 14(1), 35-45.
2814. Purdue Pharma. (2017). Biphentin (methylphenidate). *CA Product Monograph*,
2815. Purdue Pharma. (2017). Foquest (methylphenidate). *CA Product Monograph*,
2816. Purdue Pharma. (2017). Uniphyl (theophylline sr). *CA Product Monograph*,
2817. Purdue Pharma. (2018). Dilaudid (hydromorphone). *CA Product Monograph*,
2818. Purdue Pharma. (2018). MS-IR (morphine sulphate). *CA Product Monograph*,
2819. Purdue Pharma. (2018). Oxy-IR (oxycodone). *CA Product Monograph*,
2820. Purdue Pharma LP. (2016). Dilaudid (hydromorphone) *US Product Monograph*,
2821. Purdue Pharma LP. (2018). Oxycontin (oxycodone). *US Product Monograph*,
2822. Puska, P., Korhonen, H. J., Vartiainen, E., Urjanheimo, E. L., Gustavsson, G., & Westin, A. (1995). Combined use of nicotine patch and gum compared with gum alone in smoking cessation - a clinical trial in North Karelia. *Tobacco Control*, 4(3), 231-235.
2823. Putnam, G. P., O'Quinn, S., Bolden-Watson, C. P., Davis, R. L., Gutterman, D. L., & Fox, A. W. (1999). Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. *Cephalalgia*, 19(7), 668-675.
2824. Puymirat, E., Riant, E., Aissoui, N., Soria, A., Ducrocq, G., Coste, P., . . . Danchin, N. (2016). beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. *BMJ*, 354, i4801.
2825. Qaseem, A., Forcica, M. A., McLean, R. M., Denberg, T. D., & Clinical Guidelines Committee of the American College of, P. (2017). Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. *Ann Intern Med*, 166(11), 818-839.
2826. Qaseem, A., Harris, R. P., & Forcica, M. A. (2016). Management of acute and recurrent gout: A clinical practice guideline From the American College of Physicians. *Ann Intern Med*.
2827. Qin, X. P., Xie, H. G., Wang, W., He, N., Huang, S. L., Xu, Z. H., . . . Zhou, H. H. (1999). Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. *Clin Pharmacol Ther*, 66(6), 642-646.
2828. Quan, C., & Talley, N. J. (2002). Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. *Am J Gastroenterol*, 97(12), 2950-2961.

2829. Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. *Biol Psychiatry*, *68*(2), 156-162.
2830. Quraishi, S., & David, A. (2000). Depot haloperidol decanoate for schizophrenia. *Cochrane Database Syst Rev*(2), CD001361.
2831. Rabbie, R., Derry, S., & Moore, R. A. (2013). Ibuprofen with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*(4), Cd008039.
2832. Rabe, K. F. (2011). Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. *Br J Pharmacol*, *163*(1), 53-67.
2833. Rabe, K. F., Fabbri, L. M., Israel, E., Kogler, H., Riemann, K., Schmidt, H., . . . Vogelmeier, C. F. (2014). Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. *Lancet Respir Med*, *2*(1), 44-53.
2834. Rabeneck, L., Soucek, J., Wristers, K., Menke, T., Ambriz, E., Huang, I., & Wray, N. (2002). A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. *Am J Gastroenterol*, *97*(12), 3045-3051.
2835. Ragguett, R. M., Yim, S. J., Ho, P. T., & McIntyre, R. S. (2017). Efficacy of levomilnacipran extended release in treating major depressive disorder. *Expert Opin Pharmacother*, *18*(18), 2017-2024.
2836. Raghunath, A. S., Hungin, A. P., Wooff, D., & Childs, S. (2004). Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. *Aliment Pharmacol Ther*, *20*(7), 733-744.
2837. Rahme, E., Joseph, L., Kong, S. X., Watson, D. J., Pellissier, J. M., & LeLorier, J. (2001). Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs. *Pharmacoeconomics*, *19*(5 Pt 2), 577-588.
2838. Rainer, T. H., Cheng, C. H., Janssens, H. J., Man, C. Y., Tam, L. S., Choi, Y. F., . . . Graham, C. A. (2016). Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. *Ann Intern Med*, *164*(7), 464-471.
2839. Ram, F. S., Jardin, J. R., Atallah, A., Castro, A. A., Mazzini, R., Goldstein, R., . . . Cendon, S. (2005). Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Respir Med*, *99*(2), 135-144.
2840. Ram, F. S., Jones, P. W., Castro, A. A., De Brito, J. A., Atallah, A. N., Lacasse, Y., . . . Cendon, S. (2002). Oral theophylline for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(4), CD003902.
2841. Ramakumari, N., Indumathi, B., Katkam, S. K., & Kutala, V. K. (2018). Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. *Indian Heart J*, *70 Suppl 3*, S120-S125.
2842. Ramanuj, P., Ferenchick, E. K., & Pincus, H. A. (2019). Depression in primary care: part 2-management. *BMJ*, *365*, l835.

2843. Ramirez, E., Bellon, T., Tong, H. Y., Borobia, A. M., de Abajo, F. J., Lerma, V., . . . Frias, J. (2017). Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. *Pharmacol Res*, *115*, 168-178.
2844. Ramos, R., Garcia-Gil, M., Comas-Cufi, M., Quesada, M., Marrugat, J., Elosua, R., . . . Bolibar, B. (2016). Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. *J Am Coll Cardiol*, *67*(6), 630-640.
2845. Ramoz, N., Boni, C., Downing, A. M., Close, S. L., Peters, S. L., Prokop, A. M., . . . Gorwood, P. (2009). A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). *Neuropsychopharmacology*, *34*(9), 2135-2142.
2846. Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., . . . Niemi, M. (2014). The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. *Clin Pharmacol Ther*, *96*(4), 423-428.
2847. Rangel, L. B., Taraba, J. L., Frei, C. R., Smith, L., Rodriguez, G., & Kuhn, J. G. (2014). Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. *Breast Cancer Res Treat*, *148*(3), 571-580.
2848. Raposeiras-Roubin, S., Abu-Assi, E., Redondo-Dieguez, A., Gonzalez-Ferreiro, R., Lopez-Lopez, A., Bouzas-Cruz, N., . . . Gonzalez-Juanatey, J. R. (2015). Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today? *Rev Esp Cardiol*, *68*(7), 585-591.
2849. Raskin, J. B., White, R. H., Jackson, J. E., Weaver, A. L., Tindall, E. A., Lies, R. B., & Stanton, D. S. (1995). Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. *Ann Intern Med*, *123*(5), 344-350.
2850. Raskin, J. B., White, R. H., Jaszewski, R., Korsten, M. A., Schubert, T. T., & Fort, J. G. (1996). Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. *Am J Gastroenterol*, *91*(2), 223-227.
2851. Rasmussen-Torvik, L. J., Pacheco, J. A., Wilke, R. A., Thompson, W. K., Ritchie, M. D., Kho, A. N., . . . Chisholm, R. L. (2012). High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. *Clin Transl Sci*, *5*(5), 394-399.
2852. Rattehalli, R. D., Jayaram, M. B., & Smith, M. (2010). Risperidone versus placebo for schizophrenia. *Cochrane Database Syst Rev*(1), CD006918.
2853. Rau, T., Heide, R., Bergmann, K., Wuttke, H., Werner, U., Feifel, N., & Eschenhagen, T. (2002). Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. *Pharmacogenetics*, *12*(6), 465-472.
2854. Read, A. E., Laidlaw, J., & McCarthy, C. F. (1969). Effects of chlorpromazine in patients with hepatic disease. *BMJ*, *3*(5669), 497-499.

2855. Rebordosa, C., Kogevinas, M., Guerra, S., Castro-Giner, F., Jarvis, D., Cazzoletti, L., . . . Janson, C. (2011). ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. *Eur Respir J*, 38(5), 1029-1035.
2856. Regardh, C. G., Jordo, L., Ervik, M., Lundborg, P., Olsson, R., & Ronn, O. (1981). Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. *Clin Pharmacokinet*, 6(5), 375-388.
2857. Regeneron Pharmaceuticals Inc. (2019). Dupixent (dupilumab) *US Product Monograph*,
2858. Regula, J., Butruk, E., Dekkers, C. P., de Boer, S. Y., Raps, D., Simon, L., . . . Fischer, R. (2006). Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. *Am J Gastroenterol*, 101(8), 1747-1755.
2859. Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., . . . Draper, M. W. (2004). A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. *Arch Intern Med*, 164(8), 871-879.
2860. Reid, T. (2012). Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. *Clinical Diabetes*, 30(1), 3-12.
2861. Reid, T., Gao, L., Gill, J., Stuhr, A., Traylor, L., Vlajnic, A., & Rhinehart, A. (2015). How much is too much? Outcomes in patients using high-dose insulin glargine. *Int J Clin Pract*.
2862. Reimherr, F. W., Hedges, D. W., Strong, R. E., Marchant, B. K., & Williams, E. D. (2005). Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. *Neuropsychiatr Dis Treat*, 1(3), 245-251.
2863. Reiner, Z., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M. R., Wiklund, O., . . . Wood, D. (2011). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*, 32(14), 1769-1818.
2864. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. *Nature*, 526(7573), 343-350.
2865. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., . . . Clinical Pharmacogenetics Implementation, C. (2013). Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. *Clin Pharmacol Ther*, 93(4), 324-325.
2866. Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C. H., Stein, C. M., . . . Yang, J. J. (2019). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. *Clin Pharmacol Ther*, 105(5), 1095-1105.
2867. Remonti, L. R., Dias, S., Leitao, C. B., Kramer, C. K., Klassman, L. P., Welton, N. J., . . . Gross, J. L. (2016). Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes-Network meta-analysis of randomized trials. *J Diabetes Complications*, 30(6), 1192-1200.
2868. Ren, Q., Han, X., Zhang, S., Cai, X., & Ji, L. (2016). Combined influence of genetic variants and gene-gene interaction on sulfonylurea efficacy in Type 2 Diabetic patients. *Exp Clin Endocrinol Diabetes*, 124(3), 157-162.

2869. Ren, Z. Y., Xu, X. Q., Bao, Y. P., He, J., Shi, L., Deng, J. H., . . . Lu, L. (2015). The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. *Pain Physician, 18*(2), 131-152.
2870. Rendell, J. M., & Geddes, J. R. (2006). Risperidone in long-term treatment for bipolar disorder. *Cochrane Database Syst Rev*(4), CD004999.
2871. Rendell, J. M., Gijsman, H. J., Bauer, M. S., Goodwin, G. M., & Geddes, G. R. (2006). Risperidone alone or in combination for acute mania. *Cochrane Database Syst Rev*(1), CD004043.
2872. Rendell, J. M., Gijsman, H. J., Keck, P., Goodwin, G. M., & Geddes, J. R. (2003). Olanzapine alone or in combination for acute mania. *Cochrane Database Syst Rev*(3), CD004040.
2873. Resmini, G., Ratti, C., Canton, G., Murena, L., Moretti, A., & Iolascon, G. (2015). Treatment of complex regional pain syndrome. *Clin Cases Miner Bone Metab, 12*(Suppl 1), 26-30.
2874. Rey, J. F., Legras, B., Verdier, A., Vicari, F., & Gorget, C. (1989). Comparative study of sucralfate versus cimetidine in the treatment of acute gastroduodenal ulcer. Randomized trial with 667 patients. *Am J Med, 86*(6A), 116-121.
2875. Reyes-Gibby, C. C., Shete, S., Rakvag, T., Bhat, S. V., Skorpen, F., Bruera, E., . . . Klepstad, P. (2007). Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. *Pain, 130*(1-2), 25-30.
2876. Reynolds, D., Albert, N. M., Curtis, A. B., Gheorghiadu, M., Heywood, J. T., McBride, M. L., . . . Fonarow, G. C. (2012). Race and improvements in the use of guideline-recommended therapies for patients with heart failure: findings from IMPROVE HF. *J Natl Med Assoc, 104*(5-6), 287-298.
2877. Rho, R. H., Brewer, R. P., Lamer, T. J., & Wilson, P. R. (2002). Complex regional pain syndrome. *Mayo Clin Proc, 77*(2), 174-180.
2878. Rhodes Pharmaceuticals LP. (2015). Aptensio XR (methylphenidate). *US Product Monograph*,
2879. Ribeiro, L., Busnello, J. V., Kauer-Sant'Anna, M., Madruga, M., Quevedo, J., Busnello, E. A., & Kapczinski, F. (2001). Mirtazapine versus fluoxetine in the treatment of panic disorder. *Braz J Med Biol Res, 34*(10), 1303-1307.
2880. Richards, D. (2015). Guidance on converting between anticoagulants.
2881. Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castaneda-Sanabria, J., . . . Bardin, T. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis, 76*(1), 29-42.
2882. Richter, J. E., Sabesin, S. M., Kogut, D. G., Kerr, R. M., Wruble, L. D., & Collen, M. J. (1996). Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. *Am J Gastroenterol, 91*(9), 1766-1772.
2883. Rickels, K., Downing, R., Schweizer, E., & Hassman, H. (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. *Arch Gen Psychiatry, 50*(11), 884-895.

2884. Rickels, K., Mangano, R., & Khan, A. (2004). A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. *J Clin Psychopharmacol*, 24(5), 488-496.
2885. Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Jr., Kastelein, J. J., . . . Glynn, R. J. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*, 359(21), 2195-2207.
2886. Riedel, M., Schwarz, M. J., Strassnig, M., Spellmann, I., Muller-Arends, A., Weber, K., . . . Moller, H. J. (2005). Risperidone plasma levels, clinical response and side-effects. *Eur Arch Psychiatry Clin Neurosci*, 255(4), 261-268.
2887. Rifkind, B. M. (1984). Lipid research clinics coronary primary prevention trial: results and implications. *Am J Cardiol*, 54(5), 30c-34c.
2888. Rigotti, N. A., Pipe, A. L., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010). Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation*, 121(2), 221-229.
2889. Rindfleisch, J. A., & Muller, D. (2005). Diagnosis and management of rheumatoid arthritis. *Am Fam Physician*, 72(6), 1037-1047.
2890. Risselada, A. J., Mulder, H., Heerdink, E. R., Gonera, R. K., & Egberts, T. C. G. (2012). Association between the HTR2C rs1414334 and ADRA2A 1291 C/G polymorphisms and lipid levels in obese patients. In *Genetic determinants for metabolic abnormalities* (pp. 107).
2891. Risselada, A. J., Vehof, J., Bruggeman, R., Wilffert, B., Cohen, D., Al Hadithy, A. F., . . . Mulder, H. (2012). Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. *Pharmacogenomics J*, 12(1), 62-67.
2892. Roberts, R. L., Mulder, R. T., Joyce, P. R., Luty, S. E., & Kennedy, M. A. (2004). No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. *Hum Psychopharmacol*, 19(1), 17-23.
2893. Robertson, L., & Andras, A. (2013). Prostanoids for intermittent claudication. *Cochrane Database Syst Rev*(4), Cd000986.
2894. Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Aversa, M., . . . Kastelein, J. J. (2015). Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 372(16), 1489-1499.
2895. Robinson, M., Sahba, B., Avner, D., Jhala, N., Greski-Rose, P. A., & Jennings, D. E. (1995). A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. *Aliment Pharmacol Ther*, 9(1), 25-31.
2896. Rocha, A., Coelho, E. B., Moussa, S. A., & Lanchote, V. L. (2008). Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. *Eur J Clin Pharmacol*, 64(9), 901-906.
2897. Rocha, F. L., Fuzikawa, C., Riera, R., & Hara, C. (2012). Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. *J Clin Psychopharmacol*, 32(2), 278-281.

2898. Roddy, E., Romilly, N., Challenger, A., Lewis, S., & Britton, J. (2006). Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. *Tob Control, 15*(5), 373-376.
2899. Rodrigo, G. J., Neffen, H., & Castro-Rodriguez, J. A. (2011). Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. *Chest, 139*(1), 28-35.
2900. Rodrigues, A. C., Perin, P. M., Purim, S. G., Silbiger, V. N., Genvigir, F. D., Willrich, M. A., . . . Hirata, R. D. (2011). Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. *Int J Mol Sci, 12*(9), 5815-5827.
2901. Rodriguez-Gonzalez, F., Martinez-Quintana, E., Saavedra, P., Medina-Gil, J. M., Riano, M., Garay-Sanchez, P., & Tugores, A. (2018). CYP2C19 or CYP3A5 genotyping does not predict clinical response to clopidogrel. *J Clin Pharmacol, 58*(10), 1274-1283.
2902. Roe, M. T., Armstrong, P. W., Fox, K. A., White, H. D., Prabhakaran, D., Goodman, S. G., . . . Ohman, E. M. (2012). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med, 367*(14), 1297-1309.
2903. Roerig Div of Pfizer Inc. (2013). Relpax (eletriptan). *US Product Monograph*,
2904. Roerig Div of Pfizer Inc. (2016). Cardura (doxazosin). *US Product Monograph*,
2905. Roerig Div of Pfizer Inc. (2016). Zoloft (sertraline). *US Product Monograph*,
2906. Roerig Div of Pfizer Inc. (2018). Cardura XL (doxazosin). *US Product Monograph*,
2907. Roerig Div of Pfizer Inc. (2018). Geodon (ziprasidone). *US Product Monograph*,
2908. Roffi, M., Patrono, C., Collet, J. P., Mueller, C., Valgimigli, M., Andreotti, F., . . . Luis Zamorano, J. (2016). 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J, 37*(3), 267-315.
2909. Rogers, H. L., Bhattaram, A., Zineh, I., Gobburu, J., Mathis, M., Laughren, T. P., & Pacanowski, M. (2012). CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. *J Clin Psychiatry, 73*(9), 1187-1190.
2910. Roghani, H. S., Massarrat, S., Pahlewanzadeh, M. R., & Dashti, M. (1999). Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of *Helicobacter pylori* and its resistant strains. *Eur J Gastroenterol Hepatol, 11*(7), 709-712.
2911. Roh, H. K., Chung, J. Y., Oh, D. Y., Park, C. S., Svensson, J. O., Dahl, M. L., & Bertilsson, L. (2001). Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. *Br J Clin Pharmacol, 52*(3), 265-271.
2912. Roh, H. K., Kim, C. E., Chung, W. G., Park, C. S., Svensson, J. O., & Bertilsson, L. (2001). Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. *Eur J Clin Pharmacol, 57*(9), 671-675.

2913. Roh, H. K., Kim, P. S., Lee, D. H., Tybring, G., Sagar, M., Park, C. S., . . . Bertilsson, L. (2004). Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. *Basic Clin Pharmacol Toxicol*, 95(3), 112-119.
2914. Rojas, L., Neumann, I., Herrero, M. J., Boso, V., Reig, J., Poveda, J. L., . . . Alino, S. F. (2015). Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. *Pharmacogenomics J*, 15(1), 38-48.
2915. Roke, Y., van Harten, P. N., Franke, B., Galesloot, T. E., Boot, A. M., & Buitelaar, J. K. (2013). The effect of the Taq1A variant in the dopamine D(2) receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. *Pharmacogenet Genomics*, 23(9), 487-493.
2916. Roman, M., Ochoa, D., Sanchez-Rojas, S. D., Talegon, M., Prieto-Perez, R., Rivas, A., . . . Cabaleiro, T. (2014). Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. *Pharmacogenomics*, 15(15), 1893-1901.
2917. Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L. K., . . . Society for Vascular, S. (2011). 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. *J Vasc Surg*, 54(5), e32-58.
2918. Rosenberg, K. (2016). Melatonin: Safe And Effective for the Prevention of Migraine Headache. *Am J Nurs*, 116(9), 69.
2919. Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L., Jr., . . . Oparil, S. (2007). Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. *Circulation*, 115(21), 2761-2788.
2920. Roshanaei-Moghaddam, B., Pauly, M. C., Atkins, D. C., Baldwin, S. A., Stein, M. B., & Roy-Byrne, P. (2011). Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety? *Depress Anxiety*, 28(7), 560-567.
2921. Rosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E., . . . Tomlinson, I. (2014). Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. *J Clin Oncol*, 32(10), 1031-1039.
2922. Rossebo, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., . . . Willenheimer, R. (2008). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med*, 359(13), 1343-1356.

2923. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., . . . Writing Group for the Women's Health Initiative, I. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama*, *288*(3), 321-333.
2924. Rostain, A. L. (2008). Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management. *Postgrad Med*, *120*(3), 27-38.
2925. Rostom, A., Dube, C., Wells, G., Tugwell, P., Welch, V., Jolicoeur, E., & McGowan, J. (2002). Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev*(4), Cd002296.
2926. Rotberg, B., Kronenberg, S., Carmel, M., Frisch, A., Brent, D., Zalsman, G., . . . Weizman, A. (2013). Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. *J Child Adolesc Psychopharmacol*, *23*(2), 117-122.
2927. Rothacker, D. Q., Lee, I., & Littlejohn, T. W., 3rd. (1998). Effectiveness of a single topical application of 10|x% trolamine salicylate cream in the symptomatic treatment of osteoarthritis. *J Clin Rheumatol*, *4*(1), 6-12.
2928. Roush, G. C., Ernst, M. E., Kostis, J. B., Tandon, S., & Sica, D. A. (2015). Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. *Hypertension*, *65*(5), 1041-1046.
2929. Rowbotham, M. C. (2006). Pharmacologic management of complex regional pain syndrome. *Clin J Pain*, *22*(5), 425-429.
2930. Rowe, B. H., Spooner, C. H., Ducharme, F. M., Bretzlaff, J. A., & Bota, G. W. (2007). Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database Syst Rev*(3), CD000195.
2931. Royal Australian College of General Practitioners. (2009). *Clinical guideline for the diagnosis and management of early rheumatoid arthritis*. Melbourne: The Royal Australian College of General Practitioners.
2932. Royal College of Physicians. (2014). Why asthma still kills: the National Review of Asthma Deaths (NRAD) confidential enquiry report.
2933. Rubboli, A., Halperin, J. L., Airaksinen, K. E., Buerke, M., Eeckhout, E., Freedman, S. B., . . . Lip, G. Y. (2008). Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. *Ann Med*, *40*(6), 428-436.
2934. Rubin, B. R., Burton, R., Navarra, S., Antigua, J., Londono, J., Pryhuber, K. G., . . . Geba, G. P. (2004). Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. *Arthritis Rheum*, *50*(2), 598-606.
2935. Rubin, D. J., Rybin, D., Doros, G., & McDonnell, M. E. (2011). Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. *Diabetes Care*, *34*(8), 1723-1728.

2936. Rudberg, I., Hermann, M., Refsum, H., & Molden, E. (2008). Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. *Eur J Clin Pharmacol*, *64*(12), 1181-1188.
2937. Ruiz-Iruela, C., Padro-Miquel, A., Pinto-Sala, X., Baena-Diez, N., Caixas-Pedragos, A., Guell-Miro, R., . . . Candas-Estebanez, B. (2018). KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment. *PLoS One*, *13*(10), e0205430.
2938. Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., . . . Leucht, S. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Schizophr Res*, *123*(2-3), 225-233.
2939. Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., . . . Niederehe, G. (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. *Control Clin Trials*, *25*(1), 119-142.
2940. Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., . . . Wisniewski, S. R. (2011). Combining medications to enhance depression outcomes (COMED): acute and long-term outcomes of a single-blind randomized study. *Am J Psychiatry*, *168*(7), 689-701.
2941. Russolillo, A., Di Minno, M. N., Tufano, A., Prisco, D., & Di Minno, G. (2012). Filling the gap between science & clinical practice: prevention of stroke recurrence. *Thromb Res*, *129*(1), 3-8.
2942. Rutjes, A. W., Juni, P., da Costa, B. R., Trelle, S., Nuesch, E., & Reichenbach, S. (2012). Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. *Ann Intern Med*, *157*(3), 180-191.
2943. Rutten, F. H., Zuithoff, N. P., Hak, E., Grobbee, D. E., & Hoes, A. W. (2010). Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med*, *170*(10), 880-887.
2944. Ryan, R. E., Sr. (1984). Comparative study of nadolol and propranolol in prophylactic treatment of migraine. *Am Heart J*, *108*(4 Pt 2), 1156-1159.
2945. Ryan, R. E., Sr., Ryan, R. E., Jr., & Sudilovsky, A. (1983). Nadolol: its use in the prophylactic treatment of migraine. *Headache*, *23*(1), 26-31.
2946. Rydzanicz, M., Wrobel, M., Pollak, A., Gawecki, W., Brauze, D., Kostrzewska-Poczekaj, M., . . . Szyfter, K. (2010). Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. *Biochem Biophys Res Commun*, *395*(1), 116-121.
2947. Ryu, R. J., Eyal, S., Easterling, T. R., Caritis, S. N., Venkataraman, R., Hankins, G., . . . Hebert, M. F. (2016). Pharmacokinetics of metoprolol during pregnancy and lactation. *J Clin Pharmacol*, *56*(5), 581-589.
2948. Ryu, S., Park, S., Lee, J. H., Kim, Y. R., Na, H. S., Lim, H. S., . . . Choi, S. E. (2017). A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. *Clin Transl Sci*, *10*(2), 93-101.
2949. Saag, K. G., Fitz-Patrick, D., Kopicko, J., Fung, M., Bhakta, N., Adler, S., . . . Becker, M. A. (2017). Lesinurad combined with allopurinol: a randomized, double-blind, placebo-

- controlled study in gout patients with an inadequate response to standard-of-care allopurinol. *Arthritis Rheumatol*, 69(1), 203-212.
2950. Sabatine, M. S., Cannon, C. P., Gibson, C. M., Lopez-Sendon, J. L., Montalescot, G., Theroux, P., . . . Braunwald, E. (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med*, 352(12), 1179-1189.
2951. Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., . . . Pedersen, T. R. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*, 376(18), 1713-1722.
2952. Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., . . . Stein, E. A. (2015). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 372(16), 1500-1509.
2953. Sabih, A., & Leslie, S. (2019). Complicated Urinary Tract Infections - StatPearls - NCBI Bookshelf. *NCBI Bookshelf*,
2954. Sachs, G. S., Greenberg, W. M., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., . . . Durgam, S. (2015). Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. *J Affect Disord*, 174, 296-302.
2955. Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. *Am J Psychiatry*, 159(7), 1146-1154.
2956. Sachs, G. S., Ice, K. S., Chappell, P. B., Schwartz, J. H., Gurtovaya, O., Vanderburg, D. G., & Kasuba, B. (2011). Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*, 72(10), 1413-1422.
2957. Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M., Thibault, A. B., Tohen, M., & Rosenbaum, J. F. (1994). A double-blind trial of bupropion versus desipramine for bipolar depression. *J Clin Psychiatry*, 55(9), 391-393.
2958. Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., . . . Thase, M. E. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. *N Engl J Med*, 356(17), 1711-1722.
2959. Sachs, G. S., Vanderburg, D. G., Karayal, O. N., Kolluri, S., Bachinsky, M., & Cavus, I. (2012). Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*, 73(11), 1412-1419.
2960. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., . . . Braunwald, E. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*, 335(14), 1001-1009.
2961. Safgren, S. L., Suman, V. J., Kosel, M. L., Gilbert, J. A., Buhrow, S. A., Black, J. L., . . . Goetz, M. P. (2015). Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. *Pharmacogenet Genomics*, 25(4), 157-163.

2962. Sagar, M., Tybring, G., Dahl, M. L., Bertilsson, L., & Seensalu, R. (2000). Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. *Gastroenterology*, *119*(3), 670-676.
2963. Saha, K. B., Bo, L., Zhao, S., Xia, J., Sampson, S., & Zaman, R. U. (2016). Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*, *4*, CD010631.
2964. Sahara, S., Sugimoto, M., Uotani, T., Ichikawa, H., Yamade, M., Iwaizumi, M., . . . Furuta, T. (2013). Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. *Aliment Pharmacol Ther*, *38*(9), 1129-1137.
2965. Saito, Y., Serizawa, H., Kato, Y., Nakano, M., Nakamura, M., Saito, H., . . . Kanai, T. (2015). First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. *World J Gastroenterol*, *21*(48), 13548-13554.
2966. Saito, Y., Stamp, L. K., Caudle, K. E., Hershfield, M. S., McDonagh, E. M., Callaghan, J. T., . . . Lee, M. T. (2016). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. *Clin Pharmacol Ther*, *99*(1), 36-37.
2967. Saitoh, T., Otsuka, H., Kawasaki, T., Endo, H., Iga, D., Tomimatsu, M., . . . Otsuka, K. (2009). Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. *Hepatogastroenterology*, *56*(91-92), 703-706.
2968. Saiz-Rodriguez, M., Belmonte, C., Derqui-Fernandez, N., Cabaleiro, T., Roman, M., Ochoa, D., . . . Abad-Santos, F. (2017). Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. *Pharmacogenomics*, *18*(16), 1491-1502.
2969. Saiz-Rodriguez, M., Belmonte, C., Roman, M., Ochoa, D., Jiang-Zheng, C., Koller, D., . . . Abad-Santos, F. (2018). Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. *Basic Clin Pharmacol Toxicol*, *123*(4), 474-485.
2970. Sajatovic, M., Coconcea, N., Ignacio, R. V., Blow, F. C., Hays, R. W., Cassidy, K. A., & Meyer, W. J. (2008). Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. *J Clin Psychiatry*, *69*(1), 41-46.
2971. Sajatovic, M., Dines, P., Fuentes-Casiano, E., Athey, M., Cassidy, K. A., Sams, J., . . . Tatsuoka, C. (2015). Asenapine in the treatment of older adults with bipolar disorder. *Int J Geriatr Psychiatry*, *30*(7), 710-719.
2972. Sajatovic, M., Forester, B. P., Tsai, J., Kroger, H., Pikalov, A., Cucchiari, J., & Loebel, A. (2016). Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. *J Clin Psychiatry*, *77*(10), e1324-e1331.
2973. Sajatovic, M., Gildengers, A., Al Jurdi, R. K., Gyulai, L., Cassidy, K. A., Greenberg, R. L., . . . Young, R. C. (2011). Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. *Bipolar Disord*, *13*(3), 294-302.

2974. Sakurai, K., Nagahara, A., Inoue, K., Akiyama, J., Mabe, K., Suzuki, J., . . . Haruma, K. (2012). Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). *BMC Gastroenterol*, *12*, 42.
2975. Saladores, P., Murdter, T., Eccles, D., Chowbay, B., Zgheib, N. K., Winter, S., . . . Brauch, H. (2015). Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. *Pharmacogenomics J*, *15*(1), 84-94.
2976. Salas, M., Ward, A., & Caro, J. (2002). Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. *BMC Gastroenterol*, *2*, 17.
2977. Salathia, K. S., Barber, J. M., McIlmoyle, E. L., Nicholas, J., Evans, A. E., Elwood, J. H., . . . Boyle, D. M. (1985). Very early intervention with metoprolol in suspected acute myocardial infarction. *Eur Heart J*, *6*(3), 190-198.
2978. Salhiyyah, K., Forster, R., Senanayake, E., Abdel-Hadi, M., Booth, A., & Michaels, J. A. (2015). Pentoxifylline for intermittent claudication. *Cochrane Database Syst Rev*, *9*, Cd005262.
2979. Sallee, F. R., McGough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry*, *48*(2), 155-165.
2980. Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev*(4), CD002967.
2981. Sam, W. J., Chamberlain, C. E., Lee, S. J., Goldstein, J. A., Hale, D. A., Mannon, R. B., . . . Hon, Y. Y. (2011). Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. *Transplantation*, *92*(12), 1342-1347.
2982. Sambhi, M. P., Eggena, P., Barrett, J. D., Thananopavarn, C., Tuck, M., & Wiedman, C. (1977). Antihypertensive and renin angiotensin effects of metolazone with and without propranolol. *J Clin Pharmacol*, *17*(4), 214-224.
2983. Samer, C. F., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C. B., Rebsamen, M. C., . . . Desmeules, J. A. (2010). Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. *Br J Pharmacol*, *160*(4), 919-930.
2984. Sampford, J. R., Sampson, S., Li, B. G., Zhao, S., Xia, J., & Furtado, V. A. (2016). Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*, *7*, CD010832.
2985. Sampson, S., Hosalli, P., Furtado, V. A., & Davis, J. M. (2016). Risperidone (depot) for schizophrenia. *Cochrane Database Syst Rev*, *4*, CD004161.
2986. Sanchez, C., Bogeso, K. P., Ebert, B., Reines, E. H., & Braestrup, C. (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. *Psychopharmacology (Berl)*, *174*(2), 163-176.

2987. Sanchez-Borges, M., Acevedo, N., Vergara, C., Jimenez, S., Zabner-Oziel, P., Monzon, A., & Caraballo, L. (2009). The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. *J Investig Allergol Clin Immunol*, 19(5), 375-382.
2988. Sanchez-Ibarra, H. E., Reyes-Cortes, L. M., Jiang, X. L., Luna-Aguirre, C. M., Aguirre-Trevino, D., Morales-Alvarado, I. A., . . . Barrera-Saldana, H. A. (2018). Genotypic and phenotypic factors influencing drug response in Mexican patients with Type 2 Diabetes Mellitus. *Front Pharmacol*, 9, 320.
2989. Sanchez-Iglesias, S., Garcia-Solaesa, V., Garcia-Berrocal, B., Sanchez-Martin, A., Lorenzo-Romo, C., Martin-Pinto, T., . . . Isidoro-Garcia, M. (2016). Role of pharmacogenetics in improving the safety of psychiatric care by predicting the potential risks of mania in CYP2D6 poor metabolizers diagnosed with bipolar disorder. *Medicine (Baltimore)*, 95(6), e2473.
2990. Sandor, P. S., Di Clemente, L., Coppola, G., Saenger, U., Fumal, A., Magis, D., . . . Schoenen, J. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. *Neurology*, 64(4), 713-715.
2991. Sandoz Canada Inc. (2013). Haloperidol LA. *CA Product Monograph*,
2992. Sandoz Canada Inc. (2013). Sandoz Cefprozil
2993. Sandoz Canada Inc. (2017). Gentamicin USP. *CA Product Monograph*,
2994. Sandoz Canada Inc. (2017). Sandoz Colchicine. *CA Product Monograph*,
2995. Sandoz Canada Inc. (2018). Lisinopril. *CA Product Monograph*,
2996. Sandoz Inc. (2013). Ipratropium Bromide. *US Product Monograph*,
2997. Sandoz Inc. (2014). Terazosin. *US Product Monograph*,
2998. Sandoz Inc. (2015). Ampicillin. *US Product Monograph*,
2999. Sanford, J. P., Gilbert, D. N., & Sande, M. A. The Sanford guide to antimicrobial therapy. In (Pocket sized ed., pp. volumes). Dallas, TX
3000. Sperryville, VA: Antimicrobial Therapy.
3001. Sanis Health Inc. (2014). Famotidine. *CA Product Monograph*,
3002. Sanis Health Inc. (2015). Domperidone. *CA Product Monograph*,
3003. Sanis Health Inc. (2015). Furosemide. *CA Product Monograph*,
3004. Sanis Health Inc. (2017). Bupropion SR. *CA Product Monograph*,
3005. Sanis Health Inc. (2017). Naproxen. *CA Product Monograph*,
3006. Sanis Health Inc. (2017). Trazodone. *CA Canada Monograph*,
3007. Sanofi. (2019). Roloids. *US Product Information*,
3008. sanofi-aventis Canada Inc. (2011). Piportil L4 (pipotiazine palmitate). *CA Product Monograph*,
3009. sanofi-aventis Canada Inc. (2014). Sectral (acebutolol). *CA Product Monograph*,
3010. sanofi-aventis Canada Inc. (2015). Arava (leflunomide). *CA Product Monograph*,
3011. sanofi-aventis Canada Inc. (2015). Avapro (irbesartan). *CA Drug Monograph*,
3012. sanofi-aventis Canada Inc. (2015). Nitrolingual pumpspray (nitroglycerin). *CA Product Monograph*,
3013. sanofi-aventis Canada Inc. (2015). Nozinan. *CA Product Monograph*,
3014. sanofi-aventis Canada Inc. (2016). Amaryl (glimepiride). *CA Product Monograph*,

3015. sanofi-aventis Canada Inc. (2016). Diabeta (glyburide). *CA Product Monograph*,
3016. sanofi-aventis Canada Inc. (2016). Plavix (clopidogrel). *CA Product Monograph*,
3017. sanofi-aventis Canada Inc. (2017). Apidra (insulin glulisine). *CA Product Monograph*,
3018. sanofi-aventis Canada Inc. (2017). Lantus (insulin glargine). *CA Product Monograph*,
3019. sanofi-aventis Canada Inc. (2018). Flagyl (metronidazole). *CA Product Monograph*,
3020. sanofi-aventis Canada Inc. (2018). Plaquenil (hydroxychloroquine). *CA Product Monograph*,
3021. sanofi-aventis Canada Inc. (2018). Zaroxolyn (metolazone). *CA Product Monograph*,
3022. sanofi-aventis Canada Inc. (2019). Dupixent (dupilumab). *CA Product Monograph*,
3023. sanofi-aventis Canada Inc. (2019). Praluent (alirocumab). *CA Product Monograph*,
3024. sanofi-aventis US LLC. (2014). Norpramin (desipramine). *US Product Monograph*,
3025. sanofi-aventis US LLC. (2015). Praluent (alirocumab). *US Product Monograph*,
3026. sanofi-aventis US LLC. (2016). Diabeta (glyburide). *US Product Monograph*,
3027. sanofi-aventis US LLC. (2018). Amaryl (glimepiride). *US Product Monograph*,
3028. sanofi-aventis US LLC. (2018). Arava (leflunomide) *US Product Monograph*,
3029. sanofi-aventis US LLC. (2018). Avapro (irbesartan). *US Product Monograph*,
3030. sanofi-aventis US LLC. (2018). Lantus (insulin glargine). *US Product Monograph*,
3031. Sansone, S., Rottensteiner, J., Stocker, J., Rosanelli, C., & Wiedermann, C. J. (2010). Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report. *Ann Hematol*, *89*(9), 935-937.
3032. Santangeli, P., Di Biase, L., Pelargonio, G., Dello Russo, A., Casella, M., Bartoletti, S., . . . Natale, A. (2011). Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis. *J Interv Card Electrophysiol*, *32*(2), 125-135.
3033. Santangeli, P., Ferrante, G., Pelargonio, G., Dello Russo, A., Casella, M., Bartoletti, S., . . . Natale, A. (2010). Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. *Europace*, *12*(5), 649-654.
3034. Santoro, A., Felipe, C. R., Tedesco-Silva, H., Medina-Pestana, J. O., Struchiner, C. J., Ojopi, E. B., & Suarez-Kurtz, G. (2011). Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. *Pharmacogenomics*, *12*(9), 1293-1303.
3035. Santos, P. C., Gagliardi, A. C., Miname, M. H., Chacra, A. P., Santos, R. D., Krieger, J. E., & Pereira, A. C. (2012). SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. *Eur J Clin Pharmacol*, *68*(3), 273-279.
3036. Saper, J. R., Lake, A. E., 3rd, Cantrell, D. T., Winner, P. K., & White, J. R. (2002). Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. *Headache*, *42*(6), 470-482.
3037. Sapone, A., Vaira, D., Trespidi, S., Perna, F., Gatta, L., Tampieri, A., . . . Paolini, M. (2003). The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. *Am J Gastroenterol*, *98*(5), 1010-1015.
3038. Sarafoff, N., Martischnig, A., Wealer, J., Mayer, K., Mehilli, J., Sibbing, D., & Kastrati, A. (2013). Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. *J Am Coll Cardiol*, *61*(20), 2060-2066.

3039. Sarchiapone, M., Amore, M., De Risio, S., Carli, V., Faia, V., Poterzio, F., . . . Ferrari, G. (2003). Mirtazapine in the treatment of panic disorder: an open-label trial. *Int Clin Psychopharmacol*, 18(1), 35-38.
3040. Saricicek, A., Maloney, K., Muralidharan, A., Ruf, B., Blumberg, H. P., Sanacora, G., . . . Bhagwagar, Z. (2011). Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*, 72(6), 744-750.
3041. Saruwatari, J., Ogusu, N., Shimomasuda, M., Nakashima, H., Seo, T., Tanikawa, K., . . . Nakagawa, K. (2014). Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. *Ther Drug Monit*, 36(3), 302-309.
3042. Satia, A., King, I. B., Abouta, J. S., Thornquist, M. D., Bigler, J., Patterson, R. E., . . . White, E. (2002). Buccal Cell DNA Yield, Quality, and Collection Costs. *Cancer Epidemiology Biomarkers & Prevention*, 11(10), 1130.
3043. Satoh, K., Yoshino, J., Akamatsu, T., Itoh, T., Kato, M., Kamada, T., . . . Shimosegawa, T. (2016). Evidence-based clinical practice guidelines for peptic ulcer disease 2015. *J Gastroenterol*, 51(3), 177-194.
3044. Sauer, J. M., Ponsler, G. D., Mattiuz, E. L., Long, A. J., Witcher, J. W., Thomasson, H. R., & Desante, K. A. (2003). Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. *Drug Metab Dispos*, 31(1), 98-107.
3045. Saunders, K. E., & Geddes, J. R. (2016). The management of bipolar disorder. *Br J Hosp Med (Lond)*, 77(3), 175-179.
3046. Savarino, V., Zentilin, P., Bisso, G., Pivari, M., Mele, M. R., Mela, G. S., . . . Celle, G. (1999). Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate *Helicobacter pylori*. *Aliment Pharmacol Ther*, 13(5), 643-649.
3047. Savient Pharmaceuticals. (2012). Krystexxa (pegloticase). *Product Monograph*,
3048. Sawamura, K., Suzuki, Y., & Someya, T. (2004). Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. *Eur J Clin Pharmacol*, 60(8), 553-557.
3049. Schaeffeler, E., Jaeger, S. U., Klumpp, V., Yang, J. J., Igel, S., Hinze, L., . . . Schwab, M. (2019). Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. *Genet Med*, 21(9), 2145-2150.
3050. Schaffer, S. D., Yoon, S., & Zadezensky, I. (2009). A review of smoking cessation: potentially risky effects on prescribed medications. *J Clin Nurs*, 18(11), 1533-1540.
3051. Schatzberg, A. F. (2019). A word to the wise about intranasal esketamine. *Am J Psychiatry*, 176(6), 422-424.
3052. Schatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006). Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. *J Clin Psychiatry*, 67 Suppl 4, 27-30.
3053. Scheen, A. J., & Paquot, N. (2013). Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. *Diabetes Metab*, 39(3), 179-190.
3054. Scheiman, J. M. (2013). The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. *Arthritis Res Ther*, 15 Suppl 3, S5.

3055. Scheiman, J. M., Devereaux, P. J., Herlitz, J., Katelaris, P. H., Lanas, A., Veldhuyzen van Zanten, S., . . . Svedberg, L. E. (2011). Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). *Heart*, *97*(10), 797-802.
3056. Scheiman, J. M., Yeomans, N. D., Talley, N. J., Vakil, N., Chan, F. K., Tulassay, Z., . . . Hawkey, C. (2006). Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. *Am J Gastroenterol*, *101*(4), 701-710.
3057. Schellenberg, R., Lichtenthal, A., Wohling, H., Graf, C., & Brixius, K. (2008). Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? *Headache*, *48*(1), 118-125.
3058. Schepke, M., Wiest, R., Flacke, S., Heller, J., Stoffel-Wagner, B., Herold, T., . . . Sauerbruch, T. (2008). Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. *Am J Gastroenterol*, *103*(5), 1152-1158.
3059. Scherk, H., Pajonk, F. G., & Leucht, S. (2007). Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. *Arch Gen Psychiatry*, *64*(4), 442-455.
3060. Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., . . . Meininger, G. (2013). Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes Care*, *36*(9), 2508-2515.
3061. Schildcrout, J. S., Denny, J. C., Bowton, E., Gregg, W., Pulley, J. M., Basford, M. A., . . . Roden, D. M. (2012). Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. *Clin Pharmacol Ther*, *92*(2), 235-242.
3062. Schlatter, C., Egger, S. S., Tschambaz, L., & Krahenbuhl, S. (2009). Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. *Drug Saf*, *32*(7), 561-578.
3063. Schlemper, R. J., van der Werf, S. D., Biemond, I., & Lamers, C. B. (1995). Dyspepsia and Helicobacter pylori in Japanese employees with and without ulcer history. *J Gastroenterol Hepatol*, *10*.
3064. Schlesinger, N. (2012). Canakinumab in gout. *Expert Opin Biol Ther*, *12*(9), 1265-1275.
3065. Schlesinger, N., Alten, R. E., Bardin, T., Schumacher, H. R., Bloch, M., Gimona, A., . . . So, A. K. (2012). Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. *Ann Rheum Dis*, *71*(11), 1839-1848.
3066. Schlesinger, N., Schumacher, R., Catton, M., & Maxwell, L. (2006). Colchicine for acute gout. *Cochrane Database Syst Rev*(4), CD006190.
3067. Schleuning, M., Brumme, V., & Wilmanns, W. (1993). Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. *Anticancer Res*, *13*(3), 599-602.
3068. Schneider, N. G., Olmstead, R., Nilsson, F., Mody, F. V., Franzon, M., & Doan, K. (1996). Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction*, *91*(9), 1293-1306.

3069. Schnoll, R. A., Goelz, P. M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., Leone, F. T., . . . Hitsman, B. (2015). Long-term nicotine replacement therapy: a randomized clinical trial. *JAMA Intern Med*, *175*(4), 504-511.
3070. Schoenen, J., Jacquy, J., & Lenaerts, M. (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. *Neurology*, *50*(2), 466-470.
3071. Schomig, A., Neumann, F. J., Kastrati, A., Schuhlen, H., Blasini, R., Hadamitzky, M., . . . Ulm, K. (1996). A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med*, *334*(17), 1084-1089.
3072. Schrader, H., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2001). Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. *BMJ*, *322*(7277), 19-22.
3073. Schroner, Z., Javorsky, M., Tkacova, R., Klimcakova, L., Dobrikova, M., Habalova, V., . . . Tkac, I. (2011). Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. *Diabetes Obes Metab*, *13*(1), 89-91.
3074. Schueler, Y. B., Koesters, M., Wieseler, B., Grouven, U., Kromp, M., Kerekes, M. F., . . . Weinmann, S. (2011). A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. *Acta Psychiatr Scand*, *123*(4), 247-265.
3075. Schuh-Hofer, S., Flach, U., Meisel, A., Israel, H., Reuter, U., & Arnold, G. (2007). Efficacy of lisinopril in migraine prophylaxis--an open label study. *Eur J Neurol*, *14*(6), 701-703.
3076. Schukro, R. P., Oehmke, M. J., Geroldinger, A., Heinze, G., Kress, H. G., & Pramhas, S. (2016). Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial. *Anesthesiology*, *124*(1), 150-158.
3077. Schumacher, H. R., Jr., Becker, M. A., Wortmann, R. L., Macdonald, P. A., Hunt, B., Streit, J., . . . Joseph-Ridge, N. (2008). Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Rheum*, *59*(11), 1540-1548.
3078. Schumacher, H. R., Berger, M. F., Li-Yu, J., Perez-Ruiz, F., Burgos-Vargas, R., & Li, C. (2012). Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. *J Rheumatol*, *39*(9), 1859-1866.
3079. Schumacher, H. R., Jr., Boice, J. A., Daikh, D. I., Mukhopadhyay, S., Malmstrom, K., Ng, J., . . . Molina, J. (2002). Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. *BMJ*, *324*(7352), 1488-1492.
3080. Schumann, S. A., & Hickner, J. (2008). When not to use beta-blockers in seniors with hypertension. *J Fam Pract*, *57*(1), 18-21.
3081. Schuster, B. (2017). Acid Suppression Drugs: Evidence, Tips & Pearls. *RxFiles drug comparison charts*, 67
3082. Schuster, B., Regier, L., & Jensen, B. (2017). Acid Suppression. *RxFiles drug comparison charts*, 68
3083. Schwartz, G. G., Olsson, A. G., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D., . . . Stern, T. (2001). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *Jama*, *285*(13), 1711-1718.

3084. Schwedt, T. J. (2014). Chronic migraine. *BMJ*, 348, g1416.
3085. Sciarretta, S., Palano, F., Tocci, G., Baldini, R., & Volpe, M. (2011). Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. *Arch Intern Med*, 171(5), 384-394.
3086. Sciarrone, M. T., Stella, P., Barlassina, C., Manunta, P., Lanzani, C., Bianchi, G., & Cusi, D. (2003). ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. *Hypertension*, 41(3), 398-403.
3087. Scordo, M. G., Spina, E., Facciola, G., Avenoso, A., Johansson, I., & Dahl, M. L. (1999). Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. *Psychopharmacology (Berl)*, 147(3), 300-305.
3088. Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., . . . Shuldiner, A. R. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. *Clin Pharmacol Ther*, 94(3), 317-323.
3089. Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., . . . Clinical Pharmacogenetics Implementation, C. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. *Clin Pharmacol Ther*, 94(3), 317-323.
3090. Scottish Intercollegiate Guidelines Network (SIGN). (2003). *Diagnosis and Management of Epilepsy in Adults*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3091. Scottish Intercollegiate Guidelines Network (SIGN). (2008). *Diagnosis and management of headache in adults*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3092. Scottish Intercollegiate Guidelines Network (SIGN). (2010). *Management of diabetes*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3093. Scottish Intercollegiate Guidelines Network (SIGN). (2011). *Management of early rheumatoid arthritis*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3094. Scottish Intercollegiate Guidelines Network (SIGN). (2012). *Management of Suspected Bacterial Urinary Tract Infection in Adults*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3095. Scottish Intercollegiate Guidelines Network (SIGN). (2013). *Management of chronic pain*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3096. Scottish Intercollegiate Guidelines Network (SIGN). (2013). *Management of schizophrenia*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3097. Scottish Intercollegiate Guidelines Network (SIGN). (2015). *Management of osteoporosis and the prevention of fragility fractures*. Retrieved from Edinburgh: SIGN: <http://www.sign.ac.uk>
3098. Seemungal, T. A., Wilkinson, T. M., Hurst, J. R., Perera, W. R., Sapsford, R. J., & Wedzicha, J. A. (2008). Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. *Am J Respir Crit Care Med*, 178(11), 1139-1147.
3099. Seitz, M., Wirthmuller, U., Moller, B., & Villiger, P. M. (2007). The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in

- rheumatoid arthritis and spondyloarthritis patients. *Rheumatology (Oxford)*, 46(1), 93-96.
3100. Seo, T., Nagata, R., Ishitsu, T., Murata, T., Takaishi, C., Hori, M., & Nakagawa, K. (2008). Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. *Pharmacogenomics*, 9(5), 527-537.
3101. Serebruany, V. L., Malinin, A. I., Eisert, R. M., & Sane, D. C. (2004). Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. *Am J Hematol*, 75(1), 40-47.
3102. Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. *Mol Psychiatry*, 12(3), 247-257.
3103. Servier Canada Inc. (2016). Diamicon (gliclazide). *CA Product Monograph*,
3104. Servier Canada Inc. (2016). Diamicon MR (gliclazide MR). *CA Product Monograph*,
3105. Servier Canada Inc. (2017). Coversyl (perindopril erbumine). *CA Product Monograph*,
3106. Servier Canada Inc. (2018). Lancora (ivabradine). *CA Product Monograph*,
3107. Servier Canada Inc. (2017). Lixiana (edoxaban tosylate monohydrate). *CA Product Monograph*,
3108. Sesti, G., Laratta, E., Cardellini, M., Andreozzi, F., Del Guerra, S., Irace, C., . . . Marchetti, P. (2006). The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. *J Clin Endocrinol Metab*, 91(6), 2334-2339.
3109. Seth, R., Kydd, A. S., Buchbinder, R., Bombardier, C., & Edwards, C. J. (2014). Allopurinol for chronic gout. *Cochrane Database Syst Rev*(10), CD006077.
3110. Sethi, S., Jones, P. W., Theron, M. S., Miravittles, M., Rubinstein, E., Wedzicha, J. A., & Wilson, R. (2010). Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Respir Res*, 11, 10.
3111. Severino, A., Narducci, M. L., Pedicino, D., Pazzano, V., Giglio, A. F., Biasucci, L. M., . . . Crea, F. (2012). Reversible atrial gap junction remodeling during hypoxia/reoxygenation and ischemia: a possible arrhythmogenic substrate for atrial fibrillation. *Gen Physiol Biophys*, 31(4), 439-448.
3112. Shafti, S. S. (2010). Olanzapine vs. lithium in management of acute mania. *J Affect Disord*, 122(3), 273-276.
3113. Shaikh, T., & Fallone, C. A. (2016). Effectiveness of second through sixth line salvage helicobacter pylori treatment: Bismuth quadruple therapy is almost always a reasonable choice. *Can J Gastroenterol Hepatol*, 2016, 7321574.
3114. Shaikh, W. A. (1997). Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. *Clin Exp Allergy*, 27(11), 1279-1284.
3115. Shamliyan, T. A., Choi, J. Y., Ramakrishnan, R., Miller, J. B., Wang, S. Y., Taylor, F. R., & Kane, R. L. (2013). Preventive pharmacologic treatments for episodic migraine in adults. *J Gen Intern Med*, 28(9), 1225-1237.

3116. Shams, M. E., Arneth, B., Hiemke, C., Dragicevic, A., Muller, M. J., Kaiser, R., . . . Hartter, S. (2006). CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. *J Clin Pharm Ther*, *31*(5), 493-502.
3117. Shapiro, R. E., & Tepper, S. J. (2007). The serotonin syndrome, triptans, and the potential for drug-drug interactions. *Headache*, *47*(2), 266-269.
3118. Sharp, C. F., Gardiner, S. J., Jensen, B. P., Roberts, R. L., Troughton, R. W., Lainchbury, J. G., & Begg, E. J. (2009). CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. *Pharmacogenomics J*, *9*(3), 175-184.
3119. Shaygannejad, V., Janghorbani, M., Ghorbani, A., Ashtary, F., Zakizade, N., & Nasr, V. (2006). Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. *Headache*, *46*(4), 642-648.
3120. Shea, B., Swinden, M. V., Tanjong Ghogomu, E., Ortiz, Z., Katchamart, W., Rader, T., . . . Tugwell, P. (2013). Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev*, *5*, CD000951.
3121. Shefrin, A. E., & Goldman, R. D. (2009). Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. *Can Fam Physician*, *55*(7), 704-706.
3122. Shekelle, P. G., Newberry, S. J., FitzGerald, J. D., Motala, A., O'Hanlon, C. E., Tariq, A., . . . Shanman, R. (2017). Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. *Ann Intern Med*, *166*(1), 37-51.
3123. Shen, C. H., Zhang, Y. X., Lu, R. Y., Jin, B., Wang, S., Liu, Z. R., . . . Ding, M. P. (2016). Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. *Epilepsy Res*, *127*, 186-190.
3124. Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B., & Li, C. (2007). Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. *Drug Metab Dispos*, *35*(8), 1292-1300.
3125. Shen, X., Xia, J., & Adams, C. E. (2012). Flupenthixol versus placebo for schizophrenia. *Cochrane Database Syst Rev*, *11*, CD009777.
3126. Shen, Y. C., Chen, S. F., Chen, C. H., Lin, C. C., Chen, S. J., Chen, Y. J., & Luu, S. U. (2009). Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. *J Psychiatr Res*, *43*(6), 600-606.
3127. Shen, Z., Zheng, J., Chen, B., Peng, G., Zhang, T., Gong, S., . . . Guan, M. X. (2011). Frequency and spectrum of mitochondrial 12S rRNA variants in 440 Han Chinese hearing impaired pediatric subjects from two otology clinics. *J Transl Med*, *9*, 4.
3128. Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., . . . Westendorp, R. G. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*, *360*(9346), 1623-1630.
3129. Sherva, R., Ford, C. E., Eckfeldt, J. H., Davis, B. R., Boerwinkle, E., & Arnett, D. K. (2011). Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. *Stroke*, *42*(2), 330-335.

3130. Sheu, B. S., Kao, A. W., Cheng, H. C., Hunag, S. F., Chen, T. W., Lu, C. C., & Wu, J. J. (2005). Esomeprazole 40 mg twice daily in triple therapy and the efficacy of *Helicobacter pylori* eradication related to CYP2C19 metabolism. *Aliment Pharmacol Ther*, *21*(3), 283-288.
3131. Shi, Y. W., Min, F. L., Liu, X. R., Zan, L. X., Gao, M. M., Yu, M. J., & Liao, W. P. (2011). HLA-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. *Basic Clin Pharmacol Toxicol*, *109*(1), 42-46.
3132. Shi, Y. W., Min, F. L., Qin, B., Zou, X., Liu, X. R., Gao, M. M., . . . Liao, W. P. (2012). Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? *Basic Clin Pharmacol Toxicol*, *111*(1), 58-64.
3133. Shi, Y. W., Min, F. L., Zhou, D., Qin, B., Wang, J., Hu, F. Y., . . . Liao, W. P. (2017). HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. *Neurology*, *88*(23), 2183-2191.
3134. Shibata, M. C., Flather, M. D., & Wang, D. (2001). Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. *Eur J Heart Fail*, *3*(3), 351-357.
3135. Shield, M. J. (1985). Interim results of a multicenter international comparison of misoprostol and cimetidine in the treatment of out-patients with benign gastric ulcers. *Dig Dis Sci*, *30*(11 Suppl), 178S-184S.
3136. Shiffman, D., Sabatine, M. S., Louie, J. Z., Kirchgessner, T. G., Iakoubova, O. A., Campos, H., . . . Sacks, F. M. (2010). Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. *Am J Cardiol*, *105*(9), 1300-1305.
3137. Shiffman, S., Dresler, C. M., Hajek, P., Gilbert, S. J., Targett, D. A., & Strahs, K. R. (2002). Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med*, *162*(11), 1267-1276.
3138. Shimatani, T., Inoue, M., Kuroiwa, T., & Horikawa, Y. (2004). Rabepazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. *Aliment Pharmacol Ther*, *19*(1), 113-122.
3139. Shimatani, T., Inoue, M., Kuroiwa, T., Horikawa, Y., Mieno, H., & Nakamura, M. (2003). Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂-receptor antagonist. *Aliment Pharmacol Ther*, *18*(11-12), 1149-1157.
3140. Shimell, C. J., Fritz, V. U., & Levien, S. L. (1990). A comparative trial of flunarizine and propranolol in the prevention of migraine. *S Afr Med J*, *77*(2), 75-77.
3141. Shimoda, K., Morita, S., Hirokane, G., Yokono, A., Someya, T., & Takahashi, S. (2000). Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. *Pharmacol Toxicol*, *86*(6), 245-249.
3142. Shimoda, K., Morita, S., Yokono, A., Someya, T., Hirokane, G., Sunahara, N., & Takahashi, S. (2000). CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. *Ther Drug Monit*, *22*(4), 392-396.

3143. Shimoda, K., Someya, T., Yokono, A., Morita, S., Hirokane, G., Takahashi, S., & Okawa, M. (2002). The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. *J Clin Psychopharmacol*, 22(4), 371-378.
3144. Shin, S. W., Park, B. L., Chang, H., Park, J. S., Bae, D. J., Song, H. J., . . . Park, C. S. (2014). Exonic variants associated with development of aspirin exacerbated respiratory diseases. *PLoS One*, 9(11), e111887.
3145. Shionogi Inc. (2017). Fortamet (metformin hydrochloride xr). *US Product Monograph*,
3146. Shionogi Inc. (2017). Fortamet (metformin). *US Product Monograph*,
3147. Shionogi Inc. (2018). Ponstel (mefenamic acid). *US Product Monograph*,
3148. Shiota, S., Murakami, K., Takayama, A., Yasaka, S., Okimoto, T., Yoshiiwa, A., . . . Fujioka, T. (2009). Evaluation of Helicobacter pylori status and endoscopic findings among new outpatients with dyspepsia in Japan. *J Gastroenterol*, 44.
3149. Shiota, S., Reddy, R., Alsarraj, A., El-Serag, H. B., & Graham, D. Y. (2015). Antibiotic resistance of helicobacter pylori among male United States veterans. *Clin Gastroenterol Hepatol*, 13(9), 1616-1624.
3150. Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., . . . Ishizaki, T. (2001). Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. *Aliment Pharmacol Ther*, 15(12), 1929-1937.
3151. Shirai, N., Furuta, T., Xiao, F., Kajimura, M., Hanai, H., Ohashi, K., & Ishizaki, T. (2002). Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. *Aliment Pharmacol Ther*, 16(4), 837-846.
3152. Shirazi, A., Stubbs, B., Gomez, L., Moore, S., Gaughran, F., Flanagan, R. J., . . . Lally, J. (2016). Prevalence and predictors of clozapine-associated constipation: A systematic review and meta-analysis. *Int J Mol Sci*, 17(6).
3153. Shire LLC. (2018). Vyvanse (lisdexamfetamine). *US Product Monograph*,
3154. Shire Pharma Canada ULC. (2015). Adderall XR (mixed salts amphetamine) *CA Product Monograph*,
3155. Shire Pharma Canada ULC. (2016). Vyvanse (lisdexamfetamine). *CA Product Monograph*,
3156. Shire Pharma Canada ULC. (2017). Intuniv XR (guanfacine hydrochloride). *CA Product Monograph*,
3157. Shire US Manufacturing Inc. (2018). Adderall XR (mixed salts of a single-entity amphetamine product) *US Product Monograph*,
3158. Shire US Manufacturing Inc. (2018). Intuniv (guanfacine). *US Product Monograph*,
3159. Shireman, T. I., Howard, P. A., Kresowik, T. F., & Ellerbeck, E. F. (2004). Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. *Stroke*, 35(10), 2362-2367.
3160. Shiroma, P. R., Drews, M. S., Geske, J. R., & Mrazek, D. A. (2014). SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. *Am J Geriatr Psychiatry*, 22(11), 1140-1148.
3161. Shoeb, M., & Fang, M. C. (2013). Assessing bleeding risk in patients taking anticoagulants. *J Thromb Thrombolysis*, 35(3), 312-319.

3162. Shokri, F., Ghaedi, H., Ghafouri Fard, S., Movafagh, A., Abediankenari, S., Mahrooz, A., . . . Omrani, M. D. (2016). Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients. *Int J Mol Cell Med*, *5*(1), 1-7.
3163. Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M. E., . . . Ling, W. (2002). Smoking cessation in methadone maintenance. *Addiction*, *97*(10), 1317-1328; discussion 1325.
3164. Shord, S. S., Cavallari, L. H., Gao, W., Jeong, H. Y., Deyo, K., Patel, S. R., . . . Molokie, R. E. (2009). The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. *Eur J Clin Pharmacol*, *65*(7), 651-658.
3165. Sidney H. Kennedy, S. V. P., Sophie Grigoriadis. (2018). Depression. *Compendium of Therapeutic Choices*,
3166. Sidney, S., Petitti, D. B., Soff, G. A., Cundiff, D. L., Tolan, K. K., & Quesenberry, C. P., Jr. (2004). Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. *Contraception*, *70*(1), 3-10.
3167. Sidor, M. M., & Macqueen, G. M. (2011). Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. *J Clin Psychiatry*, *72*(2), 156-167.
3168. Sigterman, K. E., van Pinxteren, B., Bonis, P. A., Lau, J., & Numans, M. E. (2013). Short-term treatment with proton pump inhibitors, H₂-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev*(5), Cd002095.
3169. Silberstein, S., Dodick, D., Lindblad, A., Holroyd, K., Harrington, M., Mathew, N., & Hirtz, D. (2012). Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. *Neurology*, *78*(13), 976-984.
3170. Silberstein, S. D. (2017). Topiramate in Migraine Prevention: A 2016 Perspective. *Headache*, *57*(1), 165-178.
3171. Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., . . . Aycardi, E. (2017). Fremanezumab for the preventive treatment of chronic migraine. *N Engl J Med*, *377*(22), 2113-2122.
3172. Silberstein, S. D., Elkind, A. H., Schreiber, C., & Keywood, C. (2004). A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. *Neurology*, *63*(2), 261-269.
3173. Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012). Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*, *78*(17), 1337-1345.
3174. Silberstein, S. D., Hulihan, J., Karim, M. R., Wu, S. C., Jordan, D., Karvois, D., & Kamin, M. (2006). Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. *Clin Ther*, *28*(7), 1002-1011.
3175. Silberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., . . . Hulihan, J. (2007). Efficacy and safety of topiramate for the treatment of chronic

- migraine: a randomized, double-blind, placebo-controlled trial. *Headache*, 47(2), 170-180.
3176. Silberstein, S. D., Neto, W., Schmitt, J., Jacobs, D., & Group, M.-S. (2004). Topiramate in migraine prevention: results of a large controlled trial. *Arch Neurol*, 61(4), 490-495.
3177. Siller-Matula, J. M., Jilma, B., Schror, K., Christ, G., & Huber, K. (2010). Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. *J Thromb Haemost*, 8(12), 2624-2641.
3178. Silva, M. T., Zimmermann, I. R., Galvao, T. F., & Pereira, M. G. (2013). Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. *J Affect Disord*, 146(3), 310-318.
3179. Silva-Neto, R. P., Almeida, K. J., & Bernardino, S. N. (2014). Analysis of the duration of migraine prophylaxis. *J Neurol Sci*, 337(1-2), 38-41.
3180. Silver, H. J., Niswender, K. D., Keil, C. D., Jiang, L., Feng, Q., Chiu, S., . . . Wilke, R. A. (2012). CNR1 genotype influences HDL-cholesterol response to change in dietary fat intake. *PLoS One*, 7(5), e36166.
3181. Silverstein, F. E., Graham, D. Y., Senior, J. R., Davies, H. W., Struthers, B. J., Bittman, R. M., & Geis, G. S. (1995). Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*, 123(4), 241-249.
3182. Sim, S. C., Risinger, C., Dahl, M. L., Aklillu, E., Christensen, M., Bertilsson, L., & Ingelman-Sundberg, M. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin Pharmacol Ther*, 79(1), 103-113.
3183. Simon, B., & Muller, P. (1994). Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients. *Scand J Gastroenterol Suppl*, 206, 25-28.
3184. Simon, J. A., Duncan, C., Carmody, T. P., & Hudes, E. S. (2004). Bupropion for smoking cessation: a randomized trial. *Arch Intern Med*, 164(16), 1797-1803.
3185. Simpson, D. M., Hallett, M., Ashman, E. J., Comella, C. L., Green, M. W., Gronseth, G. S., . . . Yablon, S. A. (2016). Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*, 86(19), 1818-1826.
3186. Simren, M., Vos, R., Janssens, J., & Tack, J. (2003). Acid infusion enhances duodenal mechanosensitivity in healthy subjects. *Am J Physiol Gastrointest Liver Physiol*, 285.
3187. Sindrup, S. H., Broesen, K., & Gram, L. F. (1992). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. *Clin Pharmacol Ther*, 51(3), 288-295.
3188. Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., . . . Zussman, B. D. (1992). The relationship between paroxetine and the sparteine oxidation polymorphism. *Clinical Pharmacology & Therapeutics*, 51(3), 278-287.

3189. Singh, A. B. (2015). Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. *Clin Psychopharmacol Neurosci*, 13(2), 150-156.
3190. Singh, D., Agusti, A., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., . . . Vogelmeier, C. (2019). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. *Eur Respir J*, 53(5).
3191. Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., . . . Tugwell, P. (2009). Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database Syst Rev*(4), CD007848.
3192. Singh, J. A., Saag, K. G., Bridges, S. L., Jr., Akl, E. A., Bannuru, R. R., Sullivan, M. C., . . . American College of, R. (2016). 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*, 68(1), 1-25.
3193. Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011). Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. *CMAJ*, 183(12), 1359-1366.
3194. Singkham, N., Towanabut, S., Lertkachatarn, S., & Punyawudho, B. (2013). Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. *Eur J Clin Pharmacol*, 69(6), 1285-1291.
3195. Sistonen, J., Madadi, P., Ross, C. J., Yazdanpanah, M., Lee, J. W., Landsmeer, M. L., . . . Hayden, M. R. (2012). Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. *Clin Pharmacol Ther*, 91(4), 692-699.
3196. Siu, A. L., & Force, U. S. P. S. T. (2015). Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. preventive services task force recommendation statement. *Ann Intern Med*, 163(8), 622-634.
3197. Sivaraman, P., Rattehalli, R. D., & Jayaram, M. B. (2010). Levomepromazine for schizophrenia. *Cochrane Database Syst Rev*(10), CD007779.
3198. Sivem Pharmaceuticals ULC. (2014). Irbesartan. *CA Product Monograph*,
3199. Sivem Pharmaceuticals ULC. (2015). Domperidone. *CA Product Monograph*,
3200. Sivem Pharmaceuticals ULC. (2015). Tramadol / Acetaminophen *CA Product Monograph*,
3201. Sivem Pharmaceuticals ULC. (2016). Amiodarone. *CA Product Monograph*,
3202. Sivem Pharmaceuticals ULC. (2018). Carvedilol *CA Product Monograph*,
3203. Sivera, F., Wechalekar, M. D., Andres, M., Buchbinder, R., & Carmona, L. (2014). Interleukin-1 inhibitors for acute gout. *Cochrane Database Syst Rev*(9), CD009993.
3204. Skanes, A. C., Healey, J. S., Cairns, J. A., Dorian, P., Gillis, A. M., McMurtry, M. S., . . . Nattel, S. (2012). Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. *Can J Cardiol*, 28(2), 125-136.
3205. Skljarevski, V., Desai, D., Liu-Seifert, H., Zhang, Q., Chappell, A. S., Detke, M. J., . . . Backonja, M. (2010). Efficacy and safety of duloxetine in patients with chronic low back pain. *Spine (Phila Pa 1976)*, 35(13), E578-585.
3206. Skljarevski, V., Ossanna, M., Liu-Seifert, H., Zhang, Q., Chappell, A., Iyengar, S., . . . Backonja, M. (2009). A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. *Eur J Neurol*, 16(9), 1041-1048.

3207. Skljarevski, V., Zhang, S., Desai, D., Alaka, K. J., Palacios, S., Miazgowski, T., & Patrick, K. (2010). Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. *J Pain, 11*(12), 1282-1290.
3208. Slankard, M., Michelis, M. A., Mansukhani, M., McGoey, B., Paige, A., Andrews, H., . . . DiMango, E. (2016). Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma. *J Asthma, 53*(8), 783-789.
3209. Slobodnick, A., Shah, B., Krasnokutsky, S., & Pillinger, M. H. (2018). Update on colchicine, 2017. *Rheumatology (Oxford), 57*(suppl_1), i4-i11.
3210. Slooter, A. J., Rosendaal, F. R., Tanis, B. C., Kemmeren, J. M., van der Graaf, Y., & Algra, A. (2005). Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. *J Thromb Haemost, 3*(6), 1213-1217.
3211. Smith, D. A., Cleary, E. W., Watkins, S., Huffman, C. S., & Polvino, W. J. (1998). Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. *Int J Clin Pharmacol Ther, 36*(6), 301-305.
3212. Smith, J. A. (1980). Neutropenia associated with metronidazole therapy. *Can Med Assoc J, 123*(3), 202.
3213. Smith, J. C., & Curry, S. C. (2011). Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. *J Med Toxicol, 7*(3), 220-223.
3214. Smith, L. A., Cornelius, V., Warnock, A., Tacchi, M. J., & Taylor, D. (2007). Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. *Acta Psychiatr Scand, 115*(1), 12-20.
3215. Smith, P. K., Goodnough, L. T., Levy, J. H., Poston, R. S., Short, M. A., Weerakkody, G. J., & Lenarz, L. A. (2012). Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. *J Am Coll Cardiol, 60*(5), 388-396.
3216. Smith, R. L., Haslemo, T., Refsum, H., & Molden, E. (2016). Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring data. *Eur J Clin Pharmacol, 72*(9), 1099-1104.
3217. Smith, S. C., Jr., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., . . . Taubert, K. A. (2011). AHA/ACC secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. *J Am Coll Cardiol, 58*(23), 2432-2446.
3218. Smith, S. R., Deshpande, B. R., Collins, J. E., Katz, J. N., & Losina, E. (2016). Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. *Osteoarthritis Cartilage, 24*(6), 962-972.
3219. Smith, S. S., McCarthy, D. E., Japuntich, S. J., Christiansen, B., Piper, M. E., Jorenby, D. E., . . . Jackson, T. C. (2009). Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med, 169*(22), 2148-2155.

3220. Smolen, J. S., Aletaha, D., Bijlsma, J. W., Breedveld, F. C., Boumpas, D., Burmester, G., . . . van der Heijde, D. (2010). Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*, *69*(4), 631-637.
3221. Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., . . . van der Heijde, D. (2016). Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*, *75*(1), 3-15.
3222. Smolen, J. S., Landewe, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., . . . van der Heijde, D. (2014). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*, *73*(3), 492-509.
3223. So, A., De Meulemeester, M., Pikhak, A., Yucel, A. E., Richard, D., Murphy, V., . . . Schlesinger, N. (2010). Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. *Arthritis Rheum*, *62*(10), 3064-3076.
3224. So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007). A pilot study of IL-1 inhibition by anakinra in acute gout. *Arthritis Res Ther*, *9*(2), R28.
3225. Sofi, F., Giusti, B., Marcucci, R., Gori, A. M., Abbate, R., & Gensini, G. F. (2011). Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. *Pharmacogenomics J*, *11*(3), 199-206.
3226. Soko, N. D., Chimusa, E., Masimirembwa, C., & Dandara, C. (2019). An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. *Pharmacogenomics J*, *19*(3), 240-248.
3227. Soleimani, F., Fahimi, F., Adimi Naghan, P., Nadji, S. A., Morowati, S., Naderi, N., & Masjedi, M. R. (2013). The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients. *Iran J Allergy Asthma Immunol*, *12*(4), 383-390.
3228. Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., . . . Carvalho, A. F. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. *Ther Clin Risk Manag*, *13*, 757-777.
3229. Solomon, G. D., Steel, J. G., & Spaccavento, L. J. (1983). Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. *Jama*, *250*(18), 2500-2502.
3230. Solomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., . . . McMurray, J. J. (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet*, *380*(9851), 1387-1395.
3231. Solvd Investigators, Yusuf, S., Pitt, B., Davis, C. E., Hood, W. B., & Cohn, J. N. (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*, *325*(5), 293-302.
3232. Solvd Investigators, Yusuf, S., Pitt, B., Davis, C. E., Hood, W. B., Jr., & Cohn, J. N. (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med*, *327*(10), 685-691.

3233. Somberg, J. C., Achari, R., & Laddu, A. R. (1991). Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. *Am Heart J*, *122*(3 Pt 2), 901-905.
3234. Someya, T., Shimoda, K., Suzuki, Y., Sato, S., Kawashima, Y., Hirokane, G., . . . Takahashi, S. (2003). Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. *Neuropsychopharmacology*, *28*(8), 1501-1505.
3235. Someya, T., Suzuki, Y., Shimoda, K., Hirokane, G., Morita, S., Yokono, A., . . . Takahashi, S. (1999). The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. *Psychiatry Clin Neurosci*, *53*(5), 593-597.
3236. Sonbolestan, S. A., Heshmat, K., Javanmard, S. H., & Saadatnia, M. (2013). Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. *Int J Prev Med*, *4*(1), 72-77.
3237. Song, G. G., Seo, Y. H., Kim, J. H., Choi, S. J., Ji, J. D., & Lee, Y. H. (2015). Association between TNF-alpha (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-alpha blockers in spondyloarthritis, psoriasis and Crohn's disease: a meta-analysis. *Pharmacogenomics*, *16*(12), 1427-1437.
3238. Sonne, D. P., & Hemmingsen, B. (2017). Comment on American Diabetes Association. Standards of medical care in diabetes-2017. *Diabetes Care* 2017;40(Suppl. 1):S1-S135. *Diabetes Care*, *40*(7), e92-e93.
3239. Sontag, S., Graham, D. Y., Belsito, A., Weiss, J., Farley, A., Grunt, R., . . . et al. (1984). Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. *N Engl J Med*, *311*(11), 689-693.
3240. Sorich, M. J., Rowland, A., McKinnon, R. A., & Wiese, M. D. (2014). CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. *Circ Cardiovasc Genet*, *7*(6), 895-902.
3241. Sorkness, C. A., Lemanske, R. F., Jr., Mauger, D. T., Boehmer, S. J., Chinchilli, V. M., Martinez, F. D., . . . Taussig, L. M. (2007). Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. *J Allergy Clin Immunol*, *119*(1), 64-72.
3242. SpecGx LLC. (2018). Nortriptyline. *US Product Monograph*,
3243. Spencer, T., Biederman, J., Wilens, T., Harding, M., O'Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. *J Am Acad Child Adolesc Psychiatry*, *35*(4), 409-432.
3244. Spencer, T. J., Greenbaum, M., Ginsberg, L. D., & Murphy, W. R. (2009). Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*, *19*(5), 501-510.
3245. Spigset, O., Axelsson, S., Norstrom, A., Hagg, S., & Dahlqvist, R. (2001). The major fluvoxamine metabolite in urine is formed by CYP2D6. *Eur J Clin Pharmacol*, *57*(9), 653-658.

3246. Spigset, O., Granberg, K., Hagg, S., Norstrom, A., & Dahlqvist, R. (1997). Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. *Eur J Clin Pharmacol*, 52(2), 129-133.
3247. Spiller, H. A., Hays, H. I., & Aleguas, A. (2013). Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. *CNS drugs*, 27(7), 531-543.
3248. Spina, E., Birgersson, C., von Bahr, C., Ericsson, O., Mellstrom, B., Steiner, E., & Sjoqvist, F. (1984). Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. *Clin Pharmacol Ther*, 36(5), 677-682.
3249. Spina, E., Steiner, E., Ericsson, O., & Sjoqvist, F. (1987). Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. *Clin Pharmacol Ther*, 41(3), 314-319.
3250. Spinasse, L. B., Santos, A. R., Suffys, P. N., Muxfeldt, E. S., & Salles, G. F. (2014). Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. *Pharmacogenomics*, 15(2), 169-178.
3251. Squibb & Sons LLC, E. R. (2017). Pravachol (pravastatin). *US Product Monograph*,
3252. Squibb & Sons LLC, E. R. (2018). Kenalog-40 (triamcinolone acetonide). *US Product Monograph*,
3253. Srinivasan, S., Kaur, V., Chamarthi, B., Littleton, K. R., Chen, L., Manning, A. K., . . . Florez, J. C. (2018). TCF7L2 genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). *Diabetes Care*, 41(3), 554-561.
3254. Sriranganathan, M. K., Vinik, O., Bombardier, C., & Edwards, C. J. (2014). Interventions for tophi in gout. *Cochrane Database Syst Rev*(10), CD010069.
3255. Srisurapanont, M., Maneeton, B., & Maneeton, N. (2004). Quetiapine for schizophrenia. *Cochrane Database Syst Rev*(2), CD000967.
3256. Srivastava, S., Wang, P. W., Hill, S. J., Childers, M. E., Keller, K. L., & Ketter, T. A. (2012). Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients. *J Psychiatr Res*, 46(7), 920-926.
3257. Stage, T. B., Christensen, M. M., Feddersen, S., Beck-Nielsen, H., & Brosen, K. (2013). The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARGgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. *Pharmacogenet Genomics*, 23(4), 219-227.
3258. Stahl, S. M. (2016). Mechanism of action of brexpiprazole: comparison with aripiprazole. *CNS Spectr*, 21(1), 1-6.
3259. Staiger, T. O., Gaster, B., Sullivan, M. D., & Deyo, R. A. (2003). Systematic review of antidepressants in the treatment of chronic low back pain. *Spine (Phila Pa 1976)*, 28(22), 2540-2545.

3260. Stamer, U. M., Lehnen, K., Hothker, F., Bayerer, B., Wolf, S., Hoeft, A., & Stuber, F. (2003). Impact of CYP2D6 genotype on postoperative tramadol analgesia. *Pain, 105*(1-2), 231-238.
3261. Stamer, U. M., Zhang, L., Book, M., Lehmann, L. E., Stuber, F., & Musshoff, F. (2013). CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. *PLoS One, 8*(3), e60239.
3262. Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., . . . Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. *Ann Rheum Dis, 76*(9), 1522-1528.
3263. Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011). Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. *Arthritis Rheum, 63*(2), 412-421.
3264. Stamp, L. K., Taylor, W. J., Jones, P. B., Dockerty, J. L., Drake, J., Frampton, C., & Dalbeth, N. (2012). Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum, 64*(8), 2529-2536.
3265. Stanton, A., & Grimshaw, G. (2013). Tobacco cessation interventions for young people. *Cochrane Database Syst Rev*(8), CD003289.
3266. Stavroulakis, G. A., Makris, T. K., Krespi, P. G., Hatzizacharias, A. N., Gialeraki, A. E., Anastasiadis, G., . . . Kyriakidis, M. (2000). Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. *Cardiovasc Drugs Ther, 14*(4), 427-432.
3267. Stead, L. F., Koilpillai, P., Fanshawe, T. R., & Lancaster, T. (2016). Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev, 3*, CD008286.
3268. Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012). Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev, 11*, CD000146.
3269. Steele, M., Weiss, M., Swanson, J., Wang, J., Prinzo, R. S., & Binder, C. E. (2006). A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. *Can J Clin Pharmacol, 13*(1), e50-62.
3270. Steg, P. G., James, S., Harrington, R. A., Ardissino, D., Becker, R. C., Cannon, C. P., . . . Group, P. S. (2010). Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. *Circulation, 122*(21), 2131-2141.
3271. Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blomstrom-Lundqvist, C., Borger, M. A., . . . Zahger, D. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J, 33*(20), 2569-2619.
3272. Steg, P. G., Mehta, S. R., Jukema, J. W., Lip, G. Y., Gibson, C. M., Kovar, F., . . . Granger, C. B. (2011). RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and

- tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. *Eur Heart J*, 32(20), 2541-2554.
3273. Steimer, W., Zopf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., . . . Leucht, S. (2004). Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. *Clin Chem*, 50(9), 1623-1633.
3274. Steimer, W., Zopf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., . . . Leucht, S. (2005). Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. *Clin Chem*, 51(2), 376-385.
3275. Stein, D. J., Cameron, A., Amrein, R., & Montgomery, S. A. (2002). Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. *Int Clin Psychopharmacol*, 17(4), 161-170.
3276. Stein, D. J., Ipser, J. C., & Balkom, A. J. (2004). Pharmacotherapy for social phobia. *Cochrane Database Syst Rev*(4), CD001206.
3277. Stein, M. B., Fyer, A. J., Davidson, J. R., Pollack, M. H., & Wiita, B. (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. *Am J Psychiatry*, 156(5), 756-760.
3278. Stein, M. B., Pollack, M. H., Bystritsky, A., Kelsey, J. E., & Mangano, R. M. (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. *Psychopharmacology (Berl)*, 177(3), 280-288.
3279. Steinberg, B. A., Beckley, P. D., Deering, T. F., Clark, C. L., Amin, A. N., Bauer, K. A., . . . Bhatt, D. L. (2013). Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. *Crit Pathw Cardiol*, 12(3), 107-115.
3280. Steiner, E., & Spina, E. (1987). Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. *Clin Pharmacol Ther*, 42(3), 278-282.
3281. Steiner, T. J., Ahmed, F., Findley, L. J., MacGregor, E. A., & Wilkinson, M. (1998). S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. *Cephalalgia*, 18(5), 283-286.
3282. Steiner, T. J., Joseph, R., Hedman, C., & Rose, F. C. (1988). Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. *Headache*, 28(1), 15-23.
3283. Stellar, S., Ahrens, S. P., Meibohm, A. R., & Reines, S. A. (1984). Migraine prevention with timolol. A double-blind crossover study. *Jama*, 252(18), 2576-2580.
3284. Stenkvist, J., Sonnerborg, A., & Weiland, O. (2013). HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. *J Viral Hepat*, 20(3), 193-199.
3285. Stepan, J. J., Burr, D. B., Li, J., Ma, Y. L., Petto, H., Sipos, A., . . . Pavo, I. (2010). Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. *Osteoporosis International*, 21(12), 2027-2036.

3286. Stephens, C., Lopez-Nevot, M. A., Ruiz-Cabello, F., Ulzurrun, E., Soriano, G., Romero-Gomez, M., . . . Andrade, R. J. (2013). HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. *PLoS One*, *8*(7), e68111.
3287. Stergiopoulos, K., & Brown, D. L. (2014). Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. *JAMA Intern Med*, *174*(8), 1330-1338.
3288. SteriMax Inc. (2004). Migranal (dihydroergotamine mesylate). *CA Product Monograph*,
3289. SteriMax Inc. (2015). Cefotaxime. *CA Product Monograph*,
3290. Stevens, J. W., Simpson, E., Harnan, S., Squires, H., Meng, Y., Thomas, S., . . . Stansby, G. (2012). Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. *Br J Surg*, *99*(12), 1630-1638.
3291. Stewart, A. (2013). SLCO1B1 polymorphisms and statin-induced myopathy. *PLoS Curr*, *5*,
3292. Stewart, M., Cibere, J., Sayre, E. C., & Kopec, J. A. (2018). Efficacy of commonly prescribed analgesics in the management of osteoarthritis: a systematic review and meta-analysis. *Rheumatol Int*, *38*(11), 1985-1997.
3293. Stiell, I. G., & Macle, L. (2011). Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. *Can J Cardiol*, *27*(1), 38-46.
3294. Stocker, S. L., Morrissey, K. M., Yee, S. W., Castro, R. A., Xu, L., Dahlin, A., . . . Giacomini, K. M. (2013). The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. *Clin Pharmacol Ther*, *93*(2), 186-194.
3295. Stone, N. J., Robinson, J. G., & Lichtenstein, A. (2014). The new cholesterol treatment guidelines. *N Engl J Med*, *370*(20), 1957.
3296. Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., . . . American College of Cardiology/American Heart Association Task Force on Practice, G. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*, *63*(25 Pt B), 2889-2934.
3297. Storey, J. R., Calder, C. S., Hart, D. E., & Potter, D. L. (2001). Topiramate in migraine prevention: a double-blind, placebo-controlled study. *Headache*, *41*(10), 968-975.
3298. Stott, D. J., Dewar, R. I., Garratt, C. J., Griffith, K. E., Harding, N. J., James, M. A., . . . Trueland, J. (2012). RCPE UK Consensus Conference on 'Approaching the comprehensive management of atrial fibrillation: evolution or revolution?'. *J R Coll Physicians Edinb*, *42 Suppl 18*, 3-4.
3299. Stovner, L. J., Linde, M., Gravdahl, G. B., Tronvik, E., Aamodt, A. H., Sand, T., & Hagen, K. (2014). A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. *Cephalalgia*, *34*(7), 523-532.

3300. Stranges, P. M., Drew, A. M., Rafferty, P., Shuster, J. E., & Brooks, A. D. (2015). Treatment of hypertension with chronotherapy: is it time of drug administration? *Ann Pharmacother*, *49*(3), 323-334.
3301. Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., . . . Young, A. H. (2019). Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. *Br J Psychiatry*, *214*(1), 42-51.
3302. Strohmaier, J., Wust, S., Uher, R., Henigsberg, N., Mors, O., Hauser, J., . . . Rietschel, M. (2011). Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. *World J Biol Psychiatry*, *12*(7), 528-538.
3303. Stupnicki, T., Dietrich, K., Gonzalez-Carro, P., Straszak, A., Terjung, A., Thomas, K. B., . . . Fischer, R. (2003). Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. *Digestion*, *68*(4), 198-208.
3304. Subcommittee on Attention-Deficit/Hyperactivity Disorder Steering Committee on Quality Improvement Management, Wolraich, M., Brown, L., Brown, R. T., DuPaul, G., Earls, M., . . . Visser, S. (2011). ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics*, *128*(5), 1007-1022.
3305. Sudilovsky, A., Elkind, A. H., Ryan, R. E., Sr., Saper, J. R., Stern, M. A., & Meyer, J. H. (1987). Comparative efficacy of nadolol and propranolol in the management of migraine. *Headache*, *27*(8), 421-426.
3306. Sugahara, H., Maebara, C., Ohtani, H., Handa, M., Ando, K., Mine, K., . . . Sawada, Y. (2009). Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. *Eur J Clin Pharmacol*, *65*(7), 699-704.
3307. Sugai, T., Suzuki, Y., Sawamura, K., Fukui, N., Inoue, Y., & Someya, T. (2006). The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. *Pharmacogenomics J*, *6*(5), 351-356.
3308. Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Hishida, A., & Ishizaki, T. (2006). Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of *Helicobacter pylori* by triple therapy. *Clin Pharmacol Ther*, *80*(1), 41-50.
3309. Sugimoto, M., Furuta, T., Shirai, N., Ikuma, M., Hishida, A., & Ishizaki, T. (2006). Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. *Clin Pharmacol Ther*, *80*(5), 539-548.
3310. Sugimoto, M., Furuta, T., Shirai, N., Kajimura, M., Hishida, A., Sakurai, M., . . . Ishizaki, T. (2004). Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. *Clin Pharmacol Ther*, *76*(4), 290-301.
3311. Sugimoto, M., Furuta, T., Shirai, N., Nakamura, A., Kajimura, M., Hishida, A., . . . Ishizaki, T. (2005). Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid

- inhibition in relation to cytochrome P450 2C19 genotypes. *Clin Pharmacol Ther*, 77(4), 302-311.
3312. Sugimoto, M., Shirai, N., Nishino, M., Kodaira, C., Uotani, T., Sahara, S., . . . Furuta, T. (2014). Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. *Eur J Clin Pharmacol*, 70(9), 1073-1078.
3313. Sukasem, C., Hongkaew, Y., Ngamsamut, N., Puangpetch, A., Vanwong, N., Chamnanphon, M., . . . Limsila, P. (2016). Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. *J Clin Psychopharmacol*, 36(2), 141-146.
3314. Sun, H., Guo, S., Chen, D., Yang, F., Zou, Y., Di, X., . . . Zhang, X. Y. (2012). Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. *J Neural Transm (Vienna)*, 119(12), 1491-1498.
3315. Sun Pharmaceutical Industries Inc. (2018). Riomet (metformin). *US Product Monograph*,
3316. Sun Pharmaceutical Industries Inc. (2018). Riomet (metformin). *US Product Monograph*,
3317. Sun, X., Yu, W. Y., Ma, W. L., Huang, L. H., & Yang, G. P. (2016). Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. *Biomed Rep*, 4(4), 498-506.
3318. Sun, Y., Wu, Z., Li, S., Qin, X., Li, T., Xie, L., . . . Chen, J. (2015). Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. *Thromb Res*, 135(4), 739-747.
3319. Sundy, J. S., Baraf, H. S., Yood, R. A., Edwards, N. L., Gutierrez-Urena, S. R., Treadwell, E. L., . . . Becker, M. A. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. *Jama*, 306(7), 711-720.
3320. Sundy, J. S., Becker, M. A., Baraf, H. S., Barkhuizen, A., Moreland, L. W., Huang, W., . . . Pegloticase Phase 2 Study, I. (2008). Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. *Arthritis Rheum*, 58(9), 2882-2891.
3321. Sundy, J. S., Schumacher, H. R., Kivitz, A., Weinstein, S. P., Wu, R., King-Davis, S., & Evans, R. R. (2014). Riloncept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. *J Rheumatol*, 41(8), 1703-1711.
3322. Sung, J. J., Lau, J. Y., Ching, J. Y., Wu, J. C., Lee, Y. T., Chiu, P. W., . . . Chan, F. K. (2010). Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. *Ann Intern Med*, 152(1), 1-9.
3323. Sunovion Pharmaceuticals Canada Inc. (2016). Latuda (lurasidone HCl). *CA Product Monograph*,
3324. Sunovion Pharmaceuticals Inc. (2017). Arcapta Neohaler (indacaterol maleate). *US Product Monograph*,
3325. Sunovion Pharmaceuticals Inc. (2017). Xopenex HFA (levalbuterol tartrate). *US Product Monograph*,

3326. Sunovion Pharmaceuticals Inc. (2018). Brovana (arformoterol tartrate). *US Product Monograph*,
3327. Suonsyrja, T., Hannila-Handelberg, T., Fodstad, H., Donner, K., Kontula, K., & Hiltunen, T. P. (2009). Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. *Am J Hypertens*, 22(2), 169-175.
3328. Supernus Pharmaceuticals Inc. (2015). Oxtellar XR (oxcarbazepine). *US Product Monograph*,
3329. Suppes, T., Silva, R., Cucchiario, J., Mao, Y., Targum, S., Streicher, C., . . . Loebel, A. (2016). Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*, 173(4), 400-407.
3330. Suppes, T., Vieta, E., Gustafsson, U., & Ekholm, B. (2013). Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. *Depress Anxiety*, 30(11), 1089-1098.
3331. Susce, M. T., Murray-Carmichael, E., & de Leon, J. (2006). Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. *Prog Neuropsychopharmacol Biol Psychiatry*, 30(7), 1356-1358.
3332. Susser, S., Herrmann, E., Lange, C., Hamdi, N., Muller, T., Berg, T., . . . Sarrazin, C. (2014). Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. *PLoS One*, 9(11), e112592.
3333. Sutaria, S., Katbamna, R., & Underwood, M. (2006). Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. *Rheumatology (Oxford)*, 45(11), 1422-1431.
3334. Sutiman, N., Chen, S., Ling, K. L., Chuah, S. W., Leong, W. F., Nadiger, V., . . . Chowbay, B. (2018). Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. *Pharmacogenomics*, 19(1), 31-43.
3335. Suttajit, S., Srisurapanont, M., Xia, J., Suttajit, S., Maneeton, B., & Maneeton, N. (2013). Quetiapine versus typical antipsychotic medications for schizophrenia. *Cochrane Database Syst Rev*(5), CD007815.
3336. Suzuki, F., Suzuki, Y., Akuta, N., Sezaki, H., Hirakawa, M., Kawamura, Y., . . . Kumada, H. (2011). Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. *Hepatology*, 53(2), 415-421.
3337. Suzuki, H., Hibi, T., & Marshall, B. J. (2007). Helicobacter pylori: Present status and future prospects in Japan. *J Gastroenterol*, 42.
3338. Suzuki, Y., Sawamura, K., & Someya, T. (2006). Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. *Neuropsychopharmacology*, 31(4), 825-831.
3339. Suzuki, Y., Sugai, T., Fukui, N., Watanabe, J., Ono, S., Inoue, Y., . . . Someya, T. (2011). CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. *J Psychopharmacol*, 25(7), 908-914.

3340. Svanstrom, H., Pasternak, B., & Hviid, A. (2012). Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. *BMJ*, *345*, e7176.
3341. Svensson-Farbom, P., Wahlstrand, B., Almgren, P., Dahlberg, J., Fava, C., Kjeldsen, S., . . . Melander, O. (2011). A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. *J Hypertens*, *29*(2), 388-395.
3342. Swan, G. E., Valdes, A. M., Ring, H. Z., Khroyan, T. V., Jack, L. M., Ton, C. C., . . . McAfee, T. (2005). Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. *Pharmacogenomics J*, *5*(1), 21-29.
3343. Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., . . . Group, C. S. (2004). A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). *Pediatrics*, *113*(3 Pt 1), e206-216.
3344. Swartz, M. S., Stroup, T. S., McEvoy, J. P., Davis, S. M., Rosenheck, R. A., Keefe, R. S., . . . Lieberman, J. A. (2008). What CATIE found: results from the schizophrenia trial. *Psychiatr Serv*, *59*(5), 500-506.
3345. Swedberg, K., Held, P., Kjekshus, J., Rasmussen, K., Ryden, L., & Wedel, H. (1992). Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med*, *327*(10), 678-684.
3346. Swedberg, K., & Kjekshus, J. (1988). Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *Am J Cardiol*, *62*(2), 60A-66A.
3347. Swedberg, K., Komajda, M., Bohm, M., Borer, J. S., Ford, I., Dubost-Brama, A., . . . Tavazzi, L. (2010). Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet*, *376*(9744), 875-885.
3348. Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., . . . Guchelaar, H. J. (2011). Pharmacogenetics: from bench to byte--an update of guidelines. *Clin Pharmacol Ther*, *89*(5), 662-673.
3349. Swen, J. J., Wilting, I., de Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., . . . Deneer, V. H. (2008). Pharmacogenetics: from bench to byte. *Clin Pharmacol Ther*, *83*(5), 781-787.
3350. Szeffler, S. J., Baker, J. W., Uryniak, T., Goldman, M., & Silkoff, P. E. (2007). Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. *J Allergy Clin Immunol*, *120*(5), 1043-1050.
3351. Szegedi, A., Calabrese, J. R., Stet, L., Mackle, M., Zhao, J., & Panagides, J. (2012). Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. *J Clin Psychopharmacol*, *32*(1), 46-55.
3352. Szegedi, A., Durgam, S., Mackle, M., Yu, S. Y., Wu, X., Mathews, M., & Landbloom, R. P. (2018). Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. *Am J Psychiatry*, *175*(1), 71-79.

3353. Szegedi, A., Jansen, W. T., van Willigenburg, A. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. *J Clin Psychiatry, 70*(3), 344-353.
3354. Szegedi, A., Muller, M. J., Anghelescu, I., Klawe, C., Kohnen, R., & Benkert, O. (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. *J Clin Psychiatry, 64*(4), 413-420.
3355. Szegedi, A., Zhao, J., van Willigenburg, A., Nations, K. R., Mackle, M., & Panagides, J. (2011). Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. *BMC Psychiatry, 11*, 101.
3356. Szeinberg, A., Pras, M., Sheba, C., Adam, A., & Ramot, B. (1959). The hemolytic effect of various sulfonamides on subjects with a deficiency of glucose-6-phosphate dehydrogenase of erythrocytes. *Isr Med J, 18*, 176-183.
3357. Tacke, U., Leinonen, E., Lillsunde, P., Seppala, T., Arvela, P., Pelkonen, O., & Ylitalo, P. (1992). Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. *J Clin Psychopharmacol, 12*(4), 262-267.
3358. Taguchi, M., Nozawa, T., Kameyama, T., Inoue, H., Takesono, C., Mizukami, A., & Hashimoto, Y. (2003). Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. *Eur J Clin Pharmacol, 59*(5-6), 385-388.
3359. Taguchi, M., Nozawa, T., Mizumaki, K., Inoue, H., Tahara, K., Takesono, C., & Hashimoto, Y. (2004). Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. *Biol Pharm Bull, 27*(10), 1642-1648.
3360. Taha, A. S., Hudson, N., Hawkey, C. J., Swannell, A. J., Trye, P. N., Cottrell, J., . . . Russell, R. I. (1996). Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. *N Engl J Med, 334*(22), 1435-1439.
3361. Taha, A. S., McCloskey, C., Prasad, R., & Bezlyak, V. (2009). Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. *Lancet, 374*(9684), 119-125.
3362. Takahashi, R., Sakuma, A., Itoh, K., Itoh, H., & Kurihara, M. (1975). Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Report of collaborative study group on treatment of mania in Japan. *Arch Gen Psychiatry, 32*(10), 1310-1318.
3363. Take, S., Mizuno, M., Ishiki, K., Nagahara, Y., Yoshida, T., Inaba, T., . . . Shiratori, Y. (2003). Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. *Am J Gastroenterol, 98*(11), 2403-2408.
3364. Takeda Canada Inc. (2012). Alvesco (ciclesonide). *CA Product Monograph*,
3365. Takeda Canada Inc. (2016). Dexilant (dexlansoprazole). *CA Product Monograph*,
3366. Takeda Canada Inc. (2018). Actos (pioglitazone hydrochloride). *CA Product Monograph*,
3367. Takeda Canada Inc. (2018). Pantoloc (pantoprazole sodium). *CA Product Monograph*,

3368. Takeda Canada Inc. (2018). Tecta (pantoprazole magnesium) *CA Product Monograph*,
3369. Takeda Canada Inc. (2018). Uloric (febuxostat). *CA Product Monograph*,
3370. Takeda Pharmaceuticals America, I. (2018). Colcrys (colchicine). *US Product Monograph*,
3371. Takeda Pharmaceuticals America Inc. (2016). Nesina (alogliptin). *US Product Monograph*,
3372. Takeda Pharmaceuticals America Inc. (2016). Trintellix (vortioxetine). *US Product Monograph*,
3373. Takeda Pharmaceuticals America Inc. (2017). Actos (pioglitazone). *US Product Monograph*,
3374. Takeda Pharmaceuticals America Inc. (2018). Dexilant (dexlansoprazole). *US Product Monograph*,
3375. Takeda Pharmaceuticals America Inc. (2018). Prevacid (lansoprazole). *US Product Monograph*,
3376. Takeda Pharmaceuticals America Inc. (2018). Uloric (febuxostat). *US Product Monograph*,
3377. Takekuma, Y., Takenaka, T., Kiyokawa, M., Yamazaki, K., Okamoto, H., Kitabatake, A., . . . Sugawara, M. (2007). Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. *Biol Pharm Bull*, 30(3), 537-542.
3378. Talaei, A., Pourgholami, M., Khatibi-Moghadam, H., Faridhosseini, F., Farhoudi, F., Askari-Noghani, A., & Sadeghi, R. (2016). Tamoxifen: A protein kinase C inhibitor to treat mania: a systematic review and meta-analysis of randomized, placebo-controlled trials. *J Clin Psychopharmacol*, 36(3), 272-275.
3379. Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., . . . Church, D. A. (2000). Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *Jama*, 283(12), 1583-1590.
3380. Talebi, M., & Goldust, M. (2013). Oral magnesium; migraine prophylaxis. *J Pak Med Assoc*, 63(2), 286.
3381. Talley, N. J. (2005). Dyspepsia: management guidelines for the millennium. *Gut*, 50.
3382. Talley, N. J., Janssens, J., Lauritsen, K., Racz, I., & Bolling-Sternevald, E. (1999). Eradication of *Helicobacter pylori* in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The optimal regimen cures *Helicobacter* induced dyspepsia (ORCHID) study group. *BMJ*, 318.
3383. Talley, N. J., Locke, G. R., 3rd, Herrick, L. M., Silvernail, V. M., Prather, C. M., Lacy, B. E., . . . Zinsmeister, A. R. (2012). Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. *Contemp Clin Trials*, 33(3), 523-533.
3384. Talley, N. J., Locke, G. R., Saito, Y. A., Almazar, A. E., Bouras, E. P., Howden, C. W., . . . Zinsmeister, A. R. (2015). Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. *Gastroenterology*, 149(2), 340-349.e342.

3385. Talley, N. J., & Vakil, N. (2005). Guidelines for the management of dyspepsia. *Am J Gastroenterol*, 100.
3386. Tan, V. P., Cheung, T. K., Wong, W. M., Pang, R., & Wong, B. C. (2012). Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. *World J Gastroenterol*, 18(42), 6127-6133.
3387. Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Jr., Okasha, A., Singh, B., . . . Moeller, H. J. (2008). World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophr Res*, 100(1-3), 20-38.
3388. Tandon, R., Cucchiaro, J., Phillips, D., Hernandez, D., Mao, Y., Pikalov, A., & Loebel, A. (2016). A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. *J Psychopharmacol*, 30(1), 69-77.
3389. Tang, H. L., Li, Y., Hu, Y. F., Xie, H. G., & Zhai, S. D. (2013). Effects of CYP2C19 loss-of-function variants on the eradication of *H. pylori* infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. *PLoS One*, 8(4), e62162.
3390. Tang, H. L., Xie, H. G., Yao, Y., & Hu, Y. F. (2011). Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. *Pharmacogenet Genomics*, 21(11), 713-720.
3391. Tang, W., Shi, Q. P., Ding, F., Yu, M. L., Hua, J., & Wang, Y. X. (2017). Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies. *Int J Clin Pharmacol Ther*, 55(4), 304-321.
3392. Tang, W. H., Vagelos, R. H., Yee, Y. G., & Fowler, M. B. (2004). Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. *Am Heart J*, 148(5), 889-894.
3393. Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M., & Tassaneeyakul, W. (2013). Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. *JAMA Dermatology*, 149(9), 1025-1032.
3394. Tanguay, J. F., Bell, A. D., Ackman, M. L., Bauer, R. D., Cartier, R., Chan, W. S., . . . Mehta, S. R. (2013). Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. *Can J Cardiol*, 29(11), 1334-1345.
3395. Tanigawara, Y., Aoyama, N., Kita, T., Shirakawa, K., Komada, F., Kasuga, M., & Okumura, K. (1999). CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by *helicobacter pylori*. *Clin Pharmacol Ther*, 66(5), 528-534.
3396. Tanner, R. M., Lynch, A. I., Brophy, V. H., Eckfeldt, J. H., Davis, B. R., Ford, C. E., . . . Arnett, D. K. (2011). Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. *PLoS One*, 6(8), e23609.
3397. Tantisira, K. G., Lake, S., Silverman, E. S., Palmer, L. J., Lazarus, R., Silverman, E. K., . . . Weiss, S. T. (2004). Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. *Hum Mol Genet*, 13(13), 1353-1359.

3398. Tao, X. R., Xia, X. Y., Zhang, J., Tong, L. Y., Zhang, W., Zhou, X., . . . Song, H. T. (2015). CYP3A4 *18B and CYP3A5 *3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. *Eur J Pharm Sci*, 76, 238-244.
3399. Tardy, M., Dold, M., Engel, R. R., & Leucht, S. (2014). Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*(9), CD009227.
3400. Tardy, M., Dold, M., Engel, R. R., & Leucht, S. (2014). Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*(7), CD009396.
3401. Tardy, M., Huhn, M., Engel, R. R., & Leucht, S. (2014). Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*(8), CD009230.
3402. Tardy, M., Huhn, M., Engel, R. R., & Leucht, S. (2014). Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*(10), CD009369.
3403. Tardy, M., Huhn, M., Kissling, W., Engel, R. R., & Leucht, S. (2014). Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev*(7), CD009268.
3404. Targownik, L. E., Bolton, J. M., Metge, C. J., Leung, S., & Sareen, J. (2009). Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. *Am J Gastroenterol*, 104(6), 1475-1482.
3405. Targownik, L. E., Lix, L. M., Metge, C. J., Prior, H. J., Leung, S., & Leslie, W. D. (2008). Use of proton pump inhibitors and risk of osteoporosis-related fractures. *CMAJ*, 179(4), 319-326.
3406. Targownik, L. E., Metge, C. J., Leung, S., & Chateau, D. G. (2008). The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. *Gastroenterology*, 134(4), 937-944.
3407. Targum, S. D., Daly, E., Fedgchin, M., Cooper, K., & Singh, J. B. (2019). Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. *J Psychiatr Res*, 111, 68-73.
3408. Tarkiainen, E. K., Holmberg, M. T., Tornio, A., Neuvonen, M., Neuvonen, P. J., Backman, J. T., & Niemi, M. (2015). Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. *Clin Pharmacol Ther*, 97(6), 650-658.
3409. Tarlaci, S. (2009). Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. *Clin Neuropharmacol*, 32(5), 254-258.
3410. Taro Pharmaceuticals USA Inc. (2014). Oxcarbazepine *US Product Monograph*,
3411. Tarr, G. P., Glue, P., & Herbison, P. (2011). Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania. *J Affect Disord*, 134(1-3), 14-19.
3412. Tartaglione, G., Pagan, M., Morese, R., Cappellini, G. A., Zappala, A. R., Sebastiani, C., . . . Rubello, D. (2010). Intradermal lymphoscintigraphy at rest and after exercise: a new

- technique for the functional assessment of the lymphatic system in patients with lymphoedema. *Nucl Med Commun*, 31(6), 547-551.
3413. Tassaneeyakul, W., Prabmeechai, N., Sukasem, C., Kongpan, T., Konyoung, P., Chumworathayi, P., . . . Tassaneeyakul, W. (2016). Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. *Pharmacogenet Genomics*, 26(5), 225-234.
3414. Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Chen, P., Lin, S. Y., Chen, W. H., . . . Yodnopaglaw, P. (2010). Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. *Epilepsia*, 51(5), 926-930.
3415. Tata, L. J., Fortun, P. J., Hubbard, R. B., Smeeth, L., Hawkey, C. J., Smith, C. J., . . . West, J. (2005). Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? *Aliment Pharmacol Ther*, 22(3), 175-181.
3416. Tatarunas, V., Kupstyte, N., Giedraitiene, A., Skipskis, V., Jakstas, V., Zvikas, V., & Lesauskaite, V. (2017). The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy. *Blood Coagul Fibrinolysis*, 28(8), 658-664.
3417. Tatham, E. L., Hall, G. B., Clark, D., Foster, J., & Ramasubbu, R. (2017). The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression. *Eur Arch Psychiatry Clin Neurosci*, 267(2), 135-147.
3418. Tavares, M., de Lima, C., Fernandes, W., Martinelli, V., de Lucena, M., Lima, F., . . . de Melo Junior, M. (2016). Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients. *Int J Immunogenet*, 43(6), 376-382.
3419. Tayar, J. H., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2012). Febuxostat for treating chronic gout. *Cochrane Database Syst Rev*, 11, CD008653.
3420. Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., . . . Turco, M. (2009). Extended-release niacin or ezetimibe and carotid intima-media thickness. *N Engl J Med*, 361(22), 2113-2122.
3421. Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Jr., Ferdinand, K., . . . Cohn, J. N. (2004). Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med*, 351(20), 2049-2057.
3422. Taylor, D., Stewart, S., & Connolly, A. (2006). Antidepressant withdrawal symptoms--telephone calls to a national medication helpline. *J Affect Disord*, 95(1-3), 129-133.
3423. Taylor, D. M., & Smith, L. (2009). Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies. *Acta Psychiatr Scand*, 119(6), 419-425.
3424. Taylor, T. H., Mecchella, J. N., Larson, R. J., Kerin, K. D., & Mackenzie, T. A. (2012). Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. *Am J Med*, 125(11), 1126-1134 e1127.

3425. Teh, L. K., Selvaraj, M., Bannur, Z., Ismail, M. I., Rafia, H., Law, W. C., . . . Salleh, M. Z. (2016). Coupling genotyping and computational modeling in prediction of anti-epileptic drugs that cause Stevens Johnson Syndrome and toxic epidermal necrolysis for carrier of HLA-B*15:02. *J Pharm Pharm Sci*, 19(1), 147-160.
3426. ten Wolde, S., Dijkmans, B. A., Janssen, M., Hermans, J., & Lamers, C. B. (1996). High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. *Aliment Pharmacol Ther*, 10(3), 347-351.
3427. Tepper, S., Allen, C., Sanders, D., Greene, A., & Boccuzzi, S. (2003). Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. *Headache*, 43(1), 44-48.
3428. Tepper, S. J. (2012). Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice. *Headache*, 52(2), 195-197.
3429. Terkeltaub, R., Sundry, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., . . . Radin, A. (2009). The interleukin 1 inhibitor riloncept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. *Ann Rheum Dis*, 68(10), 1613-1617.
3430. Terkeltaub, R. A., Furst, D. E., Bennett, K., Kook, K. A., Crockett, R. S., & Davis, M. W. (2010). High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum*, 62(4), 1060-1068.
3431. Terkeltaub, R. A., Furst, D. E., Digiacinto, J. L., Kook, K. A., & Davis, M. W. (2011). Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. *Arthritis Rheum*, 63(8), 2226-2237.
3432. Terkeltaub, R. A., Schumacher, H. R., Carter, J. D., Baraf, H. S., Evans, R. R., Wang, J., . . . Weinstein, S. P. (2013). Riloncept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. *Arthritis Res Ther*, 15(1), R25.
3433. Terra, S. G., Pauly, D. F., Lee, C. R., Patterson, J. H., Adams, K. F., Schofield, R. S., . . . Johnson, J. A. (2005). beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. *Clin Pharmacol Ther*, 77(3), 127-137.
3434. Terrazzino, S., Cargnin, S., Del Re, M., Danesi, R., Canonico, P. L., & Genazzani, A. A. (2013). DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. *Pharmacogenomics*, 14(11), 1255-1272.
3435. Terrazzino, S., Quaglia, M., Stratta, P., Canonico, P. L., & Genazzani, A. A. (2012). The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. *Pharmacogenet Genomics*, 22(8), 642-645.
3436. Teva Canada Limited. (2011). Nitrofurantoin. *CA Product Monograph*,
3437. Teva Canada Limited. (2011). Prazosin. *CA Product Monograph*,
3438. Teva Canada Limited. (2011). Sulindac. *CA Product Monograph*,

- 3439. Teva Canada Limited. (2011). Theophylline SR. *CA Product Monograph*,
- 3440. Teva Canada Limited. (2011). Timolol. *CA Product Monograph*,
- 3441. Teva Canada Limited. (2012). Chlorpromazine. *CA Product Monograph*,
- 3442. Teva Canada Limited. (2013). Ceftriaxone. *CA Product Monograph*,
- 3443. Teva Canada Limited. (2013). Ipratropium UDV. *CA Product Monograph*,
- 3444. Teva Canada Limited. (2014). Doxycycline. *CA Product Monograph*,
- 3445. Teva Canada Limited. (2015). Cephalexin. *CA Product Monograph*,
- 3446. Teva Canada Limited. (2015). Flurbiprofen. *CA Product Monograph*,
- 3447. Teva Canada Limited. (2015). Gemfibrozil. *CA Product Monograph*,
- 3448. Teva Canada Limited. (2015). Indomethacin. *CA Product Monograph*,
- 3449. Teva Canada Limited. (2016). Fluvastatin. *CA Product Monograph*,
- 3450. Teva Canada Limited. (2016). Haloperidol. *CA Product Monograph*,
- 3451. Teva Canada Limited. (2017). Alerte (modafinil). *CA Product Monograph*,
- 3452. Teva Canada Limited. (2017). Budesonide. *CA Product Monograph*,
- 3453. Teva Canada Limited. (2017). Cinqair (reslizumab). *CA Product Monograph*,
- 3454. Teva Canada Limited. (2017). Etidronate (etidronate). *CA Product Monograph*,
- 3455. Teva Canada Limited. (2018). Oxycocet (oxycodone / acetaminophen). *CA Product Monograph*,
- 3456. Teva Canada Limited. (2018). Piperacillin / Tazobactam. *CA Product Monograph*,
- 3457. Teva Canada Ltd. (2011). Propranolol. *CA Product Monograph*,
- 3458. Teva Canada Ltd. (2011). Timolol. *CA Product Monograph*,
- 3459. Teva Pharmaceuticals USA Inc. (2015). Epitol (carbamazepine). *US Product Monograph*,
- 3460. Teva Pharmaceuticals USA Inc. (2015). Provigil (modafinil) *US Product Monograph*,
- 3461. Teva Pharmaceuticals USA Inc. (2016). Fosinopril. *US Product Monograph*,
- 3462. Teva Respiratory LLC. (2018). Airduo Respiclick (fluticasone propionate / salmeterol). *US Product Monograph*,
- 3463. Teva Respiratory LLC. (2018). Armonair Respiclick (fluticasone propionate). *US Product Monograph*,
- 3464. Teva Respiratory LLC. (2018). Proair Respiclick (albuterol sulphate). *US Product Monograph*,
- 3465. Teva Respiratory LLC. (2018). QVAR Redihaler (beclomethasone dipropionate hfa). *US Product Monograph*,
- 3466. Teva Respiratory LLC. (2019). Cinqair (reslizumab). *US Product Monograph*,
- 3467. Teva Select Brands. (2018). Orap (pimozide). *US Product Monograph*,
- 3468. Tfelt-Hansen, P., Standnes, B., Kangasneimi, P., Hakkarainen, H., & Olesen, J. (1984). Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. *Acta Neurol Scand*, 69(1), 1-8.
- 3469. Thaker, S. J., Gandhe, P. P., Godbole, C. J., Bendkhale, S. R., Mali, N. B., Thatte, U. M., & Gogtay, N. J. (2017). A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy. *J Ayurveda Integr Med*, 8(1), 37-41.

3470. Tham, T. C., Collins, J. S., Molloy, C., Sloan, J. M., Bamford, K. B., & Watson, R. G. (1996). Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of helicobacter pylori. *Ulster Med J*, 65(2), 131-136.
3471. Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., . . . Owen, R. (2008). Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. *J Clin Psychopharmacol*, 28(1), 13-20.
3472. Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., . . . Eriksson, H. (2015). Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. *J Clin Psychiatry*, 76(9), 1224-1231.
3473. Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., . . . Eriksson, H. (2015). Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. *J Clin Psychiatry*, 76(9), 1232-1240.
3474. The Management of Major Depressive Disorder Working Group. (2016). VA/DoD Clinical practice guideline for the management of major depressive disorder. v3,
3475. The NAMS Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause*, 24(7), 728-753.
3476. Then, S. M., Rani, Z. Z., Raymond, A. A., Ratnaningrum, S., & Jamal, R. (2011). Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. *Asian Pac J Allergy Immunol*, 29(3), 290-293.
3477. Thomas, P., Srivastava, V., Singh, A., Mathur, P., Nimgaonkar, V. L., Lerer, B., . . . Deshpande, S. N. (2008). Correlates of response to Olanzapine in a North Indian Schizophrenia sample. *Psychiatry Res*, 161(3), 275-283.
3478. Thomas, P., & Vieta, E. (2008). Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. *Neuropsychiatr Dis Treat*, 4(3), 675-686.
3479. Thomashow, B., Crapo, J., Yawn, B., Mclvor, A., Cerreta, S., Walsh, J., . . . Rennard, S. (2014). The COPD Foundation Pocket Consultant Guide. *Chronic Obstr Pulm Dis*, 1(1), 83-87.
3480. Thompson, J. F., Hyde, C. L., Wood, L. S., Paciga, S. A., Hinds, D. A., Cox, D. R., . . . Kastelein, J. J. (2009). Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. *Circ Cardiovasc Genet*, 2(2), 173-181.
3481. Thompson, J. F., Man, M., Johnson, K. J., Wood, L. S., Lira, M. E., Lloyd, D. B., . . . Sasiela, W. J. (2005). An association study of 43 SNPs in 16 candidate genes with atorvastatin response. *Pharmacogenomics J*, 5(6), 352-358.
3482. Thukral, C., & Wolf, J. L. (2006). Therapy insight: drugs for gastrointestinal disorders in pregnant women. *Nat Clin Pract Gastroenterol Hepatol*, 3(5), 256-266.

3483. Tian, L., Zhang, J., Xiao, S., Huang, J., Zhang, Y., & Shen, J. (2015). Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis. *Meta Gene*, 5, 43-54.
3484. Tidey, J. W., & Miller, M. E. (2015). Smoking cessation and reduction in people with chronic mental illness. *BMJ*, 351, h4065.
3485. Tillman, L. A., Drake, F. M., Dixon, J. S., & Wood, J. R. (1996). Review article: safety of bismuth in the treatment of gastrointestinal diseases. *Aliment Pharmacol Ther*, 10(4), 459-467.
3486. Tleyjeh, I. M., Bin Abdulhak, A. A., Riaz, M., Alasmari, F. A., Garbati, M. A., AlGhamdi, M., . . . Sutton, A. J. (2012). Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. *PLoS One*, 7(12), e50836.
3487. Tobacco Genetics Consortium. (2010). Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet*, 42(5), 441-447.
3488. Tobe, S. W., Stone, J. A., Anderson, T., Bacon, S., Cheng, A. Y. Y., Daskalopoulou, S. S., . . . Liu, P. P. (2018). Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. *CMAJ*, 190(40), E1192-E1206.
3489. Tofferi, J. K., Jackson, J. L., & O'Malley, P. G. (2004). Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. *Arthritis Rheum*, 51(1), 9-13.
3490. Toffol, E., Hatonen, T., Tanskanen, A., Lonnqvist, J., Wahlbeck, K., Joffe, G., . . . Partonen, T. (2015). Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. *J Affect Disord*, 183, 159-165.
3491. Toh, D. S., Tan, L. L., Aw, D. C., Pang, S. M., Lim, S. H., Thirumoorthy, T., . . . Sung, C. (2014). Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. *Pharmacogenomics J*, 14(4), 316-321.
3492. Tohen, M., Bowden, C. L., Smulevich, A. B., Bergstrom, R., Quinlan, T., Osuntokun, O., . . . Greil, W. (2008). Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. *Br J Psychiatry*, 192(2), 135-143.
3493. Tohen, M., Chengappa, K. N., Suppes, T., Zarate, C. A., Jr., Calabrese, J. R., Bowden, C. L., . . . Breier, A. (2002). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. *Arch Gen Psychiatry*, 59(1), 62-69.
3494. Tohen, M., McDonnell, D. P., Case, M., Kanba, S., Ha, K., Fang, Y. R., . . . Gomez, J. C. (2012). Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. *Br J Psychiatry*, 201(5), 376-382.
3495. Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., . . . Breier, A. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry*, 60(11), 1079-1088.
3496. Tomaz, P. R., Santos, J. R., Issa, J. S., Abe, T. O., Gaya, P. V., Krieger, J. E., . . . Santos, P. C. (2015). CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. *Eur J Clin Pharmacol*, 71(9), 1067-1073.

3497. Tomlinson, B., Hu, M., Lee, V. W., Lui, S. S., Chu, T. T., Poon, E. W., . . . Li, E. K. (2010). ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. *Clin Pharmacol Ther*, *87*(5), 558-562.
3498. Tondo, L., Hennen, J., & Baldessarini, R. J. (2001). Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. *Acta Psychiatr Scand*, *104*(3), 163-172.
3499. Tong, Q., Zhao, L., Qian, X. D., Zhang, L. L., Xu, X., Dai, S. M., . . . Zhao, D. B. (2013). Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. *Pharmacogenomics*, *14*(14), 1691-1700.
3500. Tong, Y., Lin, Y., Zhang, Y., Yang, J., Zhang, Y., Liu, H., & Zhang, B. (2009). Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. *BMC Med Genet*, *10*, 15.
3501. Tonnesen, P., Lauri, H., Perfekt, R., Mann, K., & Batra, A. (2012). Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. *Eur Respir J*, *40*(3), 548-554.
3502. Tonnesen, P., & Mikkelsen, K. L. (2000). Smoking cessation with four nicotine replacement regimes in a lung clinic. *Eur Respir J*, *16*(4), 717-722.
3503. Tonnesen, P., Norregaard, J., Mikkelsen, K., Jorgensen, S., & Nilsson, F. (1993). A double-blind trial of a nicotine inhaler for smoking cessation. *Jama*, *269*(10), 1268-1271.
3504. Tonozzi, T. R., Braunstein, G. D., Kammesheidt, A., Curran, C., Golshan, S., & Kelsoe, J. (2018). Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study. *Pharmacogenomics*, *19*(15), 1169-1179.
3505. Tonstad, S., Tonnesen, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *Jama*, *296*(1), 64-71.
3506. Toward Optimized Practice (TOP) Program. (2016). *Guideline for Primary Care Management of Headache in Adults*. Retrieved from Edmonton, AB:
3507. Toward Optimized Practice Program. (2015). *Guideline for the Evidence-Informed Primary Care Management of Low Back Pain*. Retrieved from Edmonton, AB: www.topalbertadoctors.org
3508. Toyofyuku, M., Imazu, M., Sumii, K., Yamamoto, H., Hayashi, Y., Hiyama, K., & Kohno, N. (2002). Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. *Atherosclerosis*, *160*(2), 339-344.
3509. Tran, T., Lowry, A. M., & El-Serag, H. B. (2007). Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. *Aliment Pharmacol Ther*, *25*(2), 143-153.
3510. Tribute Pharmaceuticals Canada Inc. (2015). Cambia (diclofenac potassium). *CA Product Monograph*,
3511. Tribute Pharmaceuticals Canada Inc. (2016). Visken (pindolol). *CA Product Monograph*,

3512. Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., . . . Team, S. D. S. (2006). Medication augmentation after the failure of SSRIs for depression. *N Engl J Med*, *354*(12), 1243-1252.
3513. Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *Jama*, *289*(1), 65-69.
3514. Trzepacz, P. T., Williams, D. W., Feldman, P. D., Wrishko, R. E., Witcher, J. W., & Buitelaar, J. K. (2008). CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. *Eur Neuropsychopharmacol*, *18*(2), 79-86.
3515. Tsartsali, L., Papadopoulos, M., Lagona, E., Papadimitriou, A., Kanaka-Gantenbein, C., Louizou, E., . . . Chrousos, G. (2012). Association of hypothalamic-pituitary-adrenal axis-related polymorphisms with stress in asthmatic children on inhaled corticosteroids. *Neuroimmunomodulation*, *19*(2), 88-95.
3516. Tseng, C. Y., Wang, S. L., Lai, M. D., Lai, M. L., & Huang, J. D. (1996). Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. *Clin Pharmacol Ther*, *60*(2), 177-182.
3517. Tsoi, D. T., Porwal, M., & Webster, A. C. (2013). Interventions for smoking cessation and reduction in individuals with schizophrenia. *Cochrane Database Syst Rev*(2), CD007253.
3518. Tsubota, A., Shimada, N., Atsukawa, M., Abe, H., Kato, K., Ika, M., . . . Aizawa, Y. (2014). Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. *J Gastroenterol Hepatol*, *29*(1), 144-150.
3519. Tuchman, M. M., Hee, A., Emeribe, U., & Silberstein, S. (2008). Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. *CNS drugs*, *22*(10), 877-886.
3520. Tudur Smith, C., Marson, A. G., Chadwick, D. W., & Williamson, P. R. (2007). Multiple treatment comparisons in epilepsy monotherapy trials. *Trials*, *8*, 34.
3521. Tumbarello, M., Trecarichi, E. M., De Rosa, F. G., Giannella, M., Giacobbe, D. R., Bassetti, M., . . . Isgri, S. (2015). Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother*, *70*(7), 2133-2143.
3522. Tunis, S. R., Sheinhait, I. A., Schmid, C. H., Bishop, D. J., & Ross, S. D. (1997). Lansoprazole compared with histamine₂-receptor antagonists in healing gastric ulcers: a meta-analysis. *Clin Ther*, *19*(4), 743-757.
3523. Turbott, J., & Smeeton, W. M. (1984). Sudden death and flupenthixol decanoate. *Aust N Z J Psychiatry*, *18*(1), 91-94.
3524. Turner, S., Francis, B., Vijverberg, S., Pino-Yanes, M., Maitland-van der Zee, A. H., Basu, K., . . . Pharmacogenomics in Childhood Asthma Consortium. (2016). Childhood asthma exacerbations and the Arg16 beta₂-receptor polymorphism: A meta-analysis stratified by treatment. *J Allergy Clin Immunol*, *138*(1), 107-113 e105.
3525. Turner, S. T., Bailey, K. R., Fridley, B. L., Chapman, A. B., Schwartz, G. L., Chai, H. S., . . . Boerwinkle, E. (2008). Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. *Hypertension*, *52*(2), 359-365.

3526. Turner, S. T., Boerwinkle, E., O'Connell, J. R., Bailey, K. R., Gong, Y., Chapman, A. B., . . . Johnson, J. A. (2013). Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. *Hypertension*, *62*(2), 391-397.
3527. Turner, S. T., Chapman, A. B., Schwartz, G. L., & Boerwinkle, E. (2003). Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. *Am J Hypertens*, *16*(10), 834-839.
3528. Turner-Stokes, L., Goebel, A., & Guideline Development Group. (2011). Complex regional pain syndrome in adults: concise guidance. *Clin Med (Lond)*, *11*(6), 596-600.
3529. Tveit, A. H., Bruce, M. G., Bruden, D. L., Morris, J., Reasonover, A., Hurlburt, D. A., . . . McMahon, B. (2011). Alaska sentinel surveillance study of *Helicobacter pylori* isolates from Alaska Native persons from 2000 to 2008. *J Clin Microbiol*, *49*(10), 3638-3643.
3530. Uceyler, N., Sommer, C., Walitt, B., & Hauser, W. (2013). Anticonvulsants for fibromyalgia. *Cochrane Database Syst Rev*(10), CD010782.
3531. Ueda, M., Hirokane, G., Morita, S., Okawa, M., Watanabe, T., Akiyama, K., & Shimoda, K. (2006). The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. *Prog Neuropsychopharmacol Biol Psychiatry*, *30*(3), 486-491.
3532. Ueki, N., Miyake, K., Kusunoki, M., Shindo, T., Kawagoe, T., Futagami, S., . . . Sakamoto, C. (2009). Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against *Helicobacter pylori* infection following clarithromycin-containing triple-therapy failure. *Helicobacter*, *14*(2), 91-99.
3533. Ueta, M. (2015). Genetic predisposition to Stevens-Johnson syndrome with severe ocular surface complications. *Cornea*, *34 Suppl 11*, S158-165.
3534. Ueta, M., Kaniwa, N., Sotozono, C., Tokunaga, K., Saito, Y., Sawai, H., . . . Kinoshita, S. (2014). Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. *Sci Rep*, *4*, 4862.
3535. Ueta, M., Kannabiran, C., Wakamatsu, T. H., Kim, M. K., Yoon, K. C., Seo, K. Y., . . . Kinoshita, S. (2014). Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications. *Sci Rep*, *4*, 5981.
3536. Ulehlova, J., Slavik, L., Kucerova, J., Krcova, V., Vaclavik, J., & Indrak, K. (2014). Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy. *Genet Test Mol Biomarkers*, *18*(9), 599-604.
3537. Ulvestad, M., Skottheim, I. B., Jakobsen, G. S., Bremer, S., Molden, E., Asberg, A., . . . Christensen, H. (2013). Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. *Clin Pharmacol Ther*, *93*(3), 275-282.
3538. Ungprasert, P., Cheungpasitporn, W., Crowson, C. S., & Matteson, E. L. (2015). Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. *Eur J Intern Med*, *26*(4), 285-291.
3539. Upsher-Smith Laboratories Inc. (2017). Chlorpromazine. *US Product Monograph*,

3540. Upsher-Smith Laboratories Inc. (2017). Pacerone (amiodarone). *US Product Monograph*,
3541. Urquhart, D. M., Hoving, J. L., Assendelft, W. W., Roland, M., & van Tulder, M. W. (2008). Antidepressants for non-specific low back pain. *Cochrane Database Syst Rev*(1), CD001703.
3542. Usami, S., Abe, S., Kasai, M., Shinkawa, H., Moeller, B., Kenyon, J. B., & Kimberling, W. J. (1997). Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. *Laryngoscope*, *107*(4), 483-490.
3543. Uygun, A., Kadayifci, A., Safali, M., Ilgan, S., & Bagci, S. (2007). The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. *J Dig Dis*, *8*(4), 211-215.
3544. Uzun, S., Djamin, R. S., Kluytmans, J. A., Mulder, P. G., van't Veer, N. E., Ermens, A. A., . . . van der Eerden, M. M. (2014). Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*, *2*(5), 361-368.
3545. Vale, N., Nordmann, A. J., Schwartz, G. G., de Lemos, J., Colivicchi, F., den Hartog, F., . . . Briel, M. (2014). Statins for acute coronary syndrome. *Cochrane Database Syst Rev*(9), CD006870.
3546. Valeant Canada LP. (2012). Glumetza (metformin). *CA Product Monograph*,
3547. Valeant Canada LP. (2013). QVAR (beclomethasone dipropionate) *CA Product Monograph*,
3548. Valeant Canada LP. (2013). Theolair (theophylline). *CA Product Monograph*,
3549. Valeant Canada LP. (2015). Manerix (moclobemide). *CA Product Monograph*,
3550. Valeant Canada LP. (2016). Edarbi (azilsartan medoxomil). *CA Product Monograph*,
3551. Valeant Canada LP. (2016). Zyban (bupropion). *CA Product Monograph*,
3552. Valeant Canada LP. (2017). Airomir (salbutamol). *CA Product Monograph*,
3553. Valeant Canada LP. (2017). Altace (ramipril). *CA Product Monograph*,
3554. Valeant Canada LP. (2017). Wellbutrin XL (bupropion). *CA Product Monograph*,
3555. Valeant Pharmaceuticals North America LLC. (2008). D.H.E. 45 (dihydroergotamine mesylate). *US Product Monograph*,
3556. Valeant Pharmaceuticals North America LLC. (2016). Cardizem LA (diltiazem). *US Product Monograph*,
3557. Valeant Pharmaceuticals North America LLC. (2016). Isordil (isosorbide dinitrate). *US Product Monograph*,
3558. Valeant Pharmaceuticals North America LLC. (2016). Pepcid (famotidine). *US Product Monograph*,
3559. Valeant Pharmaceuticals North America LLC. (2017). Cardizem CD (diltiazem). *US Product Monograph*,
3560. Valeant Pharmaceuticals North America LLC. (2017). Migranal (dihydroergotamine). *US Product Monograph*,
3561. Valeant Pharmaceuticals North America LLC. (2018). Pepcid (famotidine). *US Product Monograph*,
3562. Valeant Pharmaceuticals North America LLC. (2018). Vastotec (enalapril). *US Product Monograph*,

3563. Validus Pharmaceuticals LLC. (2016). Equetro (carbamazepine). *US Product Monograph*, 3564.
3564. Validus Pharmaceuticals LLC. (2017). Lopressor (metoprolol). *US Product Monograph*, 3565.
3565. Validus Pharmaceuticals LLC. (2017). Lotensin (benazepril). *US Product Monograph*, 3566.
3566. Validus Pharmaceuticals LLC. (2018). Bumex (bumetanide). *US Product Monograph*, 3567.
3567. Validus Pharmaceuticals LLC. (2018). Lasix (furosemide). *US Product Monograph*, 3568.
3568. van Boxel, O. S., van Oijen, M. G., Hagenars, M. P., Smout, A. J., & Siersema, P. D. (2010). Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. *Am J Gastroenterol*, 105(11), 2430-2436; quiz 2437.
3569. Van de Mierop, L., Rutgeerts, L., Van den Langenberg, B., & Staessen, A. (1979). Oral domperidone in chronic postprandial dyspepsia. *Digestion*, 19(4), 244-250.
3570. van de Ven, L. L., Franke, C. L., & Koehler, P. J. (1997). Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. *Cephalalgia*, 17(5), 596-599.
3571. van de Vusse, A. C., Stomp-van den Berg, S. G., Kessels, A. H., & Weber, W. E. (2004). Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1. *BMC Neurol*, 4, 13.
3572. van der Weide, J., van Baalen-Benedek, E. H., & Kootstra-Ros, J. E. (2005). Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. *Ther Drug Monit*, 27(4), 478-483.
3573. van der Weide, K., Looovers, H., Pondman, K., Bogers, J., van der Straaten, T., Langemeijer, E., . . . van der Weide, J. (2016). Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. *Pharmacogenomics J*.
3574. van Durme, C. M., Wechalekar, M. D., Buchbinder, R., Schlesinger, N., van der Heijde, D., & Landewe, R. B. (2014). Non-steroidal anti-inflammatory drugs for acute gout. *Cochrane Database Syst Rev*(9), Cd010120.
3575. van Echteld, I., Wechalekar, M. D., Schlesinger, N., Buchbinder, R., & Aletaha, D. (2014). Colchicine for acute gout. *Cochrane Database Syst Rev*(8), CD006190.
3576. van Eijs, F., Stanton-Hicks, M., Van Zundert, J., Faber, C. G., Lubenow, T. R., Mekhail, N., . . . Huygen, F. (2011). Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome. *Pain Pract*, 11(1), 70-87.
3577. van Gennep, S., Konte, K., Meijer, B., Heymans, M. W., D'Haens, G. R., Lowenberg, M., & de Boer, N. K. H. (2019). Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. *Aliment Pharmacol Ther*, 50(5), 484-506.
3578. van Kerkhoven, L. A., Laheij, R. J., Aparicio, N., De Boer, W. A., Van den Hazel, S., Tan, A. C., . . . Jansen, J. B. (2008). Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. *Clin Gastroenterol Hepatol*, 6(7), 746-752; quiz 718.
3579. van Leeuwen, N., Nijpels, G., Becker, M. L., Deshmukh, H., Zhou, K., Stricker, B. H., . . . Pearson, E. R. (2012). A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. *Diabetologia*, 55(7), 1971-1977.

3580. Van Nieuwerburgh, F. C., Denys, D. A., Westenberg, H. G., & Deforce, D. L. (2009). Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. *Int J Psychiatry Clin Pract*, 13(1), 345-348.
3581. van Pinxteren, B., Numans, M. E., Bonis, P. A., & Lau, J. (2006). Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev*(3), Cd002095.
3582. van Vliet, I. M., den Boer, J. A., & Westenberg, H. G. (1994). Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. *Psychopharmacology (Berl)*, 115(1-2), 128-134.
3583. van Vlijmen, E. F., Wiewel-Verschueren, S., Monster, T. B., & Meijer, K. (2016). Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. *J Thromb Haemost*, 14(7), 1393-1403.
3584. Vandembroucke, J. P., Koster, T., Briet, E., Reitsma, P. H., Bertina, R. M., & Rosendaal, F. R. (1994). Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet*, 344(8935), 1453-1457.
3585. Vantrappen, G., Rutgeerts, L., Schurmans, P., & Coenegrachts, J. L. (1988). Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. *Dig Dis Sci*, 33(5), 523-529.
3586. Vanwong, N., Ngamsamut, N., Medhasi, S., Puangpetch, A., Chamnanphon, M., Tan-Kam, T., . . . Sukasem, C. (2017). Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-Hydroxyrisperidone in Thai children and adolescents with autism spectrum disorder. *J Child Adolesc Psychopharmacol*, 27(2), 185-191.
3587. Varenhorst, C., Alstrom, U., Scirica, B. M., Hogue, C. W., Asenblad, N., Storey, R. F., . . . Held, C. (2012). Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. *J Am Coll Cardiol*, 60(17), 1623-1630.
3588. Vasudev, A., Macritchie, K., Rao, S. N., Geddes, J., & Young, A. H. (2011). Tiagabine in the maintenance treatment of bipolar disorder. *Cochrane Database Syst Rev*(12), CD005173.
3589. Vasudev, A., Macritchie, K., Watson, S., Geddes, J. R., & Young, A. H. (2008). Oxcarbazepine in the maintenance treatment of bipolar disorder. *Cochrane Database Syst Rev*(1), CD005171.
3590. Vazquez-Mellado, J., Morales, E. M., Pacheco-Tena, C., & Burgos-Vargas, R. (2001). Relation between adverse events associated with allopurinol and renal function in patients with gout. *Ann Rheum Dis*, 60(10), 981-983.
3591. Veefkind, A. H., Haffmans, P. M., & Hoencamp, E. (2000). Venlafaxine serum levels and CYP2D6 genotype. *Ther Drug Monit*, 22(2), 202-208.
3592. Veldhuyzen van Zanten, S. J., Bradette, M., Chiba, N., Armstrong, D., Barkun, A., Flook, N., . . . Bursey, F. (2005). Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. *Can J Gastroenterol*, 19(5), 285-303.

3593. Veldhuyzen van Zanten, S. J., Chiba, N., Armstrong, D., Barkun, A., Thomson, A., Smyth, S., . . . Sinclair, P. (2005). A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. *Am J Gastroenterol*, *100*(7), 1477-1488.
3594. Veldhuyzen van Zanten, S. J., Jones, M. J., Verlinden, M., & Talley, N. J. (2001). Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. *Am J Gastroenterol*, *96*(3), 689-696.
3595. Veldic, M., Ahmed, A. T., Blacker, C. J., Geske, J. R., Biernacka, J. M., Borreggine, K. L., . . . Frye, M. A. (2019). Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. *Front Pharmacol*, *10*, 83.
3596. Venerito, M., Krieger, T., Ecker, T., Leandro, G., & Malfertheiner, P. (2013). Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. *Digestion*, *88*(1), 33-45.
3597. Verbeeck, R., Tjandramaga, T. B., Mullie, A., Verbesselt, R., Verberckmoes, R., & De Schepper, P. J. (1979). Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency. *Br J Clin Pharmacol*, *7*(3), 273-282.
3598. Verbeeck, W., Bekkering, G. E., Van den Noortgate, W., & Kramers, C. (2017). Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev*, *10*, Cd009504.
3599. Verdickt, W., Moran, C., Hantzschel, H., Fraga, A. M., Stead, H., & Geis, G. S. (1992). A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. *Scand J Rheumatol*, *21*(2), 85-91.
3600. Verma, A., Cairns, J. A., Mitchell, L. B., Macle, L., Stiell, I. G., Gladstone, D., . . . Healey, J. S. (2014). 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Can J Cardiol*, *30*(10), 1114-1130.
3601. Verma, A., Srivastava, D., Kumar, A., & Singh, V. (2013). Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India. *Clin Neuropharmacol*, *36*(6), 193-197.
3602. Verma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., . . . Marso, S. P. (2018). Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. *Circulation*, *138*(25), 2884-2894.
3603. Verschuren, J. J., Boden, H., Wessels, J. A., van der Hoeven, B. L., Trompet, S., Heijmans, B. T., . . . Jukema, J. W. (2013). Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. *Int J Cardiol*, *167*(6), 2882-2888.
3604. Versiani, M., Amrein, R., & Montgomery, S. A. (1997). Social phobia: long-term treatment outcome and prediction of response--a moclobemide study. *Int Clin Psychopharmacol*, *12*(5), 239-254.
3605. Versiani, M., Nardi, A. E., Mundim, F. D., Alves, A. B., Liebowitz, M. R., & Amrein, R. (1992). Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. *Br J Psychiatry*, *161*, 353-360.

3606. Verspeelt, J., De Locht, P., & Amery, W. K. (1996). Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. *Cephalalgia*, 16(5), 328-336; discussion 288.
3607. Vertical Pharmaceuticals LLC. (2018). Conzip (tramadol ER). *US Product Monograph*,
3608. Vevelstad, M., Pettersen, S., Tallaksen, C., & Brors, O. (2009). O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. *Eur J Clin Pharmacol*, 65(8), 795-801.
3609. Vieta, E., Gunther, O., Locklear, J., Ekman, M., Miltenburger, C., Chatterton, M. L., . . . Paulsson, B. (2011). Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. *Int J Neuropsychopharmacol*, 14(8), 1029-1049.
3610. Vieta, E., Langosch, J. M., Figueira, M. L., Souery, D., Blasco-Colmenares, E., Medina, E., . . . Bellivier, F. (2013). Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). *Int J Neuropsychopharmacol*, 16(8), 1719-1732.
3611. Vieta, E., Locklear, J., Gunther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., . . . Paulsson, B. (2010). Treatment options for bipolar depression: a systematic review of randomized, controlled trials. *J Clin Psychopharmacol*, 30(5), 579-590.
3612. Vieta, E., Nuamah, I. F., Lim, P., Yuen, E. C., Palumbo, J. M., Hough, D. W., & Berwaerts, J. (2010). A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. *Bipolar Disord*, 12(3), 230-243.
3613. Vigneri, S., Termini, R., Leandro, G., Badalamenti, S., Pantalena, M., Savarino, V., . . . et al. (1995). A comparison of five maintenance therapies for reflux esophagitis. *N Engl J Med*, 333(17), 1106-1110.
3614. Viguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000). Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. *Am J Psychiatry*, 157(2), 179-184.
3615. Viikki, M., Huuhka, K., Leinonen, E., Illi, A., Setälä-Soikkeli, E., Huuhka, M., . . . Kampman, O. (2011). Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. *Neurosci Lett*, 501(1), 20-24.
3616. Virchow, J. C., Backer, V., Kuna, P., Prieto, L., Nolte, H., Villesen, H. H., . . . de Blay, F. (2016). Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. *Jama*, 315(16), 1715-1725.
3617. Vogel, T. R., Dombrovskiy, V. Y., Galinanes, E. L., & Kruse, R. L. (2013). Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. *Circ Cardiovasc Interv*, 6(6), 694-700.
3618. Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Molken, M. P., Beeh, K. M., . . . Investigators, P.-C. (2011). Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med*, 364(12), 1093-1103.
3619. Volkan-Salanci, B., Dagdelen, S., Alikasifoglu, M., Erbas, T., Hayran, M., & Erbas, B. (2009). Impact of renin-angiotensin system polymorphisms on renal haemodynamic

- responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus. *J Renin Angiotensin Aldosterone Syst*, 10(1), 41-50.
3620. Vollenweider, D. J., Jarrett, H., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A. (2012). Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 12, CD010257.
3621. Vongpatanasin, W. (2015). Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. *Curr Opin Cardiol*, 30(4), 361-365.
3622. Vonkeman, H. E., van de Laar, M. A., van der Palen, J., Brouwers, J. R., & Vermes, I. (2006). Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. *Clin Ther*, 28(10), 1670-1676.
3623. Voora, D., Shah, S. H., Reed, C. R., Zhai, J., Crosslin, D. R., Messer, C., . . . Ginsburg, G. S. (2008). Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. *Circ Cardiovasc Genet*, 1(2), 100-106.
3624. Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. *J Am Coll Cardiol*, 54(17), 1609-1616.
3625. Vormfelde, S. V., & Brockmoller, J. (2012). The genetics of loop diuretic effects. *Pharmacogenomics J*, 12(1), 45-53.
3626. Voronov, P., Przybylo, H. J., & Jagannathan, N. (2007). Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. *Paediatr Anaesth*, 17(7), 684-687.
3627. Vries, M. J., van der Meijden, P. E., Henskens, Y. M., ten Cate-Hoek, A. J., & ten Cate, H. (2016). Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review. *Thromb Haemost*, 115(1), 7-24.
3628. Waade, R. B., Hermann, M., Moe, H. L., & Molden, E. (2014). Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. *Eur J Clin Pharmacol*, 70(8), 933-940.
3629. Wachman, E. M., Hayes, M. J., Brown, M. S., Paul, J., Harvey-Wilkes, K., Terrin, N., . . . Davis, J. M. (2013). Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. *Jama*, 309(17), 1821-1827.
3630. Wagenlehner, F. M., Grabe, M., Naber, K. G., Bjerklund Johansen, T. E., Naber, C. K., & Weidner, W. (2011). Antibiotic prophylaxis in urology. *Urologe A*, 50(11), 1469-1478; quiz 1479-1480.
3631. Wagner, G., Schultes, M. T., Titscher, V., Teufer, B., Klerings, I., & Gartlehner, G. (2018). Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. *J Affect Disord*, 228, 1-12.
3632. Wagner, S., Gebel, M., Haruma, K., Bar, W., Lange, P., Freise, J., . . . Schmidt, F. W. (1992). Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori. *Gut*, 33(2), 179-183.

3633. Wakamatsu, T. H., Ueta, M., Tokunaga, K., Okada, Y., Loureiro, R. R., Costa, K. A., . . . Kinoshita, S. (2017). Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications Following Use of Cold Medicine in a Brazilian Population. *JAMA Ophthalmol*, *135*(4), 355-360.
3634. Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009). Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, *122*(3), 290-300.
3635. Walitt, B., Urrutia, G., Nishishinya, M. B., Cantrell, S. E., & Hauser, W. (2015). Selective serotonin reuptake inhibitors for fibromyalgia syndrome. *Cochrane Database Syst Rev*, *6*, CD011735.
3636. Walker, E., Lyman, A., Gupta, K., Mahoney, M. V., Snyder, G. M., & Hirsch, E. B. (2016). Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. *Clin Infect Dis*, *63*(7), 960-965.
3637. Wall, G. C., Bigner, D., & Craig, S. (2003). Ethacrynic acid and the sulfa-sensitive patient. *Arch Intern Med*, *163*(1), 116-117.
3638. Wallace, S. L., Singer, J. Z., Duncan, G. J., Wigley, F. M., & Kuncl, R. W. (1991). Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. *J Rheumatol*, *18*(2), 264-269.
3639. Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., . . . Thorsen, M. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*, *361*(11), 1045-1057.
3640. Wallentin, L., James, S., Storey, R. F., Armstrong, M., Barratt, B. J., Horrow, J., . . . Becker, R. C. (2010). Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet*, *376*(9749), 1320-1328.
3641. Walters, E. H., & Walters, J. (2000). Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. *Cochrane Database Syst Rev*(4), CD001285.
3642. Walters, E. H., & Walters, J. (2003). Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. *Cochrane Database Syst Rev*(2), CD001285.
3643. Walters, J. A., Gibson, P. G., Wood-Baker, R., Hannay, M., & Walters, E. H. (2009). Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(1), CD001288.
3644. Walters, J. A., Tan, D. J., White, C. J., Gibson, P. G., Wood-Baker, R., & Walters, E. H. (2014). Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, *9*, CD001288.
3645. Wan, Z., Wang, G., Li, T., Xu, B., Pei, Q., Peng, Y., . . . Zhu, Y. S. (2015). Marked alteration of rosuvastatin pharmacokinetics in healthy Chinese with ABCG2 34G>A and 421C>A homozygote or compound heterozygote. *J Pharmacol Exp Ther*, *354*(3), 310-315.
3646. Wand, G. S., McCaul, M., Yang, X., Reynolds, J., Gotjen, D., Lee, S., & Ali, A. (2002). The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. *Neuropsychopharmacology*, *26*(1), 106-114.

3647. Wang, H. H., He, Y., Wang, H. X., Liao, C. L., Peng, Y., Tao, L. J., . . . Yang, H. X. (2018). Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease. *World J Gastroenterol*, 24(8), 941-948.
3648. Wang, J., Hu, F., Feng, T., Zhao, J., Yin, L., Li, L., . . . Hu, D. (2013). Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population. *BMC Med Genet*, 14, 8.
3649. Wang, J., Omori, I. M., Fenton, M., & Soares, B. (2010). Sulpiride augmentation for schizophrenia. *Cochrane Database Syst Rev*(1), CD008125.
3650. Wang, J. H., Liu, Z. Q., Wang, W., Chen, X. P., Shu, Y., He, N., & Zhou, H. H. (2001). Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. *Clin Pharmacol Ther*, 70(1), 42-47.
3651. Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011). Genomics and drug response. *N Engl J Med*, 364(12), 1144-1153.
3652. Wang, L., Yu, L., Zhang, A. P., Fang, C., Du, J., Gu, N. F., . . . He, L. (2007). Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. *J Psychopharmacol*, 21(8), 837-842.
3653. Wang, L., Yu, L., Zhang, A.-P., Fang, C., Du, J., Gu, N.-F., . . . Xing, Q.-H. (2007). Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. *Journal of psychopharmacology*, 21(8), 837-842.
3654. Wang, Q., You, Y., & Zhang, Q. (2013). [The molecular epidemiology analysis of heavy-profound hearing loss in Nangtong]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*, 27(7), 366-370.
3655. Wang, Q., Zhou, J. Q., Zhou, L. M., Chen, Z. Y., Fang, Z. Y., Chen, S. D., . . . Wang, H. X. (2011). Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. *Seizure*, 20(6), 446-448.
3656. Wang, Q. J., Zhao, Y. L., Rao, S. Q., Guo, Y. F., He, Y., Lan, L., . . . Shen, Y. (2011). Newborn hearing concurrent gene screening can improve care for hearing loss: a study on 14,913 Chinese newborns. *Int J Pediatr Otorhinolaryngol*, 75(4), 535-542.
3657. Wang, S. M., Han, C., Lee, S. J., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Vilazodone for the treatment of depression: an update. *Chonnam Med J*, 52(2), 91-100.
3658. Wang, W. H., Huang, J. Q., Zheng, G. F., Xia, H. H., Wong, W. M., Liu, X. G., . . . Wong, B. C. (2007). Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. *Clinical Gastroenterology and Hepatology*, 5(2), 178-185.
3659. Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A., 3rd, Ezekowitz, M. D., Jackman, W. M., . . . Tracy, C. M. (2011). 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol*, 57(11), 1330-1337.
3660. Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A., 3rd, . . . Yancy, C. W. (2011). 2011 ACCF/AHA/HRS focused update on the management of

- patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Heart Rhythm*, 8(1), 157-176.
3661. Warfarin Antiplatelet Vascular Evaluation Trial, I., Anand, S., Yusuf, S., Xie, C., Pogue, J., Eikelboom, J., . . . Gosselin, G. (2007). Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. *N Engl J Med*, 357(3), 217-227.
3662. Warner, C. H., Bobo, W., Warner, C., Reid, S., & Rachal, J. (2006). Antidepressant discontinuation syndrome. *Am Fam Physician*, 74(3), 449-456.
3663. Watanabe, J., Suzuki, Y., Fukui, N., Sugai, T., Ono, S., Inoue, Y., & Someya, T. (2008). Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. *Ther Drug Monit*, 30(6), 705-708.
3664. Watts, G. F., Lewis, B., Brunt, J. N., Lewis, E. S., Coltart, D. J., Smith, L. D., . . . Swan, A. V. (1992). Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). *Lancet*, 339(8793), 563-569.
3665. Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., . . . Force, A. O. T. (2010). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. *Endocr Pract*, 16 Suppl 3, 1-37.
3666. Waugh, N., Royle, P., Scotland, G., Henderson, R., Hollick, R., & McNamee, P. (2011). Denosumab for the prevention of osteoporotic fractures in postmenopausal women. *Health Technol Assess*, 15 Suppl 1, 51-59.
3667. Wechalekar, M. D., Vinik, O., Schlesinger, N., & Buchbinder, R. (2013). Intra-articular glucocorticoids for acute gout. *Cochrane Database Syst Rev*(4), CD009920.
3668. Wechsler, M. E., Kunselman, S. J., Chinchilli, V. M., Bleecker, E., Boushey, H. A., Calhoun, W. J., . . . Israel, E. (2009). Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. *Lancet*, 374(9703), 1754-1764.
3669. Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F., Jr., Boushey, H. A., Deykin, A., . . . Israel, E. (2006). beta-Adrenergic receptor polymorphisms and response to salmeterol. *Am J Respir Crit Care Med*, 173(5), 519-526.
3670. Wechsler, M. E., Yawn, B. P., Fuhlbrigge, A. L., Pace, W. D., Pencina, M. J., Doros, G., . . . Investigators, B. (2015). Anticholinergic vs Long-Acting beta-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. *Jama*, 314(16), 1720-1730.
3671. Wedzicha, J. A., Miravittles, M., Hurst, J. R., Calverley, P. M., Albert, R. K., Anzueto, A., . . . Krishnan, J. A. (2017). Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*, 49(3).
3672. Wei, Q., Wang, S., Yao, J., Lu, Y., Chen, Z., Xing, G., & Cao, X. (2013). Genetic mutations of GJB2 and mitochondrial 12S rRNA in nonsyndromic hearing loss in Jiangsu Province of China. *J Transl Med*, 11, 163.

3673. Wei, W. Q., Li, X., Feng, Q., Kubo, M., Kullo, I. J., Peissig, P. L., . . . Denny, J. C. (2018). LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. *Circulation*, *138*(17), 1839-1849.
3674. Weiner, E., Buchholz, A., Coffay, A., Liu, F., McMahon, R. P., Buchanan, R. W., & Kelly, D. L. (2011). Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. *Schizophr Res*, *129*(1), 94-95.
3675. Weisler, R. H., Biederman, J., Spencer, T. J., Wilens, T. E., Faraone, S. V., Chrisman, A. K., . . . Tulloch, S. J. (2006). Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. *CNS Spectr*, *11*(8), 625-639.
3676. Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, A., & Paulsson, B. (2011). Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder. *J Clin Psychiatry*, *72*(11), 1452-1464.
3677. Welsh, E. J., & Cates, C. J. (2010). Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. *Cochrane Database Syst Rev*(9), Cd008418.
3678. Welzen, M. E., Dezentje, V. O., van Schaik, R. H., Colbers, A. P., Guchelaar, H. J., van Erp, N. P., . . . van Laarhoven, H. W. (2015). The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity. *Ther Drug Monit*, *37*(4), 501-507.
3679. Weng, W. K., & Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol*, *21*(21), 3940-3947.
3680. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L. L., & Ingelman-Sundberg, M. (2001). Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. *Pharmacogenetics*, *11*(5), 417-427.
3681. Werner, F. M., & Covenas, R. (2015). New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. *Ther Clin Risk Manag*, *11*, 1657-1661.
3682. Wessel, J., McDonald, S. M., Hinds, D. A., Stokowski, R. P., Javitz, H. S., Kennemer, M., . . . Bergen, A. W. (2010). Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerstrom test for nicotine dependence. *Neuropsychopharmacology*, *35*(12), 2392-2402.
3683. Westenberg, H. G., Stein, D. J., Yang, H., Li, D., & Barbato, L. M. (2004). A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. *J Clin Psychopharmacol*, *24*(1), 49-55.
3684. Westin, G. G., Armstrong, E. J., Bang, H., Yeo, K. K., Anderson, D., Dawson, D. L., . . . Laird, J. R. (2014). Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. *J Am Coll Cardiol*, *63*(7), 682-690.
3685. West-Ward Pharmaceuticals Corp. (2016). Codeine Sulfate *US Product Monograph*,
3686. West-Ward Pharmaceuticals Corp. (2016). Fluphenazine Decanoate. *US Product Monograph*,

3687. West-Ward Pharmaceuticals Corp. (2017). Perindopril Erbumine. *US Product Monograph*,
3688. West-Ward Pharmaceuticals Corp. (2018). Cefotaxime. *US Product Monograph*,
3689. West-Ward Pharmaceuticals Corp. (2018). Ceftriaxone. *US Product Monograph*,
3690. West-Ward Pharmaceuticals Corp. (2018). Labetolol. *US Product Monograph*,
3691. Whayne, T. F. (2012). A review of the role of anticoagulation in the treatment of peripheral arterial disease. *Int J Angiol*, 21(4), 187-194.
3692. Whelton, A., Stout, R. L., Spilman, P. S., & Klassen, D. K. (1990). Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: A prospective, randomized, crossover comparison. *Ann Intern Med*, 112(8), 568-576.
3693. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Jr., Collins, K. J., Dennison Himmelfarb, C., . . . Wright, J. T., Jr. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*, 71(19), e127-e248.
3694. Whittle, S. L., Richards, B. L., Husni, E., & Buchbinder, R. (2011). Opioid therapy for treating rheumatoid arthritis pain. *Cochrane Database Syst Rev*(11), CD003113.
3695. Wienecke, T., & Gotzsche, P. C. (2004). Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. *Cochrane Database Syst Rev*(1), CD003789.
3696. Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D., Cole, P., Rice, A. S., . . . Kalso, E. A. (2013). Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. *Cochrane Database Syst Rev*, 11, CD010567.
3697. Wiffen, P. J., Derry, S., Moore, R. A., & McQuay, H. J. (2011). Carbamazepine for acute and chronic pain in adults. *Cochrane Database Syst Rev*(1), CD005451.
3698. Wilens, T. E., Biederman, J., Prince, J., Spencer, T. J., Faraone, S. V., Warburton, R., . . . Geller, D. (1996). Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. *Am J Psychiatry*, 153(9), 1147-1153.
3699. Wilens, T. E., Hammerness, P., Utzinger, L., Schillinger, M., Georgiopoulos, A., Doyle, R. L., . . . Brodziak, K. (2009). An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. *J Child Adolesc Psychopharmacol*, 19(5), 485-492.
3700. Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., . . . Parekh, A. (2001). A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. *Am J Psychiatry*, 158(2), 282-288.
3701. Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., . . . Clinical Pharmacogenomics Implementation Consortium. (2012). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. *Clin Pharmacol Ther*, 92(1), 112-117.
3702. Williams, A. K., Klein, M. D., Martin, J., Weck, K. E., Rossi, J. S., Stouffer, G. A., & Lee, C. R. (2019). CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. *Circ Genom Precis Med*, 12(2), e002441.

3703. Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., . . . Brown, M. J. (2015). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet*, *386*(10008), 2059-2068.
3704. Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., . . . Group, E. S. C. S. D. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, *39*(33), 3021-3104.
3705. Williams, D. G., Patel, A., & Howard, R. F. (2002). Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. *Br J Anaesth*, *89*(6), 839-845.
3706. Williams, M. P., & Pounder, R. E. (1999). Review article: the pharmacology of rabeprazole. *Aliment Pharmacol Ther*, *13 Suppl 3*, 3-10.
3707. Williamson, O. D., Sagman, D., Bruins, R. H., Boulay, L. J., & Schacht, A. (2014). Antidepressants in the treatment for chronic low back pain: questioning the validity of meta-analyses. *Pain Pract*, *14*(2), E33-41.
3708. Windle, S. B., Filion, K. B., Mancini, J. G., Auye-White, L., Joseph, L., Gore, G. C., . . . Eisenberg, M. J. (2016). Combination Therapies for Smoking Cessation: A Hierarchical Bayesian Meta-Analysis. *Am J Prev Med*, *51*(6), 1060-1071.
3709. Winner, J. G., Carhart, J. M., Altar, C. A., Allen, J. D., & Dechairo, B. M. (2013). A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. *Discov Med*, *16*(89), 219-227.
3710. Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., . . . Antman, E. M. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*, *357*(20), 2001-2015.
3711. Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017). Beta-blockers for hypertension. *Cochrane Database Syst Rev*, *1*, CD002003.
3712. Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., Wilson, M. G., Greist, J. H., Delgado, P. L., & Fava, M. (2005). Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. *Ann Clin Psychiatry*, *17*(4), 259-268.
3713. Wolthers, O. D. (2016). Extra-fine particle inhaled corticosteroids, pharmacokinetics and systemic activity in children with asthma. *Pediatr Allergy and Immunol*, *27*:13-21,
3714. Wong, B. C. Y., & Kinoshita, Y. (2006). Systematic review on epidemiology of gastroesophageal reflux disease in Asia. *Clin Gastroenterol Hepatol*, *4*.
3715. Wong, C. A., McCarthy, R. J., Blouin, J., & Landau, R. (2010). Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia. *Int J Obstet Anesth*, *19*(3), 246-253.
3716. Wong, P. F., Chong, L. Y., Mikhailidis, D. P., Robless, P., & Stansby, G. (2011). Antiplatelet agents for intermittent claudication. *Cochrane Database Syst Rev*(11), CD001272.
3717. Wong, W. M., Wong, B. C. Y., Hung, W. K., Yee, Y. K., Yip, A. W. C., Szeto, M. L., . . . Lam, S. K. (2002). Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. *Gut*, *51*(4), 502-506.

3718. Working Group of the Clinical Practice Guideline on the Management of Depression in Adults for Spanish NHS. (2015). Clinical Practice Guideline on the Management of Depression in Adults. *Spanish NHS Guideline*,
3719. Worrall, S. P. R. S. P. (2004). Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. *Nephron. Clinical practice*, 97(3), c83-c89.
3720. Worthington, I., Pringsheim, T., Gawel, M. J., Gladstone, J., Cooper, P., Dilli, E., . . . Becker, W. J. (2013). Canadian Headache Society Guideline: acute drug therapy for migraine headache. *Can J Neurol Sci*, 40(5 Suppl 3), S1-s80.
3721. Wortmann, R. L., Macdonald, P. A., Hunt, B., & Jackson, R. L. (2010). Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. *Clin Ther*, 32(14), 2386-2397.
3722. Wright, J. M., & Musini, V. M. (2009). First-line drugs for hypertension. *Cochrane Database Syst Rev*(3), Cd001841.
3723. Wu, C. C., Hung, C. C., Lin, S. Y., Hsieh, W. S., Tsao, P. N., Lee, C. N., . . . Hsu, C. J. (2011). Newborn genetic screening for hearing impairment: a preliminary study at a tertiary center. *PLoS One*, 6(7), e22314.
3724. Wu, D. C., Hsu, P. I., Wu, J. Y., Opekun, A. R., Kuo, C. H., Wu, I. C., . . . Graham, D. Y. (2010). Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. *Clin Gastroenterol Hepatol*, 8(1), 36-41 e31.
3725. Wu, E. Q., Patel, P. A., Mody, R. R., Yu, A. P., Cahill, K. E., Tang, J., & Krishnan, E. (2009). Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? *J Rheumatol*, 36(5), 1032-1040.
3726. Wu, R., Cheng, Y. J., Zhu, L. L., Yu, L., Zhao, X. K., Jia, M., . . . Cai, G. J. (2016). Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. *Oncotarget*, 7(49), 81870-81879.
3727. Wu, X. T., Hu, F. Y., An, D. M., Yan, B., Jiang, X., Kwan, P., . . . Zhou, D. (2010). Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. *Epilepsy Behav*, 19(3), 405-408.
3728. Wu, Y., Zhou, Y., Pan, Y., Zhao, X., Liu, L., Wang, D., . . . Investigators, C. (2018). Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. *Pharmacogenomics J*, 18(6), 713-720.
3729. Wuttke, H., Rau, T., Heide, R., Bergmann, K., Bohm, M., Weil, J., . . . Eschenhagen, T. (2002). Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. *Clin Pharmacol Ther*, 72(4), 429-437.
3730. Wyeth Pharmaceuticals Inc. (2018). Effexor XR (venlafaxine). *US Product Monograph*,
3731. Wyeth Pharmaceuticals Inc. (2018). Pristiq (desvenlafaxine). *US Product Monograph*,
3732. Wyeth Pharmaceuticals LLC. (2018). Protonix (pantoprazole). *US Product Monograph*,
3733. X-GEN Pharmaceuticals Inc. (2018). Piperacillin / Tazobactam. *US Product Monograph*,
3734. Xiang, Q., Chen, S. Q., Ma, L. Y., Hu, K., Zhang, Z., Mu, G. Y., . . . Cui, Y. M. (2018). Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. *Pharmacogenomics J*, 18(6), 721-729.

3735. Xing, Q., Qian, X., Li, H., Wong, S., Wu, S., Feng, G., . . . Qin, W. (2007). The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. *International Journal of Neuropsychopharmacology*, 10(5), 631-637.
3736. Xing, Q., Qian, X., Li, H., Wong, S., Wu, S., Feng, G., . . . He, L. (2007). The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. *Int J Neuropsychopharmacol*, 10(5), 631-637.
3737. Xu, H., Xie, X., Wang, B., Chen, Y., Meng, T., Ma, S., & Wang, F. (2014). Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. *Int J Cardiol*, 177(2), 654-657.
3738. Xu, S., Liu, X., Ming, J., Chen, S., Wang, Y., Liu, X., . . . Ji, Q. (2015). A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. *Int J Rheum Dis*, 18(6), 669-678.
3739. Yagdiran, O., Haasen, C., Nika, E., Krausz, M., & Naber, D. (2002). Switching to amisulpride due to hepatic complications. *Eur Psychiatry*, 17(3), 170-171.
3740. Yamamoto, Y., Takahashi, Y., Imai, K., Miyakawa, K., Nishimura, S., Kasai, R., . . . Kagawa, Y. (2013). Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. *Ther Drug Monit*, 35(3), 305-312.
3741. Yamanaka, H., Tamaki, S., Ide, Y., Kim, H., Inoue, K., Sugimoto, M., . . . Yamamoto, T. (2017). Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. *Ann Rheum Dis*.
3742. Yamano, H. O., Matsushita, H. O., & Yanagiwara, S. (2008). Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. *J Gastroenterol Hepatol*, 23(4), 534-540.
3743. Yampayon, K., Sukasem, C., Limwongse, C., Chinvarun, Y., Tempark, T., Rerkpattanapipat, T., & Kijsanayotin, P. (2017). Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. *Eur J Clin Pharmacol*, 73(7), 855-865.
3744. Yancey, S. W., Klotsman, M., Ortega, H. G., Edwards, L. D., & Anderson, W. H. (2009). Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. *Curr Med Res Opin*, 25(4), 1011-1018.
3745. Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Jr., Colvin, M. M., . . . Westlake, C. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol*, 70(6), 776-803.
3746. Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Jr., Drazner, M. H., . . . American Heart Association Task Force on Practice Guidelines. (2013). 2013 ACCF/AHA

- guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*, 62(16), e147-239.
3747. Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M. (2012). Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(7), CD002991.
3748. Yang, I. A., Fong, K. M., Sim, E. H., Black, P. N., & Lasserson, T. J. (2007). Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*(2), CD002991.
3749. Yang, J. C., Wang, H. L., Chern, H. D., Shun, C. T., Lin, B. R., Lin, C. J., & Wang, T. H. (2011). Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for *Helicobacter pylori* eradication. *Pharmacotherapy*, 31(3), 227-238.
3750. Yang, J. C., Yang, Y. F., Uang, Y. S., Lin, C. J., & Wang, T. H. (2009). Pharmacokinetic-pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against *Helicobacter pylori*. *Br J Clin Pharmacol*, 67(5), 503-510.
3751. Yang, X. L., & Xu, Z. M. (2010). [Establishment of the multiplex quantitative ligase chain reaction for detecting mutations of deafness genes]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*, 27(5), 530-534.
3752. Yang, Y. Y., Lin, H. C., Lin, M. W., Chu, C. J., Lee, F. Y., Hou, M. C., . . . Jap, T. S. (2011). Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites. *Clin Sci (Lond)*, 121(11), 509-521.
3753. Yano, T., Nishio, S. Y., & Usami, S. (2014). Frequency of mitochondrial mutations in non-syndromic hearing loss as well as possibly responsible variants found by whole mitochondrial genome screening. *J Hum Genet*, 59(2), 100-106.
3754. Yasuda, S., Kaikita, K., Akao, M., Ako, J., Matoba, T., Nakamura, M., . . . Ogawa, H. (2019). Antithrombotic therapy for atrial fibrillation with stable coronary disease. *N Engl J Med*, 381(12), 1103-1113.
3755. Yasui-Furukori, N., Kondo, T., Suzuki, A., Mihara, K., Tokinaga, N., Inoue, Y., . . . Kaneko, S. (2001). Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. *Schizophr Res*, 52(1), 139-142.
3756. Yasui-Furukori, N., Mihara, K., Takahata, T., Suzuki, A., Nakagami, T., De Vries, R., . . . Kaneko, S. (2004). Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. *Br J Clin Pharmacol*, 57(5), 569-575.
3757. Yasui-Furukori, N., Saito, M., Tsuchimine, S., Nakagami, T., Sato, Y., Sugawara, N., & Kaneko, S. (2008). Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry*, 32(6), 1491-1495.
3758. Yasui-Furukori, N., Tsuchimine, S., Saito, M., Nakagami, T., Sato, Y., & Kaneko, S. (2007). Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and

- plasma concentration of prolactin during risperidone treatment in schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry*, 31(6), 1230-1234.
3759. Yatham, L. N. (2011). A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. *J Affect Disord*, 128 Suppl 1, S21-28.
3760. Yatham, L. N., Beaulieu, S., Schaffer, A., Kauer-Sant'Anna, M., Kapczynski, F., Lafer, B., . . . Wong, H. (2016). Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. *Mol Psychiatry*, 21(8), 1050-1056.
3761. Yatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003). Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. *Br J Psychiatry*, 182, 141-147.
3762. Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., . . . Gorman, C. P. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. *Bipolar Disord*, 7 Suppl 3, 5-69.
3763. Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., . . . Berk, M. (2013). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord*, 15(1), 1-44.
3764. Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., . . . Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*, 20(2), 97-170.
3765. Ye, P., Yang, S., Zhang, W., Lv, Q., Cheng, Q., Mei, M., . . . Li, Q. (2013). Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. *Clin Ther*, 35(2), 180-189.
3766. Yeh, R. W., Secemsky, E. A., Kereiakes, D. J., Normand, S. L., Gershlick, A. H., Cohen, D. J., . . . Mauri, L. (2016). Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *Jama*, 315(16), 1735-1749.
3767. Yelensky, R., Li, Y., Lewitzky, S., Leroy, E., Hurwitz, C., Rodman, D., . . . Paulding, C. A. (2012). A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. *Pharmacogenomics J*, 12(6), 484-488.
3768. Yeomans, N. D., Tulassay, Z., Juhasz, L., Racz, I., Howard, J. M., van Rensburg, C. J., . . . Hawkey, C. J. (1998). A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. *N Engl J Med*, 338(11), 719-726.
3769. Yevtushenko, O. O., Oros, M. M., & Reynolds, G. P. (2010). Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. *J Affect Disord*, 123(1-3), 308-311.

3770. Yi, E. S., Choi, Y. B., Choi, R., Lee, N. H., Lee, J. W., Yoo, K. H., . . . Koo, H. H. (2018). NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia. *Cancer Res Treat*, *50*(3), 872-882.
3771. Yildiz, A., Nikodem, M., Vieta, E., Correll, C. U., & Baldessarini, R. J. (2015). A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. *Psychol Med*, *45*(2), 299-317.
3772. Yildiz, A., Vieta, E., Leucht, S., & Baldessarini, R. J. (2011). Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. *Neuropsychopharmacology*, *36*(2), 375-389.
3773. Yin, D., Xia, X., Zhang, J., Zhang, S., Liao, F., Zhang, G., . . . Shu, Y. (2017). Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose. *Oncotarget*, *8*(8), 13575-13585.
3774. Yip, V. L., Marson, A. G., Jorgensen, A. L., Pirmohamed, M., & Alfirevic, A. (2012). HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. *Clin Pharmacol Ther*, *92*(6), 757-765.
3775. Yoon, H. J., Lee, K. Y., & Sun, I. O. (2016). Clinical severity of drug-induced hyponatremia: thiazides vs. psychotropics. *Clin Nephrol*, *85*(6), 321-325.
3776. Yoshida, K., Nishizawa, D., Ichinomiya, T., Ichinohe, T., Hayashida, M., Fukuda, K., & Ikeda, K. (2015). Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses. *PLoS One*, *10*(1), e0116885.
3777. Yoshimura, R., Hori, H., Umene-Nakano, W., Ikenouchi-Sugita, A., Katsuki, A., Atake, K., & Nakamura, J. (2014). Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. *Ther Adv Psychopharmacol*, *4*(3), 123-129.
3778. Young, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., . . . Brecher, M. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). *J Clin Psychiatry*, *71*(2), 150-162.
3779. Youngster, I., Arcavi, L., Schechmaster, R., Akayzen, Y., Popliski, H., Shimonov, J., . . . Berkovitch, M. (2010). Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. *Drug Saf*, *33*(9), 713-726.
3780. Yu, K. H., Lai, J. H., Hsu, P. N., Chen, D. Y., Chen, C. J., & Lin, H. Y. (2016). Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. *Scand J Rheumatol*, *45*(4), 304-311.
3781. Yu, K. H., Yu, C. Y., & Fang, Y. F. (2017). Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. *Int J Rheum Dis*, *20*(9), 1057-1071.
3782. Yuan, Y., Ford, A. C., Khan, K. J., Gisbert, J. P., Forman, D., Leontiadis, G. I., . . . Moayyedi, P. (2013). Optimum duration of regimens for Helicobacter pylori eradication. *Cochrane Database Syst Rev*(12), Cd008337.

3783. Yuan, Y., You, Y., Huang, D., Cui, J., Wang, Y., Wang, Q., . . . Dai, P. (2009). Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China. *J Transl Med*, 7, 79.
3784. Yuan, Y., Zhang, X., Huang, S., Zuo, L., Zhang, G., Song, Y., . . . Dai, P. (2012). Common molecular etiologies are rare in nonsyndromic Tibetan Chinese patients with hearing impairment. *PLoS One*, 7(2), e30720.
3785. Yuan, Y. Y., Dai, P., Zhu, X. H., Kang, D. Y., Zhang, X., & Huang, D. L. (2009). [Etiologic analysis of severe to profound hearing loss patients from Chifeng city in Inner Mongolia]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*, 44(4), 292-296.
3786. Yue, Q. Y., Alm, C., Svensson, J. O., & Sawe, J. (1997). Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. *Ther Drug Monit*, 19(5), 539-542.
3787. Yue, Q. Y., Hasselstrom, J., Svensson, J. O., & Sawe, J. (1991). Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. *Br J Clin Pharmacol*, 31(6), 635-642.
3788. Yue, Q. Y., Svensson, J. O., Alm, C., Sjoqvist, F., & Sawe, J. (1989). Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. *Br J Clin Pharmacol*, 28(6), 639-645.
3789. Yue, Q. Y., Svensson, J. O., Sjoqvist, F., & Sawe, J. (1991). A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. *Br J Clin Pharmacol*, 31(6), 643-647.
3790. Yue, Q. Y., Zhong, Z. H., Tybring, G., Dalen, P., Dahl, M. L., Bertilsson, L., & Sjoqvist, F. (1998). Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. *Clin Pharmacol Ther*, 64(4), 384-390.
3791. Yurekli, V. A., Akhan, G., Kutluhan, S., Uzar, E., Koyuncuoglu, H. R., & Gultekin, F. (2008). The effect of sodium valproate on chronic daily headache and its subgroups. *J Headache Pain*, 9(1), 37-41.
3792. Yusuf, S., Pitt, B., Davis, C. E., Hood, W. B., & Cohn, J. N. (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*, 325(5), 293-302.
3793. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*, 342(3), 145-153.
3794. Yusuf, S., Teo, K., Anderson, C., Pogue, J., Dyal, L., Copland, I., . . . Sleight, P. (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet*, 372(9644), 1174-1183.
3795. Yusuf, S., Teo, K. K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., . . . Anderson, C. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*, 358(15), 1547-1559.

3796. Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., & Fox, K. K. (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*, *345*(7), 494-502.
3797. Zabala-Fernandez, W., Barreiro-de Acosta, M., Echarri, A., Carpio, D., Lorenzo, A., Castro, J., . . . Barros, F. (2011). A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. *J Gastrointest Liver Dis*, *20*(3), 247-253.
3798. Zacarias, E. C., Castro, A. A., & Cendon, S. (2007). Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. *J Bras Pneumol*, *33*(2), 152-160.
3799. Zahger, D., & Ilija, R. (2009). Coronary stenting in warfarin treated patients. *EuroIntervention*, *5*(2), 277-281.
3800. Zai, C. C., De Luca, V., Hwang, R. W., Voineskos, A., Muller, D. J., Remington, G., & Kennedy, J. L. (2007). Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. *Mol Psychiatry*, *12*(9), 794-795.
3801. Zannad, F., McMurray, J. J., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., . . . Pitt, B. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*, *364*(1), 11-21.
3802. Zarinara, A. R., Mohammadi, M. R., Hazrati, N., Tabrizi, M., Rezazadeh, S. A., Rezaie, F., & Akhondzadeh, S. (2010). Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. *Hum Psychopharmacol*, *25*(7-8), 530-535.
3803. Zastrozhin, M. S., Grishina, E. A., Denisenko, N. P., Skryabin, V. Y., Markov, D. D., Savchenko, L. M., . . . Sychev, D. A. (2018). Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. *Pharmgenomics Pers Med*, *11*, 113-119.
3804. Zembutsu, H., Nakamura, S., Akashi-Tanaka, S., Kuwayama, T., Watanabe, C., Takamaru, T., . . . Nakamura, Y. (2017). Significant effect of polymorphisms in CYP2D6 on response to tamoxifen therapy for breast cancer: a prospective multicenter study. *Clin Cancer Res*, *23*(8), 2019-2026.
3805. Zeng, C., Wei, J., Persson, M. S. M., Sarmanova, A., Doherty, M., Xie, D., . . . Zhang, W. (2018). Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. *Br J Sports Med*, *52*(10), 642-650.
3806. Zeng, T., Long, Y. S., Min, F. L., Liao, W. P., & Shi, Y. W. (2015). Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. *Int J Dermatol*, *54*(4), 488-493.
3807. Zeng, Z., Duan, Z., Zhang, T., Wang, S., Li, G., Gao, J., . . . Pan, F. (2013). Association between tumor necrosis factor-alpha (TNF-alpha) promoter -308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis. *Mod Rheumatol*, *23*(3), 489-495.

3808. Zeng, Z., Liu, Y., Liu, Z., You, J., Chen, Z., Wang, J., . . . Qin, X. (2013). CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. *Cancer Chemother Pharmacol*, *72*(2), 287-303.
3809. Zhang, B., Thayaparan, A., Horner, N., Bedi, A., Alolabi, B., & Khan, M. (2018). Outcomes of hyaluronic acid injections for glenohumeral osteoarthritis: a systematic review and meta-analysis. *J Shoulder Elbow Surg*.
3810. Zhang, J., Chen, Z., & Chen, C. (2016). Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. *Meta Gene*, *9*, 197-209.
3811. Zhang, J., Tian, L., Huang, J., Huang, S., Chai, T., & Shen, J. (2017). Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. *Cardiovasc Ther*, *35*(1), 26-32.
3812. Zhang, J., Tian, L., Zhang, Y., & Shen, J. (2015). The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. *Thromb Res*, *136*(5), 955-961.
3813. Zhang, J., Zhang, L., Zhao, X., Shen, S., Luo, X., & Zhang, Y. (2018). Association between MDR1/CYP3A4/OPRM1 gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women. *Gene*, *661*, 78-84.
3814. Zhang, J. P., Lencz, T., & Malhotra, A. K. (2010). D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. *Am J Psychiatry*, *167*(7), 763-772.
3815. Zhang, J. P., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L., John, M., . . . Correll, C. U. (2016). Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. *Schizophr Bull*, *42*(6), 1418-1437.
3816. Zhang, J.-P., Lencz, T., & Malhotra, A. K. (2010). D2 Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. *American Journal of Psychiatry*, *167*(7), 763-772.
3817. Zhang, L., Mei, Q., Li, Q. S., Hu, Y. M., & Xu, J. M. (2010). The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxicillin and clarithromycin in Chinese people. *J Clin Pharm Ther*, *35*(6), 713-722.
3818. Zhang, Q., Qian, J., & Zhu, Y. (2015). Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials. *Int J Clin Exp Med*, *8*(3), 3338-3348.
3819. Zhang, W., Chen, B. L., Ozdemir, V., He, Y. J., Zhou, G., Peng, D. D., . . . Zhou, H. H. (2007). SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. *Br J Clin Pharmacol*, *64*(3), 346-352.
3820. Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V., Conaghan, P., . . . Zimmermann-Gorska, I. (2006). EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis*, *65*(10), 1312-1324.

3821. Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., . . . Zimmermann-Gorska, I. (2007). EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis*, 66(3), 377-388.
3822. Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., . . . Tugwell, P. (2008). OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage*, 16(2), 137-162.
3823. Zhang, W., Nuki, G., Moskowitz, R. W., Abramson, S., Altman, R. D., Arden, N. K., . . . Tugwell, P. (2010). OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage*, 18(4), 476-499.
3824. Zhang, W., Ouyang, H., Dass, C. R., & Xu, J. (2016). Current research on pharmacologic and regenerative therapies for osteoarthritis. *Bone Res*, 4, 15040.
3825. Zhang, W., Yu, B. N., He, Y. J., Fan, L., Li, Q., Liu, Z. Q., . . . Zhou, H. H. (2006). Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. *Clin Chim Acta*, 373(1-2), 99-103.
3826. Zhang, W., Yuan, J. J., Kan, Q. C., Zhang, L. R., Chang, Y. Z., & Wang, Z. Y. (2011). Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. *Minerva Anesthesiol*, 77(1), 33-39.
3827. Zhang, X., Lynch, A. I., Davis, B. R., Ford, C. E., Boerwinkle, E., Eckfeldt, J. H., . . . Arnett, D. K. (2012). Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. *PLoS One*, 7(3), e34217.
3828. Zhang, X., Pu, Z., Ge, J., Shen, J., Yuan, X., & Xie, H. (2015). Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. *Med Sci Monit*, 21, 563-569.
3829. Zhang, Y., Wang, J., Zhao, L. M., Peng, W., Shen, G. Q., Xue, L., . . . Miao, L. Y. (2011). Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. *Eur J Clin Pharmacol*, 67(9), 885-887.
3830. Zhang, Y., Yang, H., Yang, S., Liang, W., Dai, P., Wang, C., & Zhang, Y. (2013). Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials. *Neural Regen Res*, 8(31), 2962-2974.
3831. Zhang, Y. K., Yang, H., Zhang, J. Y., Song, L. J., & Fan, Y. C. (2014). Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. *Int J Clin Pract*, 68(5), 633-638.
3832. Zhao, F., Wang, J., Yang, Y., Wang, X., Shi, R., Xu, Z., . . . Zhang, G. (2008). Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for *Helicobacter pylori* eradication: a meta-analysis. *Helicobacter*, 13(6), 532-541.
3833. Zhao, P., Xu, P., Wan, C., & Wang, Z. (2011). Evening versus morning dosing regimen drug therapy for hypertension. *Cochrane Database Syst Rev*(10), CD004184.

3834. Zhao, Q., Sun, J., Tao, Y., Wang, S., Jiang, C., Zhu, Y., . . . Zhu, J. (2014). A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. *Pharmacogenomics*, *15*(4), 487-495.
3835. Zhao, Y., Han, S., Shang, J., Zhao, X., Pu, R., & Shi, L. (2015). Effectiveness of drug treatment strategies to prevent asthma exacerbations and increase symptom-free days in asthmatic children: a network meta-analysis. *J Asthma*, *52*(8), 846-857.
3836. Zheng, B. J., Peng, G. H., Chen, B. B., Fang, F., Zheng, J., Wu, Y., . . . Guan, M. X. (2012). [Spectrum and frequency of mitochondrial 12S rRNA variants in the Chinese subjects with nonsyndromic hearing loss in Zhejiang Province]. *Yi Chuan*, *34*(6), 695-704.
3837. Zheng, S., Tasnif, Y., Hebert, M. F., Davis, C. L., Shitara, Y., Calamia, J. C., . . . Thummel, K. E. (2013). CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. *Transplantation*, *95*(6), 821-827.
3838. Zhou, B. T., Zhou, Q. H., Yin, J. Y., Li, G. L., Qu, J., Xu, X. J., . . . Liu, Z. Q. (2012). Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. *CNS Neurosci Ther*, *18*(7), 566-572.
3839. Zhou, K., Bellenguez, C., Spencer, C. C., Bennett, A. J., Coleman, R. L., Tavendale, R., . . . Pearson, E. R. (2011). Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. *Nat Genet*, *43*(2), 117-120.
3840. Zhou, K., Yee, S. W., Seiser, E. L., van Leeuwen, N., Tavendale, R., Bennett, A. J., . . . Pearson, E. R. (2016). Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nat Genet*, *48*(9), 1055-1059.
3841. Zhou, L., Liu, L., Liu, X., Chen, P., Liu, L., Zhang, Y., . . . Yi, D. (2014). Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. *PLoS One*, *9*(1), e85008.
3842. Zhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., . . . Xie, P. (2015). Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. *Int J Neuropsychopharmacol*, *18*(11), pyv060.
3843. Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., . . . Xie, P. (2015). Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. *J Clin Psychiatry*, *76*(4), e487-498.
3844. Zhou, Y., Wang, X., Li, H., Zhang, J., Chen, Z., Xie, W., . . . Huang, M. (2015). Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients. *Drug Metab Pharmacokinet*, *30*(4), 282-287.
3845. Zhou, Y., Wang, X., Zeng, X., Qiu, R., Xie, J., Liu, S., . . . Ran, P. (2006). Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. *Respirology*, *11*(5), 603-610.
3846. Zhu, A. Z., Renner, C. C., Hatsukami, D. K., Benowitz, N. L., & Tyndale, R. F. (2013). CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. *Addiction*, *108*(10), 1818-1828.

3847. Zhu, H. J., Wang, X., Gawronski, B. E., Brinda, B. J., Angiolillo, D. J., & Markowitz, J. S. (2013). Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. *J Pharmacol Exp Ther*, *344*(3), 665-672.
3848. Zhu, H. J., Yuan, S. H., Fang, Y., Sun, X. Z., Kong, H., & Ge, W. H. (2011). The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. *Pharmacogenomics J*, *11*(3), 237-246.
3849. Zhu, X., Yun, W., Sun, X., Qiu, F., Zhao, L., & Guo, Y. (2014). Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. *Pharmacogenomics*, *15*(15), 1867-1879.
3850. Ziegler, D. K., Hurwitz, A., Hassanein, R. S., Kodanaz, H. A., Preskorn, S. H., & Mason, J. (1987). Migraine prophylaxis. A comparison of propranolol and amitriptyline. *Arch Neurol*, *44*(5), 486-489.
3851. Zineh, I., Beitelshes, A. L., Gaedigk, A., Walker, J. R., Pauly, D. F., Eberst, K., . . . Johnson, J. A. (2004). Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. *Clin Pharmacol Ther*, *76*(6), 536-544.
3852. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., . . . Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. *N Engl J Med*, *373*(22), 2117-2128.
3853. Zong, Y. P., Wang, Z. J., Zhou, W. L., Zhou, W. M., Ma, T. L., Huang, Z. K., . . . Gu, M. (2017). Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. *World J Pediatr*, *13*(5), 421-426.
3854. Zou, Y. F., Wang, F., Feng, X. L., Li, W. F., Tao, J. H., Pan, F. M., . . . Su, H. (2010). Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. *Neurosci Lett*, *484*(1), 56-61.
3855. Zullo, A., Scaccianoce, G., De Francesco, V., Ruggiero, V., D'Ambrosio, P., Castorani, L., . . . Portincasa, P. (2013). Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. *Clin Res Hepatol Gastroenterol*, *37*(6), 647-650.
3856. Zuurhout, M. J., Vijverberg, S. J., Raaijmakers, J. A., Koenderman, L., Postma, D. S., Koppelman, G. H., & Maitland-van der Zee, A. H. (2013). Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. *Pharmacogenomics*, *14*(16), 1965-1971.
3857. ZuWallack, R. L., Mahler, D. A., Reilly, D., Church, N., Emmett, A., Rickard, K., & Knobil, K. (2001). Salmeterol plus theophylline combination therapy in the treatment of COPD. *Chest*, *119*(6), 1661-1670.
3858. Zwisler, S. T., Enggaard, T. P., Mikkelsen, S., Brosen, K., & Sindrup, S. H. (2010). Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. *Acta Anaesthesiol Scand*, *54*(2), 232-240.
3859. Zwisler, S. T., Enggaard, T. P., Mikkelsen, S., Verstuyft, C., Becquemont, L., Sindrup, S. H., & Brosen, K. (2012). Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. *J Clin Pharmacol*, *52*(2), 234-242.

3860. Zwisler, S. T., Enggaard, T. P., Noehr-Jensen, L., Pedersen, R. S., Mikkelsen, S., Nielsen, F., . . . Sindrup, S. H. (2009). The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. *Basic Clin Pharmacol Toxicol*, 104(4), 335-344.
3861. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. (1982). *Jama*, 247(12), 1707-1714.
3862. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. (1983). *Jama*, 250(20), 2814-2819.
3863. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. (1986). *Lancet*, 2(8498), 57-66.
3864. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). (1987). *N Engl J Med*, 316(23), 1429-1435.
3865. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). *Lancet*, 2(8607), 349-360.
3866. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). (1990). *Am J Cardiol*, 66(10), 779-785.
3867. Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. (1990). *Am J Cardiol*, 66(21), 331-401.
3868. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. (1993). *Lancet*, 342(8875), 821-828.
3869. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. (1994). *Lancet*, 343(8906), 1115-1122.
3870. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). (1994). *Lancet*, 344(8934), 1383-1389.
3871. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. (1995). *Headache*, 35(4), 177-184.
3872. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. (1995). *Lancet*, 345(8951), 669-685.
3873. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). (1995). *Lancet*, 345(8951), 686-687.
3874. Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. (1996). *Am J Psychiatry*, 153(10 Suppl), 1-31.

3875. The effect of digoxin on mortality and morbidity in patients with heart failure. (1997). *N Engl J Med*, 336(8), 525-533.
3876. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. (1998). *N Engl J Med*, 339(19), 1349-1357.
3877. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999). *Lancet*, 353(9146), 9-13.
3878. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). (1999). *Lancet*, 353(9169), 2001-2007.
3879. Transfer of drugs and other chemicals into human milk. (2001). *Pediatrics*, 108(3), 776-789.
3880. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. (2002). *Lancet*, 360(9326), 7-22.
3881. Practice guideline for the treatment of patients with bipolar disorder (revision). (2002). *Am J Psychiatry*, 159(4 Suppl), 1-50.
3882. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. (2004). *Am J Kidney Dis*, 43(5 Suppl 1), S1-290.
3883. Clinical practice guidelines. Treatment of schizophrenia. (2005). *Can J Psychiatry*, 50(13 Suppl 1), 7s-57s.
3884. Clinical practice guidelines. Management of anxiety disorders. (2006). *Can J Psychiatry*, 51(8 Suppl 2), 9s-91s.
3885. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. (2007). *J Vasc Surg*, 45(4), 645-654; discussion 653-644.
3886. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. (2008). *Am J Prev Med*, 35(2), 158-176.
3887. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. (2010). *Circ J*, 74(11), 2479-2500.
3888. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. (2010). *Menopause*, 17(1), 25-54; quiz 55-26.
3889. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. (2012). *Am J Kidney Dis*, 60(5), 850-886.
3890. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. (2015). *J Am Geriatr Soc*, 63(11), 2227-2246.
3891. Biologic Switching for Patients with Rheumatoid Arthritis: A Review of Clinical Effectiveness, Safety, and Guidelines. (2015). *CADTH Rapid Response Reports*. (Accession No. 26764440)
3892. PL Detail-Document, Clinical Use of Metformin in Special Populations. (2015). *Pharmacist's Letter/Prescriber's Letter*,

3893. PL Detail-Document, Empagliflozin and Cardiovascular Disease. (2015). *Pharmacist's Letter/Prescriber's Letter*,
3894. PL Detail-Document, Non-statin Lipid-Lowering Agents. (2015). *Pharmacist's Letter/Prescriber's Letter*,
3895. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Correction. (2016). *Circulation*, 134(10), e192-194.
3896. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Correction. . (2016). *Circulation*, 134(10), e195-197.
3897. PL Detail-Document, Clinically Significant Statin Drug Interactions. (2016). *Pharmacist's Letter/Prescriber's Letter*,
3898. Diagnosis and Management of Gout: Clinical Practice Guidelines From the American College of Physicians. (2017). *Ann Intern Med*, 166(1).
3899. Pharmacogenomic testing for psychotropic medication selection: A systematic review of the Assurex GeneSight psychotropic test. (2017). *Ont Health Technol Assess Ser*, 17(4), 1-39.
3900. Stroke Prevention in Atrial fibrillation. (2017). *Thrombosis Canada*,